<?xml version="1.0" encoding="UTF-8"?>
<drugbank xmlns="http://www.drugbank.ca" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd" version="5.0" exported-on="2017-09-20">
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00001</drugbank-id>
  <drugbank-id>BTD00024</drugbank-id>
  <drugbank-id>BIOD00024</drugbank-id>
  <name>Lepirudin</name>
  <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.</description>
  <cas-number>138068-37-8</cas-number>
  <unii>Y43GF64R34</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>16244762</pubmed-id>
        <citation>Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.</citation>
      </article>
      <article>
        <pubmed-id>16690967</pubmed-id>
        <citation>Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.</citation>
      </article>
      <article>
        <pubmed-id>16241940</pubmed-id>
        <citation>Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Google books</title>
        <url>http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of heparin-induced thrombocytopenia</indication>
  <pharmacodynamics>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacodynamics>
  <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>
  <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>
  <metabolism>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</metabolism>
  <absorption>Bioavailability is 100% following injection.</absorption>
  <half-life>Approximately 1.3 hours</half-life>
  <protein-binding/>
  <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>
  <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#13;
* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#13;
* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#13;
* 32.1 L [HIT patients (n = 73)]</volume-of-distribution>
  <clearance>* 164 ml/min [Healthy 18-60 yrs]&#13;
* 139 ml/min [Healthy 65-80 yrs]&#13;
* 61 ml/min [renal impaired]&#13;
* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Hirudin variant-1</synonym>
    <synonym language="" coder="">Lepirudin recombinant</synonym>
  </synonyms>
  <products>
    <product>
      <name>Refludan</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240996</dpd-id>
      <started-marketing-on>2000-01-31</started-marketing-on>
      <ended-marketing-on>2013-07-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
    <mixture>
      <name>Refludan</name>
      <ingredients>Lepirudin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Berlex Labs</name>
      <url>http://www.berlex.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Bayer healthcare pharmaceuticals inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Refludan 50 mg vial</description>
      <cost currency="USD">273.19</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Antithrombin Proteins</category>
      <mesh-id>D058833</mesh-id>
    </category>
    <category>
      <category>Antithrombins</category>
      <mesh-id>D000991</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Proteinase Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>Serpins</category>
      <mesh-id>D015843</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AE02">
      <level code="B01AE">Direct thrombin inhibitors</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.04.12</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>4HIR</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00001.pdf?1265924858</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00001.pdf?1368416245</msds>
  <patents>
    <patent>
      <number>5180668</number>
      <country>United States</country>
      <approved>1993-01-19</approved>
      <expires>2010-01-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Lepirudin can be increased when combined with St. John&amp;#39;s Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The serum concentration of Cisapride can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Edoxaban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Lepirudin may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Lovastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Urokinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of adverse effects can be increased when Vorapaxar is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The serum concentration of Ergonovine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The serum concentration of Triazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Mestranol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Estrone sulfate can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Estrogens, esterified</name>
      <description>The serum concentration of Estrogens, esterified can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>The serum concentration of Chlorotrianisene can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Estramustine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>The serum concentration of Dienestrol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>The serum concentration of Hexestrol can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>The serum concentration of Methallenestril can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10532</drugbank-id>
      <name>Garlic</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Garlic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The metabolism of Tacrolimus can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The serum concentration of Alprazolam can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Lepirudin can be decreased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Lepirudin can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Delavirdine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06401</drugbank-id>
      <name>Bazedoxifene</name>
      <description>Bazedoxifene may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>S Equol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12179</drugbank-id>
      <name>Secoisolariciresinol</name>
      <description>Secoisolariciresinol may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Nefazodone can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dydrogesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Allylestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Altrenogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestrinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lynestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The serum concentration of Riociguat can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The serum concentration of Rosuvastatin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Diltiazem can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Pentosan Polysulfate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The serum concentration of Mirtazapine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Desipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Clomipramine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The serum concentration of Amineptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The serum concentration of Esmirtazapine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The serum concentration of Dosulepin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The serum concentration of Tianeptine can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The serum concentration of Opipramol can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>The serum concentration of Abacavir can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00109</drugbank-id>
      <name>Enfuvirtide</name>
      <description>The serum concentration of Enfuvirtide can be increased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The serum concentration of Etravirine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Deoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>Sugammadex may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>Etanercept may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>Masoprocol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>Adapalene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>Pimecrolimus may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Chloroquine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Mycophenolate mofetil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>Naftifine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>Zileuton may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Olopatadine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>Suprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>Bromfenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Leflunomide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Trisalicylate-choline may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>Niflumic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>Pirfenidone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>PTC299 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Apremilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>HMPL-004 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Icatibant may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>exisulind</name>
      <description>exisulind may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>Seratrodast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>Nepafenac may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Teriflunomide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>D-Limonene</name>
      <description>D-Limonene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>Tolfenamic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Evening primrose oil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>Orgotein may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>Curcumin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E-6201</name>
      <description>E6201 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Duvelisib may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>Bucillamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>Lisofylline may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>Betulinic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>Ebselen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Apocynin</name>
      <description>Acetovanillone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>Higenamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Nafamostat may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>Mizoribine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Lepirudin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Lepirudin may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Lepirudin may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Lepirudin may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Lepirudin may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Lepirudin may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Lepirudin may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Lepirudin may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Lepirudin may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Lepirudin may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Lepirudin may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Lepirudin may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Lepirudin may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Lepirudin may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Lepirudin may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Lepirudin may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Lepirudin may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Lepirudin may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Lepirudin may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Lepirudin may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Lepirudin may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Lepirudin may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Lepirudin may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Lepirudin may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Lepirudin may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Lepirudin may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Lepirudin may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Lepirudin may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Lepirudin may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Lepirudin may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Lepirudin may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Lepirudin may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Lepirudin may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>Aminosalicylic Acid may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>dersalazine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Alteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Reteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Anistreplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Tenecteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Streptokinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Desmoteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Plasmin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>ALX-0081</name>
      <description>ALX-0081 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Astaxanthin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Tinzaparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09005</drugbank-id>
      <name>Batroxobin</name>
      <description>Batroxobin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>Ticagrelor may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Ditazole may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Bemiparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Parnaparin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Selexipag may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12017</drugbank-id>
      <name>Ozagrel</name>
      <description>Kct 0809 may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The serum concentration of Valproic Acid can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be decreased when it is combined with Lepirudin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00001 sequence
LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP
EEYLQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>65 °C</value>
      <source>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.777</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>4.04</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>6963.425</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C287H440N80O110S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11916</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06880</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01050</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000541</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lepirudin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201666</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/lepirudin.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00278</smpdb-id>
      <name>Lepirudin Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00001</drugbank-id>
          <name>Lepirudin</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000048</id>
      <name>Prothrombin</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10505536</pubmed-id>
            <citation>Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.</citation>
          </article>
          <article>
            <pubmed-id>10912644</pubmed-id>
            <citation>Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.</citation>
          </article>
          <article>
            <pubmed-id>11055889</pubmed-id>
            <citation>Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.</citation>
          </article>
          <article>
            <pubmed-id>11467439</pubmed-id>
            <citation>Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.</citation>
          </article>
          <article>
            <pubmed-id>11807012</pubmed-id>
            <citation>Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00734" source="Swiss-Prot">
    <name>Prothrombin</name>
    <general-function>Thrombospondin receptor activity</general-function>
    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>
    <gene-name>F2</gene-name>
    <locus>11p11-q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>5.7</theoretical-pi>
    <molecular-weight>70036.295</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3535</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M17262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339641</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00734</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>THRB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.5</synonym>
      <synonym>Coagulation factor II</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016004|Prothrombin
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016005|Prothrombin (F2)
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF09396</identifier>
        <name>Thrombin_light</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thrombospondin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to wounding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of collagen biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytosolic calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of astrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell shape</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-09-01">
  <drugbank-id primary="true">DB00002</drugbank-id>
  <drugbank-id>BTD00071</drugbank-id>
  <drugbank-id>BIOD00071</drugbank-id>
  <name>Cetuximab</name>
  <description>Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.</description>
  <cas-number>205923-56-4</cas-number>
  <unii>PQX0D8J21J</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>10480573</pubmed-id>
        <citation>Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90.</citation>
      </article>
      <article>
        <pubmed-id>10601294</pubmed-id>
        <citation>Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91.</citation>
      </article>
      <article>
        <pubmed-id>10628369</pubmed-id>
        <citation>Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5.</citation>
      </article>
      <article>
        <pubmed-id>11408594</pubmed-id>
        <citation>Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910.</citation>
      </article>
      <article>
        <pubmed-id>11431346</pubmed-id>
        <citation>Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101.</citation>
      </article>
      <article>
        <pubmed-id>11752352</pubmed-id>
        <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
      </article>
      <article>
        <pubmed-id>15269308</pubmed-id>
        <citation>Schrag D: The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):317-9.</citation>
      </article>
      <article>
        <pubmed-id>16336752</pubmed-id>
        <citation>Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.</indication>
  <pharmacodynamics>Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</pharmacodynamics>
  <mechanism-of-action>Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</mechanism-of-action>
  <toxicity>Pulmonary Toxicity&#13;
&#13;
Interstitial lung disease (ILD) was reported in 3 of 633 (&lt;0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmonary edema resulting in death was reported in one case. Two patients had pre-existing fibrotic lung disease and experienced an acute exacerbation of their disease while receiving cetuximab in combination with irinotecan. In the clinical investigational program, an additional case of interstitial pneumonitis was reported in a patient with head and neck cancer treated with cetuximab and cisplatin. The onset of symptoms occurred between the fourth and eleventh doses of treatment in all reported cases.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>The mean half-life for Cetuximab is 114 hours (range 75-188 hours).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>appeared to be independent of dose and approximated the vascular space of 2-3 L/m2.</volume-of-distribution>
  <clearance>Female patients had 25% lower intrinsic clearance than male patients.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="German/Spanish" coder="INN">Cetuximab</synonym>
    <synonym language="French" coder="INN">Cétuximab</synonym>
    <synonym language="Latin" coder="INN">Cetuximabum</synonym>
    <synonym language="" coder="WHO">Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer</synonym>
  </synonyms>
  <products>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02271249</dpd-id>
      <started-marketing-on>2008-10-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66733-948</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125084</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Erbitux</name>
      <labeller>Im Clone Llc</labeller>
      <ndc-id/>
      <ndc-product-code>66733-958</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-10-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125084</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
    <mixture>
      <name>Erbitux</name>
      <ingredients>Cetuximab</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>ImClone Systems Inc.</name>
      <url>http://www.imclone.com</url>
    </packager>
    <packager>
      <name>Oso Biopharmaceuticals Manufacturing LLC</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal</category>
      <mesh-id>D000911</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal, Humanized</category>
      <mesh-id>D061067</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2 mg/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XC06">
      <level code="L01XC">Monoclonal antibodies</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1IGT</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00002.pdf?1265922813</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00002.pdf?1458412933</msds>
  <patents>
    <patent>
      <number>1340417</number>
      <country>Canada</country>
      <approved>1999-03-02</approved>
      <expires>2016-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of CDX-110 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Cetuximab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Cetuximab heavy chain
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN
TPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
    <sequence format="FASTA">&gt;Cetuximab light chain
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS
RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.413</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.48</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>145781.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6484H10042N1732O2023S36</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13175</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03455</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00228</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10040</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000788</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cetuximab</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201577</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/erbitux.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cetuximab.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00474</smpdb-id>
      <name>Cetuximab Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00002</drugbank-id>
          <name>Cetuximab</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00533</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects>
    <effect>
      <protein-name>Low affinity immunoglobulin gamma Fc region receptor II-a</protein-name>
      <gene-symbol>FCGR2A</gene-symbol>
      <uniprot-id>P12318</uniprot-id>
      <rs-id>rs1801274</rs-id>
      <allele/>
      <defining-change>H allelle</defining-change>
      <description>Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.</description>
      <pubmed-id>17704420</pubmed-id>
    </effect>
    <effect>
      <protein-name>Low affinity immunoglobulin gamma Fc region receptor III-A</protein-name>
      <gene-symbol>FCGR3A</gene-symbol>
      <uniprot-id>P08637</uniprot-id>
      <rs-id>rs396991</rs-id>
      <allele/>
      <defining-change>G &gt; T</defining-change>
      <description>Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.</description>
      <pubmed-id>17704420</pubmed-id>
    </effect>
  </snp-effects>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000767</id>
      <name>Epidermal growth factor receptor</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10480573</pubmed-id>
            <citation>Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90.</citation>
          </article>
          <article>
            <pubmed-id>10601294</pubmed-id>
            <citation>Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91.</citation>
          </article>
          <article>
            <pubmed-id>10628369</pubmed-id>
            <citation>Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5.</citation>
          </article>
          <article>
            <pubmed-id>11408594</pubmed-id>
            <citation>Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910.</citation>
          </article>
          <article>
            <pubmed-id>11431346</pubmed-id>
            <citation>Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00533" source="Swiss-Prot">
    <name>Epidermal growth factor receptor</name>
    <general-function>Ubiquitin protein ligase binding</general-function>
    <specific-function>Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.</specific-function>
    <gene-name>EGFR</gene-name>
    <locus>7p12</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>646-668</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>6.67</theoretical-pi>
    <molecular-weight>134276.185</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3236</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>EGFR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X00588</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>757924</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1797</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EGFR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>ERBB</synonym>
      <synonym>ERBB1</synonym>
      <synonym>HER1</synonym>
      <synonym>Proto-oncogene c-ErbB-1</synonym>
      <synonym>Receptor tyrosine-protein kinase erbB-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001530|Epidermal growth factor receptor
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)
ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG
GCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG
TTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG
GTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG
ACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT
TTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA
GTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA
CAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG
AGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC
CAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG
GGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC
GGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC
ACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC
AAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC
CCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG
GTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA
GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA
AACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC
TTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA
ATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT
GAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC
GTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
GTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG
TTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG
GCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC
AGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC
CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA
GAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC
CATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG
CCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG
AGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC
CAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC
GGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC
GATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC
TGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC
TATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG
ATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC
AGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA
CTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC
AGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
ATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG
TTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC
ATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC
CTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
CAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA
ACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC
AAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
AGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG
CCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC
AGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC
ACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA
GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA
GCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC
GCGCCACAAAGCAGTGAATTTATTGGAGCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
      <pfam>
        <identifier>PF14843</identifier>
        <name>GF_recep_IV</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>multivesicular body, internal vesicle lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Shc-EGFR complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>double-stranded DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane receptor protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>epidermal growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>actin filament binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chromatin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>MAP kinase kinase kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein phosphatase binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebral cortex cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of nitric-oxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA repair</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase A2 activity by calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to estradiol stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to amino acid stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>morphogenesis of an epithelial fold</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to epidermal growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to UV-A</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of catenin import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic placenta development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair follicle development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ossification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>single organismal cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein insertion into membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000901</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>16336752</pubmed-id>
            <citation>Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75015" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.</specific-function>
    <gene-name>FCGR3B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>6.71</theoretical-pi>
    <molecular-weight>26215.64</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3620</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X16863</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31322</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O75015</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16B</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-beta</synonym>
      <synonym>Fc-gamma RIIIb</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIb</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)
ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
TTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of defense response to virus by host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitophagy in response to mitochondrial depolarization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002093</id>
      <name>Complement C1r subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00736" source="Swiss-Prot">
    <name>Complement C1r subcomponent</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.</specific-function>
    <gene-name>C1R</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>6.24</theoretical-pi>
    <molecular-weight>80118.04</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1246</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04701</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29539</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2334</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00736</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.41</synonym>
      <synonym>Complement component 1 subcomponent r</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011518|Complement C1r subcomponent
MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
ELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011519|Complement C1r subcomponent (C1R)
ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
ATGGAGGAGGAGGACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002094</id>
      <name>Complement C1q subcomponent subunit A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02745" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit A</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QA</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>9.45</theoretical-pi>
    <molecular-weight>26016.47</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1241</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF135157</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4894854</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02745</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit A precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016678|Complement C1q subcomponent subunit A
MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
IFPSA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)
ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA
GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
ATCTTCCCATCTGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0002095</id>
      <name>Complement C1q subcomponent subunit B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02746" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit B</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QB</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>8.87</theoretical-pi>
    <molecular-weight>26721.62</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1242</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X03084</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>573114</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit B precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016676|Complement C1q subcomponent subunit B
MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG
EKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ
KIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL
CVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS
IFSGFLLFPDMEA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)
ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC
CTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC
CCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA
GAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA
GGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC
CCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG
AAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC
CGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC
ACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG
TGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT
GCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG
AACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC
ATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002096</id>
      <name>Complement C1q subcomponent subunit C</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02747" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit C</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QC</gene-name>
    <locus>1p36.11</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>25773.56</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1245</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QC</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF087892</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33150626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QC_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C1QG</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011520|Complement C1q subcomponent subunit C
MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
LLFPD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)
ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
CTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
CCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
AACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC
AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
CTGCTCTTCCCCGACTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of macrophage differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of granulocyte differentiation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002097</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17704420</pubmed-id>
            <citation>Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08637" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.</specific-function>
    <gene-name>FCGR3A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>209-229</transmembrane-regions>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>8.21</theoretical-pi>
    <molecular-weight>29088.895</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3619</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X52645</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16A</synonym>
      <synonym>CD16a antigen</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-alpha</synonym>
      <synonym>Fc-gamma RIIIa</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIa</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT
TTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG
CTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA
AAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT
CTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG
AGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT
GGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC
CATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT
GGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC
AAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG
ACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA
CCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA
CTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA
TTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0001529</id>
      <name>Complement C1s subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P09871" source="Swiss-Prot">
    <name>Complement C1s subcomponent</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.</specific-function>
    <gene-name>C1S</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>4.59</theoretical-pi>
    <molecular-weight>76683.905</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1S</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X06596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>763110</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2335</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P09871</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1S_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.42</synonym>
      <synonym>C1 esterase</synonym>
      <synonym>Complement component 1 subcomponent s</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011082|Complement C1s subcomponent
MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011083|Complement C1s subcomponent (C1S)
ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0000710</id>
      <name>High affinity immunoglobulin gamma Fc receptor I</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>7547242</pubmed-id>
            <citation>Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12314" source="Swiss-Prot">
    <name>High affinity immunoglobulin gamma Fc receptor I</name>
    <general-function>Receptor signaling protein activity</general-function>
    <specific-function>High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.</specific-function>
    <gene-name>FCGR1A</gene-name>
    <locus>1q21.2-q21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>293-313</transmembrane-regions>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>8.08</theoretical-pi>
    <molecular-weight>42631.525</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3613</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X14356</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31332</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12314</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCGR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-gamma RI</synonym>
      <synonym>Fc-gamma RIA</synonym>
      <synonym>FCG1</synonym>
      <synonym>FcgammaRIa</synonym>
      <synonym>FCGR1</synonym>
      <synonym>FcRI</synonym>
      <synonym>IGFR1</synonym>
      <synonym>IgG Fc receptor I</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phagocytosis, engulfment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0002098</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17704420</pubmed-id>
            <citation>Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12318" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
    <general-function/>
    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.</specific-function>
    <gene-name>FCGR2A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-33</signal-regions>
    <theoretical-pi>6.78</theoretical-pi>
    <molecular-weight>35000.42</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3616</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M31932</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182474</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-a</synonym>
      <synonym>Fc-gamma-RIIa</synonym>
      <synonym>FCG2</synonym>
      <synonym>FCGR2A1</synonym>
      <synonym>FcRII-a</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-a</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a
MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS
HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
KNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)
ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
AAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002099</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31994" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.</specific-function>
    <gene-name>FCGR2B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.12</theoretical-pi>
    <molecular-weight>34043.355</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3618</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U87560</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4099445</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31994</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-b</synonym>
      <synonym>Fc-gamma-RIIb</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-b</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-b</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG
CTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC
ATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC
AAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC
GACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG
TTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC
AAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC
TCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC
TACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG
ATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA
GTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG
GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
CTGGAAGAGCCTGATGACCAGAACCGTATTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0002100</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31995" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.</specific-function>
    <gene-name>FCGR2C</gene-name>
    <locus>1q23.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions>224-246</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.9</theoretical-pi>
    <molecular-weight>35577.96</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X17652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>32074</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31995</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-c</synonym>
      <synonym>Fc-gamma-RIIc</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-c</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
GTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
TCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
GCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC
AGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-14">
  <drugbank-id primary="true">DB00003</drugbank-id>
  <drugbank-id>BTD00001</drugbank-id>
  <drugbank-id>BIOD00001</drugbank-id>
  <name>Dornase alfa</name>
  <description>Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.</description>
  <cas-number>143831-71-4</cas-number>
  <unii>953A26OA1Y</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>8792953</pubmed-id>
        <citation>Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.</citation>
      </article>
      <article>
        <pubmed-id>20238314</pubmed-id>
        <citation>Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001127. doi: 10.1002/14651858.CD001127.pub2.</citation>
      </article>
      <article>
        <pubmed-id>19255515</pubmed-id>
        <citation>Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. doi: 10.1159/000204109. Epub 2009 Feb  18.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Used as adjunct therapy in the treatment of cystic fibrosis. </indication>
  <pharmacodynamics>Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals. </pharmacodynamics>
  <mechanism-of-action>Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.</mechanism-of-action>
  <toxicity>Adverse reactions occur at a frequency of &lt; 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old. </toxicity>
  <metabolism>While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids. </metabolism>
  <absorption>Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.</volume-of-distribution>
  <clearance>Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Deoxyribonuclease (human clone 18-1 protein moiety)</synonym>
    <synonym language="" coder="">Dornase alfa, recombinant</synonym>
    <synonym language="" coder="">Dornase alpha</synonym>
    <synonym language="" coder="">Recombinant deoxyribonuclease (DNAse)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Pulmozyme</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-100</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA103532</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pulmozyme 1mg/ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02046733</dpd-id>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Viscozyme</name>
      <company>Roche (Chile)</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Pulmozyme 1mg/ml</name>
      <ingredients>Dornase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pulmozyme</name>
      <ingredients>Dornase alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Catalent Pharma Solutions</name>
      <url>http://www.catalent.com</url>
    </packager>
    <packager>
      <name>F Hoffmann-La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
    <packager>
      <name>Genentech Inc.</name>
      <url>http://www.gene.com</url>
    </packager>
    <packager>
      <name>Meda AB</name>
      <url>http://www.meda.se</url>
    </packager>
    <packager>
      <name>Medpointe Pharmaceuticals</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Genentech, Inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Lufyllin 200 mg tablet</description>
      <cost currency="USD">3.21</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-gg tablet</description>
      <cost currency="USD">3.84</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-GG 200-200 mg tablet</description>
      <cost currency="USD">3.99</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin-400 tablet</description>
      <cost currency="USD">4.62</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Lufyllin 400 mg tablet</description>
      <cost currency="USD">4.81</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pulmozyme 1 mg/ml ampul</description>
      <cost currency="USD">37.05</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container</description>
      <cost currency="USD">77.06</cost>
      <unit>plastic</unit>
    </price>
    <price>
      <description>Lufyllin-GG 100-100 mg/15ml Elixir</description>
      <cost currency="USD">0.6</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Cough and Cold Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Deoxyribonucleases</category>
      <mesh-id>D003851</mesh-id>
    </category>
    <category>
      <category>Endodeoxyribonucleases</category>
      <mesh-id>D004706</mesh-id>
    </category>
    <category>
      <category>Endonucleases</category>
      <mesh-id>D004720</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Esterases</category>
      <mesh-id>D004950</mesh-id>
    </category>
    <category>
      <category>Expectorants</category>
      <mesh-id>D005100</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Respiratory System</category>
      <mesh-id>D012137</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength>1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Respiratory (inhalation)</route>
      <strength>1 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R05CB13">
      <level code="R05CB">Mucolytics</level>
      <level code="R05C">EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS</level>
      <level code="R05">COUGH AND COLD PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3DNI</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00003.pdf?1410715221</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00003.pdf?1410714694</msds>
  <patents>
    <patent>
      <number>2184581</number>
      <country>Canada</country>
      <approved>2005-02-22</approved>
      <expires>2015-02-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2137237</number>
      <country>Canada</country>
      <approved>2004-10-26</approved>
      <expires>2013-05-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Dornase alfa sequence
LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP
DTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS
RFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ
WSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG
LSDQLAQAISDHYPVEVMLK</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>67 °C</value>
      <source>Chan, H.K. et al., Pharm Res. 13:756-761 (1996)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.083</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>4.58</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>29253.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1321H1999N339O396S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>650</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M55983</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10318</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P24855</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000981</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dornase_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201431</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/pulmozyme.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/dornase-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>8792953</pubmed-id>
            <citation>Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00004</drugbank-id>
  <drugbank-id>BTD00084</drugbank-id>
  <drugbank-id>BIOD00084</drugbank-id>
  <name>Denileukin diftitox</name>
  <description>A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.</description>
  <cas-number>173146-27-5</cas-number>
  <unii>25E79B5CTM</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>17187516</pubmed-id>
        <citation>Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.</citation>
      </article>
      <article>
        <pubmed-id>17454642</pubmed-id>
        <citation>Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of cutaneous T-cell lymphoma</indication>
  <pharmacodynamics>Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.</pharmacodynamics>
  <mechanism-of-action>Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>70-80 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>* 0.06 to 0.09 L/kg</volume-of-distribution>
  <clearance>* 0.6 - 2.0 mL/min/kg [Lymphoma]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Diphtheria toxin precursor</synonym>
    <synonym language="" coder="">DT</synonym>
    <synonym language="" coder="">NAD(+--diphthamide ADP- ribosyltransferase)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Ontak</name>
      <labeller>Eisai Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62856-603</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-10-15</started-marketing-on>
      <ended-marketing-on>2017-01-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103767</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Ontak</name>
      <ingredients>Denileukin diftitox</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Eisai Inc.</name>
      <url>http://www.eisai.com</url>
    </packager>
    <packager>
      <name>Hollister-Stier Laboratories LLC</name>
      <url>http://www.hollisterstier.com</url>
    </packager>
    <packager>
      <name>Ligand Pharmaceuticals Inc.</name>
      <url>http://www.ligand.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Ontak 150 mcg/ml vial</description>
      <cost currency="USD">878.4</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>ADP Ribose Transferases</category>
      <mesh-id>D036002</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bacterial Toxins</category>
      <mesh-id>D001427</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Glycosyltransferases</category>
      <mesh-id>D016695</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interleukins</category>
      <mesh-id>D007378</mesh-id>
    </category>
    <category>
      <category>Lymphokines</category>
      <mesh-id>D008222</mesh-id>
    </category>
    <category>
      <category>Pentosyltransferases</category>
      <mesh-id>D010430</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Toxins, Biological</category>
      <mesh-id>D014118</mesh-id>
    </category>
    <category>
      <category>Transferases</category>
      <mesh-id>D014166</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>150 ug/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XX29">
      <level code="L01XX">Other antineoplastic agents</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1F0L</pdb-entry>
    <pdb-entry>1M47</pdb-entry>
    <pdb-entry>1SGK</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00004.pdf?1265922800</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00004 sequence
MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK
YDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG
TEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY
EYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS
EEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK
TTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN
FVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYK
NPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVI
VLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.301</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.45</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>57647.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2560H4042N678O799S17</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>V01536</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164750594</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00587</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001098</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Denileukin_diftitox</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201550</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/denileukin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/denileukin-diftitox.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000658</id>
      <name>Interleukin-2 receptor subunit alpha</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>2786749</pubmed-id>
            <citation>Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6.</citation>
          </article>
          <article>
            <pubmed-id>3124610</pubmed-id>
            <citation>Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62.</citation>
          </article>
          <article>
            <pubmed-id>18684057</pubmed-id>
            <citation>Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.</citation>
          </article>
          <article>
            <pubmed-id>17187516</pubmed-id>
            <citation>Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01589" source="Swiss-Prot">
    <name>Interleukin-2 receptor subunit alpha</name>
    <general-function>Interleukin-2 receptor activity</general-function>
    <specific-function>Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.</specific-function>
    <gene-name>IL2RA</gene-name>
    <locus>10p15-p14</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>241-259</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>6.49</theoretical-pi>
    <molecular-weight>30818.915</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6008</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X01057</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33813</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1695</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01589</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IL-2 receptor subunit alpha</synonym>
      <synonym>p55</synonym>
      <synonym>TAC antigen</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha
MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS
LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP
QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ
VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)
ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG
GCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC
TACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC
GGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT
CAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA
CAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC
CTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT
CATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC
AGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC
CAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG
GCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT
CAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG
GTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC
TGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of T cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of T cell tolerance induction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Notch signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of T cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation-induced cell death of T cells</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of activated T cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of T cell homeostatic proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response to antigenic stimulus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000651</id>
      <name>Interleukin-2 receptor subunit beta</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15811959</pubmed-id>
            <citation>Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.</citation>
          </article>
          <article>
            <pubmed-id>16516670</pubmed-id>
            <citation>Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.</citation>
          </article>
          <article>
            <pubmed-id>18684057</pubmed-id>
            <citation>Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.</citation>
          </article>
          <article>
            <pubmed-id>17187516</pubmed-id>
            <citation>Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14784" source="Swiss-Prot">
    <name>Interleukin-2 receptor subunit beta</name>
    <general-function>Interleukin-2 receptor activity</general-function>
    <specific-function>Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.</specific-function>
    <gene-name>IL2RB</gene-name>
    <locus>22q13|22q13.1</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>241-265</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.68</theoretical-pi>
    <molecular-weight>61116.59</molecular-weight>
    <chromosome-location>22</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6009</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M26062</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307048</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14784</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>High affinity IL-2 receptor subunit beta</synonym>
      <synonym>IL-2 receptor subunit beta</synonym>
      <synonym>p70-75</synonym>
      <synonym>p75</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016166|Interleukin-2 receptor subunit beta
MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ
VHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA
IQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE
APLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT
IPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV
QKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT
NQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT
FPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP
DLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ
ELQGQDPTHLV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)
ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT
ACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG
AGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA
GTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT
CAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA
GTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC
ATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT
GTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC
TTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG
GCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA
GACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG
AGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC
ATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA
GTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT
AACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC
CAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT
GAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG
GACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC
AACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG
TACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC
ACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC
TTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC
CCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA
GAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA
GACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC
CCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG
GAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA
GAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG</gene-sequence>
    <pfams>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-2-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002102</id>
      <name>Cytokine receptor common subunit gamma</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15811959</pubmed-id>
            <citation>Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.</citation>
          </article>
          <article>
            <pubmed-id>16516670</pubmed-id>
            <citation>Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.</citation>
          </article>
          <article>
            <pubmed-id>11707860</pubmed-id>
            <citation>Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31785" source="Swiss-Prot">
    <name>Cytokine receptor common subunit gamma</name>
    <general-function>Interleukin-2 binding</general-function>
    <specific-function>Common subunit for the receptors for a variety of interleukins.</specific-function>
    <gene-name>IL2RG</gene-name>
    <locus>Xq13.1</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>263-283</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.31</theoretical-pi>
    <molecular-weight>42286.68</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6010</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D11086</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>219890</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31785</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RG_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>gammaC</synonym>
      <synonym>IL-2 receptor subunit gamma</synonym>
      <synonym>IL-2R subunit gamma</synonym>
      <synonym>IL-2RG</synonym>
      <synonym>Interleukin-2 receptor subunit gamma</synonym>
      <synonym>p64</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004122|Cytokine receptor common subunit gamma
MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV
QCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK
EIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN
HCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW
SHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV
TEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP
PCYTLKPET</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)
ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA
GTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC
TTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT
CAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC
CAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG
AAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG
GAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA
CAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA
ACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC
CACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA
TCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG
TTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG
AGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG
GAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT
TTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT
ACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT
CTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG
GCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC
CCATGTTACACCCTAAAGCCTGAAACCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF09240</identifier>
        <name>IL6Ra-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-2-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-4-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-7-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-03-10">
  <drugbank-id primary="true">DB00005</drugbank-id>
  <drugbank-id>BTD00052</drugbank-id>
  <drugbank-id>BIOD00052</drugbank-id>
  <name>Etanercept</name>
  <description>Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids</description>
  <cas-number>185243-69-0</cas-number>
  <unii>OP401G7OJC</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <title>Link</title>
        <url>http://www.genome.jp/dbget-bin/www_bget?D00742</url>
      </link>
      <link>
        <title>Link</title>
        <url>http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=4&amp;sid=eeea413d-1490-4efa-bf5d-71f40e1986a1%40sessionmgr111&amp;hid=123&amp;bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&amp;AN=232781</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference>Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, "Crystals of etanercept and methods of making thereof." U.S. Patent US07276477, issued October 02, 2007.</synthesis-reference>
  <indication>Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis. </indication>
  <pharmacodynamics>Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF. Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinase-3, also known as stromelysin. In animal models, etanarcept has been demonstrated to affect inflammation, such as in murine collagen-induced arthritis. </pharmacodynamics>
  <mechanism-of-action>There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.&#13;
&#13;
TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours. </absorption>
  <half-life>102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 160 +/- 80 mL/hr [RA patients]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">CD120b</synonym>
    <synonym language="" coder="">p75</synonym>
    <synonym language="" coder="">p80 TNF-alpha receptor</synonym>
    <synonym language="" coder="">TNF-R2</synonym>
    <synonym language="" coder="">Tumor necrosis factor receptor 2</synonym>
    <synonym language="" coder="">Tumor necrosis factor receptor superfamily member 1B precursor</synonym>
    <synonym language="" coder="">Tumor necrosis factor receptor type II</synonym>
  </synonyms>
  <products>
    <product>
      <name>Brenzys</name>
      <labeller>Samsung Bioepis Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455323</dpd-id>
      <started-marketing-on>2016-09-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Brenzys</name>
      <labeller>Samsung Bioepis Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02455331</dpd-id>
      <started-marketing-on>2016-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58406-425</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-01-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58406-435</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58406-445</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58406-455</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-11-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 mg/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242903</dpd-id>
      <started-marketing-on>2001-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Enbrel</name>
      <labeller>Immunex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274728</dpd-id>
      <started-marketing-on>2005-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erelzi</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02462850</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erelzi</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02462869</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erelzi</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02462877</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Enbrel Sureclick</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept + Water</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Brenzys</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Brenzys</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Enbrel</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Erelzi</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Erelzi</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
    <mixture>
      <name>Erelzi</name>
      <ingredients>Etanercept</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Boehringer Ingelheim Ltd.</name>
      <url>http://www.boehringer-ingelheim.com</url>
    </packager>
    <packager>
      <name>DSM Corp.</name>
      <url>http://www.dsm.com</url>
    </packager>
    <packager>
      <name>Immunex Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
      <url>http://www.vetter-pharma.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Amgen Inc. + Wyeth + Takeda</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Enbrel 25 mg kit</description>
      <cost currency="USD">250.37</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Enbrel 50 mg/ml sureclick syr</description>
      <cost currency="USD">488.74</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)</description>
      <cost currency="USD">1016.57</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box</description>
      <cost currency="USD">2033.14</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)</description>
      <cost currency="USD">2033.14</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Analgesics</category>
      <mesh-id>D000700</mesh-id>
    </category>
    <category>
      <category>Analgesics, Non-Narcotic</category>
      <mesh-id>D018712</mesh-id>
    </category>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Anti-Inflammatory Agents, Non-Steroidal</category>
      <mesh-id>D000894</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antigens</category>
      <mesh-id>D000941</mesh-id>
    </category>
    <category>
      <category>Antigens, CD</category>
      <mesh-id>D015703</mesh-id>
    </category>
    <category>
      <category>Antigens, Differentiation</category>
      <mesh-id>D000943</mesh-id>
    </category>
    <category>
      <category>Antigens, Surface</category>
      <mesh-id>D000954</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antirheumatic Agents</category>
      <mesh-id>D018501</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Biologics for Rheumatoid Arthritis Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biomarkers</category>
      <mesh-id>D015415</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin G</category>
      <mesh-id>D007074</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin Isotypes</category>
      <mesh-id>D007132</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Membrane Proteins</category>
      <mesh-id>D008565</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Receptors, Cell Surface</category>
      <mesh-id>D011956</mesh-id>
    </category>
    <category>
      <category>Receptors, Cytokine</category>
      <mesh-id>D018121</mesh-id>
    </category>
    <category>
      <category>Receptors, Immunologic</category>
      <mesh-id>D011971</mesh-id>
    </category>
    <category>
      <category>Receptors, Tumor Necrosis Factor</category>
      <mesh-id>D018124</mesh-id>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Tumor Necrosis Factor Alpha (TNF-α) Inhibitors</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>25 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>25 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; liquid; powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>25 mg/.5mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>50 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>25 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L04AB01">
      <level code="L04AB">Tumor necrosis factor alpha (TNF-α) inhibitors</level>
      <level code="L04A">IMMUNOSUPPRESSANTS</level>
      <level code="L04">IMMUNOSUPPRESSANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>92:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2DTQ</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2476934</number>
      <country>Canada</country>
      <approved>2009-06-16</approved>
      <expires>2023-02-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2123593</number>
      <country>Canada</country>
      <approved>2000-03-14</approved>
      <expires>2013-09-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7276477</number>
      <country>United States</country>
      <approved>2007-10-02</approved>
      <expires>2024-07-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>36755</number>
      <country>United States</country>
      <approved>2000-06-27</approved>
      <expires>2012-10-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of adverse effects can be increased when Floctafenine is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Etanercept may increase the immunosuppressive activities of Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>Etanercept may increase the immunosuppressive activities of Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>Tocilizumab may increase the immunosuppressive activities of Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09033</drugbank-id>
      <name>Vedolizumab</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Vedolizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of adverse effects can be increased when Ketorolac is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Morniflumate is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of adverse effects can be increased when Talniflumate is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Rabies vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with G17DT.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with INGN 201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with INGN 225.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with CDX-110.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with SRP 299.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with GI-5005.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with TG4010.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Etanercept may decrease the diuretic activities of Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Etanercept may decrease the diuretic activities of Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Etanercept may decrease the diuretic activities of Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Etanercept may decrease the diuretic activities of Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etanercept may decrease the diuretic activities of Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>The serum concentration of Lithium can be increased when it is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tenofovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Etanercept may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>Etanercept may increase the nephrotoxic activities of Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenac is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>Etanercept may decrease the excretion rate of Streptozocin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>Etanercept may decrease the excretion rate of Epirubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Etanercept may decrease the excretion rate of Framycetin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Etanercept may decrease the excretion rate of Amikacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Etanercept may decrease the excretion rate of Tobramycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Etanercept may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Etanercept may decrease the excretion rate of Gentamicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00919</drugbank-id>
      <name>Spectinomycin</name>
      <description>Etanercept may decrease the excretion rate of Spectinomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Etanercept may decrease the excretion rate of Netilmicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Etanercept may decrease the excretion rate of Neomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>Etanercept may decrease the excretion rate of Doxorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Etanercept may decrease the excretion rate of Streptomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Etanercept may decrease the excretion rate of Kanamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>Etanercept may decrease the excretion rate of Idarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Etanercept may decrease the excretion rate of Paromomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01578</drugbank-id>
      <name>Metrizamide</name>
      <description>Etanercept may decrease the excretion rate of Metrizamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Etanercept may decrease the excretion rate of Ribostamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06810</drugbank-id>
      <name>Plicamycin</name>
      <description>Etanercept may decrease the excretion rate of Plicamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Etanercept may decrease the excretion rate of Puromycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Etanercept may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Etanercept may decrease the excretion rate of Hygromycin B which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11617</drugbank-id>
      <name>Aclarubicin</name>
      <description>Etanercept may decrease the excretion rate of Aclarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Etanercept may decrease the excretion rate of Sisomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00385</drugbank-id>
      <name>Valrubicin</name>
      <description>Etanercept may decrease the excretion rate of Valrubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Etanercept may decrease the excretion rate of Geneticin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Etanercept may decrease the excretion rate of Apramycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>GENTAMICIN C1A</name>
      <description>Etanercept may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Etanercept may decrease the excretion rate of Neamine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04978</drugbank-id>
      <name>SP1049C</name>
      <description>Etanercept may decrease the excretion rate of SP1049C which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>INNO-206</name>
      <description>Etanercept may decrease the excretion rate of INNO-206 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06263</drugbank-id>
      <name>Amrubicin</name>
      <description>Etanercept may decrease the excretion rate of Amrubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>annamycin</name>
      <description>Etanercept may decrease the excretion rate of annamycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Etanercept may decrease the excretion rate of Arbekacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>Etanercept may decrease the excretion rate of Pirarubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11618</drugbank-id>
      <name>Zorubicin</name>
      <description>Etanercept may decrease the excretion rate of Zorubicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>Etanercept may decrease the antihypertensive activities of Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic Acid</name>
      <description>Etanercept may increase the neuroexcitatory activities of Nalidixic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Etanercept may increase the neuroexcitatory activities of Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Etanercept may increase the neuroexcitatory activities of Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Etanercept may increase the hyperkalemic activities of Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Etanercept may decrease the antihypertensive activities of Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Etanercept may decrease the antihypertensive activities of Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The serum concentration of Pralatrexate can be increased when it is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The serum concentration of Etanercept can be increased when it is combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>The serum concentration of Vancomycin can be increased when it is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Polythiazide can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The therapeutic efficacy of Quinethazone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Etanercept may increase the nephrotoxic activities of Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Etanercept may increase the nephrotoxic activities of Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Etanercept may increase the nephrotoxic activities of Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Etanercept may increase the nephrotoxic activities of Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00630</drugbank-id>
      <name>Alendronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Alendronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00720</drugbank-id>
      <name>Clodronic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Clodronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00884</drugbank-id>
      <name>Risedronate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01077</drugbank-id>
      <name>Etidronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Etidronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09138</drugbank-id>
      <name>Technetium Tc-99m medronate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Technetium Tc-99m Medronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Pamidronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tiludronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09411</drugbank-id>
      <name>Technetium Tc-99m etidronate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Technetium tc 99m etidronate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic Acid</name>
      <description>The therapeutic efficacy of Folic Acid can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00287</drugbank-id>
      <name>Travoprost</name>
      <description>The therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00429</drugbank-id>
      <name>Carboprost Tromethamine</name>
      <description>The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>The therapeutic efficacy of Alprostadil can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00905</drugbank-id>
      <name>Bimatoprost</name>
      <description>The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00929</drugbank-id>
      <name>Misoprostol</name>
      <description>The therapeutic efficacy of Misoprostol can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>The therapeutic efficacy of Gemeprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12789</drugbank-id>
      <name>Dinoprost</name>
      <description>The therapeutic efficacy of Dinoprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12708</drugbank-id>
      <name>Sulprostone</name>
      <description>The therapeutic efficacy of Sulprostone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00654</drugbank-id>
      <name>Latanoprost</name>
      <description>The therapeutic efficacy of Latanoprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01160</drugbank-id>
      <name>Dinoprost Tromethamine</name>
      <description>The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02304</drugbank-id>
      <name>Prostaglandin B2</name>
      <description>The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03866</drugbank-id>
      <name>Prostaglandin G2</name>
      <description>The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The therapeutic efficacy of Beraprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06826</drugbank-id>
      <name>Unoprostone</name>
      <description>The therapeutic efficacy of Unoprostone can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08819</drugbank-id>
      <name>Tafluprost</name>
      <description>The therapeutic efficacy of Tafluprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The therapeutic efficacy of Limaprost can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11411</drugbank-id>
      <name>Fenprostalene</name>
      <description>The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11425</drugbank-id>
      <name>Luprostiol</name>
      <description>The therapeutic efficacy of Luprostiol can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11454</drugbank-id>
      <name>Prostalene</name>
      <description>The therapeutic efficacy of Prostalene can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11519</drugbank-id>
      <name>Fluprostenol</name>
      <description>The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Etanercept may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Etanercept may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Etanercept may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Etanercept may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Etanercept may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Etanercept may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Etanercept may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Etanercept may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Etanercept may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Etanercept may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Etanercept may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Etanercept may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Etanercept may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Etanercept may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Etanercept may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Etanercept may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Etanercept may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Etanercept may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Etanercept may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Etanercept may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Etanercept may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Etanercept may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Etanercept may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Etanercept may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Etanercept may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Etanercept may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Etanercept may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Etanercept may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Etanercept may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Etanercept may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Etanercept may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Etanercept may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Etanercept may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Etanercept may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Etanercept may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Etanercept may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Etanercept may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Etanercept may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Etanercept may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Etanercept may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Etanercept may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Etanercept may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Etanercept may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Etanercept may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Etanercept may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Etanercept may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Diflorasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Alclometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Medrysone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Amcinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Estrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Flumethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Flurandrenolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Rimexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Prednicarbate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01536</drugbank-id>
      <name>Androstenedione</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with 4-Androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01708</drugbank-id>
      <name>Prasterone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Prasterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02187</drugbank-id>
      <name>Equilin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Equilin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02789</drugbank-id>
      <name>Pregnenolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Pregnenolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03515</drugbank-id>
      <name>Equilenin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Equilenin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with dehydroepiandrosterone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06780</drugbank-id>
      <name>Desoxycorticosterone acetate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Difluprednate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone Propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone Acetonide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone Acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01134</drugbank-id>
      <name>Desoxycorticosterone Pivalate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone Pivalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01434</drugbank-id>
      <name>19-norandrostenedione</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01456</drugbank-id>
      <name>5-androstenedione</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with 5-androstenedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04870</drugbank-id>
      <name>Oleoyl-estrone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Oleoyl estrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05107</drugbank-id>
      <name>16-Bromoepiandrosterone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with 16-Bromoepiandrosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05212</drugbank-id>
      <name>HE3286</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with HE3286.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05402</drugbank-id>
      <name>ME-609</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with ME-609.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05410</drugbank-id>
      <name>NCX 1022</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with NCX 1022.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06157</drugbank-id>
      <name>Istaroxime</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Istaroxime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06250</drugbank-id>
      <name>fluasterone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with fluasterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Anecortave.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Masoprocol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Adapalene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Naftifine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Zileuton.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Bromfenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Trisalicylate-choline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with SRT501.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with PTC299.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with HMPL-004.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Icatibant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>exisulind</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with exisulind.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Seratrodast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Nepafenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>D-Limonene</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with D-Limonene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tolfenamic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Evening primrose oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Orgotein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E-6201</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with E6201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Duvelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Bucillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Lisofylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Apocynin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Acetovanillone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Higenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>Etanercept may increase the nephrotoxic activities of Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of adverse effects can be increased when Olmesartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01349</drugbank-id>
      <name>Tasosartan</name>
      <description>The risk or severity of adverse effects can be increased when Tasosartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of adverse effects can be increased when Saralasin is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01342</drugbank-id>
      <name>Forasartan</name>
      <description>The risk or severity of adverse effects can be increased when Forasartan is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The risk or severity of adverse effects can be increased when Sacubitril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of adverse effects can be increased when Ramipril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of adverse effects can be increased when Trandolapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of adverse effects can be increased when Benazepril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of adverse effects can be increased when Enalapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of adverse effects can be increased when Lisinopril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of adverse effects can be increased when Perindopril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of adverse effects can be increased when Omapatrilat is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of adverse effects can be increased when Captopril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of adverse effects can be increased when Spirapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of adverse effects can be increased when Temocapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The risk or severity of adverse effects can be increased when Candoxatril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of adverse effects can be increased when Imidapril is combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Etanercept may decrease the antihypertensive activities of Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Etanercept may decrease the antihypertensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Etanercept may decrease the antihypertensive activities of Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Etanercept may decrease the antihypertensive activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Carteolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Etanercept may decrease the antihypertensive activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Etanercept may decrease the antihypertensive activities of Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01210</drugbank-id>
      <name>Levobunolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Levobunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01214</drugbank-id>
      <name>Metipranolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Metipranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Aop200704.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Etanercept may decrease the antihypertensive activities of Bucindolol.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt; Etanercept Sequence
LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDST
YTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRK
CRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTS
TSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSC
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.529</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.89</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>51234.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2224H3475N621O698S36</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07897</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00742</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M32315</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449515</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P20333</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000605</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Etanercept</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201572</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/etanercept.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/etanercept.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000704</id>
      <name>Tumor necrosis factor</name>
      <organism>Human</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10206649</pubmed-id>
            <citation>Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8.</citation>
          </article>
          <article>
            <pubmed-id>10338381</pubmed-id>
            <citation>Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33.</citation>
          </article>
          <article>
            <pubmed-id>10357816</pubmed-id>
            <citation>Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43.</citation>
          </article>
          <article>
            <pubmed-id>10375846</pubmed-id>
            <citation>Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74.</citation>
          </article>
          <article>
            <pubmed-id>10405518</pubmed-id>
            <citation>Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01375" source="Swiss-Prot">
    <name>Tumor necrosis factor</name>
    <general-function>Tumor necrosis factor receptor binding</general-function>
    <specific-function>Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.</specific-function>
    <gene-name>TNF</gene-name>
    <locus>6p21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>36-56</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.92</theoretical-pi>
    <molecular-weight>25644.15</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11892</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>TNF</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M16441</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339741</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2635</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01375</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TNFA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Cachectin</synonym>
      <synonym>TNF-a</synonym>
      <synonym>TNF-alpha</synonym>
      <synonym>TNFA</synonym>
      <synonym>TNFSF2</synonym>
      <synonym>Tumor necrosis factor ligand superfamily member 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001404|Tumor necrosis factor
MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR
EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR
DNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE
TPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021837|Tumor necrosis factor (TNF)
ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG
ACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC
GTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG
GAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT
TCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG
CAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA
GATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC
AAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC
GTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG
ACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC
CAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT
GCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00229</identifier>
        <name>TNF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>phagocytic cup</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>recycling endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>tumor necrosis factor receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transcription regulatory region DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein complex disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB transcription factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chemokine biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sequestering of triglyceride</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NIK/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein localization to cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway in absence of ligand</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to amino acid stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NFAT protein import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of membrane protein ectodomain proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tumor necrosis factor-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>humoral immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of hair follicle development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of glucose import</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of branching involved in lung morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>osteoclast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ceramide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vitamin D biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chronic inflammatory response to antigenic stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>necroptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein complex disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of osteoclast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of podosome assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of lipid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of humoral immune response mediated by circulating immunoglobulin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JNK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of branching involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of JUN kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>death-inducing signaling complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chemokine (C-X-C motif) ligand 2 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fever generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mononuclear cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte tethering or rolling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chemokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of sequence-specific DNA binding transcription factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of myoblast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intrinsic apoptotic signaling pathway in response to DNA damage</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cortical actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-positive bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptidyl-serine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of osteoblast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of programmed cell death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immunoglobulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic cyclic compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>establishment of protein localization to plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of interleukin-6 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to salt stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of growth of symbiont in host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronic inflammatory response to antigenic stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipopolysaccharide-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of alkaline phosphatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of bicellular tight junction assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of viral genome replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transformed cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cytokine secretion involved in immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to nicotine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of myosin-light-chain-phosphatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>I-kappaB kinase/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of lipid storage</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of establishment of endothelial barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of translational initiation by iron</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial cell proliferation involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of tumor necrosis factor-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heterotypic cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of calcidiol 1-monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-6 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of I-kappaB kinase/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic digestive tract development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein import into nucleus, translocation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000949</id>
      <name>Tumor necrosis factor receptor superfamily member 1B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20333" source="Swiss-Prot">
    <name>Tumor necrosis factor receptor superfamily member 1B</name>
    <general-function>Ubiquitin protein ligase binding</general-function>
    <specific-function>Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.</specific-function>
    <gene-name>TNFRSF1B</gene-name>
    <locus>1p36.3-p36.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>258-287</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.22</theoretical-pi>
    <molecular-weight>48290.85</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11917</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>TNFRSF1B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M32315</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189186</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P20333</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TNR1B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>p75</synonym>
      <synonym>p80 TNF-alpha receptor</synonym>
      <synonym>TNF-R2</synonym>
      <synonym>TNF-RII</synonym>
      <synonym>TNFBR</synonym>
      <synonym>TNFR-II</synonym>
      <synonym>TNFR2</synonym>
      <synonym>Tumor necrosis factor receptor 2</synonym>
      <synonym>Tumor necrosis factor receptor type II</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001890|Tumor necrosis factor receptor superfamily member 1B
MAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPG
QHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTC
RPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICR
PHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTS
FLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKV
PHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGE
ARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQ
VPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016265|Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B)
ATGGCGCCCGTCGCCGTCTGGGCCGCGCTGGCCGTCGGACTGGAGCTCTGGGCTGCGGCG
CACGCCTTGCCCGCCCAGGTGGCATTTACACCCTACGCCCCGGAGCCCGGGAGCACATGC
CGGCTCAGAGAATACTATGACCAGACAGCTCAGATGTGCTGCAGCAAATGCTCGCCGGGC
CAACATGCAAAAGTCTTCTGTACCAAGACCTCGGACACCGTGTGTGACTCCTGTGAGGAC
AGCACATACACCCAGCTCTGGAACTGGGTTCCCGAGTGCTTGAGCTGTGGCTCCCGCTGT
AGCTCTGACCAGGTGGAAACTCAAGCCTGCACTCGGGAACAGAACCGCATCTGCACCTGC
AGGCCCGGCTGGTACTGCGCGCTGAGCAAGCAGGAGGGGTGCCGGCTGTGCGCGCCGCTG
CGCAAGTGCCGCCCGGGCTTCGGCGTGGCCAGACCAGGAACTGAAACATCAGACGTGGTG
TGCAAGCCCTGTGCCCCGGGGACGTTCTCCAACACGACTTCATCCACGGATATTTGCAGG
CCCCACCAGATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGCAGTCTGC
ACGTCCACGTCCCCCACCCGGAGTATGGCCCCAGGGGCAGTACACTTACCCCAGCCAGTG
TCCACACGATCCCAACACACGCAGCCAACTCCAGAACCCAGCACTGCTCCAAGCACCTCC
TTCCTGCTCCCAATGGGCCCCAGCCCCCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTT
CCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAAC
TGTGTCATCATGACCCAGGTGAAAAAGAAGCCCTTGTGCCTGCAGAGAGAAGCCAAGGTG
CCTCACTTGCCTGCCGATAAGGCCCGGGGTACACAGGGCCCCGAGCAGCAGCACCTGCTG
ATCACAGCGCCGAGCTCCAGCAGCAGCTCCCTGGAGAGCTCGGCCAGTGCGTTGGACAGA
AGGGCGCCCACTCGGAACCAGCCACAGGCACCAGGCGTGGAGGCCAGTGGGGCCGGGGAG
GCCCGGGCCAGCACCGGGAGCTCAGATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAAT
GTCACCTGCATCGTGAACGTCTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAA
GCCAGCTCCACAATGGGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGAGCAG
GTCCCCTTCTCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCAGAGACCCTG
CTGGGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGATGCTGGGATGAAGCCC
AGTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00020</identifier>
        <name>TNFR_c6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>varicosity</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>tumor necrosis factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>RNA destabilization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intrinsic apoptotic signaling pathway in response to DNA damage</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tumor necrosis factor-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of membrane protein ectodomain proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000710</id>
      <name>High affinity immunoglobulin gamma Fc receptor I</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12314" source="Swiss-Prot">
    <name>High affinity immunoglobulin gamma Fc receptor I</name>
    <general-function>Receptor signaling protein activity</general-function>
    <specific-function>High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.</specific-function>
    <gene-name>FCGR1A</gene-name>
    <locus>1q21.2-q21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>293-313</transmembrane-regions>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>8.08</theoretical-pi>
    <molecular-weight>42631.525</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3613</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X14356</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31332</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12314</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCGR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-gamma RI</synonym>
      <synonym>Fc-gamma RIA</synonym>
      <synonym>FCG1</synonym>
      <synonym>FcgammaRIa</synonym>
      <synonym>FCGR1</synonym>
      <synonym>FcRI</synonym>
      <synonym>IGFR1</synonym>
      <synonym>IgG Fc receptor I</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phagocytosis, engulfment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002097</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15457442</pubmed-id>
            <citation>Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.</citation>
          </article>
          <article>
            <pubmed-id>15526004</pubmed-id>
            <citation>Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08637" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.</specific-function>
    <gene-name>FCGR3A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>209-229</transmembrane-regions>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>8.21</theoretical-pi>
    <molecular-weight>29088.895</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3619</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X52645</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16A</synonym>
      <synonym>CD16a antigen</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-alpha</synonym>
      <synonym>Fc-gamma RIIIa</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIa</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT
TTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG
CTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA
AAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT
CTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG
AGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT
GGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC
CATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT
GGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC
AAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG
ACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA
CCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA
CTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA
TTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0002098</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15457442</pubmed-id>
            <citation>Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.</citation>
          </article>
          <article>
            <pubmed-id>15526004</pubmed-id>
            <citation>Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P12318" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
    <general-function/>
    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.</specific-function>
    <gene-name>FCGR2A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-33</signal-regions>
    <theoretical-pi>6.78</theoretical-pi>
    <molecular-weight>35000.42</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3616</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M31932</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182474</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-a</synonym>
      <synonym>Fc-gamma-RIIa</synonym>
      <synonym>FCG2</synonym>
      <synonym>FCGR2A1</synonym>
      <synonym>FcRII-a</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-a</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a
MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS
HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
KNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)
ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
AAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002099</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31994" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.</specific-function>
    <gene-name>FCGR2B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.12</theoretical-pi>
    <molecular-weight>34043.355</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3618</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U87560</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4099445</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31994</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-b</synonym>
      <synonym>Fc-gamma-RIIb</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-b</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-b</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG
CTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC
ATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC
AAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC
GACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG
TTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC
AAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC
TCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC
TACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG
ATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA
GTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG
GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
CTGGAAGAGCCTGATGACCAGAACCGTATTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002100</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10800083</pubmed-id>
            <citation>Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.</citation>
          </article>
          <article>
            <pubmed-id>7535196</pubmed-id>
            <citation>Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31995" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.</specific-function>
    <gene-name>FCGR2C</gene-name>
    <locus>1q23.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions>224-246</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.9</theoretical-pi>
    <molecular-weight>35577.96</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X17652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>32074</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31995</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-c</synonym>
      <synonym>Fc-gamma-RIIc</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-c</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
GTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
TCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
GCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC
AGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0001087</id>
      <name>Lymphotoxin-alpha</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11302411</pubmed-id>
            <citation>Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71.</citation>
          </article>
          <article>
            <pubmed-id>1328224</pubmed-id>
            <citation>Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV: Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992 Oct 15;267(29):21172-8.</citation>
          </article>
          <article>
            <pubmed-id>15005015</pubmed-id>
            <citation>Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24.</citation>
          </article>
          <article>
            <pubmed-id>15033655</pubmed-id>
            <citation>Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19.</citation>
          </article>
          <article>
            <pubmed-id>15695296</pubmed-id>
            <citation>Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P01374" source="Swiss-Prot">
    <name>Lymphotoxin-alpha</name>
    <general-function>Receptor binding</general-function>
    <specific-function>Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.</specific-function>
    <gene-name>LTA</gene-name>
    <locus>6p21.3</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-34</signal-regions>
    <theoretical-pi>9.36</theoretical-pi>
    <molecular-weight>22296.57</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6709</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LTA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X01393</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>34445</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01374</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TNFB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>LT-alpha</synonym>
      <synonym>TNF-beta</synonym>
      <synonym>TNFB</synonym>
      <synonym>TNFSF1</synonym>
      <synonym>Tumor necrosis factor ligand superfamily member 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010761|Lymphotoxin-alpha
MTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST
LKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY
SPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ
LSTHTDGIPHLVLSPSTVFFGAFAL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010762|Lymphotoxin-alpha (LTA)
ATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC
CTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC
ACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC
CTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA
GCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG
GTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC
TCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC
CAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG
GAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG
CTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT
GGAGCCTTCGCTCTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00229</identifier>
        <name>TNF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of growth of symbiont in host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tumor necrosis factor-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>humoral immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-positive bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lymph node development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chronic inflammatory response to antigenic stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of humoral immune response mediated by circulating immunoglobulin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nutrient</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0000901</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10800083</pubmed-id>
            <citation>Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.</citation>
          </article>
          <article>
            <pubmed-id>17387033</pubmed-id>
            <citation>Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5.</citation>
          </article>
          <article>
            <pubmed-id>15457442</pubmed-id>
            <citation>Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.</citation>
          </article>
          <article>
            <pubmed-id>15526004</pubmed-id>
            <citation>Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O75015" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.</specific-function>
    <gene-name>FCGR3B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>6.71</theoretical-pi>
    <molecular-weight>26215.64</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3620</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X16863</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31322</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O75015</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16B</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-beta</synonym>
      <synonym>Fc-gamma RIIIb</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIb</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)
ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
TTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of defense response to virus by host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitophagy in response to mitochondrial depolarization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0001529</id>
      <name>Complement C1s subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P09871" source="Swiss-Prot">
    <name>Complement C1s subcomponent</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.</specific-function>
    <gene-name>C1S</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>4.59</theoretical-pi>
    <molecular-weight>76683.905</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1S</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X06596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>763110</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2335</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P09871</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1S_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.42</synonym>
      <synonym>C1 esterase</synonym>
      <synonym>Complement component 1 subcomponent s</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011082|Complement C1s subcomponent
MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011083|Complement C1s subcomponent (C1S)
ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002093</id>
      <name>Complement C1r subcomponent</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00736" source="Swiss-Prot">
    <name>Complement C1r subcomponent</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.</specific-function>
    <gene-name>C1R</gene-name>
    <locus>12p13</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>6.24</theoretical-pi>
    <molecular-weight>80118.04</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1246</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04701</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29539</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2334</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00736</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.41</synonym>
      <synonym>Complement component 1 subcomponent r</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011518|Complement C1r subcomponent
MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
ELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011519|Complement C1r subcomponent (C1R)
ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
ATGGAGGAGGAGGACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0002094</id>
      <name>Complement C1q subcomponent subunit A</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02745" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit A</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QA</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>9.45</theoretical-pi>
    <molecular-weight>26016.47</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1241</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF135157</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4894854</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02745</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit A precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016678|Complement C1q subcomponent subunit A
MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
IFPSA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)
ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA
GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
ATCTTCCCATCTGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="13">
      <id>BE0002095</id>
      <name>Complement C1q subcomponent subunit B</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02746" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit B</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QB</gene-name>
    <locus>1p36.12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>8.87</theoretical-pi>
    <molecular-weight>26721.62</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1242</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X03084</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>573114</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Complement C1q subcomponent subunit B precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016676|Complement C1q subcomponent subunit B
MMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG
EKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ
KIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL
CVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS
IFSGFLLFPDMEA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)
ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC
CTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC
CCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA
GAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA
GGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC
CCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG
AAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC
CGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC
ACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG
TGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT
GCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG
AACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC
ATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>complement component C1 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="14">
      <id>BE0002096</id>
      <name>Complement C1q subcomponent subunit C</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02747" source="Swiss-Prot">
    <name>Complement C1q subcomponent subunit C</name>
    <general-function/>
    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.</specific-function>
    <gene-name>C1QC</gene-name>
    <locus>1p36.11</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>25773.56</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1245</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C1QC</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF087892</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33150626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>C1QC_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C1QG</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011520|Complement C1q subcomponent subunit C
MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
LLFPD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)
ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
CTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
CCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
AACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC
AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
CTGCTCTTCCCCGACTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01391</identifier>
        <name>Collagen</name>
      </pfam>
      <pfam>
        <identifier>PF00386</identifier>
        <name>C1q</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>collagen trimer</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of macrophage differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of granulocyte differentiation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="15">
      <id>BE0000262</id>
      <name>Prostaglandin G/H synthase 2</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17931716</pubmed-id>
            <citation>Bawolak MT, Touzin K, Moreau ME, Desormeaux A, Adam A, Marceau F: Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept. 2008 Feb 7;146(1-3):157-68. Epub 2007 Sep 14.</citation>
          </article>
          <article>
            <pubmed-id>16303916</pubmed-id>
            <citation>Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, Cuzzocrea S: Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16. Epub 2005 Nov 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35354" source="Swiss-Prot">
    <name>Prostaglandin G/H synthase 2</name>
    <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
    <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.</specific-function>
    <gene-name>PTGS2</gene-name>
    <locus>1q25.2-q25.3</locus>
    <cellular-location>Microsome membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>7.41</theoretical-pi>
    <molecular-weight>68995.625</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PTGS2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L15326</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>291988</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1376</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35354</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PGH2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.99.1</synonym>
      <synonym>COX-2</synonym>
      <synonym>COX2</synonym>
      <synonym>Cyclooxygenase-2</synonym>
      <synonym>PGH synthase 2</synonym>
      <synonym>PGHS-2</synonym>
      <synonym>PHS II</synonym>
      <synonym>Prostaglandin H2 synthase 2</synonym>
      <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021832|Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03098</identifier>
        <name>An_peroxidase</name>
      </pfam>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peroxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>prostaglandin-endoperoxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonate 15-lipoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryo implantation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fructose</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lithium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to UV</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fatty acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fever generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to fluid shear stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vascular endothelial growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of blood-brain barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to ATP</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to tumor necrosis factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to oxidative stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to vitamin D</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transforming growth factor beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>decidualization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to manganese ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nicotinamide metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>NAD metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cyclooxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of platelet-derived growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water-soluble vitamin metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="small molecule" created="2005-06-13" updated="2017-09-01">
  <drugbank-id primary="true">DB00006</drugbank-id>
  <drugbank-id>BTD00076</drugbank-id>
  <drugbank-id>EXPT03302</drugbank-id>
  <drugbank-id>BIOD00076</drugbank-id>
  <drugbank-id>DB02351</drugbank-id>
  <name>Bivalirudin</name>
  <description>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.</description>
  <cas-number>128270-60-0</cas-number>
  <unii>TN9BEX005G</unii>
  <average-mass>2180.2853</average-mass>
  <monoisotopic-mass>2178.985813062</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>16466327</pubmed-id>
        <citation>Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41.</citation>
      </article>
      <article>
        <pubmed-id>17381384</pubmed-id>
        <citation>Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87.</citation>
      </article>
      <article>
        <pubmed-id>16553503</pubmed-id>
        <citation>Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8.</citation>
      </article>
      <article>
        <pubmed-id>11156732</pubmed-id>
        <citation>Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6.</citation>
      </article>
      <article>
        <pubmed-id>21108549</pubmed-id>
        <citation>Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. doi: 10.1586/erc.10.158.</citation>
      </article>
      <article>
        <pubmed-id>16614733</pubmed-id>
        <citation>Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60.</citation>
      </article>
      <article>
        <pubmed-id>12851152</pubmed-id>
        <citation>Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, "Process for production of Bivalirudin." U.S. Patent US20070093423, issued April 26, 2007.</synthesis-reference>
  <indication>For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.</indication>
  <pharmacodynamics>Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. </pharmacodynamics>
  <mechanism-of-action>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</mechanism-of-action>
  <toxicity>Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</toxicity>
  <metabolism>80% proteolytic cleavage</metabolism>
  <absorption>Following intravenous administration, bivalirudin exhibits linear pharmacokinetics.  The mean steady state concentration is 12.3 +/- 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</absorption>
  <half-life>* Normal renal function: 25 min (in normal conditions)&#13;
* Creatinine clearance 10-29mL/min: 57min&#13;
* Dialysis-dependant patients: 3.5h</half-life>
  <protein-binding>Other than thrombin and red blood cells, bivalirudin does not bind to plasma proteins.</protein-binding>
  <route-of-elimination>Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</route-of-elimination>
  <volume-of-distribution>0.2L/kg</volume-of-distribution>
  <clearance>* 3.4 mL/min/kg [Normal renal function]&#13;
* 3.4 mL/min/kg [mild renal function]&#13;
* 2.7 mL/min/kg [moderate renal function]&#13;
* 2.8 mL/min/kg [severe renal function]&#13;
* 1 mL/min/kg [Dialysis-dependent patients]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.</description>
    <direct-parent>Polypeptides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic Polymers</superclass>
    <class>Polypeptides</class>
    <subclass/>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Amphetamines and derivatives</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Asparagine and derivatives</alternative-parent>
    <alternative-parent>Aspartic acid and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Glutamic acid and derivatives</alternative-parent>
    <alternative-parent>Guanidines</alternative-parent>
    <alternative-parent>Hexacarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imines</alternative-parent>
    <alternative-parent>Isoleucine and derivatives</alternative-parent>
    <alternative-parent>Leucine and derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>N-acyl-L-alpha-amino acids</alternative-parent>
    <alternative-parent>N-acylpyrrolidines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Peptides</alternative-parent>
    <alternative-parent>Phenylalanine and derivatives</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Proline and derivatives</alternative-parent>
    <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tyrosine and derivatives</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Alpha peptide</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Amphetamine or derivatives</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Asparagine or derivatives</substituent>
    <substituent>Aspartic acid or derivatives</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Glutamic acid or derivatives</substituent>
    <substituent>Guanidine</substituent>
    <substituent>Hexacarboxylic acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imine</substituent>
    <substituent>Isoleucine or derivatives</substituent>
    <substituent>Leucine or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-alpha-amino acid</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>N-acyl-l-alpha-amino acid</substituent>
    <substituent>N-acylpyrrolidine</substituent>
    <substituent>N-substituted-alpha-amino acid</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenylalanine or derivatives</substituent>
    <substituent>Polypeptide</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Proline or derivatives</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
    <substituent>Pyrrolidine-2-carboxamide</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Tyrosine or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="Spanish" coder="">Bivalirudina</synonym>
    <synonym language="Latin" coder="">Bivalirudinum</synonym>
    <synonym language="" coder="">Hirulog</synonym>
  </synonyms>
  <products>
    <product>
      <name>Angiomax</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246533</dpd-id>
      <started-marketing-on>2003-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Angiomax</name>
      <labeller>The Medicines Company</labeller>
      <ndc-id/>
      <ndc-product-code>65293-001</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020873</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Angiomax</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2275</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020873</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-9158</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-10-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020873</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-562</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA090189</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-8300</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-07-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA090816</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02450402</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>55111-652</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-05-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intracavernous</route>
      <fda-application-number>ANDA201577</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-3158</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-06-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020873</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Sagent Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>25021-405</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA091602</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-6101</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>250 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA204876</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivalirudin for Injection</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02435268</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Angiox</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Angiomax</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin for Injection</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Angiomax</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Angiomax</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
    <mixture>
      <name>Bivalirudin</name>
      <ingredients>Bivalirudin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>Oryx Pharmaceuticals Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Sepracor Pharmaceuticals Inc.</name>
      <url>http://www.sepracor.com</url>
    </packager>
    <packager>
      <name>The Medicines Co.</name>
      <url>http://www.themedicinescompany.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">The medicines co</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Angiomax 250 mg vial</description>
      <cost currency="USD">780.0</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Antithrombin Proteins</category>
      <mesh-id>D058833</mesh-id>
    </category>
    <category>
      <category>Antithrombins</category>
      <mesh-id>D000991</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Proteinase Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>Serpins</category>
      <mesh-id>D015843</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>250 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intracavernous</route>
      <strength>250 mg/1</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AE06">
      <level code="B01AE">Direct thrombin inhibitors</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.04.12</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2HGT</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00006.pdf?1265922803</fda-label>
  <patents>
    <patent>
      <number>5196404</number>
      <country>United States</country>
      <approved>1993-05-23</approved>
      <expires>2010-05-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2065150</number>
      <country>Canada</country>
      <approved>1999-12-14</approved>
      <expires>2010-08-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7598343</number>
      <country>United States</country>
      <approved>2009-01-27</approved>
      <expires>2029-01-27</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7582727</number>
      <country>United States</country>
      <approved>2009-01-27</approved>
      <expires>2029-01-27</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark</food-interaction>
    <food-interaction>Echinacea</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Bivalirudin can be increased when combined with St. John&amp;#39;s Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The serum concentration of Cisapride can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Edoxaban may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Bivalirudin may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Lovastatin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Urokinase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of adverse effects can be increased when Vorapaxar is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Bivalirudin can be decreased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Cabergoline can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergonovine</name>
      <description>The serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The serum concentration of Triazolam can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The serum concentration of Mestranol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Estrone sulfate can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Estrogens, esterified</name>
      <description>The serum concentration of Estrogens, esterified can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>The serum concentration of Chlorotrianisene can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Estramustine can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00890</drugbank-id>
      <name>Dienestrol</name>
      <description>The serum concentration of Dienestrol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>The serum concentration of Hexestrol can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>The serum concentration of Methallenestril can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10532</drugbank-id>
      <name>Garlic</name>
      <description>The serum concentration of Bivalirudin can be decreased when it is combined with Garlic.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The metabolism of Tacrolimus can be decreased when combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Bivalirudin can be decreased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Bivalirudin can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Delavirdine can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>Genistein may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>Estriol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06401</drugbank-id>
      <name>Bazedoxifene</name>
      <description>Bazedoxifene may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>S Equol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12179</drugbank-id>
      <name>Secoisolariciresinol</name>
      <description>Secoisolariciresinol may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dydrogesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Allylestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Altrenogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestrinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Nomegestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Lynestrenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The serum concentration of Riociguat can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The serum concentration of Rosuvastatin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Diltiazem can be decreased when combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be decreased when combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Pentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Desipramine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The serum concentration of Amineptine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The serum concentration of Esmirtazapine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The serum concentration of Dosulepin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The serum concentration of Tianeptine can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The serum concentration of Opipramol can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>The serum concentration of Abacavir can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00109</drugbank-id>
      <name>Enfuvirtide</name>
      <description>The serum concentration of Enfuvirtide can be increased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The serum concentration of Etravirine can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>Sugammadex may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>Etanercept may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>Masoprocol may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>Adapalene may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>Indomethacin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>Pimecrolimus may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>Nabumetone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>Ketorolac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>Tenoxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>Celecoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>Tolmetin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>Rofecoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>Piroxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>Fenoprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>Valdecoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>Diclofenac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>Sulindac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Chloroquine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>Mycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>Flurbiprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>Naftifine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>Zileuton may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>Etodolac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>Olopatadine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>Mefenamic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>Naproxen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>Phenylbutazone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>Meloxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>Suprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>Meclofenamic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>Bromfenac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>Oxaprozin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>Ketoprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>Ibuprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>Leflunomide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>Lumiracoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>Magnesium salicylate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>Salsalate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>Trisalicylate-choline may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>Antipyrine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>Etoricoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>Oxyphenbutazone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>Niflumic Acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>Benoxaprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>Metamizole may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>Zomepirac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>Pirfenidone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>PTC299 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Apremilast may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>HMPL-004 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Icatibant may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>exisulind</name>
      <description>exisulind may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>Lornoxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>Aceclofenac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>Zaltoprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>Seratrodast may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>Nepafenac may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>Azapropazone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>Parecoxib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>Salicylamide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>Teriflunomide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>D-Limonene</name>
      <description>D-Limonene may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>Kebuzone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>Isoxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>Indoprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>Ibuproxam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>Floctafenine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>Fenbufen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>Etofenamate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>Epirizole may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>Loxoprofen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>Droxicam may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>Tolfenamic Acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>Clonixin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Evening primrose oil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>Orgotein may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>Tepoxalin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>Flunixin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>Curcumin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E-6201</name>
      <description>E6201 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>Duvelisib may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>Bucillamine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>Lisofylline may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>Betulinic Acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>Ebselen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Apocynin</name>
      <description>Acetovanillone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>Higenamine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>Tinoridine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Nafamostat may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>Mizoribine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Lepirudin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Bivalirudin may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Bivalirudin may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Bivalirudin may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Bivalirudin may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Bivalirudin may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Bivalirudin may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Bivalirudin may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Bivalirudin may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Bivalirudin may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Bivalirudin may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Bivalirudin may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Bivalirudin may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Bivalirudin may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Bivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Bivalirudin may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Bivalirudin may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Bivalirudin may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Bivalirudin may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Bivalirudin may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Bivalirudin may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Bivalirudin may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Bivalirudin may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Bivalirudin may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Bivalirudin may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Bivalirudin may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>Aminosalicylic Acid may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>dersalazine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Alteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Reteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Anistreplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Tenecteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Streptokinase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Desmoteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Plasmin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>ALX-0081</name>
      <description>ALX-0081 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Astaxanthin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Tinzaparin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09005</drugbank-id>
      <name>Batroxobin</name>
      <description>Batroxobin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>Ticagrelor may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Ditazole may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Bemiparin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Parnaparin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>Selexipag may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12017</drugbank-id>
      <name>Ozagrel</name>
      <description>Kct 0809 may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The serum concentration of Dyphylline can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic Acid</name>
      <description>The serum concentration of Valproic Acid can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be decreased when it is combined with Bivalirudin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.76</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.64e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-(2-{2-[2-(2-{[(2S)-1-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetamido)acetamido]acetamido}acetamido)-3-carbamoylpropanamido]acetamido}-3-carboxypropanamido]-3-phenylpropanamido]-4-carboxybutanamido]-4-{[(2S,3S)-1-[(2S)-2-{[(1S)-3-carboxy-1-{[(1S)-3-carboxy-1-{[(1S)-1-{[(1S)-1-carboxy-3-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl}butanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>bivalirudin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>2180.2853</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>2178.985813062</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C98H138N24O33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OIRCOABEOLEUMC-GEJPAHFPSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>901.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>543.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>215.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>66</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>28</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>2.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>11.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12945</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>59173</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03136</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10482069</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000542</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Bivalirudin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2103749</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/angiomax.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/bivalirudin.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00277</smpdb-id>
      <name>Bivalirudin Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00006</drugbank-id>
          <name>Bivalirudin</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000048</id>
      <name>Prothrombin</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11060732</pubmed-id>
            <citation>Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27.</citation>
          </article>
          <article>
            <pubmed-id>11504570</pubmed-id>
            <citation>Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54.</citation>
          </article>
          <article>
            <pubmed-id>11833835</pubmed-id>
            <citation>Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58.</citation>
          </article>
          <article>
            <pubmed-id>11923794</pubmed-id>
            <citation>Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93.</citation>
          </article>
          <article>
            <pubmed-id>11929334</pubmed-id>
            <citation>Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00734" source="Swiss-Prot">
    <name>Prothrombin</name>
    <general-function>Thrombospondin receptor activity</general-function>
    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>
    <gene-name>F2</gene-name>
    <locus>11p11-q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>5.7</theoretical-pi>
    <molecular-weight>70036.295</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3535</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M17262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339641</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00734</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>THRB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.5</synonym>
      <synonym>Coagulation factor II</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016004|Prothrombin
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016005|Prothrombin (F2)
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF09396</identifier>
        <name>Thrombin_light</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thrombospondin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to wounding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of collagen biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytosolic calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of astrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell shape</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0001075</id>
      <name>Myeloperoxidase</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>18701766</pubmed-id>
            <citation>Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. doi: 10.1124/jpet.108.142414. Epub  2008 Aug 13.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05164" source="Swiss-Prot">
    <name>Myeloperoxidase</name>
    <general-function>Peroxidase activity</general-function>
    <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.</specific-function>
    <gene-name>MPO</gene-name>
    <locus>17q23.1</locus>
    <cellular-location>Lysosome</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-48</signal-regions>
    <theoretical-pi>9.14</theoretical-pi>
    <molecular-weight>83867.71</molecular-weight>
    <chromosome-location>17</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:7218</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>MPO</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02694</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189040</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2789</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05164</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PERM_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.11.2.2</synonym>
      <synonym>MPO</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002139|Myeloperoxidase
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016304|Myeloperoxidase (MPO)
ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
TGGAGGGAAGCCTCCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03098</identifier>
        <name>An_peroxidase</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>azurophil granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peroxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chromatin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hypochlorous acid biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>low-density lipoprotein particle remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to oxidative stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>removal of superoxide radicals</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hydrogen peroxide catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of growth of symbiont in host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to yeast</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to fungus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>respiratory burst involved in defense response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-08-08">
  <drugbank-id primary="true">DB00007</drugbank-id>
  <drugbank-id>BTD00009</drugbank-id>
  <drugbank-id>BIOD00009</drugbank-id>
  <name>Leuprolide</name>
  <description>Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.</description>
  <cas-number>53714-56-0</cas-number>
  <unii>EFY6W0M8TG</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>15568711</pubmed-id>
        <citation>Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8.</citation>
      </article>
      <article>
        <pubmed-id>15780490</pubmed-id>
        <citation>Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54.</citation>
      </article>
      <article>
        <pubmed-id>16370917</pubmed-id>
        <citation>Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Link</title>
        <url>http://www.freepatentsonline.com/EP1790656.html</url>
      </link>
      <link>
        <title>RxMed</title>
        <url>http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference>Daniel Kadzimirzs, Gerhard Jas, Volker Autze, "Solution-Phase Synthesis of Leuprolide and Its Intermediates." U.S. Patent US20090005535, issued January 01, 2009.</synthesis-reference>
  <indication>For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty</indication>
  <pharmacodynamics>Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.</pharmacodynamics>
  <mechanism-of-action>Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.</mechanism-of-action>
  <toxicity>In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</toxicity>
  <metabolism>Primarily degraded by peptidase and not by cytochrome P450 enzymes.</metabolism>
  <absorption>Bioavailability by subcutaneous administration is comparable to that by intravenous administration.</absorption>
  <half-life>~3 hours</half-life>
  <protein-binding>43% to 49%</protein-binding>
  <route-of-elimination>Excretion in urine</route-of-elimination>
  <volume-of-distribution>* 27 L [intravenous bolus administration to healthy male volunteers]</volume-of-distribution>
  <clearance>* 8.34 L/h [healthy male receiving a 1-mg IV bolus]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000105</drugbank-id>
      <name>Leuprolide acetate</name>
      <unii>37JNS02E7V</unii>
      <cas-number>74381-53-6</cas-number>
      <inchikey>RGLRXNKKBLIBQS-XNHQSDQCSA-N</inchikey>
    </salt>
  </salts>
  <synonyms>
    <synonym language="" coder="">(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone</synonym>
    <synonym language="" coder="">L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide</synonym>
    <synonym language="" coder="">Leuprorelin</synonym>
    <synonym language="" coder="">Leuprorelina</synonym>
    <synonym language="" coder="">Leuproreline</synonym>
    <synonym language="" coder="">Leuprorelinum</synonym>
    <synonym language="" coder="">PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5</synonym>
    <synonym language="" coder="">PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet</synonym>
  </synonyms>
  <products>
    <product>
      <name>Eligard</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-0222</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-01-23</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-0605</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-01-23</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021731</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-0610</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-01-23</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021488</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-0793</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-01-23</started-marketing-on>
      <ended-marketing-on>2016-10-13</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-222</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-223</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021379</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-302</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021488</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-303</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021488</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-452</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021731</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-453</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-01-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021731</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-752</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard</name>
      <labeller>Tolmar Inc</labeller>
      <ndc-id/>
      <ndc-product-code>62935-753</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021343</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eligard 22.5mg</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248240</dpd-id>
      <started-marketing-on>2003-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>28.2 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eligard 30 mg</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248999</dpd-id>
      <started-marketing-on>2004-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>35.8 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eligard 45 mg</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02268892</dpd-id>
      <started-marketing-on>2005-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>58.2 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eligard 7.5mg</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248239</dpd-id>
      <started-marketing-on>2003-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>10.2 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Leuprolide Acetate</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-4014</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-11-06</started-marketing-on>
      <ended-marketing-on>2016-12-16</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA075471</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leuprolide Acetate</name>
      <labeller>Eon Labs, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0185-7400</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1998-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 mg/.2mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>ANDA074728</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leuprolide Acetate</name>
      <labeller>Sun Pharma Global Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>41616-936</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-03-03</started-marketing-on>
      <ended-marketing-on>2017-09-05</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>ANDA078885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leuprolide Acetate</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-4003</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1998-08-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA074728</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leuprolide Acetate</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-936</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>ANDA078885</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leuprolide Acetate Injection</name>
      <labeller>Novopharm Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240264</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupaneta Pack</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-1052</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA203696</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupaneta Pack</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-1053</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA203696</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00727695</dpd-id>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230248</dpd-id>
      <started-marketing-on>1997-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>22.5 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3663</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-11-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020708</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00884502</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>3.75 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00836273</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>7.5 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3641</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1990-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020011</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148722</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>11.25 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148730</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>15 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239833</dpd-id>
      <started-marketing-on>1999-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>30 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239834</dpd-id>
      <started-marketing-on>1999-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>11.25 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3346</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020517</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3473</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020517</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3642</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-01-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA019732</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3683</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020517</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-2108</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-2282</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-2440</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-3779</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Abbvie</labeller>
      <ndc-id/>
      <ndc-product-code>0074-9694</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-04-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lupron Depot-PED</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-736</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-07-28</started-marketing-on>
      <ended-marketing-on>2016-12-28</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020263</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zeulide Depot</name>
      <labeller>Pendopharm Division Of De Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02429977</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>5.06 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zeulide Depot</name>
      <labeller>Pendopharm Division Of De Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02462699</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>28.13 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Enantone</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Leuplin</name>
      <company>Takeda</company>
    </international-brand>
    <international-brand>
      <name>LeuProMaxx</name>
      <company>Baxter/Teva</company>
    </international-brand>
    <international-brand>
      <name>Leupromer</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Lutrate</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Memryte</name>
      <company>Curaxis</company>
    </international-brand>
    <international-brand>
      <name>Prostap 3</name>
      <company>Takeda UK</company>
    </international-brand>
    <international-brand>
      <name>Prostap SR</name>
      <company>Takeda UK</company>
    </international-brand>
    <international-brand>
      <name>Viadur</name>
      <company>Bayer AG</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupaneta Pack</name>
      <ingredients>Leuprolide + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lupaneta Pack</name>
      <ingredients>Leuprolide + Norethisterone</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard 7.5mg</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard 22.5mg</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard 30 mg</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard 45 mg</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate Injection</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Leuprolide Acetate</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Eligard</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Zeulide Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Lupron Depot-PED</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
    <mixture>
      <name>Zeulide Depot</name>
      <ingredients>Leuprolide</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Abbott Laboratories Ltd.</name>
      <url>http://www.abbott.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Eon Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Oso Biopharmaceuticals Manufacturing LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Sanofi-Aventis Inc.</name>
      <url>http://www.sanofi-aventis.com</url>
    </packager>
    <packager>
      <name>Sun Pharmaceutical Industries Ltd.</name>
      <url>http://www.sunpharma.com</url>
    </packager>
    <packager>
      <name>Takeda Pharmaceutical Co. Ltd.</name>
      <url>http://www.takeda.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>Tolmar Inc.</name>
      <url>http://www.tolmar.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Leuprolide 2wk 1 mg/0.2 ml kit</description>
      <cost currency="USD">385.33</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit</description>
      <cost currency="USD">400.74</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Eligard 7.5 mg syringe</description>
      <cost currency="USD">493.2</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Lupron 2-wk 1 mg/0.2 ml kit</description>
      <cost currency="USD">594.37</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Eligard 22.5 mg syringe</description>
      <cost currency="USD">1479.6</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Eligard 30 mg syringe</description>
      <cost currency="USD">1972.8</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Eligard 45 mg syringe</description>
      <cost currency="USD">2959.2</cost>
      <unit>syringe</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Hormonal</category>
      <mesh-id>D018931</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endocrine Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fertility Agents</category>
      <mesh-id>D005299</mesh-id>
    </category>
    <category>
      <category>Fertility Agents, Female</category>
      <mesh-id>D005300</mesh-id>
    </category>
    <category>
      <category>Gonadotropin-Releasing Hormone</category>
      <mesh-id>D007987</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones and Related Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypothalamic Hormones</category>
      <mesh-id>D007028</mesh-id>
    </category>
    <category>
      <category>Moderate Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Oligopeptides</category>
      <mesh-id>D009842</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormone-Releasing Hormones</category>
      <mesh-id>D010906</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Reproductive Control Agents</category>
      <mesh-id>D012102</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Subcutaneous</route>
      <strength>28.2 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Subcutaneous</route>
      <strength>35.8 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Subcutaneous</route>
      <strength>58.2 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Subcutaneous</route>
      <strength>10.2 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>1 mg/.2mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Subcutaneous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>11.25 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>15 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>22.5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>3.75 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>30 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>7.5 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>28.13 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>5.06 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L02AE02">
      <level code="L02AE">Gonadotropin releasing hormone analogues</level>
      <level code="L02A">HORMONES AND RELATED AGENTS</level>
      <level code="L02">ENDOCRINE THERAPY</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1YY2</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00007.pdf?1265922813</fda-label>
  <patents>
    <patent>
      <number>6036976</number>
      <country>United States</country>
      <approved>1996-12-13</approved>
      <expires>2016-12-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8921326</number>
      <country>United States</country>
      <approved>2011-02-05</approved>
      <expires>2031-02-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7429559</number>
      <country>United States</country>
      <approved>1999-01-13</approved>
      <expires>2019-01-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8815801</number>
      <country>United States</country>
      <approved>2002-06-28</approved>
      <expires>2022-06-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5728396</number>
      <country>United States</country>
      <approved>1997-01-30</approved>
      <expires>2017-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6156331</number>
      <country>United States</country>
      <approved>1997-01-30</approved>
      <expires>2017-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6375978</number>
      <country>United States</country>
      <approved>1998-12-17</approved>
      <expires>2018-12-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6235712</number>
      <country>United States</country>
      <approved>1997-06-13</approved>
      <expires>2017-06-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6113938</number>
      <country>United States</country>
      <approved>1998-07-24</approved>
      <expires>2018-07-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6124261</number>
      <country>United States</country>
      <approved>1997-06-13</approved>
      <expires>2017-06-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6395292</number>
      <country>United States</country>
      <approved>1997-01-30</approved>
      <expires>2017-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6132420</number>
      <country>United States</country>
      <approved>1997-01-30</approved>
      <expires>2017-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5985305</number>
      <country>United States</country>
      <approved>1997-01-30</approved>
      <expires>2017-01-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5932547</number>
      <country>United States</country>
      <approved>1997-06-13</approved>
      <expires>2017-06-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6565874</number>
      <country>United States</country>
      <approved>1998-10-28</approved>
      <expires>2018-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6773714</number>
      <country>United States</country>
      <approved>1998-10-28</approved>
      <expires>2018-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6626870</number>
      <country>United States</country>
      <approved>2000-03-27</approved>
      <expires>2020-03-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9283282</number>
      <country>United States</country>
      <approved>1998-10-28</approved>
      <expires>2018-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9254307</number>
      <country>United States</country>
      <approved>1998-10-28</approved>
      <expires>2018-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8486455</number>
      <country>United States</country>
      <approved>1998-10-28</approved>
      <expires>2018-10-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8840916</number>
      <country>United States</country>
      <approved>2000-11-13</approved>
      <expires>2020-11-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8470359</number>
      <country>United States</country>
      <approved>2003-10-15</approved>
      <expires>2023-10-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9539333</number>
      <country>United States</country>
      <approved>2000-11-13</approved>
      <expires>2020-11-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin Alfa</name>
      <description>The therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>Ivabradine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Mifepristone may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Perflutren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Gadobenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>Octreotide may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>Oxytocin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>Bortezomib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Fluconazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Nelfinavir may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>Ranolazine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Olanzapine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>Alfuzosin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>Mefloquine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Sorafenib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>Trimethoprim may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Ritonavir may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>Voriconazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Nicardipine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>Trazodone may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Galantamine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Moexipril may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Tizanidine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>Ibandronate may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>Apomorphine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Paroxetine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Isoflurane may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>Propofol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>Vardenafil may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Terbutaline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Amantadine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>Metronidazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>Famotidine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Maprotiline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>Salmeterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Felbamate may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>Formoterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Salbutamol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Sulfamethoxazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Ketoconazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Tolterodine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Norfloxacin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Atazanavir may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>Diphenhydramine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Sertraline may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>Itraconazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Desflurane may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Metoclopramide may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>Lapatinib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>Posaconazole may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>Sunitinib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Arformoterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>Lithium may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Solifenacin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Thiothixene may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>Vorinostat may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ezogabine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>Indacaterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>Pasireotide may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>Degarelix may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>Buserelin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>Histrelin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>Triptorelin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>Rilpivirine may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Fingolimod may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>Eribulin may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Mirabegron may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Dabrafenib may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>Olodaterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Vilanterol may increase the QTc-prolonging activities of Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin Lispro</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin Pork</name>
      <description>The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00419</drugbank-id>
      <name>Miglustat</name>
      <description>The therapeutic efficacy of Miglustat can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of Aicar can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The therapeutic efficacy of Gusperimus can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Leuprolide
PHWSYLLR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1209.3983</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C59H84N16O12</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1756</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>6427</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07612</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08113</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450203</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000020</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Leuprolide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201199</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/eligard.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/leuprolide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000203</id>
      <name>Gonadotropin-releasing hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>16809153</pubmed-id>
            <citation>Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8.</citation>
          </article>
          <article>
            <pubmed-id>10687850</pubmed-id>
            <citation>Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43.</citation>
          </article>
          <article>
            <pubmed-id>9625809</pubmed-id>
            <citation>Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100.</citation>
          </article>
          <article>
            <pubmed-id>15758569</pubmed-id>
            <citation>Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7.</citation>
          </article>
          <article>
            <pubmed-id>10394541</pubmed-id>
            <citation>Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30968" source="Swiss-Prot">
    <name>Gonadotropin-releasing hormone receptor</name>
    <general-function>Peptide binding</general-function>
    <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.</specific-function>
    <gene-name>GNRHR</gene-name>
    <locus>4q21.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>39-58
78-97
116-137
165-184
213-232
282-300
307-326</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.93</theoretical-pi>
    <molecular-weight>37730.355</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4421</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GNRHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L03380</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>183422</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>256</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>256</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P30968</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GNRHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GnRH receptor</synonym>
      <synonym>GRHR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor
MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)
ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>gonadotropin-releasing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to gonadotropin-releasing hormone</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-09-01">
  <drugbank-id primary="true">DB00008</drugbank-id>
  <drugbank-id>BTD00043</drugbank-id>
  <drugbank-id>BIOD00043</drugbank-id>
  <name>Peginterferon alfa-2a</name>
  <description>Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2a is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed.&#13;
&#13;
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2a for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626].&#13;
&#13;
Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2a and [DB00811] have been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment.</description>
  <cas-number>198153-51-4</cas-number>
  <unii>Q46947FE7K</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>28497432</pubmed-id>
        <citation>Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x.</citation>
      </article>
      <article>
        <pubmed-id>25585348</pubmed-id>
        <citation>Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.</title>
        <url>http://hcvguidelines.org/full-report-view</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.&#13;
&#13;
Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have&#13;
compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].</indication>
  <pharmacodynamics>Peginterferon alfa-2a induces the body's innate antiviral response [FDA Label].</pharmacodynamics>
  <mechanism-of-action>Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.</mechanism-of-action>
  <toxicity>Peginterferon alfa-2a may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2a. Peginterferon alfa-2a may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2a causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2a. Peginterferon alfa-2a may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2a are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2a. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2a. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2a treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2a is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2a while pregant may result in delopmental abnormalities or death of the fetus.</toxicity>
  <metabolism/>
  <absorption>Peginterferon alfa-2a reaches peak plasma concentration 72-96 hours after subcutaneous administration [FDA Label]. Trough concentrations at week 48 are approximately 2 fold higher than week 1. The peak to trough ratio at week 48 is 2.</absorption>
  <half-life>The mean terminal half-life of peginterferon alfa-2a is 164 in a range of 84-353 hours [FDA Label].</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>The mean systemic clearance of peginterferon alfa-2a is 94 milliliters per hour [FDA Label].</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Pegylated interferon alfa-2a</synonym>
    <synonym language="" coder="">Pegylated interferon alpha2a</synonym>
  </synonyms>
  <products>
    <product>
      <name>Pegasys</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248077</dpd-id>
      <started-marketing-on>2003-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>180 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegasys</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0350</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-10-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>180 ug/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103964</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegasys</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0357</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>180 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103964</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegasys</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0360</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>135 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103964</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegasys</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0004-0365</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>180 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103964</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegasys</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248078</dpd-id>
      <started-marketing-on>2003-08-14</started-marketing-on>
      <ended-marketing-on>2017-07-27</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>180 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegasys Rbv</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02253410</dpd-id>
      <started-marketing-on>2004-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution; Tablet</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegasys Rbv</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02253429</dpd-id>
      <started-marketing-on>2004-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution; Tablet</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys</name>
      <ingredients>Peginterferon alfa-2a</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys Rbv</name>
      <ingredients>Peginterferon alfa-2a + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegasys Rbv</name>
      <ingredients>Peginterferon alfa-2a + Ribavirin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>F Hoffmann La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
    <packager>
      <name>F Hoffmann-La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Pegasys 180 mcg/ml vial</description>
      <cost currency="USD">642.64</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Pegasys 180 mcg/0.5 ml conv.pk</description>
      <cost currency="USD">2533.2</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box</description>
      <cost currency="USD">2634.53</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Alfa Interferons</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Biomedical and Dental Materials</category>
      <mesh-id>D001697</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Drug Carriers</category>
      <mesh-id>D004337</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Manufactured Materials</category>
      <mesh-id>D008420</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Organic Chemicals</category>
      <mesh-id>D009930</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Specialty Uses of Chemicals</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Technology, Industry, and Agriculture</category>
      <mesh-id>D013676</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>135 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>135 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>180 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>180 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>180 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>90 μg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>180 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution; tablet</form>
      <route>Oral; Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AB61">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
    <atc-code code="L03AB11">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:18.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1ITF</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00008.pdf?1497564068</fda-label>
  <patents>
    <patent>
      <number>2172664</number>
      <country>Canada</country>
      <approved>2000-10-03</approved>
      <expires>2016-03-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2203480</number>
      <country>Canada</country>
      <approved>2009-06-30</approved>
      <expires>2017-04-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Recommended adequate hydration.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01265</drugbank-id>
      <name>Telbivudine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Peginterferon alfa-2a can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ribavirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Peginterferon alfa-2a sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>60000.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13246</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749390</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001278</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Peginterferon_alfa-2a</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201560</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/pegasys.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/peginterferon-alfa-2a.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects>
    <effect>
      <protein-name>Interferon lambda-3</protein-name>
      <gene-symbol>IFNL3</gene-symbol>
      <uniprot-id>Q8IZI9</uniprot-id>
      <rs-id>rs12979860</rs-id>
      <allele/>
      <defining-change>C &gt; T</defining-change>
      <description>Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2a therapy.</description>
      <pubmed-id>24096968</pubmed-id>
    </effect>
  </snp-effects>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>16953837</pubmed-id>
            <citation>Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>16953837</pubmed-id>
            <citation>Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
    <name>Cytochrome P450 1A2</name>
    <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
    <gene-name>CYP1A2</gene-name>
    <locus>15q24</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.43</theoretical-pi>
    <molecular-weight>58293.76</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP1A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z00036</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1319</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05177</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP1A2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYPIA2</synonym>
      <synonym>Cytochrome P(3)450</synonym>
      <synonym>Cytochrome P450 4</synonym>
      <synonym>Cytochrome P450-P3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>demethylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>electron carrier activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular respiration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>omega-hydroxylase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monocarboxylic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative deethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to immobilization stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to cadmium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>porphyrin-containing compound metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dibenzo-p-dioxin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>methylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epoxygenase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hydrogen peroxide biosynthetic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-08">
  <drugbank-id primary="true">DB00009</drugbank-id>
  <drugbank-id>BTD00050</drugbank-id>
  <drugbank-id>BIOD00050</drugbank-id>
  <name>Alteplase</name>
  <description>Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells</description>
  <cas-number>105857-23-6</cas-number>
  <unii>1RXS4UE564</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli</indication>
  <pharmacodynamics>Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.</pharmacodynamics>
  <mechanism-of-action>Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Alteplase (genetical recombination)</synonym>
    <synonym language="" coder="">Alteplase, recombinant</synonym>
    <synonym language="" coder="">Alteplase,recombinant</synonym>
    <synonym language="" coder="">Plasminogen activator (human tissue-type protein moiety)</synonym>
    <synonym language="" coder="">rt-PA</synonym>
    <synonym language="" coder="">t-PA</synonym>
    <synonym language="" coder="">t-plasminogen activator</synonym>
    <synonym language="" coder="">Tissue plasminogen activator</synonym>
    <synonym language="" coder="">Tissue plasminogen activator alteplase</synonym>
    <synonym language="" coder="">Tissue plasminogen activator, recombinant</synonym>
    <synonym language="" coder="">tPA</synonym>
  </synonyms>
  <products>
    <product>
      <name>Activase</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-044</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1987-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103172</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Activase</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-085</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1987-11-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103172</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Activase RT-PA</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02147440</dpd-id>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Activase RT-PA</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02225689</dpd-id>
      <started-marketing-on>1998-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Activase RT-PA Inj</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00771473</dpd-id>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-31</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>29 m</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cathflo</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245859</dpd-id>
      <started-marketing-on>2002-09-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cathflo Activase</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-041</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>2.2 mg/2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103172</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lysatec RT - Pa</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02009285</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cathflo Activase</name>
      <ingredients>Alteplase</ingredients>
    </mixture>
    <mixture>
      <name>Cathflo</name>
      <ingredients>Alteplase</ingredients>
    </mixture>
    <mixture>
      <name>Lysatec RT - Pa</name>
      <ingredients>Alteplase + Water</ingredients>
    </mixture>
    <mixture>
      <name>Activase RT-PA Inj</name>
      <ingredients>Alteplase</ingredients>
    </mixture>
    <mixture>
      <name>Activase RT-PA</name>
      <ingredients>Alteplase + Water</ingredients>
    </mixture>
    <mixture>
      <name>Activase RT-PA</name>
      <ingredients>Alteplase + Water</ingredients>
    </mixture>
    <mixture>
      <name>Activase</name>
      <ingredients>Alteplase</ingredients>
    </mixture>
    <mixture>
      <name>Activase</name>
      <ingredients>Alteplase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genentech Inc.</name>
      <url>http://www.gene.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Cathflo activase 2 mg vial</description>
      <cost currency="USD">106.33</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Activase 50 mg vial</description>
      <cost currency="USD">2389.85</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Activase 100 mg vial</description>
      <cost currency="USD">4779.71</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Plasminogen Activators</category>
      <mesh-id>D010960</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>29 m</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>2.2 mg/2mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01XA13">
      <level code="S01XA">Other ophthalmologicals</level>
      <level code="S01X">OTHER OPHTHALMOLOGICALS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="B01AD02">
      <level code="B01AD">Enzymes</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1BDA</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00009.pdf?1265922802</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Alteplase may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Alteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Alteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Alteplase may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Alteplase may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Alteplase may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Alteplase may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Alteplase may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Alteplase may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Alteplase may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Alteplase may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Alteplase may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Alteplase may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Alteplase may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Alteplase may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Alteplase may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Alteplase may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Alteplase may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Alteplase may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Alteplase may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Alteplase may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Alteplase may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Alteplase may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Alteplase may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Alteplase may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Alteplase may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Alteplase may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Alteplase may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Alteplase may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Alteplase may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Alteplase may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Alteplase may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Alteplase may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Alteplase may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Alteplase may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Alteplase may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Alteplase may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Alteplase may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Alteplase may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Alteplase may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Alteplase may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Alteplase may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Alteplase may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Alteplase may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Alteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Alteplase may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>The risk or severity of adverse effects can be increased when dersalazine is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Vorapaxar may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Alteplase sequence
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA
LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS
PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>60 °C</value>
      <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.516</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.61</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>59042.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2569H3928N746O781S40</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7297</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02837</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>L00153</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164776730</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00750</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000203</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alteplase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201593</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/alteplas.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/alteplase.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00280</smpdb-id>
      <name>Alteplase Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00009</drugbank-id>
          <name>Alteplase</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
    <name>Plasminogen</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
    <gene-name>PLG</gene-name>
    <locus>6q26</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>7.25</theoretical-pi>
    <molecular-weight>90568.415</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9071</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X05199</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387026</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PLMN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00024</identifier>
        <name>PAN_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tissue remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibrinolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000538</id>
      <name>Fibrinogen alpha chain</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02671" source="Swiss-Prot">
    <name>Fibrinogen alpha chain</name>
    <general-function>Structural molecule activity</general-function>
    <specific-function>Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.</specific-function>
    <gene-name>FGA</gene-name>
    <locus>4q28</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.87</theoretical-pi>
    <molecular-weight>94972.455</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3661</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF361104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>13591824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FIBA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fibrinogen alpha chain precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001074|Fibrinogen alpha chain
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)
ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA
GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
AGGCCCCTTGTGACCCAATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00147</identifier>
        <name>Fibrinogen_C</name>
      </pfam>
      <pfam>
        <identifier>PF08702</identifier>
        <name>Fib_alpha</name>
      </pfam>
      <pfam>
        <identifier>PF12160</identifier>
        <name>Fibrinogen_aC</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>fibrinogen complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>structural molecule activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>liver regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to genistein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet aggregation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic cyclic compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>induction of bacterial agglutination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-6</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to granulocyte colony-stimulating factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heterotypic cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, fibrin clot formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cycloheximide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptide hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein polymerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adaptive immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000717</id>
      <name>Urokinase plasminogen activator surface receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q03405" source="Swiss-Prot">
    <name>Urokinase plasminogen activator surface receptor</name>
    <general-function>Urokinase plasminogen activator receptor activity</general-function>
    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.</specific-function>
    <gene-name>PLAUR</gene-name>
    <locus>19q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>36977.62</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9053</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAUR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51675</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q03405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UPAR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>MO3</synonym>
      <synonym>Monocyte activation antigen Mo3</synonym>
      <synonym>U-PAR</synonym>
      <synonym>UPAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)
ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG
CCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT
GTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00021</identifier>
        <name>UPAR_LY6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>invadopodium membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>urokinase plasminogen activator receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>attachment of GPI anchor to protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>C-terminal protein lipidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urokinase plasminogen activator signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of cytochrome c from mitochondria</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000240</id>
      <name>Plasminogen activator inhibitor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05121" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 1</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>
    <gene-name>SERPINE1</gene-name>
    <locus>7q21.3-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.22</theoretical-pi>
    <molecular-weight>45059.695</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINE1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04429</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35272</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05121</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Endothelial plasminogen activator inhibitor</synonym>
      <synonym>PAI</synonym>
      <synonym>PAI1</synonym>
      <synonym>PLANH1</synonym>
      <synonym>Serpin E1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)
ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC
TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
GAACCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronological cell aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-negative bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukotriene production involved in inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription initiation from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of wound healing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-12-08">
  <drugbank-id primary="true">DB00010</drugbank-id>
  <drugbank-id>BTD00033</drugbank-id>
  <drugbank-id>BIOD00033</drugbank-id>
  <name>Sermorelin</name>
  <description>Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues</description>
  <cas-number>86168-78-7</cas-number>
  <unii>89243S03TE</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of dwarfism, prevention of HIV-induced weight loss</indication>
  <pharmacodynamics>Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.</pharmacodynamics>
  <mechanism-of-action>Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>11-12 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001439</drugbank-id>
      <name>Sermorelin acetate</name>
      <unii>00IBG87IQW</unii>
      <cas-number>114466-38-5</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Geref</name>
      <company>Serono Pharma</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers>
    <packager>
      <name>Chengdu Shengnuo Bio Pharmaceutical Co. Ltd.</name>
      <url/>
    </packager>
    <packager>
      <name>Letco Medical Inc.</name>
      <url>http://www.letcomedical.com</url>
    </packager>
    <packager>
      <name>Live Well Drugstore LLC</name>
      <url>http://www.livewelldrugstore.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Emd serono inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anterior Pituitary Lobe Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Growth Hormone-Releasing Hormone</category>
      <mesh-id>D013007</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypothalamic Hormones</category>
      <mesh-id>D007028</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary and Hypothalamic Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pituitary Hormone-Releasing Hormones</category>
      <mesh-id>D010906</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Somatropin and Somatropin Agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes>
    <atc-code code="V04CD03">
      <level code="V04CD">Tests for pituitary function</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="H01AC04">
      <level code="H01AC">Somatropin and somatropin agonists</level>
      <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
      <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;DB00010 sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.330</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>3357.882</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C149H246N44O42S</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C08192</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749110</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001055</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sermorelin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/sermorelin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/sermorelin-acetate.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000625</id>
      <name>Growth hormone-releasing hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>14499707</pubmed-id>
            <citation>Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q02643" source="Swiss-Prot">
    <name>Growth hormone-releasing hormone receptor</name>
    <general-function>Peptide hormone binding</general-function>
    <specific-function>Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.</specific-function>
    <gene-name>GHRHR</gene-name>
    <locus>7p14</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>133-152
163-181
205-227
241-262
281-304
330-348
362-381</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.73</theoretical-pi>
    <molecular-weight>47401.53</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4266</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GHRHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L01406</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>183173</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q02643</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GHRHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GHRH receptor</synonym>
      <synonym>GRF receptor</synonym>
      <synonym>GRFR</synonym>
      <synonym>Growth hormone-releasing factor receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016157|Growth hormone-releasing hormone receptor
MDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD
GLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA
EEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF
LKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR
AFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF
LNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL
ELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT
SMC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016158|Growth hormone-releasing hormone receptor (GHRHR)
ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA
TTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC
TGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT
GGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT
TTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC
TGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT
GAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT
ATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC
CGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGAGCTGTGTTC
CTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT
CTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG
TTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA
GCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG
GTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC
TACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT
CTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC
CAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT
CACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG
GAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC
CAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA
GCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA
TCTATGTGCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>nuclear matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear inner membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear outer membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth hormone-releasing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of intracellular steroid hormone receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell maturation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>somatotropin secreting cell development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estrogen</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to insulin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of insulin-like growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lactation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal reproductive process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to insulin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>growth hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>determination of adult lifespan</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water homeostasis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00011</drugbank-id>
  <drugbank-id>BTD00096</drugbank-id>
  <drugbank-id>BIOD00096</drugbank-id>
  <drugbank-id>DB00084</drugbank-id>
  <name>Interferon alfa-n1</name>
  <description>Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues</description>
  <cas-number>74899-72-2</cas-number>
  <unii>41697D4Z5C</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, "Method for producing human leukocyte interferon alpha-2." U.S. Patent US4680260, issued January, 1982.</synthesis-reference>
  <indication>For treatment of venereal or genital warts caused by the Human Papiloma Virus</indication>
  <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
  <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>1.2 hours (mammalian reticulocytes, in vitro); &amp;gt;20 hours (yeast, in vivo); &amp;gt;10 hours (Escherichia coli, in vivo).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Interferon alpha-2</synonym>
    <synonym language="" coder="">Interferon alpha-A</synonym>
    <synonym language="" coder="">Interferon alpha-n1 (Ins)</synonym>
    <synonym language="" coder="">LeIF A</synonym>
  </synonyms>
  <products>
    <product>
      <name>Wellferon Inj 10 000 000unit/ml</name>
      <labeller>The Wellcome Foundation Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959069</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>10000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wellferon Inj 3000000unit/ml</name>
      <labeller>The Wellcome Foundation Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959077</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>3000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Wellferon</name>
      <company>GlaxoSmithKline</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Wellferon Inj 10 000 000unit/ml</name>
      <ingredients>Interferon alfa-n1</ingredients>
    </mixture>
    <mixture>
      <name>Wellferon Inj 3000000unit/ml</name>
      <ingredients>Interferon alfa-n1</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>10000000 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>3000000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AB06">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1ITF</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00011 sequence
CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.336</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>19241.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C860H1353N227O255S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7651</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001280</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108509</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10822464</pubmed-id>
            <citation>Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10822464</pubmed-id>
            <citation>Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00012</drugbank-id>
  <drugbank-id>BTD00032</drugbank-id>
  <drugbank-id>BIOD00032</drugbank-id>
  <name>Darbepoetin alfa</name>
  <description>Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.</description>
  <cas-number>209810-58-2</cas-number>
  <unii>15UQ94PT4P</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of anemia (from renal transplants or certain HIV treatment)</indication>
  <pharmacodynamics>Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.</pharmacodynamics>
  <mechanism-of-action>Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with&#13;
progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Darbepoetin</synonym>
    <synonym language="" coder="">Darbepoetin alfa,recombinant</synonym>
  </synonyms>
  <products>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-110</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>300 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-111</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 ug/.6mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-002</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-003</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-004</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>60 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-005</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-006</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-021</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 ug/.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-023</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>60 ug/.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-025</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/.5mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-027</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>150 ug/.3mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-028</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 ug/.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-032</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-053</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-09-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>150 ug/.75mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-057</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>25 ug/.42mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-098</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 ug/.4mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103951</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246354</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>25 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246355</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>40 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246357</dpd-id>
      <started-marketing-on>2002-08-20</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246358</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246360</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2015-08-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391759</dpd-id>
      <started-marketing-on>2014-05-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391767</dpd-id>
      <started-marketing-on>2014-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391775</dpd-id>
      <started-marketing-on>2014-03-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391783</dpd-id>
      <started-marketing-on>2014-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391791</dpd-id>
      <started-marketing-on>2014-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391805</dpd-id>
      <started-marketing-on>2014-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391821</dpd-id>
      <started-marketing-on>2013-11-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392364</dpd-id>
      <started-marketing-on>2014-02-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246356</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>60 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246359</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>325 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391732</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391813</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp        -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391848</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392313</dpd-id>
      <started-marketing-on>2013-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>25 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392321</dpd-id>
      <started-marketing-on>2014-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392348</dpd-id>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02392356</dpd-id>
      <started-marketing-on>2014-04-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246353</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>15 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aranesp -(hsa-free)</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02391740</dpd-id>
      <started-marketing-on>2013-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp        -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Nespo</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Aranesp -(hsa-free)</name>
      <ingredients>Darbepoetin alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Amgen Inc.</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Aranesp 25 mcg/ml vial</description>
      <cost currency="USD">156.36</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 25 mcg/ml vial</description>
      <cost currency="USD">162.61</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp 40 mcg/ml vial</description>
      <cost currency="USD">250.2</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 60 mcg/ml vial</description>
      <cost currency="USD">375.3</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 60 mcg/ml vial</description>
      <cost currency="USD">390.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp 100 mcg/ml vial</description>
      <cost currency="USD">625.44</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 200 mcg/ml vial</description>
      <cost currency="USD">1250.88</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp 300 mcg/ml vial</description>
      <cost currency="USD">1876.32</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 300 mcg/ml vial</description>
      <cost currency="USD">1951.37</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)</description>
      <cost currency="USD">2601.83</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box</description>
      <cost currency="USD">2601.83</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)</description>
      <cost currency="USD">3902.75</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antianemic Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Erythropoiesis-Stimulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Erythropoietin</category>
      <mesh-id>D004921</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematinics</category>
      <mesh-id>D006397</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 ug/.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>130 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>15 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 ug/.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 ug/.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 ug/.42mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 ug/.6mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 ug/.4mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>50 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 ug/.3mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>80 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>10 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>130 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>15 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>150 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>20 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>30 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>300 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>40 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>50 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>500 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>60 μg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>80 μg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>150 ug/.75mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>300 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>200 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>25 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>325 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>60 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>15 mcg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B03XA02">
      <level code="B03XA">Other antianemic preparations</level>
      <level code="B03X">OTHER ANTIANEMIC PREPARATIONS</level>
      <level code="B03">ANTIANEMIC PREPARATIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1EER</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2165694</number>
      <country>Canada</country>
      <approved>2003-03-18</approved>
      <expires>2010-10-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2147124</number>
      <country>Canada</country>
      <approved>2002-11-05</approved>
      <expires>2014-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>Nandrolone phenpropionate may increase the stimulatory activities of Darbepoetin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>Nandrolone decanoate may increase the stimulatory activities of Darbepoetin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Darbepoetin alfa may increase the thrombogenic activities of Thalidomide.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00012 sequence
APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA
VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS
PPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>53 °C</value>
      <source>Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.188</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.75</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>18396.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C815H1317N233O241S5</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12550</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X02158</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164743138</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01588</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000800</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Darbepoetin_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201566</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/aranesp.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000654</id>
      <name>Erythropoietin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>16505108</pubmed-id>
            <citation>LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55.</citation>
          </article>
          <article>
            <pubmed-id>17575216</pubmed-id>
            <citation>Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P19235" source="Swiss-Prot">
    <name>Erythropoietin receptor</name>
    <general-function>Identical protein binding</general-function>
    <specific-function>Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.</specific-function>
    <gene-name>EPOR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>251-273</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>4.37</theoretical-pi>
    <molecular-weight>55064.725</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3416</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>EPOR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M60459</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182245</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1718</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P19235</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EPOR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EPO-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001304|Erythropoietin receptor
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010455|Erythropoietin receptor (EPOR)
ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF09067</identifier>
        <name>EpoR_lig-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>erythropoietin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heart development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>decidualization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>erythropoietin-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00013</drugbank-id>
  <drugbank-id>BTD00030</drugbank-id>
  <drugbank-id>BIOD00030</drugbank-id>
  <name>Urokinase</name>
  <description>Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator</description>
  <cas-number>9039-53-6</cas-number>
  <unii>83G67E21XI</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>5328</pubmed-id>
        <citation>Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Koji Sasaki, Yasukazu Harada, "Urokinase preparation for oral administration." U.S. Patent US4258030, issued November, 1975.</synthesis-reference>
  <indication>Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.</indication>
  <pharmacodynamics>Urokinase is used for the treatment of pulmonary embolisms. The low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Urokinase is the low molecular weight form. Urokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.</pharmacodynamics>
  <mechanism-of-action>Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.</mechanism-of-action>
  <toxicity/>
  <metabolism>Proteolysis</metabolism>
  <absorption/>
  <half-life>12 minutes. Small fractions of the administered dose are excreted in bile and urine</half-life>
  <protein-binding/>
  <route-of-elimination>Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">U-plasminogen activator</synonym>
    <synonym language="" coder="">uPA</synonym>
    <synonym language="" coder="">Urokinase-type plasminogen activator precursor</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kinlytic (urokinase for Injection)</name>
      <labeller>Microbix Biosystems Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00749702</dpd-id>
      <started-marketing-on>1988-12-31</started-marketing-on>
      <ended-marketing-on>2009-10-28</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kinlytic Open-cath</name>
      <labeller>Microbix Biosystems Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00886777</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2009-10-28</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>5000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Abbokinase</name>
      <company>Abbott Laboratories</company>
    </international-brand>
    <international-brand>
      <name>Kinlytic</name>
      <company>Microbix Biosystems Inc.</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Kinlytic Open-cath</name>
      <ingredients>Urokinase</ingredients>
    </mixture>
    <mixture>
      <name>Kinlytic (urokinase for Injection)</name>
      <ingredients>Urokinase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>ImaRx Therapeutics</name>
      <url>http://www.imarx.com</url>
    </packager>
    <packager>
      <name>Microbix Biosystems Inc.</name>
      <url>http://www.microbix.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Microbix biosystems inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Plasminogen Activators</category>
      <mesh-id>D010960</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>250000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>5000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AD04">
      <level code="B01AD">Enzymes</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1C5W</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Urokinase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Urokinase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Urokinase may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Urokinase may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Urokinase may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Urokinase may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Urokinase may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Urokinase may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Urokinase may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Urokinase may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Urokinase may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Urokinase may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Urokinase may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Urokinase may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Urokinase may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Urokinase may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Urokinase may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Urokinase may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Urokinase may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Urokinase may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Urokinase may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Urokinase may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Urokinase may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Urokinase may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Urokinase may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Urokinase may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Urokinase may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Urokinase may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Urokinase may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Urokinase may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Urokinase may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Urokinase may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Urokinase may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Urokinase may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Urokinase may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Urokinase may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Urokinase may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Urokinase may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Urokinase may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Urokinase may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Urokinase may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Urokinase may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Urokinase may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Urokinase may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Urokinase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Urokinase may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Vorapaxar may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>The risk or severity of adverse effects can be increased when dersalazine is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00013 sequence
KPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMS
PCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHND
IALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMT
VVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVS
WGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>76 °C at pH 4.5</value>
      <source>Nowak, U.K. et al., Biochemistry 33:2951-2960 (1994)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.466</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.66</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>31126.5</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1376H2145N383O406S18</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2012</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X02419</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451836</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00749</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001194</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Urokinase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201420</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/pharmclips2.cgi?keyword=%20Abbokinase%AE</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/urokinase.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00284</smpdb-id>
      <name>Urokinase Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00013</drugbank-id>
          <name>Urokinase</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>12658774</pubmed-id>
            <citation>Zhang X, Zhou H, Shen G, Liu Z, Hu Y, Wei W, Song S: Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):21-3, 76.</citation>
          </article>
          <article>
            <pubmed-id>12666133</pubmed-id>
            <citation>Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol. 2003 Apr;72(4):234-42.</citation>
          </article>
          <article>
            <pubmed-id>12719778</pubmed-id>
            <citation>Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J: Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost. 2003 May;89(5):820-5.</citation>
          </article>
          <article>
            <pubmed-id>12720300</pubmed-id>
            <citation>Guda K, Claffey KP, Dong M, Nambiar PR, Rosenberg DW: Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2003 May;37(1):51-9.</citation>
          </article>
          <article>
            <pubmed-id>12745435</pubmed-id>
            <citation>Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
    <name>Plasminogen</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
    <gene-name>PLG</gene-name>
    <locus>6q26</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>7.25</theoretical-pi>
    <molecular-weight>90568.415</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9071</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X05199</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387026</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PLMN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00024</identifier>
        <name>PAN_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tissue remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibrinolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000717</id>
      <name>Urokinase plasminogen activator surface receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>12615913</pubmed-id>
            <citation>Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003 Mar 3;160(5):781-91.</citation>
          </article>
          <article>
            <pubmed-id>12817472</pubmed-id>
            <citation>Fuchs T, Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis. Biol Chem. 2003 May;384(5):755-61.</citation>
          </article>
          <article>
            <pubmed-id>14679304</pubmed-id>
            <citation>Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT: Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J Cell Sci. 2004 Jan 26;117(Pt 3):477-85. Epub 2003 Dec 16.</citation>
          </article>
          <article>
            <pubmed-id>14688365</pubmed-id>
            <citation>Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004 Jan 1;172(1):540-9.</citation>
          </article>
          <article>
            <pubmed-id>14720519</pubmed-id>
            <citation>Guerrero J, Santibanez JF, Gonzalez A, Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004 Jan 1;292(1):201-8.</citation>
          </article>
          <article>
            <pubmed-id>17327908</pubmed-id>
            <citation>Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS: Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007 Feb 28;2(2):e243.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q03405" source="Swiss-Prot">
    <name>Urokinase plasminogen activator surface receptor</name>
    <general-function>Urokinase plasminogen activator receptor activity</general-function>
    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.</specific-function>
    <gene-name>PLAUR</gene-name>
    <locus>19q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>36977.62</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9053</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAUR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51675</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q03405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UPAR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>MO3</synonym>
      <synonym>Monocyte activation antigen Mo3</synonym>
      <synonym>U-PAR</synonym>
      <synonym>UPAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)
ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG
CCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT
GTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00021</identifier>
        <name>UPAR_LY6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>invadopodium membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>urokinase plasminogen activator receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>attachment of GPI anchor to protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>C-terminal protein lipidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urokinase plasminogen activator signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of cytochrome c from mitochondria</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000895</id>
      <name>Urokinase-type plasminogen activator</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>12556741</pubmed-id>
            <citation>Bell WR: Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34-44.</citation>
          </article>
          <article>
            <pubmed-id>12579271</pubmed-id>
            <citation>Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6.</citation>
          </article>
          <article>
            <pubmed-id>12707394</pubmed-id>
            <citation>Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2003 May;14(5):1254-71.</citation>
          </article>
          <article>
            <pubmed-id>12745435</pubmed-id>
            <citation>Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.</citation>
          </article>
          <article>
            <pubmed-id>12824001</pubmed-id>
            <citation>Wielockx B, Libert C: Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor. Cytokine. 2003 Mar 21;21(6):281-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00749" source="Swiss-Prot">
    <name>Urokinase-type plasminogen activator</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.</specific-function>
    <gene-name>PLAU</gene-name>
    <locus>10q24</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-20</signal-regions>
    <theoretical-pi>8.48</theoretical-pi>
    <molecular-weight>48507.09</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9052</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAU</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X02419</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1834524</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2393</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00749</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UROK_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.73</synonym>
      <synonym>U-plasminogen activator</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037097|Urokinase-type plasminogen activator
MRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ
HCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN
YCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII
GGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLG
RSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL
PSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML
CAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR
SHTKEENGLAL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021654|Urokinase-type plasminogen activator (PLAU)
ATGGTCTTCCATTTGAGAACTAGATACGAACAGGCGAACTGTGACTGTCTAAATGGAGGA
ACATGTGTGTCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAGAAATTC
GGAGGGCAGCACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTT
TACCGAGGAAAGGCCAGCACTGACACCATGGGCCGGCCCTGCCTGCCCTGGAACTCTGCC
ACTGTCCTTCAGCAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGG
AAACATAATTACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTG
GGCCTAAAGCCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAAGCCC
TCCTCTCCTCCAGAAGAATTAAAATTTCAGTGTGGCCAAAAGACTCTGAGGCCCCGCTTT
AAGATTATTGGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTAC
AGGAGGCACCGGGGGGGCTCTGTCACCTACGTGTGTGGAGGCAGCCTCATCAGCCCTTGC
TGGGTGATCAGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATCGTC
TACCTGGGTCGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATGAAGTTTGAGGTGGAA
AACCTCATCCTACACAAGGACTACAGCGCTGACACGCTTGCTCACCACAACGACATTGCC
TTGCTGAAGATCCGTTCCAAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACC
ATCTGCCTGCCCTCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGC
TTTGGAAAAGAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTG
AAGCTGATTTCCCACCGGGAGTGTCAGCAGCCCCACTACTACGGCTCTGAAGTCACCACC
AAAATGCTGTGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGAGACTCAGGG
GGACCCCTCGTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGC
CGTGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCC
TGGATCCGCAGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of hepatocyte proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hepatocyte growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal muscle tissue regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hyperoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryo implantation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to staurosporine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to glucose stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ovulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to fluid shear stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0001088</id>
      <name>Tissue-type plasminogen activator</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>12745435</pubmed-id>
            <citation>Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.</citation>
          </article>
          <article>
            <pubmed-id>12787697</pubmed-id>
            <citation>Lindholt JS, Jorgensen B, Shi GP, Henneberg EW: Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003 Jun;25(6):546-51.</citation>
          </article>
          <article>
            <pubmed-id>12826021</pubmed-id>
            <citation>Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, Varela E, Ruiz E, Fernandez de Sevilla T: Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond). 2003 Nov;105(5):601-7.</citation>
          </article>
          <article>
            <pubmed-id>12893898</pubmed-id>
            <citation>Wells RG, Havens PL: Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. 2003 Aug;228(2):370-8.</citation>
          </article>
          <article>
            <pubmed-id>14507109</pubmed-id>
            <citation>Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J: In vitro simulation of therapeutic plasmatic fibrinolysis. Clin Appl Thromb Hemost. 2003 Jul;9(3):211-20.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00750" source="Swiss-Prot">
    <name>Tissue-type plasminogen activator</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.</specific-function>
    <gene-name>PLAT</gene-name>
    <locus>8p12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>7.81</theoretical-pi>
    <molecular-weight>62916.495</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9051</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAT</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L00153</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339834</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2392</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00750</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TPA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.68</synonym>
      <synonym>t-PA</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002165|Tissue-type plasminogen activator
MDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPV
LRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCE
IDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCR
NPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWN
SMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCG
LRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQ
ERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCA
QESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQH
LLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQK
DVPGVYTKVTNYLDWIRDNMRP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010763|Tissue-type plasminogen activator (PLAT)
ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTT
TCGCCCAGCCAGGAAATCCATGCCCGATTCAGAAGAGGAGCCAGATCTTACCAAGTGATC
TGCAGAGATGAAAAAACGCAGATGATATACCAGCAACATCAGTCATGGCTGCGCCCTGTG
CTCAGAAGCAACCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCACTCA
GTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCAACGGGGGCACCTGCCAGCAGGCC
CTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTGTGAA
ATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTGGAGC
ACAGCGGAGAGTGGCGCCGAGTGCACCAACTGGAACAGCAGCGCGTTGGCCCAGAAGCCC
TACAGCGGGCGGAGGCCAGACGCCATCAGGCTGGGCCTGGGGAACCACAACTACTGCAGA
AACCCAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGGAAGTACAGCTCA
GAGTTCTGCAGCACCCCTGCCTGCTCTGAGGGAAACAGTGACTGCTACTTTGGGAATGGG
TCAGCCTACCGTGGCACGCACAGCCTCACCGAGTCGGGTGCCTCCTGCCTCCCGTGGAAT
TCCATGATCCTGATAGGCAAGGTTTACACAGCACAGAACCCCAGTGCCCAGGCACTGGGC
CTGGGCAAACATAATTACTGCCGGAATCCTGATGGGGATGCCAAGCCCTGGTGCCACGTG
CTGAAGAACCGCAGGCTGACGTGGGAGTACTGTGATGTGCCCTCCTGCTCCACCTGCGGC
CTGAGACAGTACAGCCAGCCTCAGTTTCGCATCAAAGGAGGGCTCTTCGCCGACATCGCC
TCCCACCCCTGGCAGGCTGCCATCTTTGCCAAGCACAGGAGGTCGCCCGGAGAGCGGTTC
CTGTGCGGGGGCATACTCATCAGCTCCTGCTGGATTCTCTCTGCCGCCCACTGCTTCCAG
GAGAGGTTTCCGCCCCACCACCTGACGGTGATCTTGGGCAGAACATACCGGGTGGTCCCT
GGCGAGGAGGAGCAGAAATTTGAAGTCGAAAAATACATTGTCCATAAGGAATTCGATGAT
GACACTTACGACAATGACATTGCGCTGCTGCAGCTGAAATCGGATTCGTCCCGCTGTGCC
CAGGAGAGCAGCGTGGTCCGCACTGTGTGCCTTCCCCCGGCGGACCTGCAGCTGCCGGAC
TGGACGGAGTGTGAGCTCTCCGGCTACGGCAAGCATGAGGCCTTGTCTCCTTTCTATTCG
GAGCGGCTGAAGGAGGCTCATGTCAGACTGTACCCATCCAGCCGCTGCACATCACAACAT
TTACTTAACAGAACAGTCACCGACAACATGCTGTGTGCTGGAGACACTCGGAGCGGCGGG
CCCCAGGCAAACTTGCACGACGCCTGCCAGGGCGATTCGGGAGGCCCCCTGGTGTGTCTG
AACGATGGCCGCATGACTTTGGTGGGCATCATCAGCTGGGGCCTGGGCTGTGGACAGAAG
GATGTCCCGGGTGTGTACACCAAGGTTACCAACTACCTAGACTGGATTCGTGACAACATG
CGACCGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00039</identifier>
        <name>fn1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>apical part of cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein modification process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet-derived growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to peptide hormone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0000240</id>
      <name>Plasminogen activator inhibitor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>12579271</pubmed-id>
            <citation>Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6.</citation>
          </article>
          <article>
            <pubmed-id>12642587</pubmed-id>
            <citation>Shetty S, Bdeir K, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem. 2003 May 16;278(20):18124-31. Epub 2003 Mar 17.</citation>
          </article>
          <article>
            <pubmed-id>12709915</pubmed-id>
            <citation>Hellgren M: Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30.</citation>
          </article>
          <article>
            <pubmed-id>12745435</pubmed-id>
            <citation>Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47.</citation>
          </article>
          <article>
            <pubmed-id>12785198</pubmed-id>
            <citation>Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE: [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]. Vopr Onkol. 2003;49(2):165-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P05121" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 1</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>
    <gene-name>SERPINE1</gene-name>
    <locus>7q21.3-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.22</theoretical-pi>
    <molecular-weight>45059.695</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINE1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04429</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35272</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05121</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Endothelial plasminogen activator inhibitor</synonym>
      <synonym>PAI</synonym>
      <synonym>PAI1</synonym>
      <synonym>PLANH1</synonym>
      <synonym>Serpin E1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)
ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC
TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
GAACCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronological cell aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-negative bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukotriene production involved in inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription initiation from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of wound healing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0000969</id>
      <name>Plasminogen activator inhibitor 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15277569</pubmed-id>
            <citation>Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF: Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol. 2004 Oct;76(4):812-9. Epub 2004 Jul 26.</citation>
          </article>
          <article>
            <pubmed-id>15351849</pubmed-id>
            <citation>Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Gunther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost. 2004 Sep;92(3):529-40.</citation>
          </article>
          <article>
            <pubmed-id>15640330</pubmed-id>
            <citation>Iglesias D, Alegre J, Aleman C, Ruiz E, Soriano T, Armadans LI, Segura RM, Angles A, Monasterio J, de Sevilla TF: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005 Jan;25(1):104-9.</citation>
          </article>
          <article>
            <pubmed-id>15944795</pubmed-id>
            <citation>Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG, Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005 Jul;14(1):235-9.</citation>
          </article>
          <article>
            <pubmed-id>16327990</pubmed-id>
            <citation>Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon Y Cajal S: Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006 Jan;28(1):143-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P05120" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 2</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.</specific-function>
    <gene-name>SERPINB2</gene-name>
    <locus>18q21.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-</signal-regions>
    <theoretical-pi>5.34</theoretical-pi>
    <molecular-weight>46595.84</molecular-weight>
    <chromosome-location>18</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8584</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINB2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02685</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189545</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05120</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Monocyte Arg-serpin</synonym>
      <synonym>PAI-2</synonym>
      <synonym>PAI2</synonym>
      <synonym>Placental plasminogen activator inhibitor</synonym>
      <synonym>PLANH2</synonym>
      <synonym>Serpin B2</synonym>
      <synonym>Urokinase inhibitor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016268|Plasminogen activator inhibitor 2
MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF
NEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN
YLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK
IPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK
LNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM
AEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV
DVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016269|Plasminogen activator inhibitor 2 (SERPINB2)
ATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA
AAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC
ATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT
AATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG
TTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA
GATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT
TATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA
TATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA
TGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA
ATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT
GCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT
CCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG
CTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA
GATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG
CTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG
GCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC
AGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC
TCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG
GATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA
ACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCTTTTCTTTTTCTTATTATGCAT
AAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002112</id>
      <name>Plasma serine protease inhibitor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17434507</pubmed-id>
            <citation>Uhrin P, Schofer C, Zaujec J, Ryban L, Hilpert M, Weipoltshammer K, Jerabek I, Pirtzkall I, Furtmuller M, Dewerchin M, Binder BR, Geiger M: Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesis in PCI-deficient mice. Fertil Steril. 2007 Oct;88(4 Suppl):1049-57. Epub 2007 Apr 16.</citation>
          </article>
          <article>
            <pubmed-id>17253188</pubmed-id>
            <citation>Espana F, Navarro S, Medina P, Zorio E, Estelles A: The role of protein C inhibitor in human reproduction. Semin Thromb Hemost. 2007 Feb;33(1):41-5.</citation>
          </article>
          <article>
            <pubmed-id>14645112</pubmed-id>
            <citation>Odet F, Guyot R, Leduque P, Le Magueresse-Battistoni B: Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology. 2004 Mar;145(3):1481-9. Epub 2003 Nov 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05154" source="Swiss-Prot">
    <name>Plasma serine protease inhibitor</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid.</specific-function>
    <gene-name>SERPINA5</gene-name>
    <locus>14q32.1</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>9.76</theoretical-pi>
    <molecular-weight>45674.315</molecular-weight>
    <chromosome-location>14</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINA5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02639</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>180550</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05154</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IPSP_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Acrosomal serine protease inhibitor</synonym>
      <synonym>PAI-3</synonym>
      <synonym>PAI3</synonym>
      <synonym>PCI</synonym>
      <synonym>PLANH3</synonym>
      <synonym>Plasminogen activator inhibitor 3</synonym>
      <synonym>PROCI</synonym>
      <synonym>Protein C inhibitor</synonym>
      <synonym>Serpin A5</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011531|Plasma serine protease inhibitor
MQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA
PSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ
PRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT
KGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED
QYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE
LYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT
RAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011532|Plasma serine protease inhibitor (SERPINA5)
ATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC
CGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG
GCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC
CCCAGCCAGAGCATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC
CTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG
AAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG
CCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC
CTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCTACC
AACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG
AAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG
AATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG
CAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT
CAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA
GGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT
GGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG
CTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT
CTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCGGCATCAGCAACCACTCA
AATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC
AGAGCAGCGGCAGCCACGGGGACAATATTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG
AGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT
GGCAAAGTGAACCGCCCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-plasma kallikrein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-PLAT complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-PLAU complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet dense tubular network</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-thrombin complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-TMPRSS11E complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-TMPRSS7 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>acrosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-coagulation factor V complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-coagulation factor Xa complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-coagulation factor XI complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein C inhibitor-KLK3 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>retinoic acid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphatidylcholine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycosaminoglycan binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>acrosin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of hydrolase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fusion of sperm to egg plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0000942</id>
      <name>Low-density lipoprotein receptor-related protein 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>8241286</pubmed-id>
            <citation>Kanalas JJ: Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. Biochim Biophys Acta. 1993 Nov 25;1225(1):101-6.</citation>
          </article>
          <article>
            <pubmed-id>1280065</pubmed-id>
            <citation>Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60.</citation>
          </article>
          <article>
            <pubmed-id>7959795</pubmed-id>
            <citation>Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS: Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1). Genomics. 1994 Jul 1;22(1):88-93.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P98164" source="Swiss-Prot">
    <name>Low-density lipoprotein receptor-related protein 2</name>
    <general-function>Calcium ion binding</general-function>
    <specific-function>Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.</specific-function>
    <gene-name>LRP2</gene-name>
    <locus>2q24-q31</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>4424-4446</transmembrane-regions>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>4.68</theoretical-pi>
    <molecular-weight>521952.77</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6694</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LRP2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U33837</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1809240</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P98164</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LRP2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Glycoprotein 330</synonym>
      <synonym>gp330</synonym>
      <synonym>LRP-2</synonym>
      <synonym>Megalin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2
MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
GCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)
ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
ATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG
ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA
GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
CCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA
GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
TACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT
TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
TTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
ACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
CAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF12662</identifier>
        <name>cEGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>coated pit</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>apical plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>brush border membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin D metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein glycosylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>forebrain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0001656</id>
      <name>Suppressor of tumorigenicity 14 protein</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>14747469</pubmed-id>
            <citation>Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27.</citation>
          </article>
          <article>
            <pubmed-id>12815039</pubmed-id>
            <citation>Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y5Y6" source="Swiss-Prot">
    <name>Suppressor of tumorigenicity 14 protein</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.</specific-function>
    <gene-name>ST14</gene-name>
    <locus>11q24-q25</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>56-76</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.53</theoretical-pi>
    <molecular-weight>94769.01</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11344</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ST14</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF118224</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>6647302</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2418</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q9Y5Y6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ST14_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.109</synonym>
      <synonym>Matriptase</synonym>
      <synonym>Membrane-type serine protease 1</synonym>
      <synonym>MT-SP1</synonym>
      <synonym>Prostamin</synonym>
      <synonym>PRSS14</synonym>
      <synonym>Serine protease 14</synonym>
      <synonym>Serine protease TADG-15</synonym>
      <synonym>SNC19</synonym>
      <synonym>TADG15</synonym>
      <synonym>Tumor-associated differentially-expressed gene 15 protein</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016512|Suppressor of tumorigenicity 14 protein
MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA
VLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV
KDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM
LPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA
HARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS
YNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY
PPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS
NSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH
SDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK
SQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK
DCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID
DRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP
AEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL
PQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT
RLPLFRDWIKENTGV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016513|Suppressor of tumorigenicity 14 protein (ST14)
ATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC
AAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA
GTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC
GTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG
TACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT
TTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG
AAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG
TCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC
ATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG
CTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC
ACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC
CGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT
CATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC
CGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC
ACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC
TACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT
GAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT
GGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC
CCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG
CGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC
TACGTGGAGATCAACGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC
AACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC
TTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC
ACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC
AGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC
TGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG
CAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA
AGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC
AAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG
AGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG
GACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT
GCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC
TGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT
GACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC
CAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC
CCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG
GCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT
GCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG
CTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG
CCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC
TGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG
GCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA
AGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
      <pfam>
        <identifier>PF01390</identifier>
        <name>SEA</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial cell morphogenesis involved in placental branching</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neural tube closure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>keratinocyte differentiation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0002113</id>
      <name>Nidogen-1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>1499567</pubmed-id>
            <citation>Stephens RW, Aumailley M, Timpl R, Reisberg T, Tapiovaara H, Myohanen H, Murphy-Ullrich J, Vaheri A: Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. Eur J Biochem. 1992 Aug 1;207(3):937-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14543" source="Swiss-Prot">
    <name>Nidogen-1</name>
    <general-function>Proteoglycan binding</general-function>
    <specific-function>Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell-extracellular matrix interactions.</specific-function>
    <gene-name>NID1</gene-name>
    <locus>1q43</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>4.96</theoretical-pi>
    <molecular-weight>136375.93</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:7821</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>NID1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M30269</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189209</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14543</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NID1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Entactin</synonym>
      <synonym>NID</synonym>
      <synonym>NID-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037160|Nidogen-1
MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS
GALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV
YYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ
AVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA
NDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT
TRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF
HQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG
NGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV
GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI
DEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS
PSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYALSNSIGPV
REGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV
CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT
GGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV
PGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD
RDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE
GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL
GSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW
TDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ
PSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT
ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIEQK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016685|Nidogen-1 (NID1)
ATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG
CTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA
CAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT
GGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC
ATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA
TTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT
TATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA
GGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG
GCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG
GCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT
CTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA
TTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT
AATGACAGGGAATCAGTTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC
TGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC
CTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC
ACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG
GGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA
AGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT
CACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC
AGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC
GCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC
AATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA
AGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT
TACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT
GGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG
GAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT
GAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC
GATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG
TTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG
ATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT
CCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC
GATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC
CTGTACAACCAGGAGGAGAAGATCTTGCGCTATGCTCTCAGCAACTCCATTGGGCCTGTG
AGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC
ACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC
TTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG
TGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG
GGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC
TACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA
GGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC
CAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT
CCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG
CCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG
GGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG
CACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT
CGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG
AGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG
CCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG
GGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC
ATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT
TCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT
GGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT
AACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG
ACTGACTTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG
ACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG
AGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGACCTTCGATGCGTTCTCA
TCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG
CCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG
AAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT
TCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG
GCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC
CACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA
GTTGACTGTATCGAACAGAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF00086</identifier>
        <name>Thyroglobulin_1</name>
      </pfam>
      <pfam>
        <identifier>PF06119</identifier>
        <name>NIDO</name>
      </pfam>
      <pfam>
        <identifier>PF07474</identifier>
        <name>G2F</name>
      </pfam>
      <pfam>
        <identifier>PF12662</identifier>
        <name>cEGF</name>
      </pfam>
      <pfam>
        <identifier>PF12947</identifier>
        <name>EGF_3</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basement membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basal lamina</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell periphery</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>proteoglycan binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>collagen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>laminin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glomerular basement membrane development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>basement membrane organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell-substrate adhesion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="small molecule" created="2005-06-13" updated="2017-09-01">
  <drugbank-id primary="true">DB00014</drugbank-id>
  <drugbank-id>BTD00113</drugbank-id>
  <drugbank-id>BIOD00113</drugbank-id>
  <name>Goserelin</name>
  <description>Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.</description>
  <cas-number>65807-02-5</cas-number>
  <unii>0F65R8P09N</unii>
  <average-mass>1269.4105</average-mass>
  <monoisotopic-mass>1268.641439486</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Kripa S. Srivastava, Matthew R. Davis, "Solid Phase Peptide for the Production of Goserelin." U.S. Patent US20100311946, issued December 09, 2010.</synthesis-reference>
  <indication>Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.</indication>
  <pharmacodynamics>The pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.</pharmacodynamics>
  <mechanism-of-action>Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.</mechanism-of-action>
  <toxicity>No experience of overdosage from clinical trials.</toxicity>
  <metabolism>Hepatic</metabolism>
  <absorption>Inactive orally, rapidly absorbed following subcutaneous administration.</absorption>
  <half-life>4-5 hours</half-life>
  <protein-binding>27.3%</protein-binding>
  <route-of-elimination>Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.</route-of-elimination>
  <volume-of-distribution>* 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]</volume-of-distribution>
  <clearance>* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]</clearance>
  <classification>
    <description>This compound belongs to the class of chemical entities known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.</description>
    <direct-parent>Oligopeptides</direct-parent>
    <kingdom>Chemical entities</kingdom>
    <superclass>Organic compounds</superclass>
    <class>Organic acids and derivatives</class>
    <subclass>Carboxylic acids and derivatives</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>3-alkylindoles</alternative-parent>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Amphetamines and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Carboxylic acid hydrazides</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Guanidines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Histidine and derivatives</alternative-parent>
    <alternative-parent>Hydrazinecarboxamides</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidazoles</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Leucine and derivatives</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>N-acylpyrrolidines</alternative-parent>
    <alternative-parent>Organic carbonic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylalanine and derivatives</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Proline and derivatives</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Pyrrolidine-2-ones</alternative-parent>
    <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Semicarbazides</alternative-parent>
    <alternative-parent>Serine and derivatives</alternative-parent>
    <alternative-parent>Substituted pyrroles</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tryptamines and derivatives</alternative-parent>
    <alternative-parent>Tyrosine and derivatives</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>2-pyrrolidone</substituent>
    <substituent>3-alkylindole</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Alpha-oligopeptide</substituent>
    <substituent>Amphetamine or derivatives</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonic acid derivative</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid hydrazide</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Guanidine</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Histidine or derivatives</substituent>
    <substituent>Hydrazinecarboxamide</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Indole</substituent>
    <substituent>Indole or derivatives</substituent>
    <substituent>Lactam</substituent>
    <substituent>Leucine or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>N-acylpyrrolidine</substituent>
    <substituent>N-substituted-alpha-amino acid</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenylalanine or derivatives</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Proline or derivatives</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Pyrrole</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
    <substituent>Pyrrolidine-2-carboxamide</substituent>
    <substituent>Pyrrolidone</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Semicarbazide</substituent>
    <substituent>Serine or derivatives</substituent>
    <substituent>Substituted pyrrole</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Triptan</substituent>
    <substituent>Tyrosine or derivatives</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000093</drugbank-id>
      <name>Goserelin acetate</name>
      <unii>6YUU2PV0U8</unii>
      <cas-number>145781-92-6</cas-number>
      <inchikey>IKDXDQDKCZPQSZ-JHYYTBFNSA-N</inchikey>
      <average-mass>1329.4624</average-mass>
      <monoisotopic-mass>1328.662568858</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms/>
  <products>
    <product>
      <name>Zoladex</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2027</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-05-05</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Implant</dosage-form>
      <strength>3.6 mg/1</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019726</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zoladex</name>
      <labeller>Astra Zeneca Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0310-0950</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>3.6 mg/1</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019726</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zoladex</name>
      <labeller>Astra Zeneca Lp</labeller>
      <ndc-id/>
      <ndc-product-code>0310-0951</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>10.8 mg/1</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020578</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zoladex Inj Depot 3.6mg</name>
      <labeller>Astra Zeneca</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02049325</dpd-id>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>3.6 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zoladex LA Inj Depot 10.8mg</name>
      <labeller>Astra Zeneca</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02225905</dpd-id>
      <started-marketing-on>1996-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Implant</dosage-form>
      <strength>10.8 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Zoladex</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Zoladex Inj Depot 3.6mg</name>
      <ingredients>Goserelin</ingredients>
    </mixture>
    <mixture>
      <name>Zoladex LA Inj Depot 10.8mg</name>
      <ingredients>Goserelin</ingredients>
    </mixture>
    <mixture>
      <name>Zoladex</name>
      <ingredients>Goserelin</ingredients>
    </mixture>
    <mixture>
      <name>Zoladex</name>
      <ingredients>Goserelin</ingredients>
    </mixture>
    <mixture>
      <name>Zoladex</name>
      <ingredients>Goserelin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>AstraZeneca Inc.</name>
      <url>http://www.astrazeneca.ca</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Astrazeneca uk ltd</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Zoladex 3.6 mg implant syringe</description>
      <cost currency="USD">451.19</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Zoladex 10.8 mg implant syringe</description>
      <cost currency="USD">1380.65</cost>
      <unit>syringe</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Hormonal</category>
      <mesh-id>D018931</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endocrine Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropin-Releasing Hormone</category>
      <mesh-id>D007987</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones and Related Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypothalamic Hormones</category>
      <mesh-id>D007028</mesh-id>
    </category>
    <category>
      <category>Moderate Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Oligopeptides</category>
      <mesh-id>D009842</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormone-Releasing Hormones</category>
      <mesh-id>D010906</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Implant</form>
      <route>Subcutaneous</route>
      <strength>10.8 mg/1</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Subcutaneous</route>
      <strength>3.6 mg/1</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Subcutaneous</route>
      <strength>3.6 mg</strength>
    </dosage>
    <dosage>
      <form>Implant</form>
      <route>Subcutaneous</route>
      <strength>10.8 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L02AE03">
      <level code="L02AE">Gonadotropin releasing hormone analogues</level>
      <level code="L02A">HORMONES AND RELATED AGENTS</level>
      <level code="L02">ENDOCRINE THERAPY</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:18.00</ahfs-code>
    <ahfs-code>92:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00014.pdf?1265922794</fda-label>
  <patents>
    <patent>
      <number>7118552</number>
      <country>United States</country>
      <approved>2002-04-13</approved>
      <expires>2022-04-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7220247</number>
      <country>United States</country>
      <approved>2002-04-09</approved>
      <expires>2022-04-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7500964</number>
      <country>United States</country>
      <approved>2001-02-26</approved>
      <expires>2021-02-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Goserelin may increase the QTc-prolonging activities of Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Goserelin may increase the QTc-prolonging activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>Goserelin may increase the QTc-prolonging activities of Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>Goserelin may increase the QTc-prolonging activities of Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Goserelin may increase the QTc-prolonging activities of Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Goserelin may increase the QTc-prolonging activities of Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>Goserelin may increase the QTc-prolonging activities of Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Goserelin may increase the QTc-prolonging activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>Goserelin may increase the QTc-prolonging activities of Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>Goserelin may increase the QTc-prolonging activities of Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin Alfa</name>
      <description>The therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>Ivabradine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Mifepristone may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Leuprolide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Goserelin may increase the QTc-prolonging activities of Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Goserelin may increase the QTc-prolonging activities of Droperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>Goserelin may increase the QTc-prolonging activities of Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>Goserelin may increase the QTc-prolonging activities of Perflutren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Goserelin may increase the QTc-prolonging activities of Gadobenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>Goserelin may increase the QTc-prolonging activities of Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>Goserelin may increase the QTc-prolonging activities of Granisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>Goserelin may increase the QTc-prolonging activities of Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Goserelin may increase the QTc-prolonging activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>Goserelin may increase the QTc-prolonging activities of Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>Goserelin may increase the QTc-prolonging activities of Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Goserelin may increase the QTc-prolonging activities of Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>Goserelin may increase the QTc-prolonging activities of Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>Goserelin may increase the QTc-prolonging activities of Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>Goserelin may increase the QTc-prolonging activities of Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>Octreotide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>Oxytocin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>Bortezomib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>Fluconazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>Nelfinavir may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>Ranolazine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>Isradipine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Amitriptyline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Olanzapine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>Alfuzosin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>Mefloquine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Mirtazapine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>Treprostinil may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>Sorafenib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>Trimethoprim may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Imipramine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>Ritonavir may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>Voriconazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>Nicardipine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>Trazodone may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Galantamine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Moexipril may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>Tizanidine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>Ibandronate may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>Apomorphine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Paroxetine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>Isoflurane may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>Propofol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>Vardenafil may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Terbutaline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Amantadine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>Metronidazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>Famotidine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Maprotiline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>Salmeterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>Felbamate may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>Formoterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Salbutamol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Sulfamethoxazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>Ketoconazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Tolterodine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Norfloxacin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>Atazanavir may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>Diphenhydramine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Sertraline may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>Itraconazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>Desflurane may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Metoclopramide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>Clomipramine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>Dasatinib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>Lapatinib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>Posaconazole may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>Sunitinib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Arformoterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>Lithium may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Methotrimeprazine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Solifenacin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>Thiothixene may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>Vorinostat may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ezogabine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>Indacaterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>Pasireotide may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>Degarelix may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>Buserelin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>Histrelin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>Triptorelin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>Rilpivirine may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Fingolimod may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>Eribulin may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Mirabegron may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>Dabrafenib may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>Olodaterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Vilanterol may increase the QTc-prolonging activities of Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin Lispro</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin Pork</name>
      <description>The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00419</drugbank-id>
      <name>Miglustat</name>
      <description>The therapeutic efficacy of Miglustat can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of Aicar can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The therapeutic efficacy of Castanospermine can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Sulodexide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>The therapeutic efficacy of Gusperimus can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.83e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-5.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(3H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1269.4105</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1268.641439486</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C59H84N18O14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>BLCLNMBMMGCOAS-URPVMXJPSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>495.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>325.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>131.22</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.82</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11167</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>5523</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5311128</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507336</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00573</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4470656</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164747674</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000023</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Goserelin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201247</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/goserel.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/goserelin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000134</id>
      <name>Lutropin-choriogonadotropic hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>20053189</pubmed-id>
            <citation>Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22888" source="Swiss-Prot">
    <name>Lutropin-choriogonadotropic hormone receptor</name>
    <general-function>Luteinizing hormone receptor activity</general-function>
    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.</specific-function>
    <gene-name>LHCGR</gene-name>
    <locus>2p21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>364-385
396-416
440-462
483-505
526-549
571-594
606-627</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>78642.01</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6585</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LHCGR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M73746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>903746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P22888</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LSHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>LCGR</synonym>
      <synonym>LGR2</synonym>
      <synonym>LH/CG-R</synonym>
      <synonym>LHR</synonym>
      <synonym>LHRHR</synonym>
      <synonym>LSH-R</synonym>
      <synonym>Luteinizing hormone receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor
MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
SKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)
ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG
CTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC
GCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT
GTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC
TCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG
TCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA
AATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT
GTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC
ATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA
CTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT
TCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG
GCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT
GGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA
TCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT
GCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT
TCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG
CTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA
CCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC
TTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT
CTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT
CTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC
CAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC
ACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC
ACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA
AGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG
CCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA
ACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC
ATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT
ACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC
TGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA
GTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA
TTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA
TTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC
TCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG
TCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF13306</identifier>
        <name>LRR_5</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>luteinizing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled peptide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to gonadotropin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cognition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>luteinizing hormone signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male genitalia development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation cycle process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inositol trisphosphate biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>uterus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000203</id>
      <name>Gonadotropin-releasing hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20053189</pubmed-id>
            <citation>Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30968" source="Swiss-Prot">
    <name>Gonadotropin-releasing hormone receptor</name>
    <general-function>Peptide binding</general-function>
    <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.</specific-function>
    <gene-name>GNRHR</gene-name>
    <locus>4q21.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>39-58
78-97
116-137
165-184
213-232
282-300
307-326</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.93</theoretical-pi>
    <molecular-weight>37730.355</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4421</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GNRHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L03380</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>183422</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>256</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>256</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P30968</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GNRHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GnRH receptor</synonym>
      <synonym>GRHR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor
MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)
ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>gonadotropin-releasing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to gonadotropin-releasing hormone</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-08">
  <drugbank-id primary="true">DB00015</drugbank-id>
  <drugbank-id>BTD00013</drugbank-id>
  <drugbank-id>BIOD00013</drugbank-id>
  <name>Reteplase</name>
  <description>Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).</description>
  <cas-number>133652-38-7</cas-number>
  <unii>DQA630RIE9</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction</indication>
  <pharmacodynamics>Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
  <mechanism-of-action>Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Human t-PA (residues 1-3 and 176-527)</synonym>
    <synonym language="" coder="">Reteplase, recombinant</synonym>
    <synonym language="" coder="">Reteplase,recombinant</synonym>
  </synonyms>
  <products>
    <product>
      <name>Retavase</name>
      <labeller>Ekr Therapeutics</labeller>
      <ndc-id/>
      <ndc-product-code>24477-040</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-10-30</started-marketing-on>
      <ended-marketing-on>2017-03-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Retavase</name>
      <labeller>Ekr Therapeutics</labeller>
      <ndc-id/>
      <ndc-product-code>24477-041</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-10-30</started-marketing-on>
      <ended-marketing-on>2017-03-14</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Retavase</name>
      <labeller>Chiesi Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10122-141</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Retavase</name>
      <labeller>Chiesi Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10122-143</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103786</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Retavase</name>
      <labeller>Ekr Therapeutics</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02233013</dpd-id>
      <started-marketing-on>1999-02-19</started-marketing-on>
      <ended-marketing-on>2013-08-29</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>10.4 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Retavase</name>
      <ingredients>Reteplase</ingredients>
    </mixture>
    <mixture>
      <name>Retavase</name>
      <ingredients>Reteplase</ingredients>
    </mixture>
    <mixture>
      <name>Retavase</name>
      <ingredients>Reteplase</ingredients>
    </mixture>
    <mixture>
      <name>Retavase</name>
      <ingredients>Reteplase</ingredients>
    </mixture>
    <mixture>
      <name>Retavase</name>
      <ingredients>Reteplase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>EKR Therapeutics Inc.</name>
      <url>http://www.ekrtx.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>PDL BioPharma Inc.</name>
      <url>http://www.pdl.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Retavase vial half-kit</description>
      <cost currency="USD">2605.93</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Plasminogen Activators</category>
      <mesh-id>D010960</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>10.4 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AD07">
      <level code="B01AD">Enzymes</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1BDA</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2107476</number>
      <country>Canada</country>
      <approved>2007-12-18</approved>
      <expires>2012-04-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Reteplase may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Reteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Reteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Reteplase may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Reteplase may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Reteplase may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Reteplase may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Reteplase may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Reteplase may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Reteplase may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Reteplase may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Reteplase may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Reteplase may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Reteplase may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Reteplase may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Reteplase may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Reteplase may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Reteplase may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Reteplase may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Reteplase may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Reteplase may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Reteplase may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Reteplase may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Reteplase may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Reteplase may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Reteplase may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Reteplase may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Reteplase may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Reteplase may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Reteplase may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Reteplase may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Reteplase may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Reteplase may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Reteplase may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Reteplase may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Reteplase may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Reteplase may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Reteplase may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Reteplase may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Reteplase may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Reteplase may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Reteplase may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Reteplase may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Reteplase may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Reteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Reteplase may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>The risk or severity of adverse effects can be increased when dersalazine is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Vorapaxar may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00015 sequence
SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYC
RNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAA
IFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKF
EVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELS
GYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHD
ACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>60 °C</value>
      <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.435</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>6.86</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>39589.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1736H2671N499O522S22</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11534</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>L00153</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164743728</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00750</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001195</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Reteplase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2107885</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/reteplase.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/reteplase.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00285</smpdb-id>
      <name>Reteplase Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00015</drugbank-id>
          <name>Reteplase</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
    <name>Plasminogen</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
    <gene-name>PLG</gene-name>
    <locus>6q26</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>7.25</theoretical-pi>
    <molecular-weight>90568.415</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9071</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X05199</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387026</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PLMN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00024</identifier>
        <name>PAN_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tissue remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibrinolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000538</id>
      <name>Fibrinogen alpha chain</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02671" source="Swiss-Prot">
    <name>Fibrinogen alpha chain</name>
    <general-function>Structural molecule activity</general-function>
    <specific-function>Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.</specific-function>
    <gene-name>FGA</gene-name>
    <locus>4q28</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.87</theoretical-pi>
    <molecular-weight>94972.455</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3661</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF361104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>13591824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FIBA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fibrinogen alpha chain precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001074|Fibrinogen alpha chain
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)
ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA
GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
AGGCCCCTTGTGACCCAATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00147</identifier>
        <name>Fibrinogen_C</name>
      </pfam>
      <pfam>
        <identifier>PF08702</identifier>
        <name>Fib_alpha</name>
      </pfam>
      <pfam>
        <identifier>PF12160</identifier>
        <name>Fibrinogen_aC</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>fibrinogen complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>structural molecule activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>liver regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to genistein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet aggregation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic cyclic compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>induction of bacterial agglutination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-6</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to granulocyte colony-stimulating factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heterotypic cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, fibrin clot formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cycloheximide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptide hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein polymerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adaptive immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000717</id>
      <name>Urokinase plasminogen activator surface receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q03405" source="Swiss-Prot">
    <name>Urokinase plasminogen activator surface receptor</name>
    <general-function>Urokinase plasminogen activator receptor activity</general-function>
    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.</specific-function>
    <gene-name>PLAUR</gene-name>
    <locus>19q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>36977.62</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9053</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAUR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51675</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q03405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UPAR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>MO3</synonym>
      <synonym>Monocyte activation antigen Mo3</synonym>
      <synonym>U-PAR</synonym>
      <synonym>UPAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)
ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG
CCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT
GTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00021</identifier>
        <name>UPAR_LY6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>invadopodium membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>urokinase plasminogen activator receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>attachment of GPI anchor to protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>C-terminal protein lipidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urokinase plasminogen activator signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of cytochrome c from mitochondria</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000240</id>
      <name>Plasminogen activator inhibitor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05121" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 1</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>
    <gene-name>SERPINE1</gene-name>
    <locus>7q21.3-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.22</theoretical-pi>
    <molecular-weight>45059.695</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINE1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04429</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35272</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05121</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Endothelial plasminogen activator inhibitor</synonym>
      <synonym>PAI</synonym>
      <synonym>PAI1</synonym>
      <synonym>PLANH1</synonym>
      <synonym>Serpin E1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)
ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC
TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
GAACCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronological cell aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-negative bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukotriene production involved in inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription initiation from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of wound healing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-22">
  <drugbank-id primary="true">DB00016</drugbank-id>
  <drugbank-id>BTD00103</drugbank-id>
  <drugbank-id>BIOD00103</drugbank-id>
  <drugbank-id>DB08923</drugbank-id>
  <name>Erythropoietin</name>
  <description>Erythropoietin is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.</description>
  <cas-number>11096-26-7</cas-number>
  <unii>64FS3BFH5W</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>18208642</pubmed-id>
        <citation>Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R: Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264.</citation>
      </article>
      <article>
        <pubmed-id>20369312</pubmed-id>
        <citation>Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A: Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010 Feb;27(2):105-17. doi: 10.1007/s12325-010-0012-y. Epub 2010 Mar 30.</citation>
      </article>
      <article>
        <pubmed-id>20886265</pubmed-id>
        <citation>Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H: Quality of original and biosimilar epoetin products. Pharm Res. 2011 Feb;28(2):386-93. doi: 10.1007/s11095-010-0288-2. Epub 2010 Oct 1.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Link</title>
        <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>For use in the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients. Also for use in the treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). Also for used to increase the yield of autologous blood from patients in a predonation program. When administered subcutaneously, Epoetin Zeta is equivalent to Epoetin Alfa in terms of clinical effectiveness.</indication>
  <pharmacodynamics>Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.</pharmacodynamics>
  <mechanism-of-action>Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>Toxicokinetic results from rats in a 13 week toxicity study after a single subcutaneous dose:&#13;
&#13;
* 7.37 hours (+/- 0.70) with 500 IU/kg [test 1]&#13;
* 8.63 hours (+/- 2.78) with 2500 IU/kg [test 2]&#13;
* 8.76 hours (+/- 1.46) with 2500 IU/kg [reference dose]</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]&#13;
* 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]&#13;
* 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]&#13;
* 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">E.P.O.</synonym>
    <synonym language="" coder="">Epoetin alfa</synonym>
    <synonym language="" coder="">Epoetin alfa rDNA</synonym>
    <synonym language="" coder="">Epoetin alfa, recombinant</synonym>
    <synonym language="" coder="">Epoetin beta</synonym>
    <synonym language="" coder="">Epoetin beta rDNA</synonym>
    <synonym language="" coder="">Epoetin epsilon</synonym>
    <synonym language="" coder="">Epoetin gamma</synonym>
    <synonym language="" coder="">Epoetin gamma rDNA</synonym>
    <synonym language="" coder="">Epoetin kappa</synonym>
    <synonym language="" coder="">Epoetin omega</synonym>
    <synonym language="" coder="">Epoetin theta</synonym>
    <synonym language="English/German" coder="">Epoetin zeta</synonym>
    <synonym language="Spanish" coder="">Epoetina dseta</synonym>
    <synonym language="French" coder="">Epoétine zêta</synonym>
    <synonym language="Latin" coder="">Epoetinum zeta</synonym>
    <synonym language="" coder="">Erythropoiesis stimulating factor</synonym>
    <synonym language="" coder="">Erythropoietin (human, recombinant)</synonym>
    <synonym language="" coder="">Erythropoietin (recombinant human)</synonym>
    <synonym language="" coder="">ESF</synonym>
    <synonym language="" coder="">SH-polypeptide-72</synonym>
  </synonyms>
  <products>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-126</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-144</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-148</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1993-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-267</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1990-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>3000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-283</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-12-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Epogen</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-478</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eprex Sterile Solution</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02288680</dpd-id>
      <started-marketing-on>2007-11-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>30000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243239</dpd-id>
      <started-marketing-on>2005-08-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>20000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 10000iu/1.0ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231587</dpd-id>
      <started-marketing-on>1997-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 10000iu/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126591</dpd-id>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2014-10-09</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 1000iu/0.5ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231583</dpd-id>
      <started-marketing-on>1997-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 20000iu/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02206072</dpd-id>
      <started-marketing-on>1996-10-02</started-marketing-on>
      <ended-marketing-on>2010-04-29</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>20000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 2000iu/0.5ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231584</dpd-id>
      <started-marketing-on>1997-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 2000iu/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126575</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-25</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 3000iu/0.3ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231585</dpd-id>
      <started-marketing-on>1997-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 40000iu/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240722</dpd-id>
      <started-marketing-on>1999-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>40000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 4000iu/0.4ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231586</dpd-id>
      <started-marketing-on>1997-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 4000iu/ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126583</dpd-id>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>2014-10-09</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>4000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 5000iu/0.5ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243400</dpd-id>
      <started-marketing-on>2002-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 6000 Iu/0.6 Ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243401</dpd-id>
      <started-marketing-on>2001-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>6000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eprex Sterile Solution 8000 Iu/0.8 Ml</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243403</dpd-id>
      <started-marketing-on>2001-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>8000 unit</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-302</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-303</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>3000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-304</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-310</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-312</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-320</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Janssen, Lp</labeller>
      <ndc-id/>
      <ndc-product-code>59676-340</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2523</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5673</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-03-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procrit</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5802</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40000 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103234</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Binocrit</name>
      <company>Sandoz</company>
    </international-brand>
    <international-brand>
      <name>Epobel</name>
      <company>Nobel Ilac Pazarlama ve Sanayii Ltd. STI., Turkey</company>
    </international-brand>
    <international-brand>
      <name>Epocept</name>
      <company>Lupin pharma</company>
    </international-brand>
    <international-brand>
      <name>Epofit</name>
      <company>Intas pharma</company>
    </international-brand>
    <international-brand>
      <name>Epogin</name>
      <company>Chugai</company>
    </international-brand>
    <international-brand>
      <name>Eqralys</name>
      <company>Hemofarm AD</company>
    </international-brand>
    <international-brand>
      <name>Nanokine</name>
      <company>Nanogen Pharmaceutical biotechnology, Vietnam)</company>
    </international-brand>
    <international-brand>
      <name>Retacrit</name>
      <company>Hospira, Inc.</company>
    </international-brand>
    <international-brand>
      <name>Silapo</name>
      <company>Cell Pharm GmbH</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Eprex Sterile Solution 1000iu/0.5ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 2000iu/0.5ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 3000iu/0.3ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 4000iu/0.4ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 10000iu/1.0ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 40000iu/ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 5000iu/0.5ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 6000 Iu/0.6 Ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 8000 Iu/0.8 Ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 10000iu/ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 4000iu/ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 2000iu/ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eprex Sterile Solution 20000iu/ml</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Procrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Abseamed</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Silapo</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epoetin Alfa Hexal</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Binocrit</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Eporatio</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Biopoin</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
    <mixture>
      <name>Epogen</name>
      <ingredients>Erythropoietin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Centocor Ortho Biotech Inc.</name>
      <url>http://www.centocororthobiotech.com</url>
    </packager>
    <packager>
      <name>DSM Corp.</name>
      <url>http://www.dsm.com</url>
    </packager>
    <packager>
      <name>Janssen-Ortho Inc.</name>
      <url>http://www.janssen-ortho.com</url>
    </packager>
    <packager>
      <name>JHP Pharmaceuticals LLC</name>
      <url>http://www.jhppharma.com</url>
    </packager>
    <packager>
      <name>Ortho-McNeil-Janssen Pharmaceuticals Inc.</name>
      <url>http://www.ortho-mcneil.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Epogen 2000 unit/ml vial</description>
      <cost currency="USD">34.14</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 2000 unit/ml vial</description>
      <cost currency="USD">37.09</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Epogen 3000 unit/ml vial</description>
      <cost currency="USD">47.53</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 3000 unit/ml vial</description>
      <cost currency="USD">55.63</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Epogen 4000 unit/ml vial</description>
      <cost currency="USD">61.34</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 4000 unit/ml vial</description>
      <cost currency="USD">74.17</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Epogen 10000 unit/ml vial</description>
      <cost currency="USD">151.8</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Epogen 20000 unit/ml vial</description>
      <cost currency="USD">303.6</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Epogen 10000 unit/ml Solution 2ml Vial</description>
      <cost currency="USD">315.74</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 10000 unit/ml Solution 2ml Vial</description>
      <cost currency="USD">358.02</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 20000 unit/ml Solution</description>
      <cost currency="USD">378.14</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Procrit 20000 unit/ml vial</description>
      <cost currency="USD">388.97</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Epogen 40000 unit/ml vial</description>
      <cost currency="USD">640.37</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Procrit 10000 unit/ml vial</description>
      <cost currency="USD">710.87</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Procrit 40000 unit/ml vial</description>
      <cost currency="USD">767.03</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Epogen 10000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
      <cost currency="USD">1578.72</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Epogen 20000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
      <cost currency="USD">3157.44</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Epogen 40000 unit/ml Solution 1 Box Contains Ten 1ml Vials</description>
      <cost currency="USD">6852.3</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antianemic Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Erythropoiesis-Stimulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Erythropoietin</category>
      <mesh-id>D004921</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematinics</category>
      <mesh-id>D006397</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 IU/1.0ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 IU/1.0ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 IU/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30000 IU/0.75ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 IU/0.4ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40000 IU/1.0ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40000 IU/1ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>5000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>6000 IU/0.6ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>7000 IU/0.7ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>8000 IU/0.8ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>9000 IU/0.9ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 IU/1ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20000 IU/1.0ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30000 IU/1.0ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 IU/0.5ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>30000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>5000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>6000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>8000 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>20000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1000 IU/0.3ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>2000 IU/0.6ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>3000 IU/0.9ml</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B03XA01">
      <level code="B03XA">Other antianemic preparations</level>
      <level code="B03X">OTHER ANTIANEMIC PREPARATIONS</level>
      <level code="B03">ANTIANEMIC PREPARATIONS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1EER</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00016.pdf?1265922800</fda-label>
  <patents>
    <patent>
      <number>1339047</number>
      <country>Canada</country>
      <approved>1997-05-27</approved>
      <expires>2014-05-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>Nandrolone phenpropionate may increase the stimulatory activities of Erythropoietin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>Nandrolone decanoate may increase the stimulatory activities of Erythropoietin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>Erythropoietin may increase the thrombogenic activities of Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Erythropoietin may increase the thrombogenic activities of Thalidomide.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00016 (Erythropoietin) sequence
APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA
VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS
PPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>53 °C</value>
      <source>Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)</source>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.75</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>18396.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C815H1317N233O241S5</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>299</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X02158</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10072</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01588</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000202</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Epoetin_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201565</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/epoetin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/epoetin-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000654</id>
      <name>Erythropoietin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>16505108</pubmed-id>
            <citation>LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55.</citation>
          </article>
          <article>
            <pubmed-id>17575216</pubmed-id>
            <citation>Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P19235" source="Swiss-Prot">
    <name>Erythropoietin receptor</name>
    <general-function>Identical protein binding</general-function>
    <specific-function>Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.</specific-function>
    <gene-name>EPOR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>251-273</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>4.37</theoretical-pi>
    <molecular-weight>55064.725</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3416</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>EPOR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M60459</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182245</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1718</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P19235</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>EPOR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EPO-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001304|Erythropoietin receptor
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010455|Erythropoietin receptor (EPOR)
ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
CCCCCCAGCTATGTGGCTTGCTCTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF09067</identifier>
        <name>EpoR_lig-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>erythropoietin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heart development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>decidualization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>erythropoietin-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-08-08">
  <drugbank-id primary="true">DB00017</drugbank-id>
  <drugbank-id>BTD00025</drugbank-id>
  <drugbank-id>BIOD00025</drugbank-id>
  <name>Salmon Calcitonin</name>
  <description>Synthetic peptide, 32 residues long formulated as a nasal spray.</description>
  <cas-number>47931-85-1</cas-number>
  <unii>7SFC6U2VI5</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, "Procedure for preparing salmon calcitonin." U.S. Patent US5527881, issued October, 1991.</synthesis-reference>
  <indication>Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.  </indication>
  <pharmacodynamics>Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.</pharmacodynamics>
  <mechanism-of-action>Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.</mechanism-of-action>
  <toxicity>Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases.&#13;
Nausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others. </toxicity>
  <metabolism>Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. It is also metabolized in the blood and the peripheral tissue. </metabolism>
  <absorption>Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.</absorption>
  <half-life>Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes </half-life>
  <protein-binding>30 to 40%</protein-binding>
  <route-of-elimination>Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.</route-of-elimination>
  <volume-of-distribution>0.15 to 0.3 L/kg</volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Calcitonin (Salmon Synthetic)</synonym>
    <synonym language="" coder="">Calcitonin Salmon</synonym>
    <synonym language="" coder="">Calcitonin salmon recombinant</synonym>
    <synonym language="" coder="">Calcitonin-salmon</synonym>
    <synonym language="" coder="">Calcitonin, salmon</synonym>
    <synonym language="" coder="EMA">Recombinant salmon calcitonin</synonym>
    <synonym language="" coder="">Salmon calcitonin</synonym>
  </synonyms>
  <products>
    <product>
      <name>Apo-calcitonin Injectable</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246058</dpd-id>
      <started-marketing-on>2003-05-01</started-marketing-on>
      <ended-marketing-on>2013-08-02</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>200 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-calcitonin Nasal Spray</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247585</dpd-id>
      <started-marketing-on>2003-09-12</started-marketing-on>
      <ended-marketing-on>2013-10-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>200 unit</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Calcimar Solution Inj 200unit/ml</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01926691</dpd-id>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Calcitonin (salmon) Injection, BP</name>
      <labeller>Mylan Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02383233</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Calcitonin Salmon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6323</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>200 [iU]/.09mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA076979</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Calcitonin Salmon</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>0781-6320</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>200 [iU]/1</strength>
      <route>Nasal</route>
      <fda-application-number>NDA020313</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Calcitonin Salmon</name>
      <labeller>Par Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49884-161</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>200 [iU]/.09mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA076979</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Calcitonin Salmon</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0823</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>200 [iU]/1</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA076396</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Caltine Inj 100 Unit/ml (1ml Amp)</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02007134</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2014-07-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Caltine Inj 100unit/ml (0.5ml Amp)</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01940376</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-01-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fortical</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5499</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>2200 [iU]/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA021406</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fortical</name>
      <labeller>Upsher Smith Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0245-0008</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>2200 [iU]/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA021406</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miacalcin</name>
      <labeller>Sebela Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54766-149</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1986-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 [iU]/mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA017808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miacalcin</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0149</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1986-07-03</started-marketing-on>
      <ended-marketing-on>2017-02-28</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 [iU]/mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>NDA017808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miacalcin</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0311</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-08-01</started-marketing-on>
      <ended-marketing-on>2017-04-14</ended-marketing-on>
      <dosage-form>Spray, metered</dosage-form>
      <strength>200 [iU]/1</strength>
      <route>Nasal</route>
      <fda-application-number>NDA020313</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miacalcin</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>67457-675</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 [iU]/mL</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number>NDA017808</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miacalcin Injection 200iu/ml</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02144301</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>200 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Miacalcin Nasal Spray 200 Iu</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240775</dpd-id>
      <started-marketing-on>1999-09-08</started-marketing-on>
      <ended-marketing-on>2013-10-01</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>200 unit</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pro-calcitonin - 200</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311046</dpd-id>
      <started-marketing-on>2008-07-04</started-marketing-on>
      <ended-marketing-on>2011-07-27</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>200 unit</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz-calcitonin NS</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02261766</dpd-id>
      <started-marketing-on>2004-12-01</started-marketing-on>
      <ended-marketing-on>2013-10-01</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>200 unit</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Calcimar</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Miacalcin</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Fortical</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcitonin Salmon</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Miacalcin</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Fortical</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcitonin Salmon</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcitonin Salmon</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcimar Solution Inj 200unit/ml</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Caltine Inj 100 Unit/ml (1ml Amp)</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Caltine Inj 100unit/ml (0.5ml Amp)</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Miacalcin Nasal Spray 200 Iu</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Apo-calcitonin Injectable</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Apo-calcitonin Nasal Spray</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz-calcitonin NS</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Pro-calcitonin - 200</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcitonin (salmon) Injection, BP</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Miacalcin Injection 200iu/ml</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Forcaltonin</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Miacalcin</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Calcitonin Salmon</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
    <mixture>
      <name>Miacalcin</name>
      <ingredients>Salmon Calcitonin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Apotex Inc.</name>
      <url>http://www.apotex.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Par Pharmaceuticals</name>
      <url>http://www.parpharm.com</url>
    </packager>
    <packager>
      <name>Sandoz</name>
      <url>http://www.sandoz.ca</url>
    </packager>
    <packager>
      <name>Upsher Smith Laboratories</name>
      <url>http://www.upsher-smith.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Sanofi aventis us llc</manufacturer>
    <manufacturer generic="false" url="">Astrazeneca lp</manufacturer>
    <manufacturer generic="false" url="">Novartis pharmaceuticals corp</manufacturer>
    <manufacturer generic="false" url="">Apotex inc</manufacturer>
    <manufacturer generic="false" url="">Par pharmaceutical inc</manufacturer>
    <manufacturer generic="false" url="">Upsher smith laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Caltine 100 (100 Iu/Ml) 100 iu/ml</description>
      <cost currency="USD">8.81</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Calcimar 200 iu/ml</description>
      <cost currency="USD">29.94</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Miacalcin 200 unit/ml vial</description>
      <cost currency="USD">30.73</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Fortical 200 unit nasal spray</description>
      <cost currency="USD">34.3</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Calcitonin-salmon 200 unit sp</description>
      <cost currency="USD">39.51</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Miacalcin 200 unit nasal spray</description>
      <cost currency="USD">44.68</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Miacalcin For Inj, 2 unit = 1 Box 2ml Vial</description>
      <cost currency="USD">63.59</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Calcitonin (Salmon) 200 unit/act Solution 3.7ml Bottle</description>
      <cost currency="USD">123.28</cost>
      <unit>bottle</unit>
    </price>
    <price>
      <description>Miacalcin 200 unit/act Solution 3.7ml Bottle</description>
      <cost currency="USD">139.39</cost>
      <unit>bottle</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Parathyroid Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Bone Density Conservation Agents</category>
      <mesh-id>D050071</mesh-id>
    </category>
    <category>
      <category>Bone Density, drug effects</category>
      <mesh-id/>
    </category>
    <category>
      <category>Calcitonin Preparations</category>
      <mesh-id>D002116</mesh-id>
    </category>
    <category>
      <category>Calcium Homeostasis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>200 [iU]/.09mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>2200 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>200 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>200 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>200 [iU]/1</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Nasal</route>
      <strength>200 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H05BA01">
      <level code="H05BA">Calcitonin preparations</level>
      <level code="H05B">ANTI-PARATHYROID AGENTS</level>
      <level code="H05">CALCIUM HOMEOSTASIS</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:24.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2GLH</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>5733569</number>
      <country>United States</country>
      <approved>1995-03-31</approved>
      <expires>2015-03-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6440392</number>
      <country>United States</country>
      <approved>2001-02-02</approved>
      <expires>2021-02-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>RE43580</number>
      <country>United States</country>
      <approved>2001-02-02</approved>
      <expires>2021-02-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>RE40812</number>
      <country>United States</country>
      <approved>2001-02-02</approved>
      <expires>2021-02-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00399</drugbank-id>
      <name>Zoledronic acid</name>
      <description>Salmon Calcitonin may increase the hypocalcemic activities of Zoledronic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>The serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00017 sequence
CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.537</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.86</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>3431.853</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C145H240N44O48S2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13186</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06865</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00249</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>Y00765</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448715</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01263</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001302</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Calcitonin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/calcit.htm</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000431</id>
      <name>Calcitonin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>3004987</pubmed-id>
            <citation>Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7.</citation>
          </article>
          <article>
            <pubmed-id>7610922</pubmed-id>
            <citation>Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32.</citation>
          </article>
          <article>
            <pubmed-id>9231703</pubmed-id>
            <citation>Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P30988" source="Swiss-Prot">
    <name>Calcitonin receptor</name>
    <general-function>Receptor activity</general-function>
    <specific-function>This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.</specific-function>
    <gene-name>CALCR</gene-name>
    <locus>7q21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>172-191
215-234
255-277
295-314
331-354
378-395
408-429</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>8.71</theoretical-pi>
    <molecular-weight>59351.865</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1440</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CALCR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L00587</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>179880</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>43</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>43</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P30988</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CALCR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CT-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037016|Calcitonin receptor
MQFSGEKISGQRDLQKSKMRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYV
VGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDF
DPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFT
LVISLGIFVFFRKLTTIFPLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVV
PNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLG
WGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTK
MRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFF
VATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQE
PRNEPANNQGEESAEIIPLNIIEQESSA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010301|Calcitonin receptor (CALCR)
ATGCAATTTTCTGGAGAGAAGATTAGTGGACAAAGAGATCTTCAAAAATCAAAAATGAGG
TTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACCCCAATT
CTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTTTACGTC
GTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAGCAGTTA
CCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTGTGCTGG
GATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCGGATTTT
GATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAACATCCT
GAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAGAAACTG
AAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATTTTCACC
CTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTTCCTTTG
AATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCACAAGAAC
ATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAAGTAGTA
CCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTTTTCCAC
CAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTTCATACA
CTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTCTTGGGC
TGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTACTTCAAT
GACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCTGTCATG
GCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTGACCAAA
ATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCCACCATG
ATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCCAACAAG
ATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGCTTCTTT
GTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGCCAATGG
GCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGCTCTGCT
CGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCATCAGGAG
CTGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCTTTGAAT
ATCATAGAGCAAGAGTCATCTGCTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcitonin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcitonin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP biosynthetic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00018</drugbank-id>
  <drugbank-id>BTD00023</drugbank-id>
  <drugbank-id>BIOD00023</drugbank-id>
  <name>Interferon alfa-n3</name>
  <description>Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).</description>
  <cas-number/>
  <unii>47BPR3V3MP</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>10868311</pubmed-id>
        <citation>Sturgill MG, Rashidbaigi A, Liao MJ, Zhao XX, Hua J, Trout R, Knill JR, Grasing KW: Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity. J Clin Pharmacol. 2000 Jun;40(6):606-15.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the intralesional treatment of refractory or recurring external condylomata acuminata.</indication>
  <pharmacodynamics>Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.</pharmacodynamics>
  <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Alferon</name>
      <labeller>Hemispherx Biopharma</labeller>
      <ndc-id/>
      <ndc-product-code>54746-001</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-10-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>5000000 [arb'U]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103158</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alferon</name>
      <company>Interferon Sciences Inc.</company>
    </international-brand>
    <international-brand>
      <name>Alferon LDO</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Alferon N Injection</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Alferon</name>
      <ingredients>Interferon alfa-n3</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Hemispherx Biopharma Inc.</name>
      <url>http://www.hemispherx.net</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Alferon n 5 million unit vial</description>
      <cost currency="USD">412.87</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alfa Interferons</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>5000000 [arb'U]/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1ITF</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ribavirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00018 sequence (alpha-2A)
CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
    <sequence format="FASTA">&gt;DB00018 sequence (alpha-2B)
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
    <sequence format="FASTA">&gt;DB00018 sequence (alpha-2C)
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746228</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001281</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2109047</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/interferon-alfa-n3-solution.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>16953837</pubmed-id>
            <citation>Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-01-03">
  <drugbank-id primary="true">DB00019</drugbank-id>
  <drugbank-id>BTD00094</drugbank-id>
  <drugbank-id>BIOD00094</drugbank-id>
  <name>Pegfilgrastim</name>
  <description>PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation.</description>
  <cas-number>208265-92-3</cas-number>
  <unii>3A58010674</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>21456630</pubmed-id>
        <citation>Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant.</indication>
  <pharmacodynamics>Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.</pharmacodynamics>
  <mechanism-of-action>Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>15-80 hrs</half-life>
  <protein-binding/>
  <route-of-elimination>Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Granulocyte colony-stimulating factor pegfilgrastim</synonym>
    <synonym language="" coder="">Peg-filgrastim</synonym>
  </synonyms>
  <products>
    <product>
      <name>Neulasta</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-190</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>6 mg/.6mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125031</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neulasta</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code>55513-192</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2002-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125031</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neulasta</name>
      <labeller>Amgen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02249790</dpd-id>
      <started-marketing-on>2004-03-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Neulasta</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
    <mixture>
      <name>Neupopeg</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
    <mixture>
      <name>Neupopeg</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
    <mixture>
      <name>Neupopeg</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
    <mixture>
      <name>Neulasta</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
    <mixture>
      <name>Neulasta</name>
      <ingredients>Pegfilgrastim</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Neulasta 6 mg/0.6ml Solution 0.6ml Syringe</description>
      <cost currency="USD">4026.05</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Neulasta 6 mg/0.6 ml syringe</description>
      <cost currency="USD">4102.37</cost>
      <unit>syringe</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>6 mg/.6mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>6 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AA13">
      <level code="L03AA">Colony stimulating factors</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1RHG</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00019.pdf?1265922804</fda-label>
  <patents>
    <patent>
      <number>1341537</number>
      <country>Canada</country>
      <approved>2007-07-31</approved>
      <expires>2024-07-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1339071</number>
      <country>Canada</country>
      <approved>1997-07-29</approved>
      <expires>2014-07-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt; Pegfilgrastim sequence
MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA
PLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ
QMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>60 °C</value>
      <source>Luo, P., Protein Science 11:1218-1226 (2002)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.209</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.65</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>18802.8</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C845H1343N223O243S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06889</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X03438</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164781387</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P09919</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000395</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pegfilgrastim</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201568</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/neulasta.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/pegfilgrastim.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000793</id>
      <name>Granulocyte colony-stimulating factor receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17001306</pubmed-id>
            <citation>Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25.</citation>
          </article>
          <article>
            <pubmed-id>12944913</pubmed-id>
            <citation>Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57.</citation>
          </article>
          <article>
            <pubmed-id>17127322</pubmed-id>
            <citation>Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18.</citation>
          </article>
          <article>
            <pubmed-id>16033816</pubmed-id>
            <citation>Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20.</citation>
          </article>
          <article>
            <pubmed-id>15949269</pubmed-id>
            <citation>Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients]. Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8.</citation>
          </article>
          <article>
            <pubmed-id>15082029</pubmed-id>
            <citation>Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q99062" source="Swiss-Prot">
    <name>Granulocyte colony-stimulating factor receptor</name>
    <general-function>Receptor activity</general-function>
    <specific-function>Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.</specific-function>
    <gene-name>CSF3R</gene-name>
    <locus>1p35-p34.3</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions>628-650</transmembrane-regions>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>6.14</theoretical-pi>
    <molecular-weight>92155.615</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2439</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CSF3R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X55721</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31697</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q99062</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CSF3R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>G-CSF receptor</synonym>
      <synonym>GCSFR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001582|Granulocyte colony-stimulating factor receptor
MARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ
ILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG
YPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK
DGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE
AAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA
TAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP
LEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT
PVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME
QNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK
TWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL
MAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP
SVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL
PTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL
TPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010560|Granulocyte colony-stimulating factor receptor (CSF3R)
ATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC
GGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT
CCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG
ATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT
GGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC
TGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC
TACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC
ATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT
TTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG
GACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC
ATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT
CCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA
GCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG
CACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA
CTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC
ACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC
TGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA
TGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC
CTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG
GCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT
TCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGTCCCACT
CCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA
GACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG
ATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA
CAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT
GAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC
TACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG
ACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC
CACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC
TCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC
ATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC
CCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC
TGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA
AGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG
GATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG
GAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC
CCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC
CAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA
AGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC
ACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG
GTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC
CTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF06328</identifier>
        <name>Lep_receptor_Ig</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neutrophil chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>amelogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of myeloid cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell adhesion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000394</id>
      <name>Neutrophil elastase</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>14657210</pubmed-id>
            <citation>Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4.</citation>
          </article>
          <article>
            <pubmed-id>16245075</pubmed-id>
            <citation>Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36.</citation>
          </article>
          <article>
            <pubmed-id>12958067</pubmed-id>
            <citation>Pelus LM, Bian H, King AG, Fukuda S: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004 Jan 1;103(1):110-9. Epub 2003 Sep 4.</citation>
          </article>
          <article>
            <pubmed-id>15353486</pubmed-id>
            <citation>Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7.</citation>
          </article>
          <article>
            <pubmed-id>17475913</pubmed-id>
            <citation>Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08246" source="Swiss-Prot">
    <name>Neutrophil elastase</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis.</specific-function>
    <gene-name>ELANE</gene-name>
    <locus>19p13.3</locus>
    <cellular-location>Cytoplasmic</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>9.41</theoretical-pi>
    <molecular-weight>28517.81</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3309</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ELA2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Y00477</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>296665</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2358</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08246</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ELNE_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.37</synonym>
      <synonym>Bone marrow serine protease</synonym>
      <synonym>ELA2</synonym>
      <synonym>Elastase-2</synonym>
      <synonym>HLE</synonym>
      <synonym>Human leukocyte elastase</synonym>
      <synonym>Medullasin</synonym>
      <synonym>PMN elastase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000785|Neutrophil elastase
MTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI
APNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI
LQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL
CRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN
WIDSIIQRSEDNPCPHPRDPDPASRTH</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010273|Neutrophil elastase (ELANE)
ATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG
CTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG
TGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT
GCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG
CGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC
GTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT
CTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT
CAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC
AGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC
TGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG
GACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG
GGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC
TGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG
GACCCGGCCAGCAGGACCCACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>transcriptional repressor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>RNA polymerase II transcription corepressor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to UV</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to yeast</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute inflammatory response to antigenic stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of chemokine biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of growth of symbiont in host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of interleukin-8 biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neutrophil mediated killing of fungus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>collagen catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00020</drugbank-id>
  <drugbank-id>BTD00035</drugbank-id>
  <drugbank-id>BIOD00035</drugbank-id>
  <name>Sargramostim</name>
  <description>Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.</description>
  <cas-number>123774-72-1</cas-number>
  <unii>5TAA004E22</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Kaname Sugimoto, "Process for the production of human colony-stimulating factor." U.S. Patent US4621050, issued May, 1983.</synthesis-reference>
  <indication>For the treatment of cancer and bone marrow transplant</indication>
  <pharmacodynamics>Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.</pharmacodynamics>
  <mechanism-of-action>Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]&#13;
* 431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]&#13;
* 549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]&#13;
* 529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">GM-CSF</synonym>
  </synonyms>
  <products>
    <product>
      <name>Leukine</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5843</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>250 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103362</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukine</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5844</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>500 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103362</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Leukine</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0180</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-03-15</started-marketing-on>
      <ended-marketing-on>2016-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>250 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA103362</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Leucomax</name>
      <company>Novartis</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Leukine</name>
      <ingredients>Sargramostim</ingredients>
    </mixture>
    <mixture>
      <name>Leukine</name>
      <ingredients>Sargramostim</ingredients>
    </mixture>
    <mixture>
      <name>Leukine</name>
      <ingredients>Sargramostim</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Kramer-Novis</name>
      <url>http://www.kramernovis.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Wyeth Pharmaceuticals</name>
      <url>http://www.wyeth.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Leukine 250 mcg vial</description>
      <cost currency="USD">204.79</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Bio-immunex capsule</description>
      <cost currency="USD">0.42</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Colony-Stimulating Factors</category>
      <mesh-id>D003115</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycoproteins</category>
      <mesh-id>D006023</mesh-id>
    </category>
    <category>
      <category>Hematopoietic Cell Growth Factors</category>
      <mesh-id>D016298</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>250 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>500 ug/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AA09">
      <level code="L03AA">Colony stimulating factors</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>2GMF</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>1341150</number>
      <country>Canada</country>
      <approved>2000-12-05</approved>
      <expires>2017-12-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00020 sequence
APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE
LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD
CWEPVQE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.05</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>14434.5</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C639H1006N168O196S8</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M13207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748631</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P04141</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001053</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sargramostim</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201670</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/sargramostim.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/sargramostim.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000628</id>
      <name>Granulocyte-macrophage colony-stimulating factor receptor subunit alpha</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17090651</pubmed-id>
            <citation>Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7.</citation>
          </article>
          <article>
            <pubmed-id>16760463</pubmed-id>
            <citation>Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7.</citation>
          </article>
          <article>
            <pubmed-id>17522711</pubmed-id>
            <citation>Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20.</citation>
          </article>
          <article>
            <pubmed-id>16638185</pubmed-id>
            <citation>Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P15509" source="Swiss-Prot">
    <name>Granulocyte-macrophage colony-stimulating factor receptor subunit alpha</name>
    <general-function>Receptor activity</general-function>
    <specific-function>Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.</specific-function>
    <gene-name>CSF2RA</gene-name>
    <locus>Xp22.32 and Yp11.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>321-346</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>7.81</theoretical-pi>
    <molecular-weight>46206.185</molecular-weight>
    <chromosome-location>X, Y</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2435</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CSF2RA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X17648</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>32089</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1707</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P15509</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CSF2R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CDw116</synonym>
      <synonym>CSF2R</synonym>
      <synonym>CSF2RY</synonym>
      <synonym>GM-CSF-R-alpha</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001252|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
MLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC
FLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA
AQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL
DNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP
RTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD
VRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP
QIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016159|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (CSF2RA)
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTG
ATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTT
GACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGT
TTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCG
TGCACATTTCGTGAAATTTGTCTGCATGAAGGAGTCACATTTGAGGTTCACGTGAATACT
AGTCAAAGAGGATTTCAACAGAAACTGCTTTATCCAAATTCAGGAAGGGAGGGTACCGCT
GCTCAGAATTTCTCCTGTTTCATCTACAATGCGGATTTAATGAACTGTACCTGGGCGAGG
GGTCCGACGGCCCCCCGTGACGTCCAGTATTTTTTGTACATACGAAACTCAAAGAGAAGG
AGGGAGATCCGGTGTCCTTATTACATACAAGACTCAGGAACCCATGTGGGATGTCACCTG
GATAACCTGTCAGGATTAACGTCTCGCAATTACTTTCTGGTTAACGGAACCAGCCGAGAA
ATTGGCATCCAATTCTTTGATTCACTTTTGGACACAAAGAAAATAGAACGATTCAACCCT
CCCAGCAATGTCACCGTACGTTGCAACACGACGCACTGCCTCGTACGGTGGAAACAGCCC
AGGACCTATCAGAAGCTGTCGTACCTGGACTTTCAGTACCAGCTGGACGTCCACAGAAAG
AATACCCAGCCTGGCACGGAAAACCTACTGATTAATGTTTCTGGTGATTTGGAAAATAGA
TACAACTTTCCAAGCTCTGAGCCCAGAGCAAAACACAGTGTGAAGATCAGAGCTGCAGAC
GTCCGCATCTTGAATTGGAGCTCCTGGAGTGAAGCCATTGAATTTGGTTCTGACGACGGG
AACCTCGGCTCTGTGTACATTTATGTGCTCCTAATCGTGGGAACCCTTGTCTGTGGCATC
GTCCTCGGCTTCCTCTTTAAAAGGTTCCTTAGGATACAGCGGCTGTTCCCGCCAGTTCCA
CAGATCAAAGACAAACTGAATGATAACCATGAGGTGGAAGACGAGATCATCTGGGAGGAA
TTCACCCCAGAGGAAGGGAAAGGCTACCGCGAAGAGGTCTTGACCGTGAAGGAAATTACC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF09240</identifier>
        <name>IL6Ra-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>granulocyte colony-stimulating factor receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to granulocyte macrophage colony-stimulating factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0001036</id>
      <name>Interleukin-3 receptor subunit alpha</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17562355</pubmed-id>
            <citation>Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11.</citation>
          </article>
          <article>
            <pubmed-id>17500228</pubmed-id>
            <citation>Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk. 2007;(3):42-6.</citation>
          </article>
          <article>
            <pubmed-id>16698686</pubmed-id>
            <citation>Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40.</citation>
          </article>
          <article>
            <pubmed-id>17522711</pubmed-id>
            <citation>Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P26951" source="Swiss-Prot">
    <name>Interleukin-3 receptor subunit alpha</name>
    <general-function>Interleukin-3 receptor activity</general-function>
    <specific-function>This is a receptor for interleukin-3.</specific-function>
    <gene-name>IL3RA</gene-name>
    <locus>Xp22.3 or Yp11.3</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>306-325</transmembrane-regions>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>8.32</theoretical-pi>
    <molecular-weight>43329.585</molecular-weight>
    <chromosome-location>X, Y</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6012</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL3RA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M74782</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>186331</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P26951</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL3RA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IL-3 receptor subunit alpha</synonym>
      <synonym>IL3R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002063|Interleukin-3 receptor subunit alpha
MVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM
PAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL
SCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS
HILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL
QIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN
TRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG
KAGLEECLVTEVQVVQKT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020503|Interleukin-3 receptor subunit alpha (IL3RA)
ATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG
GAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGAT
TTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTG
TACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCT
CAGGGAACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAA
AGTTCCCACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAG
TTTGTCGTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAAT
AAGACACATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTAT
GAGCTTCAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACC
TCCTTCCAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTG
TATGAATTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGC
GCAAACACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTG
GTCTGTGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATC
CCTCACATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAG
GCGGGCAAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACT
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF09240</identifier>
        <name>IL6Ra-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-3 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-3</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-3-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002115</id>
      <name>Cytokine receptor common subunit beta</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>1424804</pubmed-id>
            <citation>Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2--&gt;q13.1. Cytogenet Cell Genet. 1992;61(3):175-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P32927" source="Swiss-Prot">
    <name>Cytokine receptor common subunit beta</name>
    <general-function>Receptor activity</general-function>
    <specific-function>High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.</specific-function>
    <gene-name>CSF2RB</gene-name>
    <locus>22q13.1</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>444-460</transmembrane-regions>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>5.21</theoretical-pi>
    <molecular-weight>97334.89</molecular-weight>
    <chromosome-location>22</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2436</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CSF2RB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M59941</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>487425</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P32927</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL3RB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CDw131</synonym>
      <synonym>GM-CSF/IL-3/IL-5 receptor common beta subunit</synonym>
      <synonym>IL3RB</synonym>
      <synonym>IL5RB</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004148|Cytokine receptor common subunit beta
MVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT
LIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG
TRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD
SWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG
DEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL
HTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET
MKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG
YNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN
PSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE
DPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR
SLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ
GAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT
PNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP
RNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS
SPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011533|Cytokine receptor common subunit beta (CSF2RB)
ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC
CTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC
AGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC
CTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC
ATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC
CAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC
ACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG
ATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG
AGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC
TCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG
CACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT
CGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG
GATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC
TCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC
AGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC
CACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC
GTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG
GCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA
ATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG
GCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA
GCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC
TACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG
CCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC
CGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC
CCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG
TCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG
CTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG
GACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT
CTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT
GAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC
TCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC
CCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC
CCTCTGGCCCAGGCGATGGGACCAGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG
GGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG
CCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG
GACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC
CCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG
ACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG
TCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA
AGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG
GCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC
GACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT
TCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC
CCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG
GACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF09240</identifier>
        <name>IL6Ra-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>granulocyte macrophage colony-stimulating factor receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>respiratory gaseous exchange</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-3</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-3-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-5-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002116</id>
      <name>Syndecan-2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10734053</pubmed-id>
            <citation>Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P34741" source="Swiss-Prot">
    <name>Syndecan-2</name>
    <general-function>Pdz domain binding</general-function>
    <specific-function>Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity).</specific-function>
    <gene-name>SDC2</gene-name>
    <locus>8q22-q23</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>145-169</transmembrane-regions>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>4.48</theoretical-pi>
    <molecular-weight>22159.62</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:10659</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SDC2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J04621</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>386787</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P34741</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>SDC2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fibroglycan</synonym>
      <synonym>Heparan sulfate proteoglycan core protein</synonym>
      <synonym>HSPG</synonym>
      <synonym>HSPG1</synonym>
      <synonym>SYND2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037162|Syndecan-2
MRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGAD
EDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERK
MDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYD
LGERKPSSAAYQKAPTKEFYA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011534|Syndecan-2 (SDC2)
ATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCG
AGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCT
TCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGAT
GAGGATGTAGAGAGTCCAGAGCTGACAACATCTCGACCACTTCCAAAGATACTGTTGACT
AGTGCTGCTCCAAAAGTGGAAACCACGACGCTGAATATACAGAACAAGATACCTGCTCAG
ACAAAGTCACCTGAAGAAACTGATAAAGAGAAAGTTCACCTCTCTGACTCAGAAAGGAAA
ATGGACCCAGCCGAAGAGGATACAAATGTGTATACTGAGAAACACTCAGACAGTCTGTTT
AAACGGACAGAAGTCCTAGCAGCTGTCATTGCTGGTGGAGTTATTGGCTTTCTCTTTGCA
ATTTTTCTTATCCTGCTGTTGGTGTATCGCATGAGAAAGAAGGATGAAGGAAGCTATGAC
CTTGGAGAACGCAAACCATCCAGTGCTGCTTATCAGAAGGCACCTACTAAGGAGTTTTAT
GCGTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01034</identifier>
        <name>Syndecan</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>PDZ domain binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>carbohydrate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ephrin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dendrite morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondroitin sulfate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dendrite morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bioluminescence</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0002114</id>
      <name>Bone marrow proteoglycan</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17383764</pubmed-id>
            <citation>Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22.</citation>
          </article>
          <article>
            <pubmed-id>16522458</pubmed-id>
            <citation>Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8.</citation>
          </article>
          <article>
            <pubmed-id>17600316</pubmed-id>
            <citation>Kang JH, Lee da H, Seo H, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of functional phenotypes of cord blood derived eosinophils by gamma-secretase inhibitor. Am J Respir Cell Mol Biol. 2007 Nov;37(5):571-7. Epub 2007 Jun 28.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P13727" source="Swiss-Prot">
    <name>Bone marrow proteoglycan</name>
    <general-function>Heparin binding</general-function>
    <specific-function>Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.</specific-function>
    <gene-name>PRG2</gene-name>
    <locus>11q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>25205.345</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PRG2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Y00809</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>34476</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P13727</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PRG2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>BMPG</synonym>
      <synonym>MBP</synonym>
      <synonym>Proteoglycan 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037161|Bone marrow proteoglycan
MKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW
GSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ
AWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW
NFAYWAAHQPWSRGGHCVALCTRGGHWRRAHCLRRLPFICSY</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019238|Bone marrow proteoglycan (PRG2)
ATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG
TCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG
ACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG
GGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA
GATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC
ATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGTTTACTTGCCGGAGGTGCTACAGGGGC
AACCTGGTTTCCATCCACAACTTCAATATTAATTATCGAATCCAGTGTTCTGTCAGCGCG
CTCAACCAGGGTCAAGTCTGGATTGGAGGCAGGATCACAGGCTCGGGTCGCTGCAGACGC
TTTCAGTGGGTTGACGGCAGCCGCTGGAACTTTGCGTACTGGGCTGCTCACCAGCCCTGG
TCCCGCGGTGGTCACTGCGTGGCCCTGTGTACCCGAGGAGGCCACTGGCGTCGAGCCCAC
TGCCTCAGAAGACTTCCTTTCATCTGTTCCTACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00059</identifier>
        <name>Lectin_C</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-4 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of interleukin-10 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to nematode</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cytokine biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00021</drugbank-id>
  <drugbank-id>BTD00039</drugbank-id>
  <drugbank-id>BIOD00039</drugbank-id>
  <name>Secretin</name>
  <description>This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.</description>
  <cas-number/>
  <unii>88C55N56UU</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, "Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine." U.S. Patent US4302448, issued August, 1964.</synthesis-reference>
  <indication>For diagnosis of pancreatic exocrine dysfunction and gastrinoma</indication>
  <pharmacodynamics>Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.</pharmacodynamics>
  <mechanism-of-action>Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Secretin Inj 75unit/vial</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00874000</dpd-id>
      <started-marketing-on>1990-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-04</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>75 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>SecreFlo</name>
      <company>Repligen Corp</company>
    </international-brand>
    <international-brand>
      <name>Secremax</name>
      <company>Repligen Corp</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Secretin Inj 75unit/vial</name>
      <ingredients>Secretin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Ferring pharmaceuticals inc</manufacturer>
    <manufacturer generic="false" url="">Chirhoclin inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Secretin-mannitol powder</description>
      <cost currency="USD">1.43</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Hormones</category>
      <mesh-id>D005768</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Tests for Pancreatic Function</category>
      <mesh-id/>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>75 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V04CK01">
      <level code="V04CK">Tests for pancreatic function</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1OMN</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium bromide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Ethopropazine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Ethopropazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine Triethiodide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Gallamine Triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine Methylbromide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Anisotropine Methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Tropicamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Dexetimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Scopolamine butylbromide</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Metixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Secretin can be decreased when used in combination with Propiverine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00021 sequence
HSDGTFTSELSRLRDSARLQRLLQGLV</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.463</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.45</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>3056.4</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C130H219N43O42</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2067</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164760844</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001296</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Secretin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2103754</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/secretin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/human_secretin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000318</id>
      <name>Secretin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P47872" source="Swiss-Prot">
    <name>Secretin receptor</name>
    <general-function>Secretin receptor activity</general-function>
    <specific-function>This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.</specific-function>
    <gene-name>SCTR</gene-name>
    <locus>2q14.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>144-167
175-194
217-240
255-276
295-317
344-362
370-392</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>7.77</theoretical-pi>
    <molecular-weight>50206.135</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:10608</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SCTR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U20178</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>662796</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>252</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>252</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P47872</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>SCTR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>SCT-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016064|Secretin receptor
MRPHLSPPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGTE
QPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLTSRNGSLFRNCTQDGWSETFPRPN
LACGVNVNDSSNEKRHSYLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLHCTRNYIHMH
LFVSFILRALSNFIKDAVLFSSDDVTYCDAHRAGCKLVMVLFQYCIMANYSWLLVEGLYL
HTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINANASIWWIIRG
PVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLFGIHYIVFAF
SPEDAMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLREFPLHPVASFS
NSTKASHLEQSQGTCRTSII</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016065|Secretin receptor (SCTR)
ATGCGTCCCCACCTGTCGCCGCCGCTGCAGCAGCTACTACTGCCGGTGCTGCTCGCCTGC
GCCGCGCACTCGACTGGAGCCCTTCCCCGACTATGTGACGTGCTACAAGTGCTGTGGGAA
GAGCAAGACCAGTGCCTGCAGGAACTCTCCAGAGAGCAGACAGGAGACCTGGGCACGGAG
CAGCCAGTGCCAGGTTGTGAGGGGATGTGGGACAACATAAGCTGCTGGCCCTCTTCTGTG
CCGGGCCGGATGGTGGAGGTGGAATGCCCGAGATTCCTCCGGATGCTCACCAGCAGAAAT
GGTTCCTTGTTCCGAAACTGCACACAGGATGGCTGGTCAGAAACCTTCCCCAGGCCTAAT
CTGGCCTGTGGCGTTAATGTGAACGACTCTTCCAACGAGAAGCGGCACTCCTACCTGCTG
AAGCTGAAAGTCATGTACACCGTGGGCTACAGCTCCTCCCTGGTCATGCTCCTGGTCGCC
CTTGGCATCCTCTGTGCTTTCCGGAGGCTCCACTGCACTCGCAACTACATCCACATGCAC
CTGTTCGTGTCCTTCATCCTTCGTGCCCTGTCCAACTTCATCAAGGACGCCGTGCTCTTC
TCCTCAGATGATGTCACCTACTGCGATGCCCACAGGGCGGGCTGCAAGCTGGTCATGGTG
CTGTTCCAGTACTGCATCATGGCCAACTACTCCTGGCTGCTGGTGGAAGGCCTCTACCTT
CACACACTCCTCGCCATCTCCTTCTTCTCTGAAAGAAAGTACCTCCAGGGATTTGTGGCA
TTCGGATGGGGTTCTCCAGCCATTTTTGTTGCTTTGTGGGCTATTGCCAGACACTTTCTG
GAAGATGTTGGGTGCTGGGACATCAATGCCAACGCATCCATCTGGTGGATCATTCGTGGT
CCTGTGATCCTCTCCATCCTGATTAATTTCATCCTTTTCATAAACATTCTAAGAATCCTG
ATGAGAAAACTTAGAACCCAAGAAACAAGAGGAAATGAAGTCAGCCATTATAAGCGCCTG
GCCAGGTCCACTCTCCTGCTGATCCCCCTCTTTGGCATCCACTACATCGTCTTCGCCTTC
TCCCCAGAGGACGCTATGGAGATCCAGCTGTTTTTTGAACTAGCCCTTGGCTCATTCCAG
GGACTGGTGGTGGCCGTCCTCTACTGCTTCCTCAATGGGGAGGTGCAGCTGGAGGTTCAG
AAGAAGTGGCAGCAATGGCACCTCCGTGAGTTCCCACTGCACCCCGTGGCCTCCTTCAGC
AACAGCACCAAGGCCAGCCACTTGGAGCAGAGCCAGGGCACCTGCAGGACCAGCATCATC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic microtubule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>secretin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-09-01">
  <drugbank-id primary="true">DB00022</drugbank-id>
  <drugbank-id>BTD00048</drugbank-id>
  <drugbank-id>BIOD00048</drugbank-id>
  <name>Peginterferon alfa-2b</name>
  <description>Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.&#13;
&#13;
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626].&#13;
&#13;
Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2b and [DB00811] have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.</description>
  <cas-number>215647-85-1</cas-number>
  <unii>G8RGG88B68</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>25585348</pubmed-id>
        <citation>Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13.</citation>
      </article>
      <article>
        <pubmed-id>28497432</pubmed-id>
        <citation>Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017.</title>
        <url>http://hcvguidelines.org/full-report-view</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.&#13;
</indication>
  <pharmacodynamics>Peginterferon alfa-2b inhibits viral replication in infected cells, suppresses cell proliferation, induces apoptosis, and exerts an anti-angiogenic effect [FDA Label]. Exerts immunomodulatory effects such as enhancement of the phagocytic activity of macrophages, activation of NK cells, stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset. Also increases concentrations of effector proteins such as serum neopterin and 2'5' oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts.</pharmacodynamics>
  <mechanism-of-action>Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor κB pathway.</mechanism-of-action>
  <toxicity>Peginterferon alfa-2b may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2b. Peginterferon alfa-2b may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2b causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2b. Peginterferon alfa-2b may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2b are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2b. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2b. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2b treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2b is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2b while pregant may result in delopmental abnormalities or death of the fetus.</toxicity>
  <metabolism/>
  <absorption>Peginterferon alfa-2b reaches peak plasma concentration 15-44 hours after subcutaneous administration [FDA Label]. The mean absorption half-life is 4.6 hours. After multiple doses the bioavailability of Peginterferon alfa-2b increases with trough concentrations at week 48 3-fold higher than those at week 4.&#13;
 </absorption>
  <half-life>The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours [FDA Label].&#13;
</half-life>
  <protein-binding/>
  <route-of-elimination>Renal elimination accounts for 30% of Peginterferon alfa-2b elimination [FDA Label].</route-of-elimination>
  <volume-of-distribution/>
  <clearance>The estimated apparent clearance of Peginterferon alfa-2b is 22 milliters per hour per kilogram [FDA Label].</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246026</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2017-04-04</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246030</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2017-04-04</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254581</dpd-id>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254603</dpd-id>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254638</dpd-id>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254646</dpd-id>
      <started-marketing-on>2004-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246027</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2013-01-23</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246028</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2013-01-23</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegetron</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246029</dpd-id>
      <started-marketing-on>2002-08-13</started-marketing-on>
      <ended-marketing-on>2013-01-23</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1279</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on>2017-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1291</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on>2017-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1304</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on>2017-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1368</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on>2017-06-21</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1297</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>120 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1316</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>80 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1323</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1370</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2001-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>150 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4353</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4354</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4355</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pegintron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4356</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1287</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1312</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-1388</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4347</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4348</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sylatron</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0085-4349</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103949</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Unitron Peg</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242966</dpd-id>
      <started-marketing-on>2001-03-27</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>74 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Unitron Peg</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242967</dpd-id>
      <started-marketing-on>2001-03-27</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>118.4 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Unitron Peg</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242968</dpd-id>
      <started-marketing-on>2001-03-27</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>177.6 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Unitron Peg</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242969</dpd-id>
      <started-marketing-on>2001-03-27</started-marketing-on>
      <ended-marketing-on>2012-02-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>222 mcg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Victrelis Triple</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371448</dpd-id>
      <started-marketing-on>2011-08-16</started-marketing-on>
      <ended-marketing-on>2017-01-10</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Victrelis Triple</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371456</dpd-id>
      <started-marketing-on>2011-08-16</started-marketing-on>
      <ended-marketing-on>2017-01-10</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Victrelis Triple</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371464</dpd-id>
      <started-marketing-on>2011-08-16</started-marketing-on>
      <ended-marketing-on>2016-09-02</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Victrelis Triple</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02371472</dpd-id>
      <started-marketing-on>2011-08-16</started-marketing-on>
      <ended-marketing-on>2016-09-02</ended-marketing-on>
      <dosage-form>Capsule; Powder, for solution</dosage-form>
      <strength/>
      <route>Oral; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>PEG-Intron</name>
      <company>Schering Corp</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Sylatron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Unitron Peg</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Unitron Peg</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Unitron Peg</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Unitron Peg</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Victrelis Triple</name>
      <ingredients>Boceprevir + Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Victrelis Triple</name>
      <ingredients>Boceprevir + Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Victrelis Triple</name>
      <ingredients>Boceprevir + Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Victrelis Triple</name>
      <ingredients>Boceprevir + Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegetron</name>
      <ingredients>Peginterferon alfa-2b + Ribavirin</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
    <mixture>
      <name>Pegintron</name>
      <ingredients>Peginterferon alfa-2b</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Schering Corp.</name>
      <url>http://www.schering.de</url>
    </packager>
    <packager>
      <name>Schering-Plough Inc.</name>
      <url>http://www.schering-plough.ca</url>
    </packager>
    <packager>
      <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
      <url>http://www.vetter-pharma.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Peg-Intron 50 mcg kit</description>
      <cost currency="USD">553.4</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron redipen 50 mcg</description>
      <cost currency="USD">553.4</cost>
      <unit>redipen</unit>
    </price>
    <price>
      <description>Peg-Intron redipen 80 mcg</description>
      <cost currency="USD">581.02</cost>
      <unit>redipen</unit>
    </price>
    <price>
      <description>Peg-Intron 50 mcg/0.5ml Kit</description>
      <cost currency="USD">607.19</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron 80 mcg Kit</description>
      <cost currency="USD">609.26</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron redipen 120 mcg</description>
      <cost currency="USD">610.09</cost>
      <unit>redipen</unit>
    </price>
    <price>
      <description>Peg-Intron Redipen 80 mcg/0.5ml Kit</description>
      <cost currency="USD">637.49</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron 120 mcg Kit</description>
      <cost currency="USD">639.74</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron redipen 150 mcg 4pk</description>
      <cost currency="USD">640.6</cost>
      <unit>redipen</unit>
    </price>
    <price>
      <description>Peg-Intron redipen 150 mcg</description>
      <cost currency="USD">640.61</cost>
      <unit>redipen</unit>
    </price>
    <price>
      <description>Peg-Intron Redipen 120 mcg/0.5ml Kit</description>
      <cost currency="USD">669.39</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron 150 mcg Kit</description>
      <cost currency="USD">671.74</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron Redipen 150 mcg/0.5ml Kit</description>
      <cost currency="USD">702.87</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box</description>
      <cost currency="USD">2428.8</cost>
      <unit>kit</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Alfa Interferons</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Biomedical and Dental Materials</category>
      <mesh-id>D001697</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors</category>
      <mesh-id>D065690</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Drug Carriers</category>
      <mesh-id>D004337</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Hepatitis C</category>
      <mesh-id>D006526</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Manufactured Materials</category>
      <mesh-id>D008420</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Organic Chemicals</category>
      <mesh-id>D009930</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Specialty Uses of Chemicals</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Technology, Industry, and Agriculture</category>
      <mesh-id>D013676</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule; powder, for solution</form>
      <route>Oral; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>120 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>150 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>50 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Subcutaneous</route>
      <strength>80 ug/.5mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>118.4 mcg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>177.6 mcg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>222 mcg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>74 mcg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AB60">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
    <atc-code code="L03AB10">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:18.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1ITF</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00022.pdf?1497629687</fda-label>
  <patents>
    <patent>
      <number>1341567</number>
      <country>Canada</country>
      <approved>2008-02-19</approved>
      <expires>2025-02-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2329474</number>
      <country>Canada</country>
      <approved>0002-02-26</approved>
      <expires>2016-10-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01265</drugbank-id>
      <name>Telbivudine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium bromide</name>
      <description>The serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The serum concentration of Mexiletine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>The serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>The serum concentration of Nicergoline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The serum concentration of Almotriptan can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The serum concentration of Perhexiline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorphenamine</name>
      <description>The serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The serum concentration of Arformoterol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The serum concentration of Tiotropium can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The serum concentration of Diphenhydramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquin</name>
      <description>The serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Diltiazem can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Loratadine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Quinine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The serum concentration of Mephenytoin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Delavirdine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The serum concentration of Mequitazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The serum concentration of Bupropion can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The serum concentration of Halofantrine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>The serum concentration of Palonosetron can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The serum concentration of Mianserin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Tesmilifene can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The serum concentration of Rotigotine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The serum concentration of Lisuride can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The serum concentration of Trabectedin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The serum concentration of Cinnarizine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The serum concentration of Phenacetin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06727</drugbank-id>
      <name>Sparteine</name>
      <description>The serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The serum concentration of Ticlopidine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Methamphetamine</name>
      <description>The serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The serum concentration of Aminophenazone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The serum concentration of Nevirapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03128</drugbank-id>
      <name>Acetylcholine</name>
      <description>The serum concentration of Acetylcholine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01426</drugbank-id>
      <name>Ajmaline</name>
      <description>The serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The serum concentration of Amsacrine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01429</drugbank-id>
      <name>Aprindine</name>
      <description>The serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The serum concentration of Astemizole can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The serum concentration of Caffeine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The serum concentration of Cephalexin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The serum concentration of Chlordiazepoxide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The serum concentration of Dopamine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>The serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The serum concentration of Lomustine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>The serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The serum concentration of Nateglinide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The serum concentration of Nicotine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00336</drugbank-id>
      <name>Nitrofural</name>
      <description>The serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The serum concentration of Piperazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The serum concentration of Theophylline can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The serum concentration of Yohimbine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00943</drugbank-id>
      <name>Zalcitabine</name>
      <description>The serum concentration of Zalcitabine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The serum concentration of Dexmethylphenidate can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The serum concentration of Cilostazol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Loperamide can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06506</drugbank-id>
      <name>repinotan</name>
      <description>The serum concentration of repinotan can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The serum concentration of Benzyl alcohol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06735</drugbank-id>
      <name>Enclomiphene</name>
      <description>The serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The serum concentration of Fingolimod can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The serum concentration of Lorcaserin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The serum concentration of Cariprazine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The serum concentration of Esmirtazapine can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The serum concentration of Ixazomib can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be decreased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>The serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The serum concentration of Leflunomide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The serum concentration of Telithromycin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The serum concentration of Aprepitant can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00917</drugbank-id>
      <name>Dinoprostone</name>
      <description>The serum concentration of Dinoprostone can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00724</drugbank-id>
      <name>Imiquimod</name>
      <description>The serum concentration of Imiquimod can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00772</drugbank-id>
      <name>Malathion</name>
      <description>The serum concentration of Malathion can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>The serum concentration of Menadione can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The serum concentration of Proguanil can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>The serum concentration of Pyrazinamide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The serum concentration of Rifabutin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>AV650</name>
      <description>The serum concentration of AV650 can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Toremifene can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The serum concentration of Rizatriptan can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06510</drugbank-id>
      <name>muraglitazar</name>
      <description>The serum concentration of muraglitazar can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The serum concentration of ASA404 can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The serum concentration of Ulipristal can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00022 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>31000.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12036</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164784024</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001279</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Peginterferon_alfa-2b</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201561</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/peginterferon.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/peginterferon-alfa-2b.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects>
    <effect>
      <protein-name>Interferon lambda-3</protein-name>
      <gene-symbol>IFNL3</gene-symbol>
      <uniprot-id>Q8IZI9</uniprot-id>
      <rs-id>rs12979860</rs-id>
      <allele/>
      <defining-change>C &gt; T</defining-change>
      <description>Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2b therapy.</description>
      <pubmed-id>24096968</pubmed-id>
    </effect>
  </snp-effects>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>16953837</pubmed-id>
            <citation>Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>19955815</pubmed-id>
            <citation>Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3.</citation>
          </article>
          <article>
            <pubmed-id>16953837</pubmed-id>
            <citation>Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
    <name>Cytochrome P450 1A2</name>
    <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
    <gene-name>CYP1A2</gene-name>
    <locus>15q24</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.43</theoretical-pi>
    <molecular-weight>58293.76</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP1A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z00036</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1319</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05177</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP1A2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYPIA2</synonym>
      <synonym>Cytochrome P(3)450</synonym>
      <synonym>Cytochrome P450 4</synonym>
      <synonym>Cytochrome P450-P3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>demethylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>electron carrier activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular respiration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>omega-hydroxylase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monocarboxylic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative deethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to immobilization stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to cadmium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>porphyrin-containing compound metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dibenzo-p-dioxin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>methylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epoxygenase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hydrogen peroxide biosynthetic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="2">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
    <name>Cytochrome P450 2D6</name>
    <general-function>Steroid hydroxylase activity</general-function>
    <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
    <gene-name>CYP2D6</gene-name>
    <locus>22q13.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>7.26</theoretical-pi>
    <molecular-weight>55768.94</molecular-weight>
    <chromosome-location>22</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP2D6</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M20403</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181350</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1329</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P10635</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP2D6_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYP2DL1</synonym>
      <synonym>CYPIID6</synonym>
      <synonym>Cytochrome P450-DB1</synonym>
      <synonym>Debrisoquine 4-hydroxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonic acid epoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>coumarin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>isoquinoline alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cellular organofluorine metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-08">
  <drugbank-id primary="true">DB00023</drugbank-id>
  <drugbank-id>BTD00011</drugbank-id>
  <drugbank-id>BIOD00011</drugbank-id>
  <name>Asparaginase</name>
  <description>L-asparagine amidohydrolase from E. coli</description>
  <cas-number>9015-68-3</cas-number>
  <unii>G4FQ3CKY5R</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>17554375</pubmed-id>
        <citation>Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Nov;21(11):2377-80. Epub 2007 Jun 7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Link</title>
        <url>http://www.google.com/patents/EP2046369A2</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference>Masao Nambu, "Process for producing immobilized L-asparaginase preparations for the therapy of leukemia." U.S. Patent US4617271, issued January, 1977.</synthesis-reference>
  <indication>For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma</indication>
  <pharmacodynamics>In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.</pharmacodynamics>
  <mechanism-of-action>Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>8-30 hrs</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Asparaginase (E. coli)</synonym>
    <synonym language="" coder="">Escherichia coli L-asparaginase</synonym>
    <synonym language="" coder="">L-asparaginase</synonym>
    <synonym language="" coder="">L-asparagine amidohydrolase</synonym>
  </synonyms>
  <products>
    <product>
      <name>Erwinase</name>
      <labeller>Jazz Pharmaceuticals France Sas</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237815</dpd-id>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>10000 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kidrolase</name>
      <labeller>Jazz Pharmaceuticals France Sas</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01926438</dpd-id>
      <started-marketing-on>1974-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>10000 unit</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Elspar</name>
      <company>Merck &amp; Co. Inc</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Erwinase</name>
      <ingredients>Asparaginase</ingredients>
    </mixture>
    <mixture>
      <name>Spectrila</name>
      <ingredients>Asparaginase</ingredients>
    </mixture>
    <mixture>
      <name>Spectrila</name>
      <ingredients>Asparaginase</ingredients>
    </mixture>
    <mixture>
      <name>Kidrolase</name>
      <ingredients>Asparaginase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Lundbeck Inc.</name>
      <url>http://www.lundbeckinc.com</url>
    </packager>
    <packager>
      <name>Merck &amp; Co.</name>
      <url>http://www.merck.com</url>
    </packager>
    <packager>
      <name>Prescript Pharmaceuticals</name>
      <url>http://www.prescript.net</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Elspar 10000 unit vial</description>
      <cost currency="USD">74.6</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amidohydrolases</category>
      <mesh-id>D000581</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>10000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>10000 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>10000 U</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L01XX02">
      <level code="L01XX">Other antineoplastic agents</level>
      <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
      <level code="L01">ANTINEOPLASTIC AGENTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1NNS</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00023.pdf?1265922812</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Asparaginase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt; Elspar Sequence
QMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDE
THELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMER
VSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTG
GMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAE
ACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTV
ATQ</sequence>
    <sequence format="FASTA">&gt;sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2
MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNA
VPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYF
LDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGR
DVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVY
NYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGAT
TQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.059</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>4.67</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>31731.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1377H2208N382O442S17</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2433</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>U00096</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448492</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P37595</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Asparaginase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108989</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/asparaginase.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/asparaginase.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0004798</id>
      <name>L-asparagine</name>
      <organism>Human</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17264295</pubmed-id>
            <citation>Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30.</citation>
          </article>
          <article>
            <pubmed-id>16307417</pubmed-id>
            <citation>Wenner KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, Stehn M, Kohlschutter A, Boos J, Janka-Schaub GE: Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005 Nov-Dec;217(6):321-6.</citation>
          </article>
          <article>
            <pubmed-id>14523472</pubmed-id>
            <citation>Appel IM, Pinheiro JP, den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003 Nov;17(11):2254-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-08-08">
  <drugbank-id primary="true">DB00024</drugbank-id>
  <drugbank-id>BTD00020</drugbank-id>
  <drugbank-id>BIOD00020</drugbank-id>
  <name>Thyrotropin Alfa</name>
  <description>Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.</description>
  <cas-number>194100-83-9</cas-number>
  <unii>AVX3D5A4LM</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>19366632</synthesis-reference>
  <indication>For detection of residueal or recurrent thyroid cancer</indication>
  <pharmacodynamics>Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.</pharmacodynamics>
  <mechanism-of-action>Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.</mechanism-of-action>
  <toxicity>No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised. </toxicity>
  <metabolism/>
  <absorption>Time to peak: Median: 10 hours (range: 3-24 hours)&#13;
After a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU·hr/L.</absorption>
  <half-life>25 ± 10 hours</half-life>
  <protein-binding/>
  <route-of-elimination>kidney and liver</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">rTSH</synonym>
    <synonym language="" coder="">Thyroid stimulating hormone</synonym>
    <synonym language="" coder="">Thyrotrophin-alfa</synonym>
    <synonym language="" coder="">Thyrotrophin-alpha</synonym>
    <synonym language="" coder="">Thyrotropin</synonym>
    <synonym language="" coder="">Thyrotropin-a</synonym>
    <synonym language="" coder="">Thyrotropin-alpha</synonym>
    <synonym language="" coder="">Thytrophin</synonym>
    <synonym language="" coder="">TSH</synonym>
  </synonyms>
  <products>
    <product>
      <name>Thyrogen</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246016</dpd-id>
      <started-marketing-on>2002-08-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>0.9 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Thyrogen</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0030</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1998-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>.9 mg/mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA020898</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Thyrogen</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-1849</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1998-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020898</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Thyrogen</name>
      <ingredients>Thyrotropin Alfa</ingredients>
    </mixture>
    <mixture>
      <name>Thyrogen</name>
      <ingredients>Thyrotropin Alfa</ingredients>
    </mixture>
    <mixture>
      <name>Thyrogen</name>
      <ingredients>Thyrotropin Alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
    <packager>
      <name>Organon Pharmaceuticals</name>
      <url>http://www.organonshop.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Sanofi aventis us llc</manufacturer>
    <manufacturer generic="false" url="">Genzyme corp</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Thyrogen 1.1 mg vial</description>
      <cost currency="USD">1196.4</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones</category>
      <mesh-id>D010907</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones, Anterior</category>
      <mesh-id>D010908</mesh-id>
    </category>
    <category>
      <category>Tests for Thyreoidea Function</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyrotropin</category>
      <mesh-id>D013972</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular</route>
      <strength>.9 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular</route>
      <strength>0.9 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H01AB01">
      <level code="H01AB">Thyrotropin</level>
      <level code="H01A">ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES</level>
      <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
    <atc-code code="V04CJ01">
      <level code="V04CJ">Tests for thyreoidea function</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>36:60.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1FL7</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00024.pdf?1265922804</fda-label>
  <patents>
    <patent>
      <number>5840566</number>
      <country>United States</country>
      <approved>1995-11-24</approved>
      <expires>2015-11-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
    <sequence format="FASTA">&gt;Beta chain
FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR
TVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>55 °C</value>
      <source/>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.330</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.50</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>22672.9</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C975H1513N267O304S26</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12790</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M16647</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746560</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01225</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001248</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201533</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/thyrotropin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/thyrotropin-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000490</id>
      <name>Thyrotropin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15571461</pubmed-id>
            <citation>Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40.</citation>
          </article>
          <article>
            <pubmed-id>9039330</pubmed-id>
            <citation>Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P16473" source="Swiss-Prot">
    <name>Thyrotropin receptor</name>
    <general-function>Thyroid-stimulating hormone receptor activity</general-function>
    <specific-function>Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5).</specific-function>
    <gene-name>TSHR</gene-name>
    <locus>14q31</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>414-441
451-473
495-517
538-560
581-602
626-649
661-682</transmembrane-regions>
    <signal-regions>1-20</signal-regions>
    <theoretical-pi>6.98</theoretical-pi>
    <molecular-weight>86828.965</molecular-weight>
    <chromosome-location>14</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:12373</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>TSHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M73747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>903760</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>255</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P16473</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TSHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>LGR3</synonym>
      <synonym>Thyroid-stimulating hormone receptor</synonym>
      <synonym>TSH-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000978|Thyrotropin receptor
MRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI
ETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD
ALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL
TLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA
LPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM
CNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE
DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV
VWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE
YYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA
IMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC
YVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK
ILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ
VQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010345|Thyrotropin receptor (TSHR)
ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC
GGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC
TGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT
GAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA
ATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG
AGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT
GCCCTCAAAGAGCTCCCCCTCCTAAAGTTCCTTGGCATTTTCAACACTGGACTTAAAATG
TTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC
AACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG
ACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGCTTTCAATGGGACA
AAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA
TTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC
CTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACACCTGGACTCTT
AAGAAACTTCCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA
AGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG
TGTAATGAGAGCAGTATGCAGAGCTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC
CCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG
TCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG
GATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT
TTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC
AAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG
GTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC
ACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT
TTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG
TACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC
ACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG
TATGCCATCACCTTCGCCATGCGCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC
ATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA
AGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG
GCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT
TATGTGAAGATCTACATCACAGTCCGAAATCCGCAGTACAACCCAGGGGACAAAGATACC
AAAATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCATATGCATGGCCCCAATC
TCATTCTATGCTCTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAA
ATCTTGCTGGTACTCTTCTATCCACTTAACTCCTGTGCCAATCCATTCCTCTATGCTATT
TTCACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAA
CGCCAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAG
GTTCAAAAGGTTACCCACGAGATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAA
CTGATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATG
CAAACGGTTTTGTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF13306</identifier>
        <name>LRR_5</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled peptide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thyroid-stimulating hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>thyroid-stimulating hormone signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-08-03">
  <drugbank-id primary="true">DB00025</drugbank-id>
  <drugbank-id>BTD00029</drugbank-id>
  <drugbank-id>BIOD00029</drugbank-id>
  <drugbank-id>DB13162</drugbank-id>
  <name>Antihemophilic factor, human recombinant</name>
  <description>Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells</description>
  <cas-number>139076-62-3</cas-number>
  <unii>P89DR4NY54</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>2157</pubmed-id>
        <citation>Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an "inhibitor-stop" technique. Biochem J. 1975 Sep;150(3):553-6.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>James W. Bloom, "Warm ethanol method for preparation of low fibrinogen antihemophilic factor." U.S. Patent US4478825, issued June, 1955.</synthesis-reference>
  <indication>For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.</indication>
  <pharmacodynamics>Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.</pharmacodynamics>
  <mechanism-of-action>Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>8.4-19.3 hrs</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 4.1 mL/h•kg [Previously treated pediatric patients]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002411</drugbank-id>
      <name>Lonoctocog alfa</name>
      <unii>VQ723R7O8R</unii>
      <cas-number>1388129-63-2</cas-number>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002412</drugbank-id>
      <name>Moroctocog alfa</name>
      <unii>113E3Z3CJJ</unii>
      <cas-number>284036-24-4</cas-number>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002413</drugbank-id>
      <name>Octocog alfa</name>
      <unii/>
      <cas-number>139076-62-3</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="" coder="">Antihemophilic factor (recombinant)</synonym>
    <synonym language="" coder="">Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method</synonym>
    <synonym language="" coder="">Antihemophilic factor recombinant</synonym>
    <synonym language="" coder="">Antihemophilic factor, recombinant</synonym>
    <synonym language="" coder="">Antihemophilic factor,recombinant</synonym>
    <synonym language="" coder="">Factor VIII (rDNA)</synonym>
    <synonym language="" coder="">Factor VIII (Recombinant)</synonym>
    <synonym language="" coder="">Factor VIII recombin</synonym>
    <synonym language="" coder="">Factor VIII, recombinant</synonym>
    <synonym language="" coder="">Human Factor VIII (Recombinant)</synonym>
    <synonym language="" coder="">Human factor VIII recombinant</synonym>
    <synonym language="" coder="">rAHF</synonym>
    <synonym language="" coder="">Recombinant antihemophilic factor VIII</synonym>
  </synonyms>
  <products>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2921</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2963</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2964</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2965</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3045</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3046</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3047</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3051</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3052</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3053</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-3054</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2923</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2924</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2922</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2948</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2960</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2961</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2962</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-07-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125063</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284162</dpd-id>
      <started-marketing-on>2006-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02337193</dpd-id>
      <started-marketing-on>2010-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365952</dpd-id>
      <started-marketing-on>2012-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284138</dpd-id>
      <started-marketing-on>2006-10-06</started-marketing-on>
      <ended-marketing-on>2013-10-08</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284146</dpd-id>
      <started-marketing-on>2006-10-06</started-marketing-on>
      <ended-marketing-on>2013-10-08</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365979</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365987</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284154</dpd-id>
      <started-marketing-on>2006-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02313111</dpd-id>
      <started-marketing-on>2008-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Advate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365944</dpd-id>
      <started-marketing-on>2012-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459531</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459558</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459566</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459574</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459582</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459590</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Afstyla</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459604</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antivenin</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-5424</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA101062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-8131</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-8132</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-8133</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-8134</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-8135</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243186</dpd-id>
      <started-marketing-on>2008-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243187</dpd-id>
      <started-marketing-on>2008-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243188</dpd-id>
      <started-marketing-on>2008-04-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02308592</dpd-id>
      <started-marketing-on>2009-09-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Helixate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02342723</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate - Pws IV 1000I.U./vial</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02178834</dpd-id>
      <started-marketing-on>1996-07-09</started-marketing-on>
      <ended-marketing-on>2002-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate - Pws IV 250I.U./vial</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02178818</dpd-id>
      <started-marketing-on>1996-11-20</started-marketing-on>
      <ended-marketing-on>2002-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate - Pws IV 500I.U./vial</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02178826</dpd-id>
      <started-marketing-on>1996-11-20</started-marketing-on>
      <ended-marketing-on>2002-08-01</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3782</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3783</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3785</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3786</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3787</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3792</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242489</dpd-id>
      <started-marketing-on>2004-03-31</started-marketing-on>
      <ended-marketing-on>2009-08-06</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3793</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242490</dpd-id>
      <started-marketing-on>2000-09-29</started-marketing-on>
      <ended-marketing-on>2009-08-06</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3795</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242491</dpd-id>
      <started-marketing-on>2000-09-29</started-marketing-on>
      <ended-marketing-on>2009-08-06</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3796</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-07-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3797</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103332</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291517</dpd-id>
      <started-marketing-on>2015-10-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291525</dpd-id>
      <started-marketing-on>2015-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02291533</dpd-id>
      <started-marketing-on>2015-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254476</dpd-id>
      <started-marketing-on>2006-08-04</started-marketing-on>
      <ended-marketing-on>2015-10-14</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254484</dpd-id>
      <started-marketing-on>2005-09-26</started-marketing-on>
      <ended-marketing-on>2015-08-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02254492</dpd-id>
      <started-marketing-on>2005-09-26</started-marketing-on>
      <ended-marketing-on>2015-08-27</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302217</dpd-id>
      <started-marketing-on>2015-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02342731</dpd-id>
      <started-marketing-on>2015-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS -(with Bio-set)</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02342758</dpd-id>
      <started-marketing-on>2010-05-11</started-marketing-on>
      <ended-marketing-on>2015-07-07</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate FS -(with Bio-set)</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302225</dpd-id>
      <started-marketing-on>2008-08-06</started-marketing-on>
      <ended-marketing-on>2015-08-13</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate Pws 1000iu/vial</name>
      <labeller>Miles Inc.   Pharmaceutical Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042517</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate Pws 250iu/vial</name>
      <labeller>Miles Inc.   Pharmaceutical Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042495</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kogenate Pws 500iu/vial</name>
      <labeller>Miles Inc.   Pharmaceutical Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042509</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3821</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3822</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3824</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3826</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code>0026-3828</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125574</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451603</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451611</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451638</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451646</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451654</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451441</dpd-id>
      <started-marketing-on>2016-07-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451468</dpd-id>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451476</dpd-id>
      <started-marketing-on>2016-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451484</dpd-id>
      <started-marketing-on>2016-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kovaltry</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02451492</dpd-id>
      <started-marketing-on>2016-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Monoclate-P</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7631</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1990-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103953</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Monoclate-P</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7632</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1990-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103953</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Monoclate-P</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7633</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1990-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103953</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Monoclate-P</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7634</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103953</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7810</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7815</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7820</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7825</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7830</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novoeight</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7850</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125466</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-139</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-141</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-143</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-145</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-147</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-149</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Nuwiq</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-151</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125555</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2841</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1992-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2842</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1992-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2843</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1992-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2844</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2845</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-03-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2831</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2832</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2833</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-02-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103375</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Recombinate Pws Inj 1000I.U./vial</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02015137</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2009-02-12</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Recombinate Pws Inj 250I.U./vial</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02015129</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2009-02-12</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Recombinate Pws Inj 500I.U./vial</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02015145</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2009-02-12</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Refacto</name>
      <labeller>Wyeth Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245951</dpd-id>
      <started-marketing-on>2003-02-11</started-marketing-on>
      <ended-marketing-on>2009-01-23</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-182</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125251</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)</name>
      <labeller>Octapharma Pharmazeutika Produktionsgesellschaft M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code>67467-182</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125251</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-012</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-013</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-014</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-015</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-016</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-022</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-023</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-024</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-025</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125264</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309483</dpd-id>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309491</dpd-id>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309505</dpd-id>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02309513</dpd-id>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha Solofuse</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374072</dpd-id>
      <started-marketing-on>2012-04-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha Solofuse</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374080</dpd-id>
      <started-marketing-on>2012-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha Solofuse</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374099</dpd-id>
      <started-marketing-on>2012-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha Solofuse</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374056</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xyntha Solofuse</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02374064</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Bioclate</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Helixate</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Hyate:C</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Koate-HP</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Kogenate</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Monarc-M</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>ReFacto</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Antivenin</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Monoclate-P</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Monoclate-P</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Monoclate-P</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Monoclate-P</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha Solofuse</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha Solofuse</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha Solofuse</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha Solofuse</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha Solofuse</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Refacto AF</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)</name>
      <ingredients>Antihemophilic factor, human recombinant + Von Willebrand Factor Human</ingredients>
    </mixture>
    <mixture>
      <name>Wilate - von Willebrand Factor/Coagulation Factor VIII Complex (Human)</name>
      <ingredients>Antihemophilic factor, human recombinant + Von Willebrand Factor Human</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Afstyla</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Novoeight</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Xyntha</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Nuwiq</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate Pws Inj 250I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate Pws Inj 1000I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate Pws Inj 500I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate Pws 250iu/vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate Pws 500iu/vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate Pws 1000iu/vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate - Pws IV 250I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate - Pws IV 500I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate - Pws IV 1000I.U./vial</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS -(with Bio-set)</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Helixate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kogenate FS -(with Bio-set)</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Kovaltry</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Recombinate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Advate</name>
      <ingredients>Antihemophilic factor, human recombinant</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>CSL Behring LLC</name>
      <url>http://www.cslbehring.com</url>
    </packager>
    <packager>
      <name>GlaxoSmithKline Inc.</name>
      <url>http://www.gsk.com</url>
    </packager>
    <packager>
      <name>Grifols SA</name>
      <url>http://www.grifols.com</url>
    </packager>
    <packager>
      <name>Ipsen Pharmaceuticals Inc.</name>
      <url>http://www.ipsen.com</url>
    </packager>
    <packager>
      <name>Octapharma USA</name>
      <url>http://www.octapharma.com</url>
    </packager>
    <packager>
      <name>Talecris Biotherapeutics</name>
      <url>http://www.talecris.com</url>
    </packager>
    <packager>
      <name>Wyeth Pharmaceuticals</name>
      <url>http://www.wyeth.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Monoclate-p 1000 unit kit</description>
      <cost currency="USD">1.01</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Monoclate-p 1500 unit kit</description>
      <cost currency="USD">1.01</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Monoclate-p 250 unit kit</description>
      <cost currency="USD">1.01</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Monoclate-p 500ahfu kit</description>
      <cost currency="USD">1.01</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Alphanate 1000-1500 unit vial</description>
      <cost currency="USD">1.2</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Alphanate 250-500 unit vial</description>
      <cost currency="USD">1.2</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Humate-p 1000 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Humate-p 1200 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Humate-p 2000 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Humate-p 2400 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Humate-p 500 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Humate-p 600 unit kit</description>
      <cost currency="USD">1.2</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Koate-dvi 1000 unit kit</description>
      <cost currency="USD">1.31</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Koate-dvi 250 unit kit</description>
      <cost currency="USD">1.31</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Koate-dvi 500 unit kit</description>
      <cost currency="USD">1.31</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Refacto 1000 unit vial</description>
      <cost currency="USD">1.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Refacto 2000 unit vial</description>
      <cost currency="USD">1.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Refacto 250 unit vial</description>
      <cost currency="USD">1.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Refacto 500 unit vial</description>
      <cost currency="USD">1.31</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Hemofil m 1701-2000 unit vial</description>
      <cost currency="USD">1.34</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Hemofil m 220-400 unit vial</description>
      <cost currency="USD">1.34</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Hemofil m 401-800 unit vial</description>
      <cost currency="USD">1.34</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Hemofil m 801-1700 unit vial</description>
      <cost currency="USD">1.34</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Wilate 450-450 unit kit</description>
      <cost currency="USD">1.38</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Wilate 900-900 unit kit</description>
      <cost currency="USD">1.38</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Helixate fs 1000 unit vial</description>
      <cost currency="USD">1.56</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Helixate fs 250 unit vial</description>
      <cost currency="USD">1.56</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Helixate fs 3000 unit vial</description>
      <cost currency="USD">1.56</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Helixate fs 500 unit vial</description>
      <cost currency="USD">1.56</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Xyntha 1000 unit kit</description>
      <cost currency="USD">1.66</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Xyntha 2000 unit kit</description>
      <cost currency="USD">1.66</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Xyntha 250 unit kit</description>
      <cost currency="USD">1.66</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Xyntha 500 unit kit</description>
      <cost currency="USD">1.66</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Advate 1201-1800 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Advate 1801-2400 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Advate 200-400 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Advate 2400-3600 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Advate 401-800 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Advate 801-1200 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Kogenate fs 1000 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Kogenate fs 250 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Kogenate fs 3000 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Kogenate fs 500 unit vial</description>
      <cost currency="USD">1.68</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Disaccharides</category>
      <mesh-id>D004187</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Oligosaccharides</category>
      <mesh-id>D009844</mesh-id>
    </category>
    <category>
      <category>Polysaccharides</category>
      <mesh-id>D011134</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>1500 IU</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>2500 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>3000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>2000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>3000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>500 IU</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>2000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>500 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>2000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>3000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>500 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02BD02">
      <level code="B02BD">Blood coagulation factors</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:28.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2R7E</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2124690</number>
      <country>Canada</country>
      <approved>2007-09-11</approved>
      <expires>2013-10-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1339477</number>
      <country>Canada</country>
      <approved>1997-09-23</approved>
      <expires>2014-09-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;DB00025 sequence
ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN
IAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ
REKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR
EGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR
SLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL
MDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF
DDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG
RKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI
TDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME
RDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG
VQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH
KMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE
DSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP
KIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ
LHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN
TSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW
GKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL
LIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK
KEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG
QNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK
KETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR
TKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL
PLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI
PQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK
NNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI
YQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK
LLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP
EIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIY
DEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD
GSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA
EPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHT
NTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA
INGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP
GVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS
GQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQ
FIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRS
TLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWR
PQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV
KVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.533</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>6.97</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>264725.5</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C11794H18314N3220O3553S83</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>745</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9847</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12787</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22826</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M14113</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164750168</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00451</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Antihemophilic_Factor</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108175</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/hemofilm.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/antihemophilic-factor-human.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000216</id>
      <name>Coagulation factor X</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>13801371</pubmed-id>
            <citation>BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86.</citation>
          </article>
          <article>
            <pubmed-id>14285227</pubmed-id>
            <citation>LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20.</citation>
          </article>
          <article>
            <pubmed-id>236567</pubmed-id>
            <citation>Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82.</citation>
          </article>
          <article>
            <pubmed-id>6436416</pubmed-id>
            <citation>Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28.</citation>
          </article>
          <article>
            <pubmed-id>11891806</pubmed-id>
            <citation>Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00742" source="Swiss-Prot">
    <name>Coagulation factor X</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.</specific-function>
    <gene-name>F10</gene-name>
    <locus>13q34</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-31</signal-regions>
    <theoretical-pi>5.74</theoretical-pi>
    <molecular-weight>54731.255</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3528</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F10</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>K03194</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182841</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2359</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00742</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FA10_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.6</synonym>
      <synonym>Stuart factor</synonym>
      <synonym>Stuart-Prower factor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010204|Coagulation factor X
MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
VITSSPLK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010205|Coagulation factor X (F10)
ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC
GGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG
GCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG
ACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC
TGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA
TGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC
TGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC
CACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC
GGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG
AAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG
AAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC
AACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA
TGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC
TGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA
GCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG
GCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC
TTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT
GCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT
GTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG
GAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG
AACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG
GGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA
GAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG
TGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG
GTCATAACGTCCTCTCCATTAAAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000364</id>
      <name>Coagulation factor IX</name>
      <organism>Human</organism>
      <actions>
        <action>cofactor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>1119107</pubmed-id>
            <citation>Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman]. Vnitr Lek. 1975 Mar;21(3):274-7.</citation>
          </article>
          <article>
            <pubmed-id>2994716</pubmed-id>
            <citation>Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50.</citation>
          </article>
          <article>
            <pubmed-id>14240634</pubmed-id>
            <citation>LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5.</citation>
          </article>
          <article>
            <pubmed-id>932529</pubmed-id>
            <citation>Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13.</citation>
          </article>
          <article>
            <pubmed-id>6422634</pubmed-id>
            <citation>Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00740" source="Swiss-Prot">
    <name>Coagulation factor IX</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.</specific-function>
    <gene-name>F9</gene-name>
    <locus>Xq27.1-q27.2</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>5.16</theoretical-pi>
    <molecular-weight>51778.11</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F9</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>K02402</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182609</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2364</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00740</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FA9_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.22</synonym>
      <synonym>Christmas factor</synonym>
      <synonym>Plasma thromboplastin component</synonym>
      <synonym>PTC</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000725|Coagulation factor IX
MQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNL
ERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCP
FGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGR
VSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPW
QVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRII
PHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVF
HKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVE
GTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010262|Coagulation factor IX (F9)
ATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTA
GGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATT
CTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTT
GAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAAC
ACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAAT
CCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCC
TTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGA
TGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGA
TATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA
GTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGAC
TATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCA
TTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGG
CAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAA
TGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGT
GAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATT
CCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAA
CTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAA
TACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTC
CACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCC
ACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCAT
GAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAA
GGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAA
TATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTC
ACTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>zymogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0001043</id>
      <name>von Willebrand factor</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10938981</pubmed-id>
            <citation>Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20.</citation>
          </article>
          <article>
            <pubmed-id>11858481</pubmed-id>
            <citation>Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30.</citation>
          </article>
          <article>
            <pubmed-id>14750934</pubmed-id>
            <citation>Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95.</citation>
          </article>
          <article>
            <pubmed-id>2128855</pubmed-id>
            <citation>Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9.</citation>
          </article>
          <article>
            <pubmed-id>2942172</pubmed-id>
            <citation>Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P04275" source="Swiss-Prot">
    <name>von Willebrand factor</name>
    <general-function>Protein n-terminus binding</general-function>
    <specific-function>Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.</specific-function>
    <gene-name>VWF</gene-name>
    <locus>12p13.3</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>5.21</theoretical-pi>
    <molecular-weight>309261.83</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:12726</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>VWF</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04385</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37947</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P04275</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>VWF_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>F8VWF</synonym>
      <synonym>vWF</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037116|von Willebrand factor
MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYL
LAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYL
ETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTL
TSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL
VDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGME
YRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPG
TSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQD
HSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDL
RIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSG
LAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVS
PLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQ
CGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPED
IFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADN
LRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGE
TVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGS
NPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGR
YIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVD
FGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPY
LDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGY
ECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCE
VAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVE
DISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVE
YHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRI
TLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVL
SSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVA
FVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGD
ILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLP
GDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTL
SPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITT
IDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILV
TDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTM
VTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCD
RGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNK
EQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEV
NVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRD
GTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFY
AICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHC
DGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQI
CTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHC
ERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVN
STVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAV
MGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQ
WASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERME
ACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGEC
CGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHK
CLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMY
SIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016295|von Willebrand factor (VWF)
ATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACC
CTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGT
GACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTC
CTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAG
AGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGT
ACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTA
GAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATC
GATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGG
CTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTG
ACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGT
GAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGC
CTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTG
GTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGG
CTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATG
GTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAG
TATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATG
TGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGC
CTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGC
ACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGC
AATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGAC
AACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGAC
CACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGC
ACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCAT
GGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTC
CGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATG
GACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACC
TGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGG
CTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAG
GACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCC
GAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGC
CCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAG
TGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTC
GCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAG
TGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAAT
GAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGAC
TGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGAC
ATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATG
AGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGC
AGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAAC
CTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATG
AGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGA
TGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAA
ACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGAC
CATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGG
CTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGT
AACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAA
TGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAG
GTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGG
TACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATC
TCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGAT
GGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGAC
TTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGAC
TCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGT
AGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATAT
CTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTC
TGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGG
AGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTAT
GAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCT
GAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGG
AAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAG
GTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAG
CACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCG
GGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAG
GACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTC
CTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTG
GTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAG
TACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTG
CGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTC
TTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATC
ACCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTAC
GTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCC
AACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTG
AGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTT
GCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCGACATGGCACAAGTCACTGTGGGCCCG
GGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCG
TTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTC
ATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTG
CAGTACTCCTACATGGTGACTGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGAC
ATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTG
GCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCG
CCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCT
GGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAG
AGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAG
GCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTC
TCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCC
AGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAA
GCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACC
ATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTC
ATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATAC
TTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC
ACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTG
ACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCA
GGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATG
GTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATG
GATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCAC
ACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGAGTCATCGGGTCAACTGTGAC
CGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGT
GGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACC
TTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAG
GAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGC
TGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATG
GAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTC
AACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACA
TTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAG
ACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGAT
GGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGG
CAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAG
GTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTAT
GCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTAT
GCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCT
ATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGT
GATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGAT
AAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAG
GATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATC
TGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAA
GCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGC
CCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGT
GAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGC
GCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTG
CCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAAC
TCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACTGCCACCAATGACTGTGGCTGT
ACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTG
GGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTG
ATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGC
TTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAG
GTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAG
TGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTC
TTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGC
TTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAG
GCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGC
ACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGG
AAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGT
TGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACA
CTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAG
AGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAG
TGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAG
GAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAG
TCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTAC
TCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAG
CCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAAT
GCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00093</identifier>
        <name>VWC</name>
      </pfam>
      <pfam>
        <identifier>PF00092</identifier>
        <name>VWA</name>
      </pfam>
      <pfam>
        <identifier>PF00094</identifier>
        <name>VWD</name>
      </pfam>
      <pfam>
        <identifier>PF08742</identifier>
        <name>C8</name>
      </pfam>
      <pfam>
        <identifier>PF01826</identifier>
        <name>TIL</name>
      </pfam>
      <pfam>
        <identifier>PF16164</identifier>
        <name>VWA_N2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Weibel-Palade body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>proteinaceous extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>integrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein N-terminus binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>immunoglobulin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>collagen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chaperone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to wounding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>liver development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>placenta development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein homooligomerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hemostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002117</id>
      <name>Phytanoyl-CoA dioxygenase, peroxisomal</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>11574539</pubmed-id>
            <citation>Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O14832" source="Swiss-Prot">
    <name>Phytanoyl-CoA dioxygenase, peroxisomal</name>
    <general-function>Phytanoyl-coa dioxygenase activity</general-function>
    <specific-function>Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA.</specific-function>
    <gene-name>PHYH</gene-name>
    <locus>10pter-p11.2</locus>
    <cellular-location>Peroxisome</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>8.65</theoretical-pi>
    <molecular-weight>38538.065</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8940</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PHYH</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF023462</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>2564671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O14832</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAHX_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.11.18</synonym>
      <synonym>PAHX</synonym>
      <synonym>PhyH</synonym>
      <synonym>Phytanic acid oxidase</synonym>
      <synonym>Phytanoyl-CoA alpha-hydroxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004152|Phytanoyl-CoA dioxygenase, peroxisomal
MEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQYTLDNNVLTLEQRKF
YEENGFLVIKNLVPDADIQRFRNEFEKICRKEVKPLGLTVMRDVTISKSEYAPSEKMITK
VQDFQEDKELFRYCTLPEILKYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHY
FPFRPSDLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNKMFHGIQDYE
ENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRKAISCHFASADCHYIDVKGTSQENI
EKEVVGIAHKFFGAENSVNLKDIWMFRARLVKGERTNL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016686|Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)
ATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAG
GTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTG
AAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAAC
AAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTAT
TTCCCCTTCAGGCCCAGCGATCTCATCGTTTGCGCCTGGACGGCGATGGAGCACATCAGC
CGGAACAACGGCTGTCTGGTTGTGCTCCCAGGCACACACAAGGGCTCCCTGAAGCCCCAC
GATTACCCCAAGTGGGAGGGGGGAGTTAACAAAATGTTCCACGGGATCCAGGACTACGAG
GAAAACAAGGCCCGGGTGCACCTGGTGATGGAGAAGGGCGACACTGTTTTCTTCCATCCT
TTGCTCATCCACGGATCTGGTCAGAATAAAACCCAGGGATTCCGGAAGGCAATTTCCTGC
CATTTCGCCAGTGCCGATTGCCACTACATTGACGTGAAGGGCACCAGTCAAGAAAACATC
GAGAAGGAAGTTGTAGGAATAGCACATAAATTCTTTGGAGCTGAAAATAGCGTGAACTTG
AAGGATATTTGGATGTTTCGAGCTCGACTTGTGAAAGGAGAAAGAACCAATCTTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF05721</identifier>
        <name>PhyH</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>peroxisomal matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>peroxisome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>L-ascorbic acid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phytanoyl-CoA dioxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cofactor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fatty acid alpha-oxidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>isoprenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>methyl-branched fatty acid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002118</id>
      <name>Asialoglycoprotein receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15946216</pubmed-id>
            <citation>Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07307" source="Swiss-Prot">
    <name>Asialoglycoprotein receptor 2</name>
    <general-function>Carbohydrate binding</general-function>
    <specific-function>Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.</specific-function>
    <gene-name>ASGR2</gene-name>
    <locus>17p</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>59-79</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.34</theoretical-pi>
    <molecular-weight>35092.04</molecular-weight>
    <chromosome-location>17</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:743</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ASGR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M11025</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>179081</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P07307</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ASGR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ASGP-R 2</synonym>
      <synonym>C-type lectin domain family 4 member H2</synonym>
      <synonym>CLEC4H2</synonym>
      <synonym>Hepatic lectin H2</synonym>
      <synonym>HL-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037163|Asialoglycoprotein receptor 2
MAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQRLCSMVCFS
LLALSFNILLLVVICVTGSQSEGHGGAQLQAELRSLKEAFSNFSSSTLTEVQAISTHGGS
VGDKITSLGAKLEKQQQDLKADHDALLFHLKHFPVDLRFVACQMELLHSNGSQRTCCPVN
WVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDS
DGSWKWVDGTDYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC
EKRRNATGEVA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011535|Asialoglycoprotein receptor 2 (ASGR2)
ATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTC
CATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTG
AAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGT
CTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAA
AGTGAGGGTCACAGGGGTGCACAGCTGCAAGCCGAGCTGCGGAGCCTGAAGGAAGCTTTC
AGCAACTTCTCCTCGAGCACCCTGACGGAGGTCCAGGCAATCAGCACCCACGGAGGCAGC
GTGGGTGACAAGATCACATCCCTAGGAGCCAAGCTGGAGAAACAGCAGCAGGACCTGAAA
GCAGATCACGATGCCCTGCTCTTCCATCTGAAGCACTTCCCCGTGGACCTGCGCTTCGTG
GCCTGCCAGATGGAGCTCCTCCACAGCAACGGCTCCCAAAGGACCTGCTGCCCCGTCAAC
TGGGTGGAGCACCAAGGCAGCTGCTACTGGTTCTCTCACTCCGGGAAGGCCTGGGCTGAG
GCGGAGAAGTACTGCCAGCTGGAGAACGCACACCTGGTGGTCATCAACTCCTGGGAGGAG
CAGAAATTCATTGTACAACACACGAACCCCTTCAATACCTGGATAGGTCTCACGGACAGT
GATGGCTCTTGGAAATGGGTGGATGGCACAGACTATAGGCACAACTACAAGAACTGGGCT
GTCACTCAGCCAGATAATTGGCACGGGCACGAGCTGGGTGGAAGTGAAGACTGTGTTGAA
GTCCAGCCGGATGGCCGCTGGAACGATGACTTCTGCCTGCAGGTGTACCGCTGGGTGTGT
GAGAAAAGGCGGAATGCCACCGGCGAGGTGGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00059</identifier>
        <name>Lectin_C</name>
      </pfam>
      <pfam>
        <identifier>PF03954</identifier>
        <name>Lectin_N</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>asialoglycoprotein receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of protein stability</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycoprotein metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0001098</id>
      <name>78 kDa glucose-regulated protein</name>
      <organism>Human</organism>
      <actions>
        <action>chaperone</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>9607108</pubmed-id>
            <citation>Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11021" source="Swiss-Prot">
    <name>78 kDa glucose-regulated protein</name>
    <general-function>Unfolded protein binding</general-function>
    <specific-function>Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.</specific-function>
    <gene-name>HSPA5</gene-name>
    <locus>9q33-q34.1</locus>
    <cellular-location>Endoplasmic reticulum lumen</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>4.8</theoretical-pi>
    <molecular-weight>72332.425</molecular-weight>
    <chromosome-location>9</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5238</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HSPA5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M19645</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>386758</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P11021</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GRP78_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>BiP</synonym>
      <synonym>Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78</synonym>
      <synonym>GRP-78</synonym>
      <synonym>GRP78</synonym>
      <synonym>Heat shock 70 kDa protein 5</synonym>
      <synonym>Immunoglobulin heavy chain-binding protein</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019062|78 kDa glucose-regulated protein
MKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR
ITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV
EKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ
RQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG
VFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS
SQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV
LVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC
PLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG
TFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER
MVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE
KIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019063|78 kDa glucose-regulated protein (HSPA5)
ATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG
GAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCC
TGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC
ATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC
AAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC
CGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT
GAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT
GCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT
TTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA
CGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC
GAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC
CTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT
GTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG
CGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAA
GACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCT
TCTCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAG
ACCCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAG
CCCGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTT
CTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAAT
GGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTC
CAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGT
CCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACTGATTCCAAGGAAC
ACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACT
GTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGT
ACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACC
TTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAAC
AAAAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGG
ATGGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTCAAGGAGCGCATTGAT
ACTAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAA
AAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAA
AAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAG
AAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCT
CCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00012</identifier>
        <name>HSP70</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum-Golgi intermediate compartment</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>myelin sheath</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>melanosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>midbody</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum chaperone complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>smooth endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chaperone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ribosome binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>misfolded protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATPase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>unfolded protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to glucose starvation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endoplasmic reticulum unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to antibiotic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>PERK-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>IRE1-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of signaling protein activity involved in unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-4</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ER-associated ubiquitin-dependent protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebellum structural organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein ubiquitination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of IRE1-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ER overload response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of PERK-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cerebellar Purkinje cell layer development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of protein localization in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>substantia nigra development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ATF6-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of ATF6-mediated unfolded protein response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002109</id>
      <name>Calreticulin</name>
      <organism>Human</organism>
      <actions>
        <action>chaperone</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>9525969</pubmed-id>
            <citation>Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44.</citation>
          </article>
          <article>
            <pubmed-id>17899080</pubmed-id>
            <citation>Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26.</citation>
          </article>
          <article>
            <pubmed-id>9607108</pubmed-id>
            <citation>Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27797" source="Swiss-Prot">
    <name>Calreticulin</name>
    <general-function>Zinc ion binding</general-function>
    <specific-function>Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).</specific-function>
    <gene-name>CALR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Endoplasmic reticulum lumen</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>4.04</theoretical-pi>
    <molecular-weight>48141.2</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1455</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CALR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M32294</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>337487</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P27797</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CALR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Calregulin</synonym>
      <synonym>CRP55</synonym>
      <synonym>CRTC</synonym>
      <synonym>Endoplasmic reticulum resident protein 60</synonym>
      <synonym>ERp60</synonym>
      <synonym>grp60</synonym>
      <synonym>HACBP</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011528|Calreticulin
MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE
EKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT
DMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN
TYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE
HIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS
PDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011529|Calreticulin (CALR)
ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCC
GTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC
AAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG
GAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT
TTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG
CAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA
GACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC
ACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC
ATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC
ACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG
GACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT
GAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG
CATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG
TGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC
GACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT
CCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG
GTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG
GAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA
CAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG
GAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC
AAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00262</identifier>
        <name>Calreticulin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>proteinaceous extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>acrosomal vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>smooth endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>MHC class I peptide loading complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>polysome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>integrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chaperone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>complement component C1q binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein binding involved in protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>unfolded protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>androgen receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>mRNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cortical actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chaperone-mediated protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lithium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ATF6-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiac muscle cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein maturation by protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell cycle arrest</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular senescence</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to testosterone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sequestering of calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intracellular steroid hormone receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucocorticoid receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of retinoic acid receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptide antigen assembly with MHC class I protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dendritic cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein export from nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of translation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endoplasmic reticulum unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of meiotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein stabilization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0001011</id>
      <name>Calnexin</name>
      <organism>Human</organism>
      <actions>
        <action>chaperone</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>9525969</pubmed-id>
            <citation>Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44.</citation>
          </article>
          <article>
            <pubmed-id>15213841</pubmed-id>
            <citation>Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35.</citation>
          </article>
          <article>
            <pubmed-id>17899080</pubmed-id>
            <citation>Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2008 Feb;87(2):107-12. Epub 2007 Sep 26.</citation>
          </article>
          <article>
            <pubmed-id>9607108</pubmed-id>
            <citation>Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27824" source="Swiss-Prot">
    <name>Calnexin</name>
    <general-function>Poly(a) rna binding</general-function>
    <specific-function>Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.</specific-function>
    <gene-name>CANX</gene-name>
    <locus>5q35</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions>482-502</transmembrane-regions>
    <signal-regions>1-20</signal-regions>
    <theoretical-pi>4.21</theoretical-pi>
    <molecular-weight>67567.695</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1473</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CANX</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L10284</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>186523</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P27824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CALX_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IP90</synonym>
      <synonym>Major histocompatibility complex class I antigen-binding protein p88</synonym>
      <synonym>p90</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002013|Calnexin
MEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY
KAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL
VLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH
DKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL
ILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK
PDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC
ESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS
AIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER
PWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE
EEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016282|Calnexin (CANX)
ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT
CATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA
GAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC
AAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG
TCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT
GATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT
GTGTTGATGTCTCGGGCCAAGCATCATGCCATCTCTGCTAAACTGAACAAGCCCTTCCTG
TTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT
GGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT
GACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG
CACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG
AGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA
ATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA
AATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA
GACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG
CCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC
GAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG
GATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT
GAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA
GGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG
AAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT
GCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT
TGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT
GCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC
CCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC
TTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT
CAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG
GAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT
GGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG
AACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00262</identifier>
        <name>Calreticulin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>myelin sheath</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>smooth endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ribosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ER-mitochondrion membrane contact site</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>melanosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>clathrin-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chaperone-mediated protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle endocytosis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0002119</id>
      <name>Protein ERGIC-53</name>
      <organism>Human</organism>
      <actions>
        <action>chaperone</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>14629470</pubmed-id>
            <citation>Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7.</citation>
          </article>
          <article>
            <pubmed-id>14726380</pubmed-id>
            <citation>Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P49257" source="Swiss-Prot">
    <name>Protein ERGIC-53</name>
    <general-function>Unfolded protein binding</general-function>
    <specific-function>Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins.</specific-function>
    <gene-name>LMAN1</gene-name>
    <locus>18q21.3-q22</locus>
    <cellular-location>Endoplasmic reticulum-Golgi intermediate compartment membrane</cellular-location>
    <transmembrane-regions>478-498</transmembrane-regions>
    <signal-regions>1-30</signal-regions>
    <theoretical-pi>6.76</theoretical-pi>
    <molecular-weight>57548.665</molecular-weight>
    <chromosome-location>18</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6631</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LMAN1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X71661</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>433938</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P49257</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LMAN1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ER-Golgi intermediate compartment 53 kDa protein</synonym>
      <synonym>ERGIC53</synonym>
      <synonym>F5F8D</synonym>
      <synonym>Gp58</synonym>
      <synonym>Intracellular mannose-specific lectin MR60</synonym>
      <synonym>Lectin mannose-binding 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019239|Protein ERGIC-53
MAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS
DGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA
DGLAIWYAENQGLEGPVFGSADLWNGVGIFFDSFDNDGKKNNPAIVIIGNNGQIHYDHQN
DGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA
QGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL
DKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR
RYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM
QHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH
FIIFVVVQTVLFIGYIMYRSQQEAAAKKFF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019240|Protein ERGIC-53 (LMAN1)
ATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTG
CTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCG
TTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGC
GACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATT
CGAGTAGCACCATCTTTAAAAAGCCAAAGAGGCTCAGTGTGGACAAAGACAAAAGCGGCC
TTTGAGAACTGGGAAGTTGAGGTGACATTTCGAGTGACTGGAAGAGGTCGAATTGGAGCT
GATGGCCTAGCAATTTGGTATGCAGAAAATCAAGGCTTGGAGGGCCCTGTGTTTGGATCA
GCTGATCTGTGGAATGGTGTTGGAATATTTTTTGATTCTTTTGACAATGATGGAAAGAAA
AATAATCCTGCTATAGTAATTATAGGCAACAATGGACAAATCCATTATGACCATCAAAAT
GACGGGGCTAGTCAAGCTTTGGCAAGTTGCCAGAGGGACTTCCGCAACAAACCCTATCCT
GTCCGAGCAAAGATTACCTATTACCAGAACACACTGACAGTAATGATCAATAATGGCTTT
ACACCAGATAAAAATGATTATGAATTTTGTGCCAAAGTGGAAAATATGATTATCCCTGCA
CAAGGGCATTTTGGAATATCTGCTGCAACTGGAGGTCTTGCAGATGACCATGATGTCCTT
TCTTTTCTGACTTTCCAGTTGACTGAACCTGGAAAAGAGCCGCCCACACCAGATAAAGAA
ATTTCGGAAAAGGAAAAAGAAAAGTATCAGGAGGAATTTGAGCACTTTCAACAAGAATTG
GATAAAAAAAAAGAGGAATTCCAGAAGGGCCACCCCGACCTCCAAGGGCAGCCTGCGGAG
GAAATATTTGAGAGTGTAGGAGATCGAGAGCTAAGACAAGTCTTTGAAGGACAGAATCGT
ATTCATCTTGAAATCAAGCAGCTGAACCGGCAGTTAGATATGATTCTTGATGAACAGAGA
AGATATGTCTCTTCCTTAACAGAGGAAATCTCTAAAAGAGGAGCAGGAATGCCTGGGCAG
CATGGGCAGATTACTCAACAAGAACTGGATACTGTTGTGAAAACTCAGCATGAGATTCTG
AGACAAGTAAATGAAATGAAAAATTCCATGAGTGAAACCGTCAGACTGGTCAGTGGAATG
CAGCACCCTGGCTCTGCTGGAGGCGTCTATGAGACAACACAGCACTTCATTGACATCAAA
GAGCACCTGCACATAGTAAAGAGGGACATAGATAACTTAGTGCAGCGAAATATGCCATCA
AATGAAAAGCCGAAATGCCCAGAACTACCACCATTTCCATCATGTTTGTCTACGGTCCAC
TTCATTATATTTGTTGTGGTGCAAACTGTATTATTCATTGGTTATATCATGTATAGGTCT
CAGCAAGAAGCAGCTGCCAAAAAATTCTTTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03388</identifier>
        <name>Lectin_leg-like</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum-Golgi intermediate compartment</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ER to Golgi transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>host cell perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum-Golgi intermediate compartment membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcomere</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>unfolded protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>mannose binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Golgi organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>COPII vesicle coating</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endoplasmic reticulum organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ER to Golgi vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of organelle organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0002110</id>
      <name>Prolow-density lipoprotein receptor-related protein 1</name>
      <organism>Human</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>21391865</pubmed-id>
            <citation>Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. doi: 10.1515/CCLM.2011.154. Epub 2011 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q07954" source="Swiss-Prot">
    <name>Prolow-density lipoprotein receptor-related protein 1</name>
    <general-function>Receptor activity</general-function>
    <specific-function>Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.</specific-function>
    <gene-name>LRP1</gene-name>
    <locus>12q13-q14</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>4420-4444</transmembrane-regions>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.02</theoretical-pi>
    <molecular-weight>504601.695</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6692</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LRP1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X13916</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>34339</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q07954</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LRP1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>A2MR</synonym>
      <synonym>Alpha-2-macroglobulin receptor</synonym>
      <synonym>APOER</synonym>
      <synonym>Apolipoprotein E receptor</synonym>
      <synonym>APR</synonym>
      <synonym>LRP-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1
MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA
PEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC
QHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL
LQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE
TVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI
DDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK
LVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE
NYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN
DQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG
MDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG
IHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG
WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY
DRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT
LLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV
TCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF
KCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD
CGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF
KCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW
RCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC
ESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP
GEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES
CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK
IYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT
LLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT
VDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT
LAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT
VSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL
DYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN
KKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG
QKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW
WADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL
CLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG
TSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY
WTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG
TERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS
VSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA
VANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL
NAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE
NVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD
ECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK
IERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI
PQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV
NSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS
NMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS
ATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY
FACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG
DGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD
REFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG
ENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH
INECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH
GSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV
ALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD
KGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR
SVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF
EDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG
CSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG
DHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC
TNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV
DGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ
FRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC
ADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ
CNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD
NCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP
KLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN
TKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV
RIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP
RGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW
GNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI
VAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH
QHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC
NLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT
GFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM
AADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH
CSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV
VFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT
NFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)
ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT
ATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT
ATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC
CCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG
GGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC
GGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC
CAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG
CTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC
AGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC
CTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG
CTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT
ACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG
ACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC
ATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC
CACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC
GATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG
GAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT
GACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG
CTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT
GTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC
CGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG
AATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC
CGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT
GCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC
GACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG
GCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG
AAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC
ATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC
CCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC
TACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC
ATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC
GATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG
ACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG
TGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG
AGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG
CCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC
GACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT
GAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT
CGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC
CTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG
CAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC
ACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC
ACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC
TGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG
GACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC
AAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT
GGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG
TTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC
TGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT
CAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT
GACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC
AAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC
GGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT
GGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG
CGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG
ACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC
AAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC
GAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG
CCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG
CTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT
GGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC
TGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC
AAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC
TGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG
CGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC
GCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG
ATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG
TATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG
GTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC
CTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC
CTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG
GCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC
GTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA
GCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC
CCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA
CTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC
CAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT
GAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC
GTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG
TTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT
CCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA
GACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG
CGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC
CACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT
AAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC
CTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT
GGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC
CAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC
TCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT
GCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG
TGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC
GTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC
CAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC
TGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG
AGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA
ATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG
ACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC
ATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG
ACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC
TGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC
GTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG
TACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC
ACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC
TACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC
CTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA
GTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC
AAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC
CAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG
GTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC
GCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC
CTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC
AATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC
TTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC
CACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA
AACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA
AGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC
GAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC
GAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG
GCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT
GGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG
ATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC
CACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG
GCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC
CCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT
CCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT
GTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG
AATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC
AGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC
TGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC
AACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC
AACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC
TCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT
GCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC
GAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG
GACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC
TTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC
TGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG
TGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG
GATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC
TGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT
GCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC
CGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC
CGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC
AGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC
GAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA
GAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG
GCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC
ATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG
ATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT
GCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT
GGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC
TGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC
AAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT
GCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC
AGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC
CTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC
AAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC
AGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC
TGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC
AGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT
GAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC
TCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT
GAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC
ACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC
TTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC
TGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC
TTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA
TGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG
GACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG
TGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG
GACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC
ACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA
GATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC
TCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG
GATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC
TGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT
GGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG
TTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT
TGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC
TCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC
GCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC
AAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC
GGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG
TGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG
GACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC
TTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC
AACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC
TGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC
TGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC
AAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC
ACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC
GGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC
ACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC
AAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC
CTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC
CGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC
ACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC
CACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC
AGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT
GTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT
GACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG
GGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG
CAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC
TGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT
GTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT
TACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC
AGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT
CAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC
CTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC
ACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT
AACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC
CGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT
CGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG
GGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC
ACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC
GACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG
GCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG
GTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT
GTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC
TGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA
CCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT
ATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG
GTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC
AACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG
CCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC
AACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC
CTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG
GACCCCTTGGCATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF12662</identifier>
        <name>cEGF</name>
      </pfam>
      <pfam>
        <identifier>PF16472</identifier>
        <name>DUF5050</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>coated pit</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleolus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipoprotein particle receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipoprotein transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein complex binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of lipid transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aorta morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron projection development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cholesterol transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoprotein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>beta-amyloid clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cholesterol efflux</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic cell clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet-derived growth factor receptor-beta signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of phospholipase A2 activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoprotein transport</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002120</id>
      <name>Multiple coagulation factor deficiency protein 2</name>
      <organism>Human</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>15886209</pubmed-id>
            <citation>Zhang B, Kaufman RJ, Ginsburg D: LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem. 2005 Jul 8;280(27):25881-6. Epub 2005 May 10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8NI22" source="Swiss-Prot">
    <name>Multiple coagulation factor deficiency protein 2</name>
    <general-function>Calcium ion binding</general-function>
    <specific-function>The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors.</specific-function>
    <gene-name>MCFD2</gene-name>
    <locus>2p21</locus>
    <cellular-location>Endoplasmic reticulum-Golgi intermediate compartment</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.25</theoretical-pi>
    <molecular-weight>16390.175</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:18451</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>MCFD2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF475284</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>20799383</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q8NI22</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>MCFD2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Neural stem cell-derived neuronal survival protein</synonym>
      <synonym>SDNSF</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004158|Multiple coagulation factor deficiency protein 2
MTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVI
NKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINI
IDGVLRDDDKNNDGYIDYAEFAKSLQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016687|Multiple coagulation factor deficiency protein 2 (MCFD2)
ATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGT
GCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGC
CTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATC
AACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCAT
GATTATGATGGCAATAATTTGCTTGATGGCTTAGAACTCTCCACAGCCATCACTCATGTC
CATAAGGAGGAAGGGAGTGAACAGGCACCACTAATGAGTGAAGATGAACTGATTAACATA
ATAGATGGTGTTTTGAGAGATGATGACAAGAACAATGATGGATACATTGACTATGCTGAA
TTTGCAAAATCACTGCAGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13499</identifier>
        <name>EF-hand_7</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum-Golgi intermediate compartment membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ER to Golgi transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>COPII vesicle coating</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ER to Golgi vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="12">
      <id>BE0000048</id>
      <name>Prothrombin</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10688826</pubmed-id>
            <citation>Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL: Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000 Mar 1;95(5):1694-702.</citation>
          </article>
          <article>
            <pubmed-id>1139038</pubmed-id>
            <citation>Ratnoff OD, Lewis JH: Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). Blood. 1975 Aug;46(2):161-73.</citation>
          </article>
          <article>
            <pubmed-id>12463731</pubmed-id>
            <citation>Anderson DM, Shelley S, Crick N, Buraglio M: No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 Dec;42(12):1358-65.</citation>
          </article>
          <article>
            <pubmed-id>2402772</pubmed-id>
            <citation>Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591-8.</citation>
          </article>
          <article>
            <pubmed-id>3099625</pubmed-id>
            <citation>Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA: Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00734" source="Swiss-Prot">
    <name>Prothrombin</name>
    <general-function>Thrombospondin receptor activity</general-function>
    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>
    <gene-name>F2</gene-name>
    <locus>11p11-q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-24</signal-regions>
    <theoretical-pi>5.7</theoretical-pi>
    <molecular-weight>70036.295</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3535</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M17262</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339641</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00734</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>THRB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.5</synonym>
      <synonym>Coagulation factor II</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016004|Prothrombin
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016005|Prothrombin (F2)
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF09396</identifier>
        <name>Thrombin_light</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>thrombospondin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to wounding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of collagen biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytosolic calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organismal development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of astrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell shape</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to inactivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="13">
      <id>BE0000380</id>
      <name>Vitamin K-dependent protein C</name>
      <organism>Human</organism>
      <actions>
        <action>inactivator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>21054189</pubmed-id>
            <citation>Bereczky Z, Kovacs KB, Muszbek L: Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S53-66. doi: 10.1515/CCLM.2010.369. Epub 2010 Nov 5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P04070" source="Swiss-Prot">
    <name>Vitamin K-dependent protein C</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts a protective effect on the endothelial cell barrier function (PubMed:25651845).</specific-function>
    <gene-name>PROC</gene-name>
    <locus>2q13-q14</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>6.23</theoretical-pi>
    <molecular-weight>52070.82</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9451</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PROC</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M11228</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>190334</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2396</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P04070</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PROC_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.69</synonym>
      <synonym>Anticoagulant protein C</synonym>
      <synonym>Autoprothrombin IIA</synonym>
      <synonym>Blood coagulation factor XIV</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000757|Vitamin K-dependent protein C
MWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECI
EEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSC
DCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVK
FPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGA
VLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDI
ALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVL
NFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLV
SWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020458|Vitamin K-dependent protein C (PROC)
ATGTGGCAGCTCACAAGCCTCCTGCTGTTCGTGGCCACCTGGGGAATTTCCGGCACACCA
GCTCCTCTTGACTCAGTGTTCTCCAGCAGCGAGCGTGCCCACCAGGTGCTGCGGATCCGC
AAACGTGCCAACTCCTTCCTGGAGGAGCTCCGTCACAGCAGCCTGGAGCGGGAGTGCATA
GAGGAGATCTGTGACTTCGAGGAGGCCAAGGAAATTTTCCAAAATGTGGATGACACACTG
GCCTTCTGGTCCAAGCACGTCGACGGTGACCAGTGCTTGGTCTTGCCCTTGGAGCACCCG
TGCGCCAGCCTGTGCTGCGGGCACGGCACGTGCATCGACGGCATCGGCAGCTTCAGCTGC
GACTGCCGCAGCGGCTGGGAGGGCCGCTTCTGCCAGCGCGAGGTGAGCTTCCTCAATTGC
TCGCTGGACAACGGCGGCTGCACGCATTACTGCCTAGAGGAGGTGGGCTGGCGGCGCTGT
AGCTGTGCGCCTGGCTACAAGCTGGGGGACGACCTCCTGCAGTGTCACCCCGCAGTGAAG
TTCCCTTGTGGGAGGCCCTGGAAGCGGATGGAGAAGAAGCGCAGTCACCTGAAACGAGAC
ACAGAAGACCAAGAAGACCAAGTAGATCCGCGGCTCATTGATGGGAAGATGACCAGGCGG
GGAGACAGCCCCTGGCAGGTGGTCCTGCTGGACTCAAAGAAGAAGCTGGCCTGCGGGGCA
GTGCTCATCCACCCCTCCTGGGTGCTGACAGCGGCCCACTGCATGGATGAGTCCAAGAAG
CTCCTTGTCAGGCTTGGAGAGTATGACCTGCGGCGCTGGGAGAAGTGGGAGCTGGACCTG
GACATCAAGGAGGTCTTCGTCCACCCCAACTACAGCAAGAGCACCACCGACAATGACATC
GCACTGCTGCACCTGGCCCAGCCCGCCACCCTCTCGCAGACCATAGTGCCCATCTGCCTC
CCGGACAGCGGCCTTGCAGAGCGCGAGCTCAATCAGGCCGGCCAGGAGACCCTCGTGACG
GGCTGGGGCTACCACAGCAGCCGAGAGAAGGAGGCCAAGAGAAACCGCACCTTCGTCCTC
AACTTCATCAAGATTCCCGTGGTCCCGCACAATGAGTGCAGCGAGGTCATGAGCAACATG
GTGTCTGAGAACATGCTGTGTGCGGGCATCCTCGGGGACCGGCAGGATGCCTGCGAGGGC
GACAGTGGGGGGCCCATGGTCGCCTCCTTCCACGGCACCTGGTTCCTGGTGGGCCTGGTG
AGCTGGGGTGAGGGCTGTGGGCTCCTTCACAACTACGGCGTTTACACCAAAGTCAGCCGC
TACCTCGACTGGATCCATGGGCACATCAGAGACAAGGAAGCCCCCCAGAAGAGCTGGGCA
CCTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of establishment of endothelial barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00026</drugbank-id>
  <drugbank-id>BTD00060</drugbank-id>
  <drugbank-id>BIOD00060</drugbank-id>
  <name>Anakinra</name>
  <description>Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001. </description>
  <cas-number>143090-92-0</cas-number>
  <unii>9013DUQ28K</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>11752352</pubmed-id>
        <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
      </article>
      <article>
        <pubmed-id>17947302</pubmed-id>
        <citation>Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loet X, Sibilia J: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):302-8. Epub 2007 Oct 18.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). </indication>
  <pharmacodynamics>Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.</pharmacodynamics>
  <mechanism-of-action>Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.</mechanism-of-action>
  <toxicity>Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence &gt;10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis. </toxicity>
  <metabolism/>
  <absorption>When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. &#13;
Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;&#13;
Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL. &#13;
</absorption>
  <half-life>Healthy subjects = 4 - 6 hours;&#13;
NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours). </half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors. </clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">ICIL-1RA</synonym>
    <synonym language="" coder="">IL-1ra</synonym>
    <synonym language="" coder="">IL-1RN</synonym>
    <synonym language="" coder="">IL1 inhibitor</synonym>
    <synonym language="" coder="">Interleukin-1 receptor antagonist protein precursor</synonym>
    <synonym language="" coder="">IRAP</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kineret</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245913</dpd-id>
      <started-marketing-on>2002-05-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>150 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kineret</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-234</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/.67mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103950</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kineret</name>
      <ingredients>Anakinra</ingredients>
    </mixture>
    <mixture>
      <name>Kineret</name>
      <ingredients>Anakinra</ingredients>
    </mixture>
    <mixture>
      <name>Kineret</name>
      <ingredients>Anakinra</ingredients>
    </mixture>
    <mixture>
      <name>Kineret</name>
      <ingredients>Anakinra</ingredients>
    </mixture>
    <mixture>
      <name>Kineret</name>
      <ingredients>Anakinra</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>BioVitrum AB</name>
      <url>http://www.biovitrum.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Kineret 100 mg/0.67 ml syr</description>
      <cost currency="USD">61.8</cost>
      <unit>syringe</unit>
    </price>
    <price>
      <description>Kineret 1 Box = 7 Syringes, 4.69ml Box</description>
      <cost currency="USD">449.9</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antirheumatic Agents</category>
      <mesh-id>D018501</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Biologics for Rheumatoid Arthritis Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Immunosuppressive Agents</category>
      <mesh-id>D007166</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interleukin Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Interleukin-1 Receptor Antagonist</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg/.67mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>150 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L04AC03">
      <level code="L04AC">Interleukin inhibitors</level>
      <level code="L04A">IMMUNOSUPPRESSANTS</level>
      <level code="L04">IMMUNOSUPPRESSANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>92:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1IRP</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00026.pdf?1265922808</fda-label>
  <patents>
    <patent>
      <number>2141953</number>
      <country>Canada</country>
      <approved>2008-04-08</approved>
      <expires>2013-09-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1341322</number>
      <country>Canada</country>
      <approved>2001-11-27</approved>
      <expires>2018-11-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00108</drugbank-id>
      <name>Natalizumab</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Rabies vaccine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with G17DT.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with INGN 201.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with INGN 225.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with CDX-110.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with SRP 299.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with GI-5005.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with TG4010.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>Anakinra may increase the immunosuppressive activities of Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may increase the immunosuppressive activities of Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06643</drugbank-id>
      <name>Denosumab</name>
      <description>The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06688</drugbank-id>
      <name>Sipuleucel-T</name>
      <description>The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the neutropenic activities of Anakinra.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00026 sequence
MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG
IHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW
FLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.412</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.46</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>17257.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C759H1186N208O232S10</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12604</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02934</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M55646</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10799</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P18510</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000095</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Anakinra</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201570</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/anakinra.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/anakinra.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000565</id>
      <name>Interleukin-1 receptor type 1</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17498496</pubmed-id>
            <citation>Tang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats]. Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32.</citation>
          </article>
          <article>
            <pubmed-id>12817089</pubmed-id>
            <citation>Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10.</citation>
          </article>
          <article>
            <pubmed-id>12355453</pubmed-id>
            <citation>Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96.</citation>
          </article>
          <article>
            <pubmed-id>17083033</pubmed-id>
            <citation>Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <pubmed-id>17352828</pubmed-id>
            <citation>So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.</citation>
          </article>
          <article>
            <pubmed-id>10210771</pubmed-id>
            <citation>Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14778" source="Swiss-Prot">
    <name>Interleukin-1 receptor type 1</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for IL1A, IL1B and IL1RN. After binding to interleukin-1 associates with the corecptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits. Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex.</specific-function>
    <gene-name>IL1R1</gene-name>
    <locus>2q12</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>337-356</transmembrane-regions>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>7.89</theoretical-pi>
    <molecular-weight>65401.91</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5993</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL1R1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X16896</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33801</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14778</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL1R1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD121 antigen-like family member A</synonym>
      <synonym>IL-1R-1</synonym>
      <synonym>IL-1R-alpha</synonym>
      <synonym>IL1R</synonym>
      <synonym>IL1RA</synonym>
      <synonym>IL1RT1</synonym>
      <synonym>Interleukin-1 receptor alpha</synonym>
      <synonym>Interleukin-1 receptor type I</synonym>
      <synonym>p80</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018975|Interleukin-1 receptor type 1
MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKD
DSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNL
CYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDR
LIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDL
GSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE
IESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFK
IDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCG
YKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQ
DGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPV
QRRSPSSKHQLLSPATKEKLQREAHVPLG</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018976|Interleukin-1 receptor type 1 (IL1R1)
ATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCT
GATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGAT
GTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAAGAT
GACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACACAAAGAGAAA
CTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGTAAGAAAT
TCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTA
TGTTATAATGCACAAGCCATATTTAAGCAGAAACTACCCGTTGCAGGAGACGGAGGACTT
GTGTGCCCTTATATGGAGTTTTTTAAAAATGAAAATAATGAGTTACCTAAATTACAGTGG
TATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAAAGATAGG
CTCATCGTGATGAATGTGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTAC
ACATACTTGGGCAAGCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAA
AACAAACCCACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTG
GGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGG
AAGTGGAATGGGTCAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGT
GTGGAAAATCCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAA
ATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATA
GATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGCACATGATTGGT
ATATGTGTCACGTTGACAGTCATAATTGTGTGTTCTGTTTTCATCTATAAAATCTTCAAG
ATTGACATTGTGCTTTGGTACAGGGATTCCTGCTATGATTTTCTCCCAATAAAAGCTTCA
GATGGAAAGACCTATGACGCATATATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACC
TCTGACTGTGATATTTTTGTGTTTAAAGTCTTGCCTGAGGTCTTGGAAAAACAGTGTGGA
TATAAGCTGTTCATTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATT
AATGAAAACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGC
TTCAGCTGGCTGGGTGGTTCATCTGAAGAGCAAATAGCCATGTATAATGCTCTTGTTCAG
GATGGAATTAAAGTTGTCCTGCTTGAGCTGGAGAAAATCCAAGACTATGAGAAAATGCCA
GAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTGGTCAGGGGACTTTACA
CAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAATGTCAGGTACCACATGCCAGTC
CAGCGACGGTCACCTTCATCTAAACACCAGTTACTGTCACCAGCCACTAAGGAGAAACTG
CAAAGAGAGGCTCACGTGCCTCTCGGGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
      <pfam>
        <identifier>PF01582</identifier>
        <name>TIR</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>postsynaptic density</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-1 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>signal transducer activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>platelet-derived growth factor receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-1, Type I, activating receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interleukin-1</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to radiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to glucose stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to epidermal growth factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-1-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nitric oxide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heat acclimation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to transforming growth factor beta</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00027</drugbank-id>
  <drugbank-id>BTD00036</drugbank-id>
  <drugbank-id>BIOD00036</drugbank-id>
  <name>Gramicidin D</name>
  <description>Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D.  Gramcidins are 15 residue peptides with alternating D and L amino acids.  The peptides assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix. The helix itself is not long enough to span the membrane but it dimerizes to form the elongated channel needed to span the whole membrane. Gramicidin D is used primarily as a topical antibiotic and is one of the three constituents of consumer antibiotic polysporin ophthalmic solution.</description>
  <cas-number>1405-97-6</cas-number>
  <unii>WHM29QA23F</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>8810522</pubmed-id>
        <citation>Ketchem RR, Lee KC, Huo S, Cross TA: Macromolecular structural elucidation with solid-state NMR-derived orientational constraints. J Biomol NMR. 1996 Jul;8(1):1-14.</citation>
      </article>
      <article>
        <pubmed-id>11570868</pubmed-id>
        <citation>Townsley LE, Tucker WA, Sham S, Hinton JF: Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.</citation>
      </article>
      <article>
        <pubmed-id>10397797</pubmed-id>
        <citation>Burkhart BM, Gassman RM, Langs DA, Pangborn WA, Duax WL, Pletnev V: Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers. 1999;51(2):129-44.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>U.S.Patent 2,534,541.</synthesis-reference>
  <indication>For treatment of skin lesions, surface wounds and eye infections</indication>
  <pharmacodynamics>Gramicidin is particularly effective against gram-positive bacteria. Because the drug is highly hemolytic, it cannot be administered internally and so is used only on the skin as a lotion or ointment. It is used primarily in the treatment of infected surface wounds, and in eye, nose, and throat infections. It is normally given with two other antibiotics (neomycin and polymixin B) as an ophthalmic solution</pharmacodynamics>
  <mechanism-of-action>Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Bacillus brevis gramicidin D</synonym>
    <synonym language="" coder="">Gramicidin</synonym>
    <synonym language="" coder="">Gramicidin A</synonym>
    <synonym language="" coder="">Gramicidin B</synonym>
    <synonym language="" coder="">Gramicidin C</synonym>
    <synonym language="" coder="">Gramicidine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Antibiotic Cream</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02311844</dpd-id>
      <started-marketing-on>2009-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372029</dpd-id>
      <started-marketing-on>2012-03-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream</name>
      <labeller>Technilab Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02208288</dpd-id>
      <started-marketing-on>1998-11-03</started-marketing-on>
      <ended-marketing-on>2005-08-05</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream for Kids</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317974</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream for Kids</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02315033</dpd-id>
      <started-marketing-on>2009-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream Plus Pain Relief</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317834</dpd-id>
      <started-marketing-on>2009-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream Plus Pain Relief</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02372045</dpd-id>
      <started-marketing-on>2012-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Cream Plus Pain Relief for Kids</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02377187</dpd-id>
      <started-marketing-on>2012-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Drops</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02457512</dpd-id>
      <started-marketing-on>2017-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Ear Drops</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458705</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Eye Drops</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02458713</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antibiotic Plus Pain Relief Cream</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304457</dpd-id>
      <started-marketing-on>2009-07-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Complete Antibiotic Ointment</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304465</dpd-id>
      <started-marketing-on>2009-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kenacomb Cream</name>
      <labeller>Westwood Squibb, Division Of Bristol Myers Squibb Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01999850</dpd-id>
      <started-marketing-on>1965-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kenacomb Mild Cream</name>
      <labeller>Westwood Squibb, Division Of Bristol Myers Squibb Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01999842</dpd-id>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kenacomb Mild Ointment</name>
      <labeller>Westwood Squibb, Division Of Bristol Myers Squibb Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01999834</dpd-id>
      <started-marketing-on>1968-12-31</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kenacomb Ointment</name>
      <labeller>Westwood Squibb, Division Of Bristol Myers Squibb Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01999826</dpd-id>
      <started-marketing-on>1996-07-31</started-marketing-on>
      <ended-marketing-on>2004-08-05</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kenacomb Ont</name>
      <labeller>Squibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00245267</dpd-id>
      <started-marketing-on>1965-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lidecomb Cream</name>
      <labeller>Medicis Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00492442</dpd-id>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lidosporin Cream</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01966006</dpd-id>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lidosporin Cream</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230842</dpd-id>
      <started-marketing-on>1998-07-08</started-marketing-on>
      <ended-marketing-on>2000-11-27</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mecomb Crm 0.1%</name>
      <labeller>Medic Laboratory LtÉe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00464554</dpd-id>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-17</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neocidin</name>
      <labeller>Major</labeller>
      <ndc-id/>
      <ndc-product-code>0904-3016</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-528</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6253</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-04-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0247</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-01-31</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-1188</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-01-31</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55045-1194</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-790</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA064047</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neosporin</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>61570-045</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1955-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>ANDA060582</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Neosporin Antibiotic Cream</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00666203</dpd-id>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>2007-12-19</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Neosporin Eye-ear Solution</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00694371</dpd-id>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2006-11-21</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Odan-spor</name>
      <labeller>Odan Laboratories Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00635065</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimyxin</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00701785</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Optimyxin Plus Oto-opht Gtte</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00807435</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Original Antibiotic Cream</name>
      <labeller>Crls</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02401002</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Original Antibiotic Cream</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02317656</dpd-id>
      <started-marketing-on>2010-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polycidin Eye, Ear Drops</name>
      <labeller>Novartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229903</dpd-id>
      <started-marketing-on>1997-01-30</started-marketing-on>
      <ended-marketing-on>2002-09-10</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Antibiotic Burn Cream</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230843</dpd-id>
      <started-marketing-on>1998-07-08</started-marketing-on>
      <ended-marketing-on>1999-06-18</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Antibiotic Cream</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230844</dpd-id>
      <started-marketing-on>1997-08-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Burn Formula Cream</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00068535</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Cold Sore Ointment</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284200</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Complete</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240568</dpd-id>
      <started-marketing-on>2005-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Cream</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00035335</dpd-id>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Eye and Ear Drops Sterile</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239156</dpd-id>
      <started-marketing-on>2000-02-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Eye and Ear Drops Sterile</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00035343</dpd-id>
      <started-marketing-on>1971-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin for Kids</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248189</dpd-id>
      <started-marketing-on>2004-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin for Stitches</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02446960</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Plus Pain Relief</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239201</dpd-id>
      <started-marketing-on>1999-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <labeller>Glaxo Wellcome</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02194104</dpd-id>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>2000-08-03</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <labeller>Johnson &amp; Johnson</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237226</dpd-id>
      <started-marketing-on>1998-08-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <labeller>Warner Lambert Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230847</dpd-id>
      <started-marketing-on>1998-07-08</started-marketing-on>
      <ended-marketing-on>1999-08-13</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Polytopic Cream</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00422908</dpd-id>
      <started-marketing-on>1997-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ratio-triacomb</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00550507</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Opticort</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247920</dpd-id>
      <started-marketing-on>2004-01-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Ear/eye Ointment</name>
      <labeller>Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00173606</dpd-id>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224623</dpd-id>
      <started-marketing-on>2002-07-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987712</dpd-id>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2004-07-30</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <labeller>Aventis Pharma Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224631</dpd-id>
      <started-marketing-on>1999-10-25</started-marketing-on>
      <ended-marketing-on>2006-07-28</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Auricular (otic); Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987720</dpd-id>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2001-07-20</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Nasal Spray</name>
      <labeller>Erfa Canada 2012 Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224860</dpd-id>
      <started-marketing-on>2001-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Nasal Spray</name>
      <labeller>Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00173584</dpd-id>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Nasal Spray</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987690</dpd-id>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-12</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Ointment</name>
      <labeller>Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00026972</dpd-id>
      <started-marketing-on>1961-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-05</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Skin Ointment</name>
      <labeller>Hoechst Roussel Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01987674</dpd-id>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2000-07-28</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Soframycin Skin Ointment</name>
      <labeller>Erfa Canada 2012 Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02224879</dpd-id>
      <started-marketing-on>2001-05-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Theraderm Cream</name>
      <labeller>Bimeda Mtc Animal Health Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02022818</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triple Antibiotic Ointment</name>
      <labeller>Melaleuca, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02088339</dpd-id>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triple Antibiotic Ointment</name>
      <labeller>Pharmetics (2011) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02297949</dpd-id>
      <started-marketing-on>2009-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triple Antibiotic Ointment</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246693</dpd-id>
      <started-marketing-on>2003-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triple Antibiotic Ointment</name>
      <labeller>Jamp Pharma Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02248818</dpd-id>
      <started-marketing-on>2005-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Triple Antibiotic Ointment</name>
      <labeller>Canadian Custom Packaging Company</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02381435</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Viaderm Kc Crm</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00717002</dpd-id>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Viaderm Kc Ont</name>
      <labeller>Taro Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00717029</dpd-id>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Sofradex</name>
      <company>Sanofi</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Neocidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Optimyxin Plus Oto-opht Gtte</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Ratio-triacomb</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Theraderm Cream</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Nasal Spray</name>
      <ingredients>Framycetin + Gramicidin D + Phenylephrine</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polytopic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Eye and Ear Drops Sterile</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Plus Pain Relief</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Opticort</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin for Kids</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Plus Pain Relief Cream</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream for Kids</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Original Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream Plus Pain Relief</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream Plus Pain Relief</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream Plus Pain Relief for Kids</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Viaderm Kc Crm</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Viaderm Kc Ont</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Eye and Ear Drops Sterile</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Lidosporin Cream</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Burn Formula Cream</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Kenacomb Ont</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Drops</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Nasal Spray</name>
      <ingredients>Framycetin + Gramicidin D + Phenylephrine</ingredients>
    </mixture>
    <mixture>
      <name>Kenacomb Mild Cream</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Kenacomb Cream</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Skin Ointment</name>
      <ingredients>Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Kenacomb Mild Ointment</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Kenacomb Ointment</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Nasal Spray</name>
      <ingredients>Framycetin + Gramicidin D + Phenylephrine</ingredients>
    </mixture>
    <mixture>
      <name>Mecomb Crm 0.1%</name>
      <ingredients>Gramicidin D + Neomycin + Nystatin + Triamcinolone</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Sofracort Sterile Ear/eye Ointment</name>
      <ingredients>Dexamethasone + Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Lidecomb Cream</name>
      <ingredients>Fluocinonide + Gramicidin D + Neomycin + Nystatin</ingredients>
    </mixture>
    <mixture>
      <name>Polycidin Eye, Ear Drops</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Antibiotic Burn Cream</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Lidosporin Cream</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neosporin Antibiotic Cream</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neosporin Eye-ear Solution</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Ointment</name>
      <ingredients>Framycetin + Gramicidin D</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Cream for Kids</name>
      <ingredients>Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Original Antibiotic Cream</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Optimyxin</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Complete</name>
      <ingredients>Bacitracin + Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Complete Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin for Stitches</name>
      <ingredients>Bacitracin + Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Polysporin Cold Sore Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Lidocaine + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Triple Antibiotic Ointment</name>
      <ingredients>Bacitracin + Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neosporin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Neomycin and Polymyxin B Sulfates and Gramicidin</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Ear Drops</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Eye Drops</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Antibiotic Drops</name>
      <ingredients>Gramicidin D + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Odan-spor</name>
      <ingredients>Gramicidin D + Neomycin + Polymyxin B Sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Soframycin Skin Ointment</name>
      <ingredients>Framycetin + Gramicidin D</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Johnson &amp; Johnson Healthcare</name>
      <url>http://www.jnjcanada.com</url>
    </packager>
    <packager>
      <name>Monarch Pharmacy</name>
      <url>http://www.monarch-pharmacy.co.uk</url>
    </packager>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Neosporin gu irr 40 mg/ml amp</description>
      <cost currency="USD">23.12</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gramicidin d powder</description>
      <cost currency="USD">240.0</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Neosporin + pain relief cream</description>
      <cost currency="USD">0.32</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents, Local</category>
      <mesh-id>D000891</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Macrocyclic Compounds</category>
      <mesh-id>D047028</mesh-id>
    </category>
    <category>
      <category>Membrane Proteins</category>
      <mesh-id>D008565</mesh-id>
    </category>
    <category>
      <category>P-glycoprotein/ABCB1 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Peptides, Cyclic</category>
      <mesh-id>D010456</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Polycyclic Compounds</category>
      <mesh-id>D011083</mesh-id>
    </category>
    <category>
      <category>Pore Forming Cytotoxic Proteins</category>
      <mesh-id>D052899</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Respiratory System</category>
      <mesh-id>D012137</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Throat Preparations</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tyrothricin</category>
      <mesh-id>D014449</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Pseudomonas aeruginosa</affected-organism>
    <affected-organism>Streptococcus pneumoniae</affected-organism>
    <affected-organism>Streptococcus agalactiae</affected-organism>
    <affected-organism>Neisseria meningitidis</affected-organism>
    <affected-organism>Haemophilus influenzae</affected-organism>
    <affected-organism>Neisseria gonorrhoeae</affected-organism>
    <affected-organism>Escherichia coli</affected-organism>
    <affected-organism>Staphylococcus aureus</affected-organism>
    <affected-organism>Klebsiella</affected-organism>
    <affected-organism>Enterobacter</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution / drops</form>
      <route>Auricular (otic)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Auricular (otic); Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R02AB30">
      <level code="R02AB">Antibiotics</level>
      <level code="R02A">THROAT PREPARATIONS</level>
      <level code="R02">THROAT PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1AL4</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00027.pdf?1265922740</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Silodosin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Topotecan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The serum concentration of Vincristine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Bosutinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The serum concentration of Edoxaban can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Doxorubicin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Everolimus can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Afatinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Colchicine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Ledipasvir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The serum concentration of Naloxegol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Prucalopride can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Ranolazine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Verapamil can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Saquinavir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The serum concentration of Nelfinavir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Indinavir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Rifampicin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Reserpine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Nifedipine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Carbamazepine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Ritonavir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Progesterone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Cyclosporine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Cimetidine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Tacrolimus can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Phenobarbital can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The serum concentration of Midazolam can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Erythromycin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Vinblastine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Tamoxifen can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Mitoxantrone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Daunorubicin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Quinidine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Ketoconazole can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Nicardipine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Ranitidine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Etoposide can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Paclitaxel can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Prazosin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The serum concentration of Dipyridamole can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Diltiazem can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Clarithromycin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The serum concentration of Chlorpromazine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dactinomycin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Quinine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The serum concentration of Indomethacin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Ciprofloxacin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Acetaminophen can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Lansoprazole can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Metoprolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Losartan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The serum concentration of Atenolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Bromocriptine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Loperamide can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The serum concentration of Imipramine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Haloperidol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The serum concentration of Amitriptyline can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Morphine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Ivermectin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Venlafaxine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The serum concentration of Citalopram can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic Acid</name>
      <description>The serum concentration of Taurocholic Acid can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Levofloxacin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The serum concentration of Caffeine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Fexofenadine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Propranolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Pravastatin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Imatinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The serum concentration of Sorafenib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The serum concentration of Dasatinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Gefitinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Nilotinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>The serum concentration of Estrone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Grepafloxacin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Diazepam can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Sparfloxacin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Risperidone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Quetiapine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Olanzapine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Clozapine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Naloxone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Cisplatin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Camptothecin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Acebutolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Ibuprofen can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The serum concentration of Salicylic acid can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The serum concentration of Acetylsalicylic acid can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Clonidine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Domperidone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The serum concentration of Mannitol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Toremifene can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The serum concentration of Diethylstilbestrol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Clomifene can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The serum concentration of Estradiol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Docetaxel can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Timolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Nadolol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Alitretinoin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Vecuronium can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquin</name>
      <description>The serum concentration of Debrisoquin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>The serum concentration of Gemcitabine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Dihydrotestosterone</name>
      <description>The serum concentration of Dihydrotestosterone can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>The serum concentration of Epinastine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Estriol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Sphingosine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Cerivastatin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Levetiracetam can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The serum concentration of Phenytoin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The serum concentration of Nizatidine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Erlotinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Lamotrigine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Sitagliptin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Atazanavir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Arsenic trioxide can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Cabazitaxel can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Temsirolimus can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Ketazolam can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The serum concentration of Ethinyl Estradiol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Eletriptan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Romidepsin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The serum concentration of Rivaroxaban can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Ezetimibe can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Tolvaptan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Pitavastatin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The serum concentration of Ulipristal can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Boceprevir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Telaprevir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Fidaxomicin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Indacaterol can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Clobazam can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The serum concentration of Ticagrelor can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Crizotinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The serum concentration of Apixaban can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Axitinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Mirabegron can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Ponatinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Canagliflozin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Lenalidomide can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Zidovudine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The serum concentration of Clopidogrel can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Irinotecan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Mycophenolate mofetil can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The serum concentration of Levomilnacipran can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Simeprevir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dapagliflozin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The serum concentration of Lenvatinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The serum concentration of Nintedanib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Idelalisib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Panobinostat can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Cobimetinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Ambrisentan can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Ombitasvir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Venetoclax can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The serum concentration of Rifaximin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>229 °C</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1882.2947</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C99H140N20O17</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8523</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D04369</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449808</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001327</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Gramicidin_D</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL557217</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0001032</id>
      <name>Multidrug resistance protein 1</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>14985103</pubmed-id>
            <citation>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
    <name>Multidrug resistance protein 1</name>
    <general-function>Xenobiotic-transporting atpase activity</general-function>
    <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
    <gene-name>ABCB1</gene-name>
    <locus>7q21.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.44</theoretical-pi>
    <molecular-weight>141477.255</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:40</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ABCB1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M14758</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307180</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08183</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>MDR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.6.3.44</synonym>
      <synonym>ATP-binding cassette sub-family B member 1</synonym>
      <synonym>MDR1</synonym>
      <synonym>P-glycoprotein 1</synonym>
      <synonym>PGY1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00005</identifier>
        <name>ABC_tran</name>
      </pfam>
      <pfam>
        <identifier>PF00664</identifier>
        <name>ABC_membrane</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>xenobiotic-transporting ATPase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATPase activity, coupled to transmembrane movement of substances</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>stem cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G2/M transition of mitotic cell cycle</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </transporter>
  </transporters>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00028</drugbank-id>
  <drugbank-id>BTD00091</drugbank-id>
  <drugbank-id>BIOD00091</drugbank-id>
  <name>Immune Globulin Human</name>
  <description>Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.</description>
  <cas-number>9007-83-4</cas-number>
  <unii>66Y330CJHS</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>20970960</pubmed-id>
        <citation>Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. doi: 10.1016/j.jaut.2010.09.006. Epub 2010 Dec  9.</citation>
      </article>
      <article>
        <pubmed-id>17911465</pubmed-id>
        <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
      </article>
      <article>
        <pubmed-id>16998749</pubmed-id>
        <citation>Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24.</citation>
      </article>
      <article>
        <pubmed-id>12032582</pubmed-id>
        <citation>Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Wolfgang Stephan, "Production of intravenously applicable native human immune globulin having a normal half-life." U.S. Patent US4082734, issued July, 1970.</synthesis-reference>
  <indication>IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.</indication>
  <pharmacodynamics>Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.</pharmacodynamics>
  <mechanism-of-action>IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>&gt;20 hours (mammalian reticulocytes, in vitro).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Human IGG</synonym>
    <synonym language="" coder="">Human Immunoglobulin G</synonym>
    <synonym language="" coder="">Human Normal Immunoglobulin</synonym>
    <synonym language="" coder="">Immune globulin (human)</synonym>
    <synonym language="" coder="">Immune Globulin Intravenous</synonym>
    <synonym language="" coder="">Immune Globulin Subcutaneous</synonym>
    <synonym language="" coder="">Immunoglobulin G (human)</synonym>
    <synonym language="" coder="">Immunoglobulin G, Human</synonym>
    <synonym language="" coder="">Intravenous Immunoglobulin</synonym>
    <synonym language="" coder="">IVIg</synonym>
  </synonyms>
  <products>
    <product>
      <name>Bivigam</name>
      <labeller>Kedrion Biopharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76125-918</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/10mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>Biotest</labeller>
      <ndc-id/>
      <ndc-product-code>59730-6502</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bivigam</name>
      <labeller>Biotest</labeller>
      <ndc-id/>
      <ndc-product-code>59730-6503</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-416</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on>2016-11-22</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>3 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-417</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>6 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Carimune Nanofiltered</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-418</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>12 g/1</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA102367</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cuvitru</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02461692</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cuvitru</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2850</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1 g/5mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA125596</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flebogamma DIF</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0004</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>.05 g/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flebogamma Dif</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>61953-0005</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125077</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gamastan</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00083259</dpd-id>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>16.5 %</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamastan S/d</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230579</dpd-id>
      <started-marketing-on>2004-03-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>18 %</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamastan S/d</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>13533-635</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>.165 g/mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA101134</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gamimune N 10%  (iv)</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229695</dpd-id>
      <started-marketing-on>2000-05-16</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamimune N 5%  (iv)</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02178842</dpd-id>
      <started-marketing-on>1997-01-17</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamimune N Inj 5%  (iv)</name>
      <labeller>Cutter Med &amp; Biol, Division Of Miles Canada Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00559261</dpd-id>
      <started-marketing-on>1986-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2700</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 mg/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>BLA125105</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard Liquid</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02279444</dpd-id>
      <started-marketing-on>2007-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 %</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231469</dpd-id>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on>2015-05-12</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2.5 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2623</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2625</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2627</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2620</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2656</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2655</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2658</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103133</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231471</dpd-id>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>10 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231470</dpd-id>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>5 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammagard S/d  (iv)</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02231468</dpd-id>
      <started-marketing-on>1997-08-22</started-marketing-on>
      <ended-marketing-on>2013-11-04</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>0.5 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gammaked</name>
      <labeller>Kedrion Biopharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76125-900</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125046</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammaplex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-8235</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125329</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammaplex</name>
      <labeller>Bio Products Laboratory Limited</labeller>
      <ndc-id/>
      <ndc-product-code>64208-8234</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-11-01</started-marketing-on>
      <ended-marketing-on>2017-07-18</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125329</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Gammar Inj 165mg/ml</name>
      <labeller>Armour Pharmaceutical Co.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01915312</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1999-12-15</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>165 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamunex</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247724</dpd-id>
      <started-marketing-on>2003-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 g</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gamunex-C</name>
      <labeller>Grifols</labeller>
      <ndc-id/>
      <ndc-product-code>13533-800</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125046</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-451</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>.2 g/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-452</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>.2 g/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-454</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>.2 g/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-455</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-10-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>.2 g/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125350</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02370352</dpd-id>
      <started-marketing-on>2011-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463059</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hizentra</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463067</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrho S/d Full Dose</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243524</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyperrho S/d Full Dose</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02379457</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1500 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hyqvia</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2510</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HyQvia</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2511</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HyQvia</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2512</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HyQvia</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2513</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>HyQvia</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0944-2514</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA125402</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Igivnex</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02277921</dpd-id>
      <started-marketing-on>2006-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 g</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human) 5%</name>
      <labeller>Bayer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02185342</dpd-id>
      <started-marketing-on>1996-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-28</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human), 10%</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230920</dpd-id>
      <started-marketing-on>2000-07-31</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>10 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Globulin Intravenous (human), 5%</name>
      <labeller>Talecris Biotherapeutics Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230919</dpd-id>
      <started-marketing-on>1997-11-03</started-marketing-on>
      <ended-marketing-on>2006-08-03</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>5 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Immune Serum Globulin (human)</name>
      <labeller>Grifols Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230647</dpd-id>
      <started-marketing-on>1997-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>18 %</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Iveegam Immuno 5000mg  (iv)</name>
      <labeller>Baxter Ag</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959301</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>2008-12-23</ended-marketing-on>
      <dosage-form>Kit; Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octagam 10%</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02380145</dpd-id>
      <started-marketing-on>2013-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octagam 5%</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02267713</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma Pharmazeutika Produktionsgesellschaft M.B.H.</labeller>
      <ndc-id/>
      <ndc-product-code>67467-843</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma Ab</labeller>
      <ndc-id/>
      <ndc-product-code>68209-843</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-840</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>50 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Octagam Immune Globulin (Human)</name>
      <labeller>Octapharma</labeller>
      <ndc-id/>
      <ndc-product-code>68982-850</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125062</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Panzyga</name>
      <labeller>Octapharma Pharmazeutika Produktionsges M B H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456087</dpd-id>
      <started-marketing-on>2016-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304619</dpd-id>
      <started-marketing-on>2009-01-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10 %</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-439</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>40 g/400mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-436</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5 g/50mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-437</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Privigen</name>
      <labeller>Csl Behring Ag</labeller>
      <ndc-id/>
      <ndc-product-code>44206-438</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-01-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>20 g/200mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoglobulin Nf Liquid</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287994</dpd-id>
      <started-marketing-on>2007-06-28</started-marketing-on>
      <ended-marketing-on>2010-04-20</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>120 g</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vivaglobin</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02282518</dpd-id>
      <started-marketing-on>2007-03-01</started-marketing-on>
      <ended-marketing-on>2015-04-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>160 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vivaglobin</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-7596</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-09</started-marketing-on>
      <ended-marketing-on>2016-10-19</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>160 mg/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125115</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3000</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>15000 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3100</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5000 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3120</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>600 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3300</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>1500 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Cangene Bio Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>53270-3500</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>2500 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Aptevo Bio Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70504-3000</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>15000 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Aptevo Bio Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70504-3100</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>5000 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Aptevo Bio Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70504-3300</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>1500 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Winrho</name>
      <labeller>Aptevo Bio Therapeutics Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70504-3500</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>2500 [iU]/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA103649</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Civacir</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Flebogamma</name>
      <company>Instituto Grifols SA</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Gamastan S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Immune Serum Globulin (human)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamunex</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Igivnex</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam 10%</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammar Inj 165mg/ml</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Iveegam Immuno 5000mg  (iv)</name>
      <ingredients>Immune Globulin Human + Water</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human) 5%</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N 5%  (iv)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N 10%  (iv)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human), 5%</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Immune Globulin Intravenous (human), 10%</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d  (iv)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamimune N Inj 5%  (iv)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Vivaglobin</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Sandoglobulin Nf Liquid</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Full Dose</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam 5%</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyperrho S/d Full Dose</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Vivaglobin</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamastan S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Carimune Nanofiltered</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma DIF</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Octagam Immune Globulin (Human)</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Kiovig</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gamunex-C</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Flebogamma Dif</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammaked</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard S/d</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hyqvia</name>
      <ingredients>Hyaluronidase + Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>HyQvia</name>
      <ingredients>Hyaluronidase + Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>HyQvia</name>
      <ingredients>Hyaluronidase + Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>HyQvia</name>
      <ingredients>Hyaluronidase + Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>HyQvia</name>
      <ingredients>Hyaluronidase + Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Privigen</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammagard Liquid</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Cuvitru</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Winrho</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Panzyga</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Bivigam</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammaplex</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Gammaplex</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Hizentra</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Cuvitru</name>
      <ingredients>Immune Globulin Human</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Alpha Therapeutic Corp.</name>
      <url/>
    </packager>
    <packager>
      <name>American Red Cross</name>
      <url>http://www.redcross.org</url>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Biotest Pharmaceuticals</name>
      <url>http://www.biotestpharma.com</url>
    </packager>
    <packager>
      <name>Cangene Corp.</name>
      <url>http://www.cangene.com</url>
    </packager>
    <packager>
      <name>CSL Behring LLC</name>
      <url>http://www.cslbehring.com</url>
    </packager>
    <packager>
      <name>Grifols SA</name>
      <url>http://www.grifols.com</url>
    </packager>
    <packager>
      <name>Massachusetts Public Health</name>
      <url>http://www.mphaweb.org</url>
    </packager>
    <packager>
      <name>Massbiologics</name>
      <url>http://www.massbio.org</url>
    </packager>
    <packager>
      <name>Medimmune Inc.</name>
      <url>http://www.medimmune.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Octapharma USA</name>
      <url>http://www.octapharma.com</url>
    </packager>
    <packager>
      <name>Talecris Biotherapeutics</name>
      <url>http://www.talecris.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Flebogamma 5% vial</description>
      <cost currency="USD">4.84</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Flebogamma dif 5% vial</description>
      <cost currency="USD">4.84</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Immune globulin vial</description>
      <cost currency="USD">9.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gamunex 10% vial</description>
      <cost currency="USD">11.6</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gammagard liquid 10% vial</description>
      <cost currency="USD">13.79</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Gamastan s-d vial</description>
      <cost currency="USD">24.44</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 1 gram/5 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 2 gram/10 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hizentra 4 gram/20 ml vial</description>
      <cost currency="USD">30.24</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hyperhep b s-d vial</description>
      <cost currency="USD">165.04</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Nabi-hb vial</description>
      <cost currency="USD">176.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hyperrab s-d vial</description>
      <cost currency="USD">224.07</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Hypertet s-d 250 unit syringe</description>
      <cost currency="USD">324.23</cost>
      <unit>syringe</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin G</category>
      <mesh-id>D007074</mesh-id>
    </category>
    <category>
      <category>Immunoglobulin Isotypes</category>
      <mesh-id>D007132</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
    <affected-organism>Bacteria and protozoa</affected-organism>
    <affected-organism>Various viruses</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1 g/10mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>12 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>3 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>6 g/1</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>1 g/5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>.05 g/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>50 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength>16.5 %</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular</route>
      <strength>.165 g/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>18 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>2.5 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>0.5 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular</route>
      <strength>165 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Subcutaneous</route>
      <strength>.2 g/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>1500 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 mg/ml</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>5 g</strength>
    </dosage>
    <dosage>
      <form>Kit; liquid; powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>100 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>50 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>20 g/200mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>40 g/400mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength>5 g/50mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>120 g</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>160 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>160 mg</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1500 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>15000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>2500 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>5000 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous</route>
      <strength>600 [iU]/mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>80:04.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1IGT</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The therapeutic efficacy of INGN 201 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of CDX-110 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Immune Globulin Human.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;IGG1
PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV
PDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT
LFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS
YLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV
SGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL
SSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
KPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV
DGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL</sequence>
    <sequence format="FASTA">&gt;IgA2
ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS
RFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS
GYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS
LRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV
ACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT
CHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG
ATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA
NITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL
TWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT
HVNVSVVMAEVDGTCY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.331</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.13</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>142682.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6332H9826N1692O1980S42</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7773</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>15161</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00221</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164754884</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01877</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/baygam.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/immune-globulin-human.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000710</id>
      <name>High affinity immunoglobulin gamma Fc receptor I</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P12314" source="Swiss-Prot">
    <name>High affinity immunoglobulin gamma Fc receptor I</name>
    <general-function>Receptor signaling protein activity</general-function>
    <specific-function>High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.</specific-function>
    <gene-name>FCGR1A</gene-name>
    <locus>1q21.2-q21.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>293-313</transmembrane-regions>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi>8.08</theoretical-pi>
    <molecular-weight>42631.525</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3613</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X14356</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31332</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12314</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCGR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-gamma RI</synonym>
      <synonym>Fc-gamma RIA</synonym>
      <synonym>FCG1</synonym>
      <synonym>FcgammaRIa</synonym>
      <synonym>FCGR1</synonym>
      <synonym>FcRI</synonym>
      <synonym>IGFR1</synonym>
      <synonym>IgG Fc receptor I</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phagocytosis, engulfment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0004684</id>
      <name>High affinity immunoglobulin gamma Fc receptor IB</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q92637" source="Swiss-Prot">
    <name>High affinity immunoglobulin gamma Fc receptor IB</name>
    <general-function>Immunoglobulin receptor activity</general-function>
    <specific-function>May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.</specific-function>
    <gene-name>FCGR1B</gene-name>
    <locus/>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>199-219</transmembrane-regions>
    <signal-regions>1-15</signal-regions>
    <theoretical-pi/>
    <molecular-weight>32231.795</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3614</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q92637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCGRB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-gamma RIB</synonym>
      <synonym>FcRIB</synonym>
      <synonym>hFcgammaRIB</synonym>
      <synonym>IGFRB</synonym>
      <synonym>IgG Fc receptor IB</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009601|High affinity immunoglobulin gamma Fc receptor IB
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFMEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISQYTVKGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWNLEISLDSGHE
KKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020794|High affinity immunoglobulin gamma Fc receptor IB (FCGR1B)
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGA
GTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTG
TACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAAC
CTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGA
AAGCATCGCTACACATCAGCAGGAATATCACAATACACTGTGAAAGGCCTCCAGTTACCA
ACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATGTTTTTAGTGAAC
ACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGAATTTAGAA
ATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGCCTTCAAGAAGACAGACAT
TTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAGCTGCAGGAAGGGGTGCAC
CGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>immunoglobulin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adaptive immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002098</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P12318" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
    <general-function/>
    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.</specific-function>
    <gene-name>FCGR2A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-33</signal-regions>
    <theoretical-pi>6.78</theoretical-pi>
    <molecular-weight>35000.42</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3616</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M31932</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182474</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-a</synonym>
      <synonym>Fc-gamma-RIIa</synonym>
      <synonym>FCG2</synonym>
      <synonym>FCGR2A1</synonym>
      <synonym>FcRII-a</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-a</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a
MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS
HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
KNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)
ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
AAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002099</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31994" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.</specific-function>
    <gene-name>FCGR2B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>218-240</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.12</theoretical-pi>
    <molecular-weight>34043.355</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3618</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U87560</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4099445</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31994</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-b</synonym>
      <synonym>Fc-gamma-RIIb</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-b</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-b</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
LEEPDDQNRI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG
CTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC
ATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC
AAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC
GACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG
TTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC
AAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC
TCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC
TACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG
ATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA
GTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG
GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
CTGGAAGAGCCTGATGACCAGAACCGTATTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0002100</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31995" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.</specific-function>
    <gene-name>FCGR2C</gene-name>
    <locus>1q23.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions>224-246</transmembrane-regions>
    <signal-regions>1-42</signal-regions>
    <theoretical-pi>6.9</theoretical-pi>
    <molecular-weight>35577.96</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR2C</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X17652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>32074</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31995</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG2C_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD32</synonym>
      <synonym>CDw32</synonym>
      <synonym>Fc-gamma RII-c</synonym>
      <synonym>Fc-gamma-RIIc</synonym>
      <synonym>FCG2</synonym>
      <synonym>FcRII-c</synonym>
      <synonym>IGFR2</synonym>
      <synonym>IgG Fc receptor II-c</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c
MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)
ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
GTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
TCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
GCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC
AGTAATAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002097</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P08637" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.</specific-function>
    <gene-name>FCGR3A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>209-229</transmembrane-regions>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>8.21</theoretical-pi>
    <molecular-weight>29088.895</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3619</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X52645</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16A</synonym>
      <synonym>CD16a antigen</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-alpha</synonym>
      <synonym>Fc-gamma RIIIa</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIa</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
KDHKFKWRKDPQDK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)
ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT
TTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG
CTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA
AAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT
CTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG
AGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT
GGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC
CATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT
CACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT
GGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC
AAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG
ACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA
CCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA
CTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA
TTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-gamma receptor signaling pathway involved in phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0000901</id>
      <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O75015" source="Swiss-Prot">
    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
    <general-function/>
    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.</specific-function>
    <gene-name>FCGR3B</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-16</signal-regions>
    <theoretical-pi>6.71</theoretical-pi>
    <molecular-weight>26215.64</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3620</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCGR3B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X16863</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31322</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O75015</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCG3B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CD16B</synonym>
      <synonym>Fc-gamma RIII</synonym>
      <synonym>Fc-gamma RIII-beta</synonym>
      <synonym>Fc-gamma RIIIb</synonym>
      <synonym>FCG3</synonym>
      <synonym>FCGR3</synonym>
      <synonym>FcR-10</synonym>
      <synonym>FcRIII</synonym>
      <synonym>FcRIIIb</synonym>
      <synonym>IGFR3</synonym>
      <synonym>IgG Fc receptor III-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)
ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
TTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of defense response to virus by host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitophagy in response to mitochondrial depolarization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0003455</id>
      <name>Complement C3</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01024" source="Swiss-Prot">
    <name>Complement C3</name>
    <general-function>Receptor binding</general-function>
    <specific-function>C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).</specific-function>
    <gene-name>C3</gene-name>
    <locus/>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.34</theoretical-pi>
    <molecular-weight>187146.73</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AY513239</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01024</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CO3_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1</synonym>
      <synonym>CPAMD1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020692|Complement C3
MGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH
DFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV
VLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL
SSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE
KFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV
VLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT
PKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL
SITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD
RAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA
SGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK
GVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL
QCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC
KKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE
PPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV
RNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI
VPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE
DIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP
TVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA
YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD
MALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG
RLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR
YYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR
SEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA
KNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD
RNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG
KLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE
YIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY
IIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020693|Complement C3 (C3)
ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCT
CTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAG
ACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCAC
GACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACC
AACCACATGGGCAACGTCACCTTCACGATCCCAGCCAACAGGGAGTTCAAGTCAGAAAAG
GGGCGCAACAAGTTCGTGACCGTGCAGGCCACCTTCGGGACCCAAGTGGTGGAGAAGGTG
GTGCTGGTCAGCCTGCAGAGCGGGTACCTCTTCATCCAGACAGACAAGACCATCTACACC
CCTGGCTCCACAGTTCTCTATCGGATCTTCACCGTCAACCACAAGCTGCTACCCGTGGGC
CGGACGGTCATGGTCAACATTGAGAACCCGGAAGGCATCCCGGTCAAGCAGGACTCCTTG
TCTTCTCAGAACCAGCTTGGCGTCTTGCCCTTGTCTTGGGACATTCCGGAACTCGTCAAC
ATGGGCCAGTGGAAGATCCGAGCCTACTATGAAAACTCACCACAGCAGGTCTTCTCCACT
GAGTTTGAGGTGAAGGAGTACGTGCTGCCCAGTTTCGAGGTCATAGTGGAGCCTACAGAG
AAATTCTACTACATCTATAACGAGAAGGGCCTGGAGGTCACCATCACCGCCAGGTTCCTC
TACGGGAAGAAAGTGGAGGGAACTGCCTTTGTCATCTTCGGGATCCAGGATGGCGAACAG
AGGATTTCCCTGCCTGAATCCCTCAAGCGCATTCCGATTGAGGATGGCTCGGGGGAGGTT
GTGCTGAGCCGGAAGGTACTGCTGGACGGGGTGCAGAACCCCCGAGCAGAAGACCTGGTG
GGGAAGTCTTTGTACGTGTCTGCCACCGTCATCTTGCACTCAGGCAGTGACATGGTGCAG
GCAGAGCGCAGCGGGATCCCCATCGTGACCTCTCCCTACCAGATCCACTTCACCAAGACA
CCCAAGTACTTCAAACCAGGAATGCCCTTTGACCTCATGGTGTTCGTGACGAACCCTGAT
GGCTCTCCAGCCTACCGAGTCCCCGTGGCAGTCCAGGGCGAGGACACTGTGCAGTCTCTA
ACCCAGGGAGATGGCGTGGCCAAACTCAGCATCAACACACACCCCAGCCAGAAGCCCTTG
AGCATCACGGTGCGCACGAAGAAGCAGGAGCTCTCGGAGGCAGAGCAGGCTACCAGGACC
ATGCAGGCTCTGCCCTACAGCACCGTGGGCAACTCCAACAATTACCTGCATCTCTCAGTG
CTACGTACAGAGCTCAGACCCGGGGAGACCCTCAACGTCAACTTCCTCCTGCGAATGGAC
CGCGCCCACGAGGCCAAGATCCGCTACTACACCTACCTGATCATGAACAAGGGCAGGCTG
TTGAAGGCGGGACGCCAGGTGCGAGAGCCCGGCCAGGACCTGGTGGTGCTGCCCCTGTCC
ATCACCACCGACTTCATCCCTTCCTTCCGCCTGGTGGCGTACTACACGCTGATCGGTGCC
AGCGGCCAGAGGGAGGTGGTGGCCGACTCCGTGTGGGTGGACGTCAAGGACTCCTGCGTG
GGCTCGCTGGTGGTAAAAAGCGGCCAGTCAGAAGACCGGCAGCCTGTACCTGGGCAGCAG
ATGACCCTGAAGATAGAGGGTGACCACGGGGCCCGGGTGGTACTGGTGGCCGTGGACAAG
GGCGTGTTCGTGCTGAATAAGAAGAACAAACTGACGCAGAGTAAGATCTGGGACGTGGTG
GAGAAGGCAGACATCGGCTGCACCCCGGGCAGTGGGAAGGATTACGCCGGTGTCTTCTCC
GACGCAGGGCTGACCTTCACGAGCAGCAGTGGCCAGCAGACCGCCCAGAGGGCAGAACTT
CAGTGCCCGCAGCCAGCCGCCCGCCGACGCCGTTCCGTGCAGCTCACGGAGAAGCGAATG
GACAAAGTCGGCAAGTACCCCAAGGAGCTGCGCAAGTGCTGCGAGGACGGCATGCGGGAG
AACCCCATGAGGTTCTCGTGCCAGCGCCGGACCCGTTTCATCTCCCTGGGCGAGGCGTGC
AAGAAGGTCTTCCTGGACTGCTGCAACTACATCACAGAGCTGCGGCGGCAGCACGCGCGG
GCCAGCCACCTGGGCCTGGCCAGGAGTAACCTGGATGAGGACATCATTGCAGAAGAGAAC
ATCGTTTCCCGAAGTGAGTTCCCAGAGAGCTGGCTGTGGAACGTTGAGGACTTGAAAGAG
CCACCGAAAAATGGAATCTCTACGAAGCTCATGAATATATTTTTGAAAGACTCCATCACC
ACGTGGGAGATTCTGGCTGTGAGCATGTCGGACAAGAAAGGGATCTGTGTGGCAGACCCC
TTCGAGGTCACAGTAATGCAGGACTTCTTCATCGACCTGCGGCTACCCTACTCTGTTGTT
CGAAACGAGCAGGTGGAAATCCGAGCCGTTCTCTACAATTACCGGCAGAACCAAGAGCTC
AAGGTGAGGGTGGAACTACTCCACAATCCAGCCTTCTGCAGCCTGGCCACCACCAAGAGG
CGTCACCAGCAGACCGTAACCATCCCCCCCAAGTCCTCGTTGTCCGTTCCATATGTCATC
GTGCCGCTAAAGACCGGCCTGCAGGAAGTGGAAGTCAAGGCTGCTGTCTACCATCATTTC
ATCAGTGACGGTGTCAGGAAGTCCCTGAAGGTCGTGCCGGAAGGAATCAGAATGAACAAA
ACTGTGGCTGTTCGCACCCTGGATCCAGAACGCCTGGGCCGTGAAGGAGTGCAGAAAGAG
GACATCCCACCTGCAGACCTCAGTGACCAAGTCCCGGACACCGAGTCTGAGACCAGAATT
CTCCTGCAAGGGACCCCAGTGGCCCAGATGACAGAGGATGCCGTCGACGCGGAACGGCTG
AAGCACCTCATTGTGACCCCCTCGGGCTGCGGGGAACAGAACATGATCGGCATGACGCCC
ACGGTCATCGCTGTGCATTACCTGGATGAAACGGAGCAGTGGGAGAAGTTCGGCCTAGAG
AAGCGGCAGGGGGCCTTGGAGCTCATCAAGAAGGGGTACACCCAGCAGCTGGCCTTCAGA
CAACCCAGCTCTGCCTTTGCGGCCTTCGTGAAACGGGCACCCAGCACCTGGCTGACCGCC
TACGTGGTCAAGGTCTTCTCTCTGGCTGTCAACCTCATCGCCATCGACTCCCAAGTCCTC
TGCGGGGCTGTTAAATGGCTGATCCTGGAGAAGCAGAAGCCCGACGGGGTCTTCCAGGAG
GATGCGCCCGTGATACACCAAGAAATGATTGGTGGATTACGGAACAACAACGAGAAAGAC
ATGGCCCTCACGGCCTTTGTTCTCATCTCGCTGCAGGAGGCTAAAGATATTTGCGAGGAG
CAGGTCAACAGCCTGCCAGGCAGCATCACTAAAGCAGGAGACTTCCTTGAAGCCAACTAC
ATGAACCTACAGAGATCCTACACTGTGGCCATTGCTGGCTATGCTCTGGCCCAGATGGGC
AGGCTGAAGGGGCCTCTTCTTAACAAATTTCTGACCACAGCCAAAGATAAGAACCGCTGG
GAGGACCCTGGTAAGCAGCTCTACAACGTGGAGGCCACATCCTATGCCCTCTTGGCCCTA
CTGCAGCTAAAAGACTTTGACTTTGTGCCTCCCGTCGTGCGTTGGCTCAATGAACAGAGA
TACTACGGTGGTGGCTATGGCTCTACCCAGGCCACCTTCATGGTGTTCCAAGCCTTGGCT
CAATACCAAAAGGACGCCCCTGACCACCAGGAACTGAACCTTGATGTGTCCCTCCAACTG
CCCAGCCGCAGCTCCAAGATCACCCACCGTATCCACTGGGAATCTGCCAGCCTCCTGCGA
TCAGAAGAGACCAAGGAAAATGAGGGTTTCACAGTCACAGCTGAAGGAAAAGGCCAAGGC
ACCTTGTCGGTGGTGACAATGTACCATGCTAAGGCCAAAGATCAACTCACCTGTAATAAA
TTCGACCTCAAGGTCACCATAAAACCAGCACCGGAAACAGAAAAGAGGCCTCAGGATGCC
AAGAACACTATGATCCTTGAGATCTGTACCAGGTACCGGGGAGACCAGGATGCCACTATG
TCTATATTGGACATATCCATGATGACTGGCTTTGCTCCAGACACAGATGACCTGAAGCAG
CTGGCCAATGGTGTTGACAGATACATCTCCAAGTATGAGCTGGACAAAGCCTTCTCCGAT
AGGAACACCCTCATCATCTACCTGGACAAGGTCTCACACTCTGAGGATGACTGTCTAGCT
TTCAAAGTTCACCAATACTTTAATGTAGAGCTTATCCAGCCTGGAGCAGTCAAGGTCTAC
GCCTATTACAACCTGGAGGAAAGCTGTACCCGGTTCTACCATCCGGAAAAGGAGGATGGA
AAGCTGAACAAGCTCTGCCGTGATGAACTGTGCCGCTGTGCTGAGGAGAATTGCTTCATA
CAAAAGTCGGATGACAAGGTCACCCTGGAAGAACGGCTGGACAAGGCCTGTGAGCCAGGA
GTGGACTATGTGTACAAGACCCGACTGGTCAAGGTTCAGCTGTCCAATGACTTTGACGAG
TACATCATGGCCATTGAGCAGACCATCAAGTCAGGCTCGGATGAGGTGCAGGTTGGACAG
CAGCGCACGTTCATCAGCCCCATCAAGTGCAGAGAAGCCCTGAAGCTGGAGGAGAAGAAA
CACTACCTCATGTGGGGTCTCTCCTCCGATTTCTGGGGAGAGAAGCCCAACCTCAGCTAC
ATCATCGGGAAGGACACTTGGGTGGAGCACTGGCCCGAGGAGGACGAATGCCAAGACGAA
GAGAACCAGAAACAATGCCAGGACCTCGGCGCCTTCACCGAGAGCATGGTTGTCTTTGGG
TGCCCCAACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00207</identifier>
        <name>A2M</name>
      </pfam>
      <pfam>
        <identifier>PF07678</identifier>
        <name>A2M_comp</name>
      </pfam>
      <pfam>
        <identifier>PF01835</identifier>
        <name>A2M_N</name>
      </pfam>
      <pfam>
        <identifier>PF07703</identifier>
        <name>A2M_N_2</name>
      </pfam>
      <pfam>
        <identifier>PF07677</identifier>
        <name>A2M_recep</name>
      </pfam>
      <pfam>
        <identifier>PF01821</identifier>
        <name>ANATO</name>
      </pfam>
      <pfam>
        <identifier>PF01759</identifier>
        <name>NTR</name>
      </pfam>
      <pfam>
        <identifier>PF10569</identifier>
        <name>Thiol-ester_cl</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cofactor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>C5L2 anaphylatoxin chemotactic receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of lipid storage</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of activation of membrane attack complex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fatty acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glucose transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to progesterone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of triglyceride biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic cell clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of developmental growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of type IIa hypersensitivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to magnesium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, alternative pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tolerance induction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vascular endothelial growth factor production</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0004685</id>
      <name>Complement C4-A</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0C0L4" source="Swiss-Prot">
    <name>Complement C4-A</name>
    <general-function>Endopeptidase inhibitor activity</general-function>
    <specific-function>Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.</specific-function>
    <gene-name>C4A</gene-name>
    <locus/>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi/>
    <molecular-weight>192783.805</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1323</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P0C0L4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CO4A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Acidic complement C4</synonym>
      <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2</synonym>
      <synonym>CO4</synonym>
      <synonym>CPAMD2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009602|Complement C4-A
MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
VVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTA
FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVA
LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL
TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
WIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
GCQV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0013260|Complement C4-A (C4A)
ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG
CCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG
GTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC
CCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA
GACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT
CAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT
CTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC
CTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC
TTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC
TCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT
GACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA
GATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC
TTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT
GAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA
TATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG
AGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG
GACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT
GCTGCAGCCATCATTGAGTCTCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG
TATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT
GGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC
ATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC
ATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC
ATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC
ACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT
CGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC
ACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA
GAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC
TTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG
GATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG
TACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG
CTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC
ATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG
GACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG
ACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC
GTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG
CGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA
GCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG
AGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC
CTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG
AACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC
GACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT
GTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC
ATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT
AAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC
GGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT
GTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA
TTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT
AGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA
CCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT
ACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG
GCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG
ACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG
ACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG
AAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGACAGCAGCACCTGGCTCACAGCC
TTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG
CAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCCC
TGTCCAGTGTTAGACAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA
CTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT
GCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAACTCATTTTTGGGG
GAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG
ACACTGACCAAGGCGCCTGTGGACCTGCTCGGTGTTGCCCACAACAACCTCATGGCAATG
GCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC
GTGTCGCCCACCCCGGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG
TGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG
ATGGCAGACCAGGCTTCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC
AGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC
ACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG
TCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT
TCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC
CTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA
GTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT
GAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC
CTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGCTGACCTCC
CTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCCCACGTCCTGCTGTATTTT
GACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCTGTGCAGGAAGTGCCGGTG
GGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTACAACCCCGAGCGCAGATGT
TCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCCACCTTGTGTTCTGCTGAA
GTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGCGCCCTGGAGCGGGGTCTG
CAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTACCCCCGTGTGGAGTACGGC
TTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTCCGCCTCTTTGAGACCAAG
ATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCTGCTAATCAGATGCGCAAC
TTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGGAAAGAATATTTGATCATG
GGTCTGGATGGGGCCACCTATGACCTCGAGGGACACCCCCAGTACCTGCTGGACTCGAAT
AGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGCACCCGCCAGCGGGCAGCC
TGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAGGGGTGCCAGGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00207</identifier>
        <name>A2M</name>
      </pfam>
      <pfam>
        <identifier>PF07678</identifier>
        <name>A2M_comp</name>
      </pfam>
      <pfam>
        <identifier>PF01835</identifier>
        <name>A2M_N</name>
      </pfam>
      <pfam>
        <identifier>PF07703</identifier>
        <name>A2M_N_2</name>
      </pfam>
      <pfam>
        <identifier>PF07677</identifier>
        <name>A2M_recep</name>
      </pfam>
      <pfam>
        <identifier>PF01821</identifier>
        <name>ANATO</name>
      </pfam>
      <pfam>
        <identifier>PF01759</identifier>
        <name>NTR</name>
      </pfam>
      <pfam>
        <identifier>PF10569</identifier>
        <name>Thiol-ester_cl</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>complement component C1q binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic cell clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0004686</id>
      <name>Complement C4-B</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P0C0L5" source="Swiss-Prot">
    <name>Complement C4-B</name>
    <general-function>Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.</general-function>
    <specific-function>Carbohydrate binding</specific-function>
    <gene-name>C4B</gene-name>
    <locus/>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi/>
    <molecular-weight>192749.785</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P0C0L5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CO4B_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Basic complement C4</synonym>
      <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3</synonym>
      <synonym>CO4</synonym>
      <synonym>CPAMD3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009603|Complement C4-B
MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN
PSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS
LSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN
SHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN
FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE
SQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW
YFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD
IQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS
RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS
FYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA
LGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW
TLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA
ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE
NWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP
MSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS
VVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI
PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP
TLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTA
FVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVA
LTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL
TLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL
WIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH
TTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV
LRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP
LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD
LEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY
NPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY
PRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG
KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ
GCQV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0017510|Complement C4-B (C4B)
ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAG
CCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGG
GTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAAC
CCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGA
GACTTCGCACTCCTCAGTCTCCAGGTGCCCTTGAAAGATGCGAAGAGCTGTGGCCTCCAT
CAACTCCTCAGAGGCCCTGAGGTCCAGCTGGTGGCCCATTCGCCATGGCTAAAGGACTCT
CTGTCCAGAACGACAAACATCCAGGGTATCAACCTGCTCTTCTCCTCTCGCCGGGGGCAC
CTCTTTTTGCAGACGGACCAGCCCATTTACAACCCTGGCCAGCGGGTTCGGTACCGGGTC
TTTGCTCTGGATCAGAAGATGCGCCCGAGCACTGACACCATCACAGTCATGGTGGAGAAC
TCTCACGGCCTCCGCGTGCGGAAGAAGGAGGTGTACATGCCCTCGTCCATCTTCCAGGAT
GACTTTGTGATCCCAGACATCTCAGAGCCAGGGACCTGGAAGATCTCAGCCCGATTCTCA
GATGGCCTGGAATCCAACAGCAGCACCCAGTTTGAGGTGAAGAAATATGTCCTTCCCAAC
TTTGAGGTGAAGATCACCCCTGGAAAGCCCTACATCCTGACGGTGCCAGGCCATCTTGAT
GAAATGCAGTTAGACATCCAGGCCAGGTACATCTATGGGAAGCCAGTGCAGGGGGTGGCA
TATGTGCGCTTTGGGCTCCTAGATGAGGATGGTAAGAAGACTTTCTTTCGGGGGCTGGAG
AGTCAGACCAAGCTGGTGAATGGACAGAGCCACATTTCCCTCTCAAAGGCAGAGTTCCAG
GACGCCCTGGAGAAGCTGAATATGGGCATTACTGACCTCCAGGGGCTGCGCCTCTACGTT
GCTGCAGCCATCATTGAGTATCCAGGTGGGGAGATGGAGGAGGCAGAGCTCACATCCTGG
TATTTTGTGTCATCTCCCTTCTCCTTGGATCTTAGCAAGACCAAGCGACACCTTGTGCCT
GGGGCCCCCTTCCTGCTGCAGGCCTTGGTCCGTGAGATGTCAGGCTCCCCAGCTTCTGGC
ATTCCTGTCAAAGTTTCTGCCACGGTGTCTTCTCCTGGGTCTGTTCCTGAAGTCCAGGAC
ATTCAGCAAAACACAGACGGGAGCGGCCAAGTCAGCATTCCAATAATTATCCCTCAGACC
ATCTCAGAGCTGCAGCTCTCAGTATCTGCAGGCTCCCCACATCCAGCGATAGCCAGGCTC
ACTGTGGCAGCCCCACCTTCAGGAGGCCCCGGGTTTCTGTCTATTGAGCGGCCGGATTCT
CGACCTCCTCGTGTTGGGGACACTCTGAACCTGAACTTGCGAGCCGTGGGCAGTGGGGCC
ACCTTTTCTCATTACTACTACATGATCCTATCCCGAGGGCAGATCGTGTTCATGAATCGA
GAGCCCAAGAGGACCCTGACCTCGGTCTCGGTGTTTGTGGACCATCACCTGGCACCCTCC
TTCTACTTTGTGGCCTTCTACTACCATGGAGACCACCCAGTGGCCAACTCCCTGCGAGTG
GATGTCCAGGCTGGGGCCTGCGAGGGCAAGCTGGAGCTCAGCGTGGACGGTGCCAAGCAG
TACCGGAACGGGGAGTCCGTGAAGCTCCACTTAGAAACCGACTCCCTAGCCCTGGTGGCG
CTGGGAGCCTTGGACACAGCTCTGTATGCTGCAGGCAGCAAGTCCCACAAGCCCCTCAAC
ATGGGCAAGGTCTTTGAAGCTATGAACAGCTATGACCTCGGCTGTGGTCCTGGGGGTGGG
GACAGTGCCCTTCAGGTGTTCCAGGCAGCGGGCCTGGCCTTTTCTGATGGAGACCAGTGG
ACCTTATCCAGAAAGAGACTAAGCTGTCCCAAGGAGAAGACAACCCGGAAAAAGAGAAAC
GTGAACTTCCAAAAGGCGATTAATGAGAAATTGGGTCAGTATGCTTCCCCGACAGCCAAG
CGCTGCTGCCAGGATGGGGTGACACGTCTGCCCATGATGCGTTCCTGCGAGCAGCGGGCA
GCCCGCGTGCAGCAGCCGGACTGCCGGGAGCCCTTCCTGTCCTGCTGCCAATTTGCTGAG
AGTCTGCGCAAGAAGAGCAGGGACAAGGGCCAGGCGGGCCTCCAACGAGCCCTGGAGATC
CTGCAGGAGGAGGACCTGATTGATGAGGATGACATTCCCGTGCGCAGCTTCTTCCCAGAG
AACTGGCTCTGGAGAGTGGAAACAGTGGACCGCTTTCAAATATTGACACTGTGGCTCCCC
GACTCTCTGACCACGTGGGAGATCCATGGCCTGAGCCTGTCCAAAACCAAAGGCCTATGT
GTGGCCACCCCAGTCCAGCTCCGGGTGTTCCGCGAGTTCCACCTGCACCTCCGCCTGCCC
ATGTCTGTCCGCCGCTTTGAGCAGCTGGAGCTGCGGCCTGTCCTCTATAACTACCTGGAT
AAAAACCTGACTGTGAGCGTCCACGTGTCCCCAGTGGAGGGGCTGTGCCTGGCTGGGGGC
GGAGGGCTGGCCCAGCAGGTGCTGGTGCCTGCGGGCTCTGCCCGGCCTGTTGCCTTCTCT
GTGGTGCCCACGGCAGCCGCCGCTGTGTCTCTGAAGGTGGTGGCTCGAGGGTCCTTCGAA
TTCCCTGTGGGAGATGCGGTGTCCAAGGTTCTGCAGATTGAGAAGGAAGGGGCCATCCAT
AGAGAGGAGCTGGTCTATGAACTCAACCCCTTGGACCACCGAGGCCGGACCTTGGAAATA
CCTGGCAACTCTGATCCCAATATGATCCCTGATGGGGACTTTAACAGCTACGTCAGGGTT
ACAGCCTCAGATCCATTGGACACTTTAGGCTCTGAGGGGGCCTTGTCACCAGGAGGCGTG
GCCTCCCTCTTGAGGCTTCCTCGAGGCTGTGGGGAGCAAACCATGATCTACTTGGCTCCG
ACACTGGCTGCTTCCCGCTACCTGGACAAGACAGAGCAGTGGAGCACACTGCCTCCCGAG
ACCAAGGACCACGCCGTGGATCTGATCCAGAAAGGCTACATGCGGATCCAGCAGTTTCGG
AAGGCGGATGGTTCCTATGCGGCTTGGTTGTCACGGGGCAGCAGCACCTGGCTCACAGCC
TTTGTGTTGAAGGTCCTGAGTTTGGCCCAGGAGCAGGTAGGAGGCTCGCCTGAGAAACTG
CAGGAGACATCTAACTGGCTTCTGTCCCAGCAGCAGGCTGACGGCTCGTTCCAGGACCTC
TCTCCAGTGATACATAGGAGCATGCAGGGGGGTTTGGTGGGCAATGATGAGACTGTGGCA
CTCACAGCCTTTGTGACCATCGCCCTTCATCATGGGCTGGCCGTCTTCCAGGATGAGGGT
GCAGAGCCATTGAAGCAGAGAGTGGAAGCCTCCATCTCAAAGGCAAGCTCATTTTTGGGG
GAGAAAGCAAGTGCTGGGCTCCTGGGTGCCCACGCAGCTGCCATCACGGCCTATGCCCTG
ACACTGACCAAGGCCCCTGCGGACCTGCGGGGTGTTGCCCACAACAACCTCATGGCAATG
GCCCAGGAGACTGGAGATAACCTGTACTGGGGCTCAGTCACTGGTTCTCAGAGCAATGCC
GTGTCGCCCACCCCAGCTCCTCGCAACCCATCCGACCCCATGCCCCAGGCCCCAGCCCTG
TGGATTGAAACCACAGCCTACGCCCTGCTGCACCTCCTGCTTCACGAGGGCAAAGCAGAG
ATGGCAGACCAGGCTGCGGCCTGGCTCACCCGTCAGGGCAGCTTCCAAGGGGGATTCCGC
AGTACCCAAGACACGGTGATTGCCCTGGATGCCCTGTCTGCCTACTGGATTGCCTCCCAC
ACCACTGAGGAGAGGGGTCTCAATGTGACTCTCAGCTCCACAGGCCGGAATGGGTTCAAG
TCCCACGCGCTGCAGCTGAACAACCGCCAGATTCGCGGCCTGGAGGAGGAGCTGCAGTTT
TCCTTGGGCAGCAAGATCAATGTGAAGGTGGGAGGAAACAGCAAAGGAACCCTGAAGGTC
CTTCGTACCTACAATGTCCTGGACATGAAGAACACGACCTGCCAGGACCTACAGATAGAA
GTGACAGTCAAAGGCCACGTCGAGTACACGATGGAAGCAAACGAGGACTATGAGGACTAT
GAGTACGATGAGCTTCCAGCCAAGGATGACCCAGATGCCCCTCTGCAGCCCGTGACACCC
CTGCAGCTGTTTGAGGGTCGGAGGAACCGCCGCAGGAGGGAGGCGCCCAAGGTGGTGGAG
GAGCAGGAGTCCAGGGTGCACTACACCGTGTGCATCTGGCGGAACGGCAAGGTGGGGCTG
TCTGGCATGGCCATCGCGGACGTCACCCTCCTGAGTGGATTCCACGCCCTGCGTGCTGAC
CTGGAGAAGCTGACCTCCCTCTCTGACCGTTACGTGAGTCACTTTGAGACCGAGGGGCCC
CACGTCCTGCTGTATTTTGACTCGGTCCCCACCTCCCGGGAGTGCGTGGGCTTTGAGGCT
GTGCAGGAAGTGCCGGTGGGGCTGGTGCAGCCGGCCAGCGCAACCCTGTACGACTACTAC
AACCCCGAGCGCAGATGTTCTGTGTTTTACGGGGCACCAAGTAAGAGCAGACTCTTGGCC
ACCTTGTGTTCTGCTGAAGTCTGCCAGTGTGCTGAGGGGAAGTGCCCTCGCCAGCGTCGC
GCCCTGGAGCGGGGTCTGCAGGACGAGGATGGCTACAGGATGAAGTTTGCCTGCTACTAC
CCCCGTGTGGAGTACGGCTTCCAGGTTAAGGTTCTCCGAGAAGACAGCAGAGCTGCTTTC
CGCCTCTTTGAGACCAAGATCACCCAAGTCCTGCACTTCACCAAGGATGTCAAGGCCGCT
GCTAATCAGATGCGCAACTTCCTGGTTCGAGCCTCCTGCCGCCTTCGCTTGGAACCTGGG
AAAGAATATTTGATCATGGGTCTAGATGGGGCCACCTATGACCTCGAGGGACACCCCCAG
TACCTGCTGGACTCGAATAGCTGGATCGAGGAGATGCCCTCTGAACGCCTGTGCCGGAGC
ACCCGCCAGCGGGCAGCCTGTGCCCAGCTCAACGACTTCCTCCAGGAGTATGGCACTCAG
GGGTGCCAGGTGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00207</identifier>
        <name>A2M</name>
      </pfam>
      <pfam>
        <identifier>PF07678</identifier>
        <name>A2M_comp</name>
      </pfam>
      <pfam>
        <identifier>PF01835</identifier>
        <name>A2M_N</name>
      </pfam>
      <pfam>
        <identifier>PF07703</identifier>
        <name>A2M_N_2</name>
      </pfam>
      <pfam>
        <identifier>PF07677</identifier>
        <name>A2M_recep</name>
      </pfam>
      <pfam>
        <identifier>PF01821</identifier>
        <name>ANATO</name>
      </pfam>
      <pfam>
        <identifier>PF01759</identifier>
        <name>NTR</name>
      </pfam>
      <pfam>
        <identifier>PF10569</identifier>
        <name>Thiol-ester_cl</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>other organism cell</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>complement binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic cell clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>opsonization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of molecule of bacterial origin</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0000855</id>
      <name>Complement C5</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>20441428</pubmed-id>
            <citation>Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. doi: 10.1586/eci.10.9.</citation>
          </article>
          <article>
            <pubmed-id>17351760</pubmed-id>
            <citation>Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11.</citation>
          </article>
          <article>
            <pubmed-id>17911465</pubmed-id>
            <citation>Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01031" source="Swiss-Prot">
    <name>Complement C5</name>
    <general-function>Receptor binding</general-function>
    <specific-function>Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.</specific-function>
    <gene-name>C5</gene-name>
    <locus>9q33-q34</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>6.49</theoretical-pi>
    <molecular-weight>188303.705</molecular-weight>
    <chromosome-location>9</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1331</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>C5</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M57729</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>179983</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01031</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CO5_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4</synonym>
      <synonym>CPAMD4</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019020|Complement C5
MGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP
DKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT
YDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI
GIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY
KNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT
FDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP
LFLKPGIPYPIKVQVKDSLDQLVGGVPVTLNAQTIDVNQETSDLDPSKSVTRVDDGVASF
VLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE
HLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL
LVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV
ALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD
DSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL
GPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV
PRRKQLQFALPDSLTTWEIQGVGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ
LKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV
LPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP
YRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY
VFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA
FALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN
SLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK
THPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN
LKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK
GALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK
IDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK
ALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR
PDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA
YKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM
GKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019021|Complement C5 (C5)
ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAG
CAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTG
ATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCT
GATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAA
AACTCTGCAATCTTAACAATACAACCAAAACAATTGCCTGGAGGACAAAACCCAGTTTCT
TATGTGTATTTGGAAGTTGTATCAAAGCATTTTTCAAAATCAAAAAGAATGCCAATAACC
TATGACAATGGATTTCTCTTCATTCATACAGACAAACCTGTTTATACTCCAGACCAGTCA
GTAAAAGTTAGAGTTTATTCGTTGAATGACGACTTGAAGCCAGCCAAAAGAGAAACTGTC
TTAACTTTCATAGATCCTGAAGGATCAGAAGTTGACATGGTAGAAGAAATTGATCATATT
GGAATTATCTCTTTTCCTGACTTCAAGATTCCGTCTAATCCTAGATATGGTATGTGGACG
ATCAAGGCTAAATATAAAGAGGACTTTTCAACAACTGGAACCGCATATTTTGAAGTTAAA
GAATATGTCTTGCCACATTTTTCTGTCTCAATCGAGCCAGAATATAATTTCATTGGTTAC
AAGAACTTTAAGAATTTTGAAATTACTATAAAAGCAAGATATTTTTATAATAAAGTAGTC
ACTGAGGCTGACGTTTATATCACATTTGGAATAAGAGAAGACTTAAAAGATGATCAAAAA
GAAATGATGCAAACAGCAATGCAAAACACAATGTTGATAAATGGAATTGCTCAAGTCACA
TTTGATTCTGAAACAGCAGTCAAAGAACTGTCATACTACAGTTTAGAAGATTTAAACAAC
AAGTACCTTTATATTGCTGTAACAGTCATAGAGTCTACAGGTGGATTTTCTGAAGAGGCA
GAAATACCTGGCATCAAATATGTCCTCTCTCCCTACAAACTGAATTTGGTTGCTACTCCT
CTTTTCCTGAAGCCTGGGATTCCATATCCCATCAAGGTGCAGGTTAAAGATTCGCTTGAC
CAGTTGGTAGGAGGAGTCCCAGTAACACTGAATGCACAAACAATTGATGTAAACCAAGAG
ACATCTGACTTGGATCCAAGCAAAAGTGTAACACGTGTTGATGATGGAGTAGCTTCCTTT
GTGCTTAATCTCCCATCTGGAGTGACGGTGCTGGAGTTTAATGTCAAAACTGATGCTCCA
GATCTTCCAGAAGAAAATCAGGCCAGGGAAGGTTACCGAGCAATAGCATACTCATCTCTC
AGCCAAAGTTACCTTTATATTGATTGGACTGATAACCATAAGGCTTTGCTAGTGGGAGAA
CATCTGAATATTATTGTTACCCCCAAAAGCCCATATATTGACAAAATAACTCACTATAAT
TACTTGATTTTATCCAAGGGCAAAATTATCCACTTTGGCACGAGGGAGAAATTTTCAGAT
GCATCTTATCAAAGTATAAACATTCCAGTAACACAGAACATGGTTCCTTCATCCCGACTT
CTGGTCTATTACATCGTCACAGGAGAACAGACAGCAGAATTAGTGTCTGATTCAGTCTGG
TTAAATATTGAAGAAAAATGTGGCAACCAGCTCCAGGTTCATCTGTCTCCTGATGCAGAT
GCATATTCTCCAGGCCAAACTGTGTCTCTTAATATGGCAACTGGAATGGATTCCTGGGTG
GCATTAGCAGCAGTGGACAGTGCTGTGTATGGAGTCCAAAGAGGAGCCAAAAAGCCCTTG
GAAAGAGTATTTCAATTCTTAGAGAAGAGTGATCTGGGCTGTGGGGCAGGTGGTGGCCTC
AACAATGCCAATGTGTTCCACCTAGCTGGACTTACCTTCCTCACTAATGCAAATGCAGAT
GACTCCCAAGAAAATGATGAACCTTGTAAAGAAATTCTCAGGCCAAGAAGAACGCTGCAA
AAGAAGATAGAAGAAATAGCTGCTAAATATAAACATTCAGTAGTGAAGAAATGTTGTTAC
GATGGAGCCTGCGTTAATAATGATGAAACCTGTGAGCAGCGAGCTGCACGGATTAGTTTA
GGGCCAAGATGCATCAAAGCTTTCACTGAATGTTGTGTCGTCGCAAGCCAGCTCCGTGCT
AATATCTCTCATAAAGACATGCAATTGGGAAGGCTACACATGAAGACCCTGTTACCAGTA
AGCAAGCCAGAAATTCGGAGTTATTTTCCAGAAAGCTGGTTGTGGGAAGTTCATCTTGTT
CCCAGAAGAAAACAGTTGCAGTTTGCCCTACCTGATTCTCTAACCACCTGGGAAATTCAA
GGCGTTGGCATTTCAAACACTGGTATATGTGTTGCTGATACTGTCAAGGCAAAGGTGTTC
AAAGATGTCTTCCTGGAAATGAATATACCATATTCTGTTGTACGAGGAGAACAGATCCAA
TTGAAAGGAACTGTTTACAACTATAGGACTTCTGGGATGCAGTTCTGTGTTAAAATGTCT
GCTGTGGAGGGAATCTGCACTTCGGAAAGCCCAGTCATTGATCATCAGGGCACAAAGTCC
TCCAAATGTGTGCGCCAGAAAGTAGAGGGCTCCTCCAGTCACTTGGTGACATTCACTGTG
CTTCCTCTGGAAATTGGCCTTCACAACATCAATTTTTCACTGGAGACTTGGTTTGGAAAA
GAAATCTTAGTAAAAACATTACGAGTGGTGCCAGAAGGTGTCAAAAGGGAAAGCTATTCT
GGTGTTACTTTGGATCCTAGGGGTATTTATGGTACCATTAGCAGACGAAAGGAGTTCCCA
TACAGGATACCCTTAGATTTGGTCCCCAAAACAGAAATCAAAAGGATTTTGAGTGTAAAA
GGACTGCTTGTAGGTGAGATCTTGTCTGCAGTTCTAAGTCAGGAAGGCATCAATATCCTA
ACCCACCTCCCCAAAGGGAGTGCAGAGGCGGAGCTGATGAGCGTTGTCCCAGTATTCTAT
GTTTTTCACTACCTGGAAACAGGAAATCATTGGAACATTTTTCATTCTGACCCATTAATT
GAAAAGCAGAAACTGAAGAAAAAATTAAAAGAAGGGATGTTGAGCATTATGTCCTACAGA
AATGCTGACTACTCTTACAGTGTGTGGAAGGGTGGAAGTGCTAGCACTTGGTTAACAGCT
TTTGCTTTAAGAGTACTTGGACAAGTAAATAAATACGTAGAGCAGAACCAAAATTCAATT
TGTAATTCTTTATTGTGGCTAGTTGAGAATTATCAATTAGATAATGGATCTTTCAAGGAA
AATTCACAGTATCAACCAATAAAATTACAGGGTACCTTGCCTGTTGAAGCCCGAGAGAAC
AGCTTATATCTTACAGCCTTTACTGTGATTGGAATTAGAAAGGCTTTCGATATATGCCCC
CTGGTGAAAATCGACACAGCTCTAATTAAAGCTGACAACTTTCTGCTTGAAAATACACTG
CCAGCCCAGAGCACCTTTACATTGGCCATTTCTGCGTATGCTCTTTCCCTGGGAGATAAA
ACTCACCCACAGTTTCGTTCAATTGTTTCAGCTTTGAAGAGAGAAGCTTTGGTTAAAGGT
AATCCACCCATTTATCGTTTTTGGAAAGACAATCTTCAGCATAAAGACAGCTCTGTACCT
AACACTGGTACGGCACGTATGGTAGAAACAACTGCCTATGCTTTACTCACCAGTCTGAAC
TTGAAAGATATAAATTATGTTAACCCAGTCATCAAATGGCTATCAGAAGAGCAGAGGTAT
GGAGGTGGCTTTTATTCAACCCAGGACACAATCAATGCCATTGAGGGCCTGACGGAATAT
TCACTCCTGGTTAAACAACTCCGCTTGAGTATGGACATCGATGTTTCTTACAAGCATAAA
GGTGCCTTACATAATTATAAAATGACAGACAAGAATTTCCTTGGGAGGCCAGTAGAGGTG
CTTCTCAATGATGACCTCATTGTCAGTACAGGATTTGGCAGTGGCTTGGCTACAGTACAT
GTAACAACTGTAGTTCACAAAACCAGTACCTCTGAGGAAGTTTGCAGCTTTTATTTGAAA
ATCGATACTCAGGATATTGAAGCATCCCACTACAGAGGCTACGGAAACTCTGATTACAAA
CGCATAGTAGCATGTGCCAGCTACAAGCCCAGCAGGGAAGAATCATCATCTGGATCCTCT
CATGCGGTGATGGACATCTCCTTGCCTACTGGAATCAGTGCAAATGAAGAAGACTTAAAA
GCCCTTGTGGAAGGGGTGGATCAACTATTCACTGATTACCAAATCAAAGATGGACATGTT
ATTCTGCAACTGAATTCGATTCCCTCCAGTGATTTCCTTTGTGTACGATTCCGGATATTT
GAACTCTTTGAAGTTGGGTTTCTCAGTCCTGCCACTTTCACAGTGTACGAATACCACAGA
CCAGATAAACAGTGTACCATGTTTTATAGCACTTCCAATATCAAAATTCAGAAAGTCTGT
GAAGGAGCCGCGTGCAAGTGTGTAGAAGCTGATTGTGGGCAAATGCAGGAAGAATTGGAT
CTGACAATCTCTGCAGAGACAAGAAAACAAACAGCATGTAAACCAGAGATTGCATATGCT
TATAAAGTTAGCATCACATCCATCACTGTAGAAAATGTTTTTGTCAAGTACAAGGCAACC
CTTCTGGATATCTACAAAACTGGGGAAGCTGTTGCTGAGAAAGACTCTGAGATTACCTTC
ATTAAAAAGGTAACCTGTACTAACGCTGAGCTGGTAAAAGGAAGACAGTACTTAATTATG
GGTAAAGAAGCCCTCCAGATAAAATACAATTTCAGTTTCAGGTACATCTACCCTTTAGAT
TCCTTGACCTGGATTGAATACTGGCCTAGAGACACAACATGTTCATCGTGTCAAGCATTT
TTAGCTAATTTAGATGAATTTGCCGAAGATATCTTTTTAAATGGATGCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00207</identifier>
        <name>A2M</name>
      </pfam>
      <pfam>
        <identifier>PF07678</identifier>
        <name>A2M_comp</name>
      </pfam>
      <pfam>
        <identifier>PF01835</identifier>
        <name>A2M_N</name>
      </pfam>
      <pfam>
        <identifier>PF07703</identifier>
        <name>A2M_N_2</name>
      </pfam>
      <pfam>
        <identifier>PF07677</identifier>
        <name>A2M_recep</name>
      </pfam>
      <pfam>
        <identifier>PF01821</identifier>
        <name>ANATO</name>
      </pfam>
      <pfam>
        <identifier>PF01759</identifier>
        <name>NTR</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>membrane attack complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chemokine activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of complement activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vascular endothelial growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitophagy in response to mitochondrial depolarization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>in utero embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chemokine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, classical pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of macrophage chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>complement activation, alternative pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-08">
  <drugbank-id primary="true">DB00029</drugbank-id>
  <drugbank-id>BTD00102</drugbank-id>
  <drugbank-id>BIOD00102</drugbank-id>
  <name>Anistreplase</name>
  <description>Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.</description>
  <cas-number>81669-57-0</cas-number>
  <unii>5O8V541HJ6</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction</indication>
  <pharmacodynamics>Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
  <mechanism-of-action>Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Anisoylated plasminogen streptokinase activator complex</synonym>
    <synonym language="" coder="">APSAC</synonym>
  </synonyms>
  <products>
    <product>
      <name>Eminase 30 Units</name>
      <labeller>Well Spring Pharmaceutical Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229390</dpd-id>
      <started-marketing-on>1997-12-15</started-marketing-on>
      <ended-marketing-on>2009-02-23</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>30 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Eminase</name>
      <company>Wulfing Pharma GmbH</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Eminase 30 Units</name>
      <ingredients>Anistreplase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Haupt Pharma</name>
      <url>http://haupt-pharma.de</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Plasminogen Activators</category>
      <mesh-id>D010960</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
    <category>
      <category>Streptokinase</category>
      <mesh-id>D013300</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>30 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AD03">
      <level code="B01AD">Enzymes</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1BDA</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Anistreplase may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Anistreplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Anistreplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Anistreplase may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Anistreplase may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Anistreplase may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Anistreplase may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Anistreplase may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Anistreplase may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Anistreplase may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Anistreplase may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Anistreplase may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Anistreplase may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Anistreplase may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Anistreplase may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Anistreplase may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Anistreplase may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Anistreplase may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Anistreplase may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Anistreplase may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Anistreplase may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Anistreplase may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Anistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Anistreplase may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Anistreplase may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Anistreplase may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Anistreplase may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Anistreplase may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Anistreplase may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Anistreplase may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Anistreplase may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Anistreplase may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Anistreplase may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Anistreplase may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Anistreplase may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Anistreplase may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Anistreplase may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Anistreplase may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Anistreplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Anistreplase may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>The risk or severity of adverse effects can be increased when dersalazine is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Vorapaxar may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00029 sequence
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA
LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS
PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>60 °C</value>
      <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.516</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.61</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>59042.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2569H3928N746O781S40</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1199</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>L00153</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164769075</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00750</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001197</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Anistreplase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108250</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP00281</smpdb-id>
      <name>Anistreplase Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00029</drugbank-id>
          <name>Anistreplase</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
    <name>Plasminogen</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
    <gene-name>PLG</gene-name>
    <locus>6q26</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>7.25</theoretical-pi>
    <molecular-weight>90568.415</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9071</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X05199</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387026</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PLMN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00024</identifier>
        <name>PAN_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tissue remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibrinolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000538</id>
      <name>Fibrinogen alpha chain</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02671" source="Swiss-Prot">
    <name>Fibrinogen alpha chain</name>
    <general-function>Structural molecule activity</general-function>
    <specific-function>Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.</specific-function>
    <gene-name>FGA</gene-name>
    <locus>4q28</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.87</theoretical-pi>
    <molecular-weight>94972.455</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3661</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF361104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>13591824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FIBA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fibrinogen alpha chain precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001074|Fibrinogen alpha chain
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)
ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA
GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
AGGCCCCTTGTGACCCAATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00147</identifier>
        <name>Fibrinogen_C</name>
      </pfam>
      <pfam>
        <identifier>PF08702</identifier>
        <name>Fib_alpha</name>
      </pfam>
      <pfam>
        <identifier>PF12160</identifier>
        <name>Fibrinogen_aC</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>fibrinogen complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>structural molecule activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>liver regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to genistein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet aggregation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic cyclic compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>induction of bacterial agglutination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-6</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to granulocyte colony-stimulating factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heterotypic cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, fibrin clot formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cycloheximide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptide hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein polymerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adaptive immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000717</id>
      <name>Urokinase plasminogen activator surface receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q03405" source="Swiss-Prot">
    <name>Urokinase plasminogen activator surface receptor</name>
    <general-function>Urokinase plasminogen activator receptor activity</general-function>
    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.</specific-function>
    <gene-name>PLAUR</gene-name>
    <locus>19q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>36977.62</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9053</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAUR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51675</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q03405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UPAR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>MO3</synonym>
      <synonym>Monocyte activation antigen Mo3</synonym>
      <synonym>U-PAR</synonym>
      <synonym>UPAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)
ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG
CCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT
GTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00021</identifier>
        <name>UPAR_LY6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>invadopodium membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>urokinase plasminogen activator receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>attachment of GPI anchor to protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>C-terminal protein lipidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urokinase plasminogen activator signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of cytochrome c from mitochondria</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000240</id>
      <name>Plasminogen activator inhibitor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05121" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 1</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>
    <gene-name>SERPINE1</gene-name>
    <locus>7q21.3-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.22</theoretical-pi>
    <molecular-weight>45059.695</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINE1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04429</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35272</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05121</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Endothelial plasminogen activator inhibitor</synonym>
      <synonym>PAI</synonym>
      <synonym>PAI1</synonym>
      <synonym>PLANH1</synonym>
      <synonym>Serpin E1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)
ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC
TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
GAACCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronological cell aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-negative bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukotriene production involved in inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription initiation from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of wound healing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-09-07">
  <drugbank-id primary="true">DB00030</drugbank-id>
  <drugbank-id>BTD00105</drugbank-id>
  <drugbank-id>BIOD00105</drugbank-id>
  <drugbank-id>DB01383</drugbank-id>
  <drugbank-id>DB05278</drugbank-id>
  <drugbank-id>DB05215</drugbank-id>
  <drugbank-id>DB05283</drugbank-id>
  <drugbank-id>DB08914</drugbank-id>
  <name>Insulin Human</name>
  <description>Insulin human is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.&#13;
&#13;
Inhalable insulin is a powdered form of insulin regular, delivered with a nebulizer into the lungs where it is absorbed. Exubera, developed by Inhale Therapeutics (later named Nektar Therapeutics), became the first inhaled insulin product to be marketed in 2006 by Pfizer, but poor sales led Pfizer to withdraw it in 2007. Afrezza, a monomeric inhaled insulin developed by Mannkind, was approved by the FDA in 2014.</description>
  <cas-number>11061-68-0</cas-number>
  <unii>1Y17CTI5SR</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>23512415</pubmed-id>
        <citation>Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A: Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19.</citation>
      </article>
      <article>
        <pubmed-id>11118018</pubmed-id>
        <citation>Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8.</citation>
      </article>
      <article>
        <pubmed-id>10841002</pubmed-id>
        <citation>Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R: Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000 Jun;23(6):813-9.</citation>
      </article>
      <article>
        <pubmed-id>14578244</pubmed-id>
        <citation>Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003 Nov;26(11):3087-92.</citation>
      </article>
      <article>
        <pubmed-id>18715209</pubmed-id>
        <citation>Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Humulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin.</synthesis-reference>
  <indication>Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. </indication>
  <pharmacodynamics>Insulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action. </pharmacodynamics>
  <mechanism-of-action>The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.&#13;
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.</mechanism-of-action>
  <toxicity>Hypoglycemia is one of the most frequent adverse events experienced by insulin users. </toxicity>
  <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
  <absorption>Insulin is generally well absorbed. </absorption>
  <half-life/>
  <protein-binding>5% protein bound </protein-binding>
  <route-of-elimination/>
  <volume-of-distribution>0.15 L/kg </volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001733</drugbank-id>
      <name>Insulin human zinc suspension</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001734</drugbank-id>
      <name>NPH insulin</name>
      <unii/>
      <cas-number>53027-39-7</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="" coder="">High molecular weight insulin human</synonym>
    <synonym language="" coder="">Human insulin</synonym>
    <synonym language="" coder="INN">human insulin (rDNA)</synonym>
    <synonym language="" coder="">Insulin (human)</synonym>
    <synonym language="" coder="">Insulin human </synonym>
    <synonym language="" coder="">Insulin human [rDNA origin]</synonym>
    <synonym language="" coder="">Insulin Human Regular</synonym>
    <synonym language="" coder="">Insulin human regular (rDNA)</synonym>
    <synonym language="" coder="">Insulin human, rDNA origin</synonym>
    <synonym language="" coder="">Insulin recombinant human</synonym>
    <synonym language="" coder="">Insulin recombinant purified human</synonym>
    <synonym language="" coder="">Insulin regular</synonym>
    <synonym language="" coder="">Insulin, human</synonym>
    <synonym language="" coder="">Regular Insulin, human</synonym>
  </synonyms>
  <products>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-874</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>4 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5882</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5884</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5894</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-878</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>8 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-891</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>12 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-880</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-882</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-884</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-894</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5874</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>4 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-902</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Entuzity Kwikpen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466864</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>500 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8770</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-02-01</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8770</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-02-01</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8715</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1989-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8803</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8730</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-02-01</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8315</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8805</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1429</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1994-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8215</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Parenteral</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3619</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959220</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin R U-500</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8501</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R U-500 KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8824</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1837</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024292</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2007-11-05</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024292</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2007-11-05</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024306</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2008-08-12</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024306</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2008-08-12</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024217</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024217</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025248</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025248</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 40/60 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024314</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 40/60 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024314</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 50/50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024322</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 50/50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024322</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Nph</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024225</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>100 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Nph Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024268</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>100 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Toronto</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024233</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Toronto Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024284</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-1834</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1834</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0498</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-1833</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1833</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0497</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovolinN N</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-651</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-04-07</started-marketing-on>
      <ended-marketing-on>2017-02-22</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024446</dpd-id>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024446</dpd-id>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge Nph Inj Sus 100u/ml</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024403</dpd-id>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength>100 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge Toronto Inj Liq 100u/ml</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025256</dpd-id>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Exubera</name>
      <company>Pfizer (withdrawn)</company>
    </international-brand>
    <international-brand>
      <name>Humulin N Pen</name>
      <company>Lilly</company>
    </international-brand>
    <international-brand>
      <name>lnsulatard</name>
      <company>Leo</company>
    </international-brand>
    <international-brand>
      <name>Nasulin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Novolin N Relion</name>
      <company>Novo Nordisk</company>
    </international-brand>
    <international-brand>
      <name>Novolin NPH</name>
      <company>Novo Nordisk</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Toronto</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Toronto Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge Toronto Inj Liq 100u/ml</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>NovolinN N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R Cartridge</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Infusat</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Infusat</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Infusat</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Implantable</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Implantable</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Infusat</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Innolet</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard&#13;Flexpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R U-500</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R U-500 KwikPen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Entuzity Kwikpen</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Nph</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 40/60 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 40/60 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Nph Penfill</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 50/50 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 50/50 Penfill</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge Nph Inj Sus 100u/ml</name>
      <ingredients>Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <ingredients>Insulin Human + Insulin Human</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>DispenseXpress Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Intervet International</name>
      <url>http://www.intervet.ca</url>
    </packager>
    <packager>
      <name>Novo Nordisk Inc.</name>
      <url>http://www.novonordisk.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Novo nordisk inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Novolin Ge Nph 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Nph Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.78</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.8</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>NovoLIN R InnoLet 100 unit/ml Solution 3ml Cartridge</description>
      <cost currency="USD">24.17</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin r 100 unit/ml cartridg</description>
      <cost currency="USD">33.33</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>NovoLIN R 100 unit/ml Solution 10ml Vial</description>
      <cost currency="USD">73.19</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>NovoLIN R PenFill 100 unit/ml Solution Five 3ml Cartridges Per Box = 15ml</description>
      <cost currency="USD">162.26</cost>
      <unit>cartridge</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Blood Glucose Lowering Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers</category>
      <mesh-id>D065694</mesh-id>
    </category>
    <category>
      <category>Drugs Used in Diabetes</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypoglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypoglycemic Agents</category>
      <mesh-id>D007004</mesh-id>
    </category>
    <category>
      <category>Insulin, Long-Acting</category>
      <mesh-id>D049528</mesh-id>
    </category>
    <category>
      <category>Insulins</category>
      <mesh-id>D061385</mesh-id>
    </category>
    <category>
      <category>Insulins and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pancreatic Hormones</category>
      <mesh-id>D010187</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>12 1/1</strength>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>4 1/1</strength>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>8 1/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>500 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>500 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intraperitoneal</route>
      <strength>400 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 [USP'U]/mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A10AE01">
      <level code="A10AE">Insulins and analogues for injection, long-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AF01">
      <level code="A10AF">Insulins and analogues for inhalation</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AC01">
      <level code="A10AC">Insulins and analogues for injection, intermediate-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AB01">
      <level code="A10AB">Insulins and analogues for injection, fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AD01">
      <level code="A10AD">Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:20.08</ahfs-code>
    <ahfs-code>92:02.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2VJZ</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00030.pdf?1265922794</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00030.pdf?1370754402</msds>
  <patents>
    <patent>
      <number>RE37872</number>
      <country>United States</country>
      <approved>1993-02-12</approved>
      <expires>2010-02-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2183577</number>
      <country>Canada</country>
      <approved>2007-10-30</approved>
      <expires>2015-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2253393</number>
      <country>Canada</country>
      <approved>2007-10-09</approved>
      <expires>2017-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7291132</number>
      <country>United States</country>
      <approved>2004-08-09</approved>
      <expires>2024-08-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6257233</number>
      <country>United States</country>
      <approved>1999-05-14</approved>
      <expires>2019-05-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6546929</number>
      <country>United States</country>
      <approved>1999-05-14</approved>
      <expires>2019-05-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6685967</number>
      <country>United States</country>
      <approved>1998-09-11</approved>
      <expires>2018-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6582728</number>
      <country>United States</country>
      <approved>2000-06-24</approved>
      <expires>2020-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8912193</number>
      <country>United States</country>
      <approved>2009-06-12</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7648960</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6652885</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8258095</number>
      <country>United States</country>
      <approved>2009-08-11</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8778403</number>
      <country>United States</country>
      <approved>2010-06-11</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6444226</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7943572</number>
      <country>United States</country>
      <approved>2006-08-10</approved>
      <expires>2026-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8119593</number>
      <country>United States</country>
      <approved>2009-08-11</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7943178</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8889099</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8623817</number>
      <country>United States</country>
      <approved>2009-09-18</approved>
      <expires>2029-09-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8389470</number>
      <country>United States</country>
      <approved>2000-06-29</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9192675</number>
      <country>United States</country>
      <approved>2009-06-12</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8215300</number>
      <country>United States</country>
      <approved>2002-11-24</approved>
      <expires>2022-11-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8146588</number>
      <country>United States</country>
      <approved>2003-04-24</approved>
      <expires>2023-04-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8950397</number>
      <country>United States</country>
      <approved>2001-07-20</approved>
      <expires>2021-07-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8485180</number>
      <country>United States</country>
      <approved>2010-03-25</approved>
      <expires>2030-03-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9283193</number>
      <country>United States</country>
      <approved>2006-09-14</approved>
      <expires>2026-09-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8636001</number>
      <country>United States</country>
      <approved>2012-07-12</approved>
      <expires>2032-07-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8424518</number>
      <country>United States</country>
      <approved>2011-10-17</approved>
      <expires>2031-10-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8551528</number>
      <country>United States</country>
      <approved>2010-06-11</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7464706</number>
      <country>United States</country>
      <approved>2003-03-02</approved>
      <expires>2023-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8729019</number>
      <country>United States</country>
      <approved>2008-12-26</approved>
      <expires>2028-12-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7305986</number>
      <country>United States</country>
      <approved>2003-01-16</approved>
      <expires>2023-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8499757</number>
      <country>United States</country>
      <approved>2012-02-19</approved>
      <expires>2032-02-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8156936</number>
      <country>United States</country>
      <approved>2003-01-16</approved>
      <expires>2023-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8734845</number>
      <country>United States</country>
      <approved>2010-06-11</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8227409</number>
      <country>United States</country>
      <approved>2011-03-08</approved>
      <expires>2031-03-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9393372</number>
      <country>United States</country>
      <approved>2009-07-04</approved>
      <expires>2029-07-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9339615</number>
      <country>United States</country>
      <approved>2009-10-20</approved>
      <expires>2029-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9511198</number>
      <country>United States</country>
      <approved>2010-02-16</approved>
      <expires>2030-02-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9597374</number>
      <country>United States</country>
      <approved>2011-10-08</approved>
      <expires>2031-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9358352</number>
      <country>United States</country>
      <approved>2011-02-15</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9446133</number>
      <country>United States</country>
      <approved>2009-06-12</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9662461</number>
      <country>United States</country>
      <approved>2009-06-12</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin Lispro</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>Insulin Human may increase the hypoglycemic activities of Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Insulin Human may increase the hypoglycemic activities of Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Insulin Human may increase the hypoglycemic activities of Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Insulin Human may increase the hypoglycemic activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Insulin Human may increase the hypoglycemic activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Insulin Human may increase the hypoglycemic activities of Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Insulin Human may increase the hypoglycemic activities of Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>Insulin Human may increase the hypoglycemic activities of Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>Insulin Human may increase the hypoglycemic activities of Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>Insulin Human may increase the hypoglycemic activities of Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02665</drugbank-id>
      <name>Trans-2-Phenylcyclopropylamine</name>
      <description>Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>Iproclozide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Moxifloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Grepafloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Enoxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Pefloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Ciprofloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Trovafloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic Acid</name>
      <description>Nalidixic Acid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Rosoxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Cinoxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Lomefloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Gatifloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Norfloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Levofloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Gemifloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Ofloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Sparfloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Temafloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Fleroxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Garenoxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Nemonoxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Flumequine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Pazufloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Prulifloxacin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Fluoxetine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Paroxetine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Citalopram may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Escitalopram may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Sertraline may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Duloxetine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Nefazodone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Desvenlafaxine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Milnacipran may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Levomilnacipran may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>Dapoxetine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>Indalpine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>Zimelidine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Etoperidone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>Oxandrolone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Dihydrotestosterone</name>
      <description>Dihydrotestosterone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>Oxymetholone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06718</drugbank-id>
      <name>Stanozolol</name>
      <description>Stanozolol may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01185</drugbank-id>
      <name>Fluoxymesterone</name>
      <description>Fluoxymesterone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Methyltestosterone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>Pegvisomant may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin Pork</name>
      <description>Insulin Pork may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Troglitazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Metformin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>Acetohexamide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00419</drugbank-id>
      <name>Miglustat</name>
      <description>Miglustat may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>Miglitol may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>Phenformin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>Pioglitazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>Gliquidone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>Mitiglinide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Sitagliptin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Exenatide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>Pramlintide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>Aicar may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>Buformin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>Vildagliptin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>Voglibose may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Alogliptin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Sulodexide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Saxagliptin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>Liraglutide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>Linagliptin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>Glibornuride may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Empagliflozin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>Dulaglutide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>Ciglitazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>Thiazolidinedione may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12692</drugbank-id>
      <name>Gusperimus</name>
      <description>Gusperimus may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>Balaglitazone may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12991</drugbank-id>
      <name>Deoxyspergualin</name>
      <description>Deoxyspergualin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>dersalazine may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the hypoglycemic activities of Insulin Human.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;A chain
GIVEQCCTSICSLYQLENYCN</sequence>
    <sequence format="FASTA">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>81 °C</value>
      <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>0.218</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.39</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>5808.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C257H383N65O77S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20125</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7672</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7671</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>5931</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C00723</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03230</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>AY137503</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164744571</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>Q8HXV2</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000802</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Insulin</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/novolog.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/pro/humulin-r.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000033</id>
      <name>Insulin receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>12970169</pubmed-id>
            <citation>Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11.</citation>
          </article>
          <article>
            <pubmed-id>12038982</pubmed-id>
            <citation>Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.</citation>
          </article>
          <article>
            <pubmed-id>17722952</pubmed-id>
            <citation>Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27.</citation>
          </article>
          <article>
            <pubmed-id>19683471</pubmed-id>
            <citation>Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. doi: 10.1016/j.coph.2009.07.004. Epub  2009 Aug 13.</citation>
          </article>
          <article>
            <pubmed-id>20230616</pubmed-id>
            <citation>Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. doi: 10.1186/1749-8104-5-7.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P06213" source="Swiss-Prot">
    <name>Insulin receptor</name>
    <general-function>Receptor signaling protein tyrosine kinase activity</general-function>
    <specific-function>Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
    <gene-name>INSR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>957-979</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>6.18</theoretical-pi>
    <molecular-weight>156331.465</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6091</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>INSR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M10051</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307070</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1800</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P06213</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INSR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>IR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036940|Insulin receptor
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020443|Insulin receptor (INSR)
ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
TCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG
GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
TGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
TGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
AGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT
AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
AATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
CCTTCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>insulin receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphatidylinositol 3-kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor signaling protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin receptor substrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor I binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor II binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>GTP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>PTB domain binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to insulin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glucose import</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of meiotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transformation of host cell by virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycogen biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adrenal gland development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of female gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase B activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of developmental growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction by protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>carbohydrate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heart morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of respiratory burst</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein heterotetramerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exocrine pancreas development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermis development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male sex determination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glycolytic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000858</id>
      <name>Insulin-like growth factor 1 receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08069" source="Swiss-Prot">
    <name>Insulin-like growth factor 1 receptor</name>
    <general-function>Protein tyrosine kinase activity</general-function>
    <specific-function>Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
    <gene-name>IGF1R</gene-name>
    <locus>15q26.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>936-959</transmembrane-regions>
    <signal-regions>1-30</signal-regions>
    <theoretical-pi>5.54</theoretical-pi>
    <molecular-weight>154791.73</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5465</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IGF1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04434</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>804990</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1801</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08069</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IGF1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>IGF-I receptor</synonym>
      <synonym>Insulin-like growth factor I receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001710|Insulin-like growth factor 1 receptor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00757</identifier>
        <name>Furin-like</name>
      </pfam>
      <pfam>
        <identifier>PF01030</identifier>
        <name>Recep_L_domain</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor I binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphatidylinositol 3-kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin receptor substrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin-like growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokinesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein tetramerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exocrine pancreas development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inactivation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of muscle cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein heterooligomerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostate gland epithelium morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to vitamin E</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of JNK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermis development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male sex determination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of steroid hormone biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin-like growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>establishment of cell polarity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mammary gland development</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0002123</id>
      <name>Retinoblastoma-associated protein</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06400" source="Swiss-Prot">
    <name>Retinoblastoma-associated protein</name>
    <general-function>Ubiquitin protein ligase binding</general-function>
    <specific-function>Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.</specific-function>
    <gene-name>RB1</gene-name>
    <locus>13q14.2</locus>
    <cellular-location>Nucleus</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>8.04</theoretical-pi>
    <molecular-weight>106158.335</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9884</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>RB1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M15400</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>190959</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P06400</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>RB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>p105-Rb</synonym>
      <synonym>pp110</synonym>
      <synonym>pRb</synonym>
      <synonym>Rb</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021315|Retinoblastoma-associated protein
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL
CQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL
QKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS
ISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK
TAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM
NSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS
NLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK
DIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN
IFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG
NLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH
TAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL
RLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK
FKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS
PIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG
TSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK
LAEMTSTRTRMQKQKMNDSMDTSNKEEK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021316|Retinoblastoma-associated protein (RB1)
ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC
CCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG
GACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA
TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA
GTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA
ATCTGTATCTTTATTGCAGCAGTTGACCTAGATGAGATGTCGTTCACTTTTACTGAGCTA
CAGAAAAACATAGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC
AGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA
CTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG
ATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA
GCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA
TGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA
ACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT
GCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA
CATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG
AATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA
TACGAAGAAATTTATCTTAAAAATAAAGATCTAGATGCAAGATTATTTTTGGATCATGAT
AAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT
AACCTTGATGAAGAGGTGAATGTAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC
ACTATCCAACAATTAATGATGATTTTAAATTCAGCAAGTGATCAACCTTCAGAAAATCTG
ATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG
GATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA
ATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG
CTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC
ATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA
AGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG
CTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC
AACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC
CTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA
GGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC
ACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG
CGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG
CCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC
CGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC
TGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG
GACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA
TTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA
CGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC
ATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA
CCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT
GGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA
ACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG
ACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA
AGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA
GGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA
CTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG
GATACCTCAAACAAGGAAGAGAAATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01858</identifier>
        <name>RB_A</name>
      </pfam>
      <pfam>
        <identifier>PF01857</identifier>
        <name>RB_B</name>
      </pfam>
      <pfam>
        <identifier>PF08934</identifier>
        <name>Rb_C</name>
      </pfam>
      <pfam>
        <identifier>PF11934</identifier>
        <name>DUF3452</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>SWI/SNF complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>spindle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Rb-E2F complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>PML body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>chromatin</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>core promoter binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transcription coactivator activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>androgen receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transcription factor activity, sequence-specific DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transcription factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cohesin localization to chromatin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of centromere complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell cycle arrest</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron projection development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>myoblast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of lipid kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mitotic cell cycle checkpoint</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sister chromatid biorientation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chromatin remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mitotic metaphase/anaphase transition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hepatocyte apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smoothened signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to xenobiotic stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell morphogenesis involved in neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>enucleate erythrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>striated muscle cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>androgen receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal muscle cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell cycle checkpoint</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to chromosome, centromeric region</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of mitotic sister chromatid cohesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron maturation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of macrophage differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter during mitosis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000941</id>
      <name>Cathepsin D</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07339" source="Swiss-Prot">
    <name>Cathepsin D</name>
    <general-function>Aspartic-type endopeptidase activity</general-function>
    <specific-function>Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease.</specific-function>
    <gene-name>CTSD</gene-name>
    <locus>11p15.5</locus>
    <cellular-location>Lysosome</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>6.5</theoretical-pi>
    <molecular-weight>44551.845</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2529</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CTSD</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M11233</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181180</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2345</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P07339</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CATD_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.23.5</synonym>
      <synonym>CPSD</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016260|Cathepsin D
MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP
AVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH
HKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG
EATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ
PGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL
MVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ
AGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016261|Cathepsin D (CTSD)
ATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG
CTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG
GGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA
GCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC
GGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC
TCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC
CACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC
CACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC
CAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG
GAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC
ATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG
CAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG
CCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC
TACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC
AGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC
ATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG
ATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG
AAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG
GCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG
CCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC
AACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07966</identifier>
        <name>A1_Propeptide</name>
      </pfam>
      <pfam>
        <identifier>PF00026</identifier>
        <name>Asp</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>melanosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aspartic-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>autophagy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>collagen catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0001183</id>
      <name>Insulin-degrading enzyme</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14735" source="Swiss-Prot">
    <name>Insulin-degrading enzyme</name>
    <general-function>Zinc ion binding</general-function>
    <specific-function>Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by APP and IAPP. May play a role in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia.(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).</specific-function>
    <gene-name>IDE</gene-name>
    <locus>10q23-q25</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>6.74</theoretical-pi>
    <molecular-weight>117967.49</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5381</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IDE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M21188</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>184556</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2371</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14735</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IDE_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.24.56</synonym>
      <synonym>Abeta-degrading protease</synonym>
      <synonym>Insulin protease</synonym>
      <synonym>Insulinase</synonym>
      <synonym>Insulysin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037135|Insulin-degrading enzyme
MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED
KREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK
YPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD
REVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE
LLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ
LYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV
GGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV
AFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI
VSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL
EKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELL
KDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE
IIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL
SRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ
QRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA
NGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL
SAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA
REMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016342|Insulin-degrading enzyme (IDE)
ATGAGCAAACTTTGGTTCAAACAAGATGATAAGTTTTTTTTGCCGAAGGCTTGTCTCAAC
TTTGAATTTTTCAGCCCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTG
TACCTTGAGCTCCTCAAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGC
TTGAGCTATGATCTCCAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAAT
GACAAGCAGCCAATTTTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGAT
GAAAAAAGATTTGAAATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCT
GAACAGCCTCACCAGCATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGG
ACTAAAGATGAGTTAAAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTC
ATACCTCAGCTCCTGTCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAG
CAGGCTGCATTAGGAATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACC
AAACCTCTCCTTCCAAGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGA
TGGTTTGTTTATCAGCAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTAC
CAAACAGACATGCAAAGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATC
TCGGAACCTTGCTTCAACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGC
GGGCCACGTCGAGCTAATGGCATACAGGGCTTGAGATTCATCATCCAGTCAGAAAAGCCA
CCTCACTACCTAGAAAGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAG
GACATGACAGAAGAGGCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGAC
AAACCAAAGAAGCTATCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAA
TATAATTTTGACAGAGATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGAT
ATCATCAAATTCTACAAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCC
GTCCATGTTCTTGCCAGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAA
AATGACATAAATTTGTCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATG
ACCGAATTCAAGCGTGGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATG
GCTGCAAAACTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00675</identifier>
        <name>Peptidase_M16</name>
      </pfam>
      <pfam>
        <identifier>PF05193</identifier>
        <name>Peptidase_M16_C</name>
      </pfam>
      <pfam>
        <identifier>PF16187</identifier>
        <name>Peptidase_M16_M</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>peroxisomal matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosolic proteasome complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>peroxisome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>virus receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>beta-endorphin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>insulin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>beta-amyloid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metalloendopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATPase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bradykinin catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>determination of adult lifespan</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein heterooligomerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>beta-amyloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein homooligomerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ubiquitin homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein oligomerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein homotetramerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis involved in cellular protein catabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002124</id>
      <name>Neuroendocrine convertase 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16519" source="Swiss-Prot">
    <name>Neuroendocrine convertase 2</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Responsible for the release of glucagon from proglucagon in pancreatic A cells.</specific-function>
    <gene-name>PCSK2</gene-name>
    <locus>20p11.2</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>6.47</theoretical-pi>
    <molecular-weight>70564.735</molecular-weight>
    <chromosome-location>20</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8744</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PCSK2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J05252</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189652</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2383</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P16519</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NEC2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.94</synonym>
      <synonym>KEX2-like endoprotease 2</synonym>
      <synonym>NEC 2</synonym>
      <synonym>NEC2</synonym>
      <synonym>PC2</synonym>
      <synonym>Prohormone convertase 2</synonym>
      <synonym>Proprotein convertase 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004166|Neuroendocrine convertase 2
MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL
PFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN
MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN
YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM
LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK
GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK
RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN
QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP
STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP
RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI
DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011539|Neuroendocrine convertase 2 (PCSK2)
ATGGTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCAT
AAAGGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAG
CTTCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGA
AGACGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTG
CAGCAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATC
AACATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGAT
GGCACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAA
GGTGTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCC
AACTATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGG
TACACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCC
GCCAACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGG
ATGCTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCA
CAGCTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGAT
GGGCCCCGGGAGCTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGC
AAAGGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGC
GACGGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGG
ACTGCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGG
AAAAGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGG
CATTCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAG
GCTAACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGG
AACCAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAAT
CACCTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGG
AAAACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATA
CCATCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAAT
TTTGTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGA
GACCTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGT
CCAAGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACG
TGGGGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCG
CAGAAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTAC
ATCGACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTG
GAGGAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00082</identifier>
        <name>Peptidase_S8</name>
      </pfam>
      <pfam>
        <identifier>PF01483</identifier>
        <name>P_proprotein</name>
      </pfam>
      <pfam>
        <identifier>PF16470</identifier>
        <name>S8_pro-domain</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perikaryon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nervous system development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>enkephalin processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>islet amyloid polypeptide processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autoprocessing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0001123</id>
      <name>Carboxypeptidase E</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16870" source="Swiss-Prot">
    <name>Carboxypeptidase E</name>
    <general-function>Zinc ion binding</general-function>
    <specific-function>Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.</specific-function>
    <gene-name>CPE</gene-name>
    <locus>4q32.3</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>4.78</theoretical-pi>
    <molecular-weight>53150.185</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2303</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CPE</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29667</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P16870</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CBPE_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.17.10</synonym>
      <synonym>Carboxypeptidase H</synonym>
      <synonym>CPE</synonym>
      <synonym>CPH</synonym>
      <synonym>Enkephalin convertase</synonym>
      <synonym>Prohormone-processing carboxypeptidase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002234|Carboxypeptidase E
MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR
EALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG
RELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS
NAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP
FVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC
RKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED
NKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK
LTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016324|Carboxypeptidase E (CPE)
ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG
TGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC
CGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC
GAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG
CGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT
GAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA
CGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG
ACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT
GGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC
AATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG
AATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT
CAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT
TTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG
ACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC
TTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT
CGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC
AGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC
GTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT
AACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC
CGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC
GATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA
CTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC
CCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG
GAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00246</identifier>
        <name>Peptidase_M14</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type carboxypeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carboxypeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cell adhesion molecule binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metallocarboxypeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>neurexin family protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuropeptide signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein modification process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiac left ventricle morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to membrane</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0002125</id>
      <name>Neuroendocrine convertase 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29120" source="Swiss-Prot">
    <name>Neuroendocrine convertase 1</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin, insulin and AGRP.</specific-function>
    <gene-name>PCSK1</gene-name>
    <locus>5q15-q21</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.84</theoretical-pi>
    <molecular-weight>84150.92</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8743</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PCSK1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X64810</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2382</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P29120</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NEC1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.93</synonym>
      <synonym>NEC 1</synonym>
      <synonym>NEC1</synonym>
      <synonym>PC1</synonym>
      <synonym>Prohormone convertase 1</synonym>
      <synonym>Proprotein convertase 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004168|Neuroendocrine convertase 1
MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ
IGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL
FNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN
YDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM
LDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG
SIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY
TDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL
ANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK
ANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE
RDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH
MKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE
GAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL
YNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016688|Neuroendocrine convertase 1 (PCSK1)
ATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT
GCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC
GGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG
ATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA
AGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA
CAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC
TTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC
CTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA
GTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC
TATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT
GATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA
AATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG
CTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC
GTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT
GGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG
TCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT
GGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC
CCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCAGCGGAGATTAC
ACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC
ACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA
AATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG
GCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA
TTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC
GTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA
GCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT
ATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC
CTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA
CGGGATACATCTCCTAATGGCTTTAAGAATTGGGACTTCATGTCTGTTCACACATGGGGA
GAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT
GAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT
ATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG
GAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC
CTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG
GGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG
CCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC
TACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG
TATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG
CTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00082</identifier>
        <name>Peptidase_S8</name>
      </pfam>
      <pfam>
        <identifier>PF01483</identifier>
        <name>P_proprotein</name>
      </pfam>
      <pfam>
        <identifier>PF16470</identifier>
        <name>S8_pro-domain</name>
      </pfam>
      <pfam>
        <identifier>PF12177</identifier>
        <name>Proho_convert</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptide hormone processing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0001147</id>
      <name>Protein NOV homolog</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P48745" source="Swiss-Prot">
    <name>Protein NOV homolog</name>
    <general-function>Notch binding</general-function>
    <specific-function>Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival (PubMed:15181016, PubMed:15611078, PubMed:12695522, PubMed:21344378, PubMed:12050162). Acts by binding to integrins or membrane receptors such as NOTCH1 (PubMed:12695522, PubMed:21344378, PubMed:15611078). Essential regulator of hematopoietic stem and progenitor cell function (PubMed:17463287). Inhibits myogenic differentiation through the activation of Notch-signaling pathway (PubMed:12050162). Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling (PubMed:20139355). Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival (PubMed:12695522). Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts (PubMed:15611078). Involved in bone regeneration as a negative regulator (By similarity). Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification (PubMed:21871891). Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion (By similarity). Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway (PubMed:21063504). Contributes to the control and coordination of inflammatory processes in atherosclerosis (By similarity). Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement (PubMed:21871891).</specific-function>
    <gene-name>NOV</gene-name>
    <locus>8q24.1</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-31</signal-regions>
    <theoretical-pi>7.74</theoretical-pi>
    <molecular-weight>39161.82</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:7885</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>NOV</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X78351</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>825696</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48745</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NOV_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CCN family member 3</synonym>
      <synonym>CCN3</synonym>
      <synonym>IBP-9</synonym>
      <synonym>IGF-binding protein 9</synonym>
      <synonym>IGFBP-9</synonym>
      <synonym>IGFBP9</synonym>
      <synonym>Insulin-like growth factor-binding protein 9</synonym>
      <synonym>Nephroblastoma-overexpressed gene protein homolog</synonym>
      <synonym>NOVH</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019069|Protein NOV homolog
MQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG
CSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG
EKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS
LGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ
TRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC
CTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019070|Protein NOV homolog (NOV)
ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC
CTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG
GGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC
TGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA
TGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC
ATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA
GAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT
GTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA
GTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA
CTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT
GACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT
GGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG
ACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA
GGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC
TGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC
TGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA
GTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC
AATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00093</identifier>
        <name>VWC</name>
      </pfam>
      <pfam>
        <identifier>PF00219</identifier>
        <name>IGFBP</name>
      </pfam>
      <pfam>
        <identifier>PF00007</identifier>
        <name>Cys_knot</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>proteinaceous extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>gap junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>Notch binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>integrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of SMAD protein import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of chondrocyte proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell death</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endothelial cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type B pancreatic cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of Notch signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hematopoietic stem cell homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endothelial cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of myotube differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell adhesion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0000942</id>
      <name>Low-density lipoprotein receptor-related protein 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P98164" source="Swiss-Prot">
    <name>Low-density lipoprotein receptor-related protein 2</name>
    <general-function>Calcium ion binding</general-function>
    <specific-function>Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.</specific-function>
    <gene-name>LRP2</gene-name>
    <locus>2q24-q31</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>4424-4446</transmembrane-regions>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>4.68</theoretical-pi>
    <molecular-weight>521952.77</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6694</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LRP2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U33837</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>1809240</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P98164</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LRP2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Glycoprotein 330</synonym>
      <synonym>gp330</synonym>
      <synonym>LRP-2</synonym>
      <synonym>Megalin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2
MDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI
GCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC
IPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT
EICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV
CDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN
TSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ
KCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES
QNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK
IYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER
AFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL
IPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT
NPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR
GIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA
NRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL
FFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD
GLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL
KSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE
PPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI
PAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE
KNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC
IGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS
DEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL
GHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL
LANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV
ASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR
RVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD
PRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD
YMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM
YNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC
LRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE
IHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL
IANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH
LECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY
EVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL
FSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV
DVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY
FTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL
DCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP
YGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE
VNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS
LHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV
IASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY
LYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL
TGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI
NTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC
GASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC
DYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR
TCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH
WYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR
HQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC
GYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG
SDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS
GCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP
GYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR
LYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN
GGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII
STKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI
YWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC
LIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD
GSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ
CANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC
GDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH
PVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH
YNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA
YCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH
EVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL
GCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH
CRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD
EEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY
VMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF
WTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD
GTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI
FHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP
CRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL
AIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI
DRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE
IVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP
AKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)
ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA
GCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC
ATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT
GGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC
ATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT
CAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT
ATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT
GACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC
AGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT
GAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT
GTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG
ACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT
TGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT
CATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC
TCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC
ACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG
TGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC
AATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG
AAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG
CGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT
GGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT
CAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG
ACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG
GTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA
ATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT
CGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT
GTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG
GCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT
GGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC
ATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC
ATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA
AAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG
GCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC
AATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA
GATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT
GAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT
GGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT
TCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG
TCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT
AACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG
ACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA
GTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA
TTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC
CTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT
GCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT
GGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC
ATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG
AAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG
AAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT
AACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC
CCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA
CCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC
AATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT
GGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT
CCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC
TGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG
TGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA
AAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA
TGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG
GTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT
ATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA
GGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT
GGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT
GATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC
GGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT
GATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT
GGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT
GGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT
ACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA
CTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT
AGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG
TTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG
GCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA
TTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC
TTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA
AGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT
CGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG
AGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT
CCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG
CGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC
TGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT
TACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG
ATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT
GCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG
TATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC
GTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT
CATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC
TTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC
CTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT
TTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA
ATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG
GGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT
AGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG
ATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT
GCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC
GCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC
CTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA
GGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT
TCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT
GAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT
GTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT
GGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG
TTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA
TATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG
TCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG
GATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT
GATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT
GGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT
TTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC
CGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG
AACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT
GACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA
GTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG
ATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT
TATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC
TTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC
AACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG
GTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG
CCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG
AATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC
TTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT
GTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC
TCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC
ATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT
TATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC
ACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC
CTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC
TTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT
GAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG
ACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC
TATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA
TATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC
AACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG
GGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG
GGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT
GGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT
AATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC
TGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT
GATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC
AATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC
AATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC
ACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT
TTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC
ACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT
TGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT
CACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA
AGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG
CACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT
CCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC
GGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT
GGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC
TATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG
AACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA
TCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC
AAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT
TTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT
GGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT
TACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT
TTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA
GGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT
CTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC
CTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA
TTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC
AAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT
TCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT
GGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT
GATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG
GGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC
TCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC
TGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC
ACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT
TATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT
AGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT
AGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC
CTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT
CAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT
AACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT
GGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC
AGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT
GGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG
TGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG
GATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT
CGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT
GGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC
TTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT
GGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT
CCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT
GGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA
GAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT
TACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT
GAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC
GCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA
TACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA
TGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT
GTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT
GAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT
AGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC
ATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG
GGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC
CAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT
GACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC
TGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT
GACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC
AATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT
GAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT
GTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC
CCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC
GTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT
GTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT
TCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC
TGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC
AACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC
AATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT
GGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT
GAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT
GGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC
TTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC
CTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA
GAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA
TGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG
TGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA
GGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG
GCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG
CTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA
TCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT
GACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA
TTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG
GTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG
ATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG
AATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG
ATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT
GCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC
ACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF12662</identifier>
        <name>cEGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>coated pit</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>apical plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>brush border membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin D metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein glycosylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>forebrain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002126</id>
      <name>Insulin-like growth factor-binding protein 7</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q16270" source="Swiss-Prot">
    <name>Insulin-like growth factor-binding protein 7</name>
    <general-function/>
    <specific-function>Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production. Stimulates cell adhesion.</specific-function>
    <gene-name>IGFBP7</gene-name>
    <locus>4q12</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>7.94</theoretical-pi>
    <molecular-weight>29130.055</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5476</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IGFBP7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L19182</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307151</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q16270</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IBP7_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IBP-7</synonym>
      <synonym>IGFBP-rP1</synonym>
      <synonym>MAC25</synonym>
      <synonym>MAC25 protein</synonym>
      <synonym>PGI2-stimulating factor</synonym>
      <synonym>Prostacyclin-stimulating factor</synonym>
      <synonym>PSF</synonym>
      <synonym>TAF</synonym>
      <synonym>Tumor-derived adhesion factor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004170|Insulin-like growth factor-binding protein 7
MERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC
PMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC
GSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS
CEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK
EDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011540|Insulin-like growth factor-binding protein 7 (IGFBP7)
ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTC
CTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC
CCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC
CCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC
TGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAAGGGTAAAGCCGGGGCA
GCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC
GGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC
GAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT
TCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC
TGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC
TATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC
CGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG
GAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA
GCAAAAATTACAGTGGTTGATGCCTTACATGAAATACCAGTGAAAAAAGGTACACAATAA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
      <pfam>
        <identifier>PF00219</identifier>
        <name>IGFBP</name>
      </pfam>
      <pfam>
        <identifier>PF07648</identifier>
        <name>Kazal_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell growth</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="12">
      <id>BE0002127</id>
      <name>Synaptotagmin-like protein 4</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q96C24" source="Swiss-Prot">
    <name>Synaptotagmin-like protein 4</name>
    <general-function>Zinc ion binding</general-function>
    <specific-function>Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner (By similarity).</specific-function>
    <gene-name>SYTL4</gene-name>
    <locus>-</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.42</theoretical-pi>
    <molecular-weight>76022.99</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:15588</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SYTL4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AK094110</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>21753104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q96C24</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>SYTL4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Exophilin-2</synonym>
      <synonym>Granuphilin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037164|Synaptotagmin-like protein 4
MSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD
RTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY
DQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS
VLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE
TQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL
NVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI
AFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTI
NPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL
HGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA
AKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT
VWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL
RSSMAKQKLGL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011541|Synaptotagmin-like protein 4 (SYTL4)
ATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT
GTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG
AATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT
CGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT
CGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG
AGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT
GACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG
CGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGACA
CAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT
GTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG
AGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA
TCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA
ACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG
AACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA
GAAGATGTGGTACATGAAAGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC
AATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT
CGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC
ATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT
GCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC
CATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC
CTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTATT
AATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG
ACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG
GCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA
CATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG
GTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT
AAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT
GCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC
AAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT
ACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT
GTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT
GGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG
AGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC
CGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00168</identifier>
        <name>C2</name>
      </pfam>
      <pfam>
        <identifier>PF02318</identifier>
        <name>FYVE_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>centrosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>apical plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>exocytic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>clathrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>neurexin family protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>syntaxin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium ion-dependent exocytosis of neurotransmitter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of calcium ion-dependent exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multivesicular body sorting pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vesicle fusion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme>
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <title>Drug Interactions: Cytochrome P450 Drug Interaction Table</title>
            <url>http://medicine.iupui.edu/clinpharm/ddis/table.asp</url>
          </link>
        </links>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
    <name>Cytochrome P450 1A2</name>
    <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
    <gene-name>CYP1A2</gene-name>
    <locus>15q24</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.43</theoretical-pi>
    <molecular-weight>58293.76</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP1A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z00036</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1319</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05177</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP1A2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYPIA2</synonym>
      <synonym>Cytochrome P(3)450</synonym>
      <synonym>Cytochrome P450 4</synonym>
      <synonym>Cytochrome P450-P3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>demethylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>electron carrier activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular respiration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>omega-hydroxylase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monocarboxylic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative deethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to immobilization stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to cadmium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>porphyrin-containing compound metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dibenzo-p-dioxin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>methylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epoxygenase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hydrogen peroxide biosynthetic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-07-20">
  <drugbank-id primary="true">DB00031</drugbank-id>
  <drugbank-id>BTD00019</drugbank-id>
  <drugbank-id>BIOD00019</drugbank-id>
  <name>Tenecteplase</name>
  <description>Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.</description>
  <cas-number>191588-94-0</cas-number>
  <unii>WGD229O42W</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>15650539</pubmed-id>
        <citation>Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7.</citation>
      </article>
      <article>
        <pubmed-id>15744554</pubmed-id>
        <citation>Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50.</citation>
      </article>
      <article>
        <pubmed-id>16084152</pubmed-id>
        <citation>Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88.</citation>
      </article>
      <article>
        <pubmed-id>16380055</pubmed-id>
        <citation>De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2.</citation>
      </article>
      <article>
        <pubmed-id>16488800</pubmed-id>
        <citation>Authors unspecified: Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of myocardial infarction and lysis of intracoronary emboli</indication>
  <pharmacodynamics>Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.</pharmacodynamics>
  <mechanism-of-action>Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>1.9 hours (mammalian reticulocytes, in vitro)&#13;
&gt;20 hours (yeast, in vivo)&#13;
&gt;10 hours (Escherichia coli, in vivo)</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance>* 99 - 119 mL/min [acute myocardial infarction patients]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">TNK-tPA</synonym>
  </synonyms>
  <products>
    <product>
      <name>Tnkase</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02244826</dpd-id>
      <started-marketing-on>2001-10-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TNKase</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-120</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-06-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103909</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>TNKase</name>
      <ingredients>Tenecteplase</ingredients>
    </mixture>
    <mixture>
      <name>Tnkase</name>
      <ingredients>Tenecteplase</ingredients>
    </mixture>
    <mixture>
      <name>Metalyse</name>
      <ingredients>Tenecteplase</ingredients>
    </mixture>
    <mixture>
      <name>Metalyse</name>
      <ingredients>Tenecteplase</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>F Hoffmann-La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
    <packager>
      <name>Genentech Inc.</name>
      <url>http://www.gene.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Tnkase 50 mg kit</description>
      <cost currency="USD">3238.76</cost>
      <unit>kit</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fibrin Modulating Agents</category>
      <mesh-id>D050299</mesh-id>
    </category>
    <category>
      <category>Fibrinolytic Agents</category>
      <mesh-id>D005343</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Plasminogen Activators</category>
      <mesh-id>D010960</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>10000 units</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>8000 units</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AD11">
      <level code="B01AD">Enzymes</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.20</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1BDA</pdb-entry>
  </pdb-entries>
  <patents>
    <patent>
      <number>2129660</number>
      <country>Canada</country>
      <approved>2005-06-28</approved>
      <expires>2013-05-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1341432</number>
      <country>Canada</country>
      <approved>2003-06-17</approved>
      <expires>2020-06-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Tenecteplase may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00102</drugbank-id>
      <name>Becaplermin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Becaplermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Tenecteplase may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux sodium</name>
      <description>Tenecteplase may increase the anticoagulant activities of Fondaparinux sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan Polysulfate</name>
      <description>Tenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Tenecteplase may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic Acid</name>
      <description>Tenecteplase may increase the anticoagulant activities of Edetic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Tenecteplase may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04272</drugbank-id>
      <name>Citric Acid</name>
      <description>Tenecteplase may increase the anticoagulant activities of Citric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Tenecteplase may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Tenecteplase may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Tenecteplase may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Tenecteplase may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Tenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11076</drugbank-id>
      <name>Dextran 70</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dextran 70.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Tenecteplase may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11122</drugbank-id>
      <name>Dextran 40</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dextran 40.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11241</drugbank-id>
      <name>Dextran 75</name>
      <description>Tenecteplase may increase the anticoagulant activities of Dextran 75.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>Tenecteplase may increase the anticoagulant activities of Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Tenecteplase may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Tenecteplase may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Tenecteplase may increase the anticoagulant activities of idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11728</drugbank-id>
      <name>Fondaparinux</name>
      <description>Tenecteplase may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Tenecteplase may increase the anticoagulant activities of Ym150.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Tenecteplase may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Tenecteplase may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Tenecteplase may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Tenecteplase may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>dersalazine</name>
      <description>The risk or severity of adverse effects can be increased when dersalazine is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Anagrelide may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00751</drugbank-id>
      <name>Epinastine</name>
      <description>Epinastine may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00770</drugbank-id>
      <name>Alprostadil</name>
      <description>Alprostadil may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Azelastine may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dipyridamole may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Iloprost may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Epoprostenol may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>Tesmilifene may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Defibrotide may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>SRT501 may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Beraprost may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Prasugrel may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Cangrelor may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Triflusal may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>Ifenprodil may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Vorapaxar may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06392</drugbank-id>
      <name>eplivanserine</name>
      <description>eplivanserine may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00031 sequence
SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG
TCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSA
LAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC
YFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK
PWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAAS
PGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH
KEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL
SPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG
PLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>60 °C</value>
      <source>Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.528</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.61</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>58951.2</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2561H3919N747O781S40</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12468</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D06070</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>L00153</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164776757</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P00750</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000204</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tenecteplase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108791</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/tenecteplase.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/tenecteplase.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP00283</smpdb-id>
      <name>Tenecteplase Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00031</drugbank-id>
          <name>Tenecteplase</name>
        </drug>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Human</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
    <name>Plasminogen</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
    <gene-name>PLG</gene-name>
    <locus>6q26</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>7.25</theoretical-pi>
    <molecular-weight>90568.415</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9071</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X05199</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387026</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2394</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00747</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PLMN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.7</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00051</identifier>
        <name>Kringle</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF00024</identifier>
        <name>PAN_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-substrate adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tissue remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibrinolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000538</id>
      <name>Fibrinogen alpha chain</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>19436656</pubmed-id>
            <citation>Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8.</citation>
          </article>
          <article>
            <pubmed-id>18673235</pubmed-id>
            <citation>Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02671" source="Swiss-Prot">
    <name>Fibrinogen alpha chain</name>
    <general-function>Structural molecule activity</general-function>
    <specific-function>Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.</specific-function>
    <gene-name>FGA</gene-name>
    <locus>4q28</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.87</theoretical-pi>
    <molecular-weight>94972.455</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3661</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF361104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>13591824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P02671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FIBA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fibrinogen alpha chain precursor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001074|Fibrinogen alpha chain
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW
NYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA
NNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC
RGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ
LQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS
GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW
NPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV
SPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK
EVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF
VSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS
YKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS
VYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR
GSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH
NNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG
VVWVSFRGADYSLRAVRMKIRPLVTQ</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)
ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA
GATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG
GAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG
AACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT
TTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG
GATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC
AATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC
CTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA
GCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT
CGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG
CAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC
TTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG
CTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG
TTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA
TCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT
GGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC
TGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA
ACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG
AATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT
GGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT
GGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA
AGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA
GAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA
TGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA
GAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG
TCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC
GACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT
GTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC
AGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC
AAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC
TATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG
AGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT
TCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT
GTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT
GGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT
GACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG
GGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT
CACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC
ACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC
AACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA
GAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC
TACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA
GTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT
AGGCCCCTTGTGACCCAATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00147</identifier>
        <name>Fibrinogen_C</name>
      </pfam>
      <pfam>
        <identifier>PF08702</identifier>
        <name>Fib_alpha</name>
      </pfam>
      <pfam>
        <identifier>PF12160</identifier>
        <name>Fibrinogen_aC</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>fibrinogen complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>blood microparticle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>structural molecule activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>liver regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to genistein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet aggregation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic cyclic compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>induction of bacterial agglutination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to interleukin-6</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to granulocyte colony-stimulating factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation, common pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heterotypic cell-cell adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to morphine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, fibrin clot formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cycloheximide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptide hormone secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>acute-phase response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein polymerization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adaptive immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000717</id>
      <name>Urokinase plasminogen activator surface receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15231724</pubmed-id>
            <citation>Maupas-Schwalm F, Auge N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, Negre-Salvayre A: The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J. 2004 Sep;18(12):1398-400. Epub 2004 Jul 1.</citation>
          </article>
          <article>
            <pubmed-id>11447759</pubmed-id>
            <citation>Bankl HC, Samorapoompichit P, Pikula B, Latinovic L, Bankl H, Lechner K, Valent P: Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol. 2001 Jul;116(1):97-106.</citation>
          </article>
          <article>
            <pubmed-id>12210068</pubmed-id>
            <citation>Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ: Spitz naevi may express components of the plasminogen activation system. J Pathol. 2002 Sep;198(1):92-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q03405" source="Swiss-Prot">
    <name>Urokinase plasminogen activator surface receptor</name>
    <general-function>Urokinase plasminogen activator receptor activity</general-function>
    <specific-function>Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.</specific-function>
    <gene-name>PLAUR</gene-name>
    <locus>19q13</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.64</theoretical-pi>
    <molecular-weight>36977.62</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9053</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLAUR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51675</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q03405</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>UPAR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>MO3</synonym>
      <synonym>Monocyte activation antigen Mo3</synonym>
      <synonym>U-PAR</synonym>
      <synonym>UPAR</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL
ELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC
GSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG
FHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP
MNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV
QYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)
ATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT
TGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC
CTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG
GAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG
ACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG
GGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT
GGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT
GAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA
AAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT
TTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG
GGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG
GGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC
ATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG
CCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT
GTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00021</identifier>
        <name>UPAR_LY6</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>invadopodium membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein domain specific binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>urokinase plasminogen activator receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>attachment of GPI anchor to protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>C-terminal protein lipidation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>urokinase plasminogen activator signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of release of cytochrome c from mitochondria</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="4">
      <id>BE0000240</id>
      <name>Plasminogen activator inhibitor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11163592</pubmed-id>
            <citation>Lindberg P, Kinnby B, Lecander I, Lang NP, Matsson L: Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. Arch Oral Biol. 2001 Jan;46(1):23-31.</citation>
          </article>
          <article>
            <pubmed-id>14564902</pubmed-id>
            <citation>Hattori M, Azami Y: Searching for preventive measures of cardiovascular events in aged Japanese taxi drivers--the daily rhythm of cardiovascular risk factors during a night duty day. J Hum Ergol (Tokyo). 2001 Dec;30(1-2):321-6.</citation>
          </article>
          <article>
            <pubmed-id>17963464</pubmed-id>
            <citation>Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05121" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 1</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.</specific-function>
    <gene-name>SERPINE1</gene-name>
    <locus>7q21.3-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.22</theoretical-pi>
    <molecular-weight>45059.695</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINE1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X04429</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>35272</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05121</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Endothelial plasminogen activator inhibitor</synonym>
      <synonym>PAI</synonym>
      <synonym>PAI1</synonym>
      <synonym>PLANH1</synonym>
      <synonym>Serpin E1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000479|Plasminogen activator inhibitor 1
MQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY
GVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI
FVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV
DQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD
GHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK
FSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS
STAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)
ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA
GGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG
AGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT
GGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG
ATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT
CTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC
TTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC
CGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT
GACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG
GACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT
CCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC
TCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT
GGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT
GCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG
CTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG
TTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC
ATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC
GCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA
TCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC
TTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG
GAACCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>platelet alpha granule lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chronological cell aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-negative bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukotriene production involved in inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell adhesion mediated by integrin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of monocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription initiation from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transforming growth factor beta receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell-matrix adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway via death domain receptors</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular wound healing</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of wound healing</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="5">
      <id>BE0000969</id>
      <name>Plasminogen activator inhibitor 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17141398</pubmed-id>
            <citation>Verkleij-Hagoort AC, Ursem NT, Hop WC, Geurts-Moespot A, Steegers EA, Sweep FC, Steegers-Theunissen RP: Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):47-52. Epub 2006 Dec 1.</citation>
          </article>
          <article>
            <pubmed-id>7958159</pubmed-id>
            <citation>Bremer HA, Brommer EJ, Wallenburg HC: Effects of labor and delivery on fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):163-8.</citation>
          </article>
          <article>
            <pubmed-id>3091604</pubmed-id>
            <citation>Stump DC, Thienpont M, Collen D: Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem. 1986 Sep 25;261(27):12759-66.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05120" source="Swiss-Prot">
    <name>Plasminogen activator inhibitor 2</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.</specific-function>
    <gene-name>SERPINB2</gene-name>
    <locus>18q21.3</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-</signal-regions>
    <theoretical-pi>5.34</theoretical-pi>
    <molecular-weight>46595.84</molecular-weight>
    <chromosome-location>18</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8584</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SERPINB2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02685</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>189545</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05120</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PAI2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Monocyte Arg-serpin</synonym>
      <synonym>PAI-2</synonym>
      <synonym>PAI2</synonym>
      <synonym>Placental plasminogen activator inhibitor</synonym>
      <synonym>PLANH2</synonym>
      <synonym>Serpin B2</synonym>
      <synonym>Urokinase inhibitor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016268|Plasminogen activator inhibitor 2
MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF
NEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN
YLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK
IPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK
LNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM
AEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV
DVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016269|Plasminogen activator inhibitor 2 (SERPINB2)
ATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA
AAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC
ATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT
AATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG
TTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA
GATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT
TATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA
TATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA
TGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA
ATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT
GCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT
CCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG
CTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA
GATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG
CTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG
GCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC
AGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC
TCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG
GATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA
ACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCTTTTCTTTTTCTTATTATGCAT
AAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00079</identifier>
        <name>Serpin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="6">
      <id>BE0002104</id>
      <name>Tetranectin</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>12694198</pubmed-id>
            <citation>Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE: Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003 Apr;270(8):1850-4.</citation>
          </article>
          <article>
            <pubmed-id>9034981</pubmed-id>
            <citation>Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J: Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol. 1997 Feb;24(2):262-8.</citation>
          </article>
          <article>
            <pubmed-id>17853709</pubmed-id>
            <citation>Vuckovic B, Deric M: [Lipoprotein(a): a link between thrombogenesis and atherogenesis]. Med Pregl. 2007 Jan-Feb;60(1-2):37-41.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05452" source="Swiss-Prot">
    <name>Tetranectin</name>
    <general-function>Kringle domain binding</general-function>
    <specific-function>Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis.</specific-function>
    <gene-name>CLEC3B</gene-name>
    <locus>3p22-p21.3</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>5.36</theoretical-pi>
    <molecular-weight>22536.665</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11891</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CLEC3B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X64559</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>37409</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05452</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TETN_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>C-type lectin domain family 3 member B</synonym>
      <synonym>Plasminogen kringle 4-binding protein</synonym>
      <synonym>TN</synonym>
      <synonym>TNA</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011525|Tetranectin
MELWGAYLLLCLFSLLTQVTTEPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVAL
LKEQQALQTVCLKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLGTPQTGSENDALYEY
LRQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTENCAVLSGAA
NGKWFDKRCRDQLPYICQFGIV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0004125|609 bp
ATGGAGCTCTGGGGGGCCTACCTCCTCCTCTGCCTCTTCTCCCTCCTGACCCAGGTCACC
ACCGAGCCACCAACCCAGAAGCCCAAGAAGATTGTAAATGCCAAGAAAGATGTTGTGAAC
ACAAAGATGTTTGAGGAGCTCAAGAGCCGTCTGGACACCCTGGCCCAGGAGGTGGCCCTG
CTGAAGGAGCAGCAGGCCCTGCAGACGGTCTGCCTGAAGGGGACCAAGGTGCACATGAAA
TGCTTTCTGGCCTTCACCCAGACGAAGACCTTCCACGAGGCCAGCGAGGACTGCATCTCG
CGCGGGGGCACCCTGAGCACCCCTCAGACTGGCTCGGAGAACGACGCCCTGTATGAGTAC
CTGCGCCAGAGCGTGGGCAACGAGGCCGAGATCTGGCTGGGCCTCAACGACATGGCGGCC
GAGGGCACCTGGGTGGACATGACCGGCGCCCGCATCGCCTACAAGAACTGGGAGACTGAG
ATCACCGCGCAACCCGATGGCGGCAAGACCGAGAACTGCGCGGTCCTGTCAGGCGCGGCC
AACGGCAAGTGGTTCGACAAGCGCTGCCGCGATCAGCTGCCCTACATCTGCCAGTTCGGG
ATCGTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00059</identifier>
        <name>Lectin_C</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>granular component</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>kringle domain binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to organic substance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to transforming growth factor beta stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal system development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ossification</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="7">
      <id>BE0002105</id>
      <name>Keratin, type II cytoskeletal 8</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>9988531</pubmed-id>
            <citation>Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL: Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem. 1998 Nov;17(8):845-54.</citation>
          </article>
          <article>
            <pubmed-id>8760360</pubmed-id>
            <citation>Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J. 1996 Aug 1;317 ( Pt 3):763-9.</citation>
          </article>
          <article>
            <pubmed-id>8810346</pubmed-id>
            <citation>Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996 Oct 11;271(41):25684-91.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05787" source="Swiss-Prot">
    <name>Keratin, type II cytoskeletal 8</name>
    <general-function>Structural molecule activity</general-function>
    <specific-function>Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.</specific-function>
    <gene-name>KRT8</gene-name>
    <locus>12q13</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>5.26</theoretical-pi>
    <molecular-weight>53703.76</molecular-weight>
    <chromosome-location/>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6446</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>KRT8</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M34482</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181573</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05787</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>K2C8_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CK-8</synonym>
      <synonym>CYK8</synonym>
      <synonym>Cytokeratin-8</synonym>
      <synonym>K8</synonym>
      <synonym>Keratin-8</synonym>
      <synonym>Type-II keratin Kb8</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004128|Keratin, type II cytoskeletal 8
MSIRVTQKSYKVSTSGPRAFSSRSYTSGPGSRISSSSFSRVGSSNFRGGLGGGYGGASGM
GGITAVTVNQSLLSPLVLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLE
TKWSLLQQQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKNKYE
DEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQLYEEEIRELQSQIS
DTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAEAESMYQIKYEELQSLAGKHGDDL
RRTKTEISEMNRNISRLQAEIEGLKGQRASLEAAIADAEQRGELAIKDANAKLSELEAAL
QRAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYA
GGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSESSDV
LPK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0004127|1449 bp
ATGTCCATCAGGGTGACCCAGAAGTCCTACAAGGTGTCCACCTCTGGCCCCCGGGCCTTC
AGCAGCCGCTCCTACACGAGTGGGCCCGGTTCCCGCATCAGCTCCTCGAGCTTCTCCCGA
GTGGGCAGCAGCAACTTTCGCGGTGGCCTGGGCGGCGGCTATGGTGGGGCCAGCGGCATG
GGAGGCATCACCGCAGTTACGGTCAACCAGAGCCTGCTGAGCCCCCTTGTCCTGGAGGTG
GACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCTCAACAAC
AAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTGGAGCAGCAGAACAAGATGCTGGAG
ACCAAGTGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAGCAACATGGACAACATGTTC
GAGAGCTACATCAACAACCTTAGGCGGCAGCTGGAGACTCTGGGCCAGGAGAAGCTGAAG
CTGGAGGCGGAGCTTGGCAACATGCAGGGGCTGGTGGAGGACTTCAAGAACAAGTATGAG
GATGAGATCAATAAGCGTACAGAGATGGAGAACGAATTTGTCCTCATCAAGAAGGATGTG
GATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAG
ATCAACTTCCTCAGGCAGCTATATGAAGAGGAGATCCGGGAGCTGCAGTCCCAGATCTCG
GACACATCTGTGGTGCTGTCCATGGACAACAGCCGCTCCCTGGACATGGACAGCATCATT
GCTGAGGTCAAGGCACAGTACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCTGAGAGC
ATGTACCAGATCAAGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCACGGGGATGACCTG
CGGCGCACAAAGACTGAGATCTCTGAGATGAACCGGAACATCAGCCGGCTCCAGGCTGAG
ATTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAGGCCGCCATTGCAGATGCCGAGCAG
CGTGGAGAGCTGGCCATTAAGGATGCCAACGCCAAGTTGTCCGAGCTGGAGGCCGCCCTG
CAGCGGGCCAAGCAGGACATGGCGCGGCAGCTGCGTGAGTACCAGGAGCTGATGAACGTC
AAGCTGGCCCTGGACATCGAGATCGCCACCTACAGGAAGCTGCTGGAGGGCGAGGAGAGC
CGGCTGGAGTCTGGGATGCAGAACATGAGTATTCATACGAAGACCACCGGCGGCTATGCA
GGTGGTCTGAGCTCGGCCTATGGGGGCTCACAAGCCGGCCTCAGCTACAGCCTGGGCTCC
AGCTTTGGCTCTGGCGCGGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAGGGCCGTG
GTTGTGAAGAAGATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTCCTCTGACGTCCTG
CCCAAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00038</identifier>
        <name>Filament</name>
      </pfam>
      <pfam>
        <identifier>PF16208</identifier>
        <name>Keratin_2_head</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intermediate filament</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>keratin filament</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcolemma</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Z disc</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>costamere</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell-cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dystrophin-associated glycoprotein complex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>structural molecule activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>scaffold protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>tumor necrosis factor-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to hydrostatic pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sarcomere organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hepatocyte apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell differentiation involved in embryonic placenta development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to other organism</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="8">
      <id>BE0001170</id>
      <name>Annexin A2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15194650</pubmed-id>
            <citation>Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004 Jul;53(7):993-1000.</citation>
          </article>
          <article>
            <pubmed-id>10578524</pubmed-id>
            <citation>Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med. 1999 Apr-May;9(3-4):92-102.</citation>
          </article>
          <article>
            <pubmed-id>12730231</pubmed-id>
            <citation>MacLeod TJ, Kwon M, Filipenko NR, Waisman DM: Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003 Jul 11;278(28):25577-84. Epub 2003 Apr 30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07355" source="Swiss-Prot">
    <name>Annexin A2</name>
    <general-function>S100 protein binding</general-function>
    <specific-function>Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:24808179, PubMed:22848640).</specific-function>
    <gene-name>ANXA2</gene-name>
    <locus>15q21-q22</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>7.91</theoretical-pi>
    <molecular-weight>38603.63</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:537</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>ANXA2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D00017</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>219910</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P07355</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>ANXA2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Annexin II</synonym>
      <synonym>Annexin-2</synonym>
      <synonym>ANX2</synonym>
      <synonym>ANX2L4</synonym>
      <synonym>CAL1H</synonym>
      <synonym>Calpactin I heavy chain</synonym>
      <synonym>Calpactin-1 heavy chain</synonym>
      <synonym>Chromobindin-8</synonym>
      <synonym>Lipocortin II</synonym>
      <synonym>LPC2D</synonym>
      <synonym>p36</synonym>
      <synonym>PAP-IV</synonym>
      <synonym>Placental anticoagulant protein IV</synonym>
      <synonym>Protein I</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002327|Annexin A2
MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL
TNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKG
LGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRA
EDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDM
LESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDM
LKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010817|Annexin A2 (ANXA2)
ATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCC
CCAAGTGCATATGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTG
AACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTG
ACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAA
AAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTG
GGCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGG
CTGGGAACCGACGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTG
CAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATT
TCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCA
GAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGAC
GCTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGG
AGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATG
TTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTT
CAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGC
AAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATG
TTGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAG
CAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00191</identifier>
        <name>Annexin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>lipid particle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>myelin sheath adaxonal region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basolateral plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>PCSK9-AnxA2 complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ruffle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basement membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Schmidt-Lanterman incisure</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcolemma</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extrinsic component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>melanosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>late endosome membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>midbody</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>macropinosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipase A2 inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>S100 protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phosphatidylinositol-4,5-bisphosphate binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of receptor internalization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>osteoclast development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibrinolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein targeting to plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vesicle fusion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane budding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane raft assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>body fluid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of catalytic activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of low-density lipoprotein particle receptor catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>collagen fibril organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein heterotetramerization</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="9">
      <id>BE0002109</id>
      <name>Calreticulin</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>9359841</pubmed-id>
            <citation>Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27797" source="Swiss-Prot">
    <name>Calreticulin</name>
    <general-function>Zinc ion binding</general-function>
    <specific-function>Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).</specific-function>
    <gene-name>CALR</gene-name>
    <locus>19p13.3-p13.2</locus>
    <cellular-location>Endoplasmic reticulum lumen</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>4.04</theoretical-pi>
    <molecular-weight>48141.2</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1455</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CALR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M32294</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>337487</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P27797</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CALR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Calregulin</synonym>
      <synonym>CRP55</synonym>
      <synonym>CRTC</synonym>
      <synonym>Endoplasmic reticulum resident protein 60</synonym>
      <synonym>ERp60</synonym>
      <synonym>grp60</synonym>
      <synonym>HACBP</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011528|Calreticulin
MLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE
EKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT
DMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN
TYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE
HIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS
PDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK
QDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011529|Calreticulin (CALR)
ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCC
GTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC
AAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG
GAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT
TTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG
CAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA
GACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC
ACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC
ATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC
ACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG
GACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT
GAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG
CATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG
TGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC
GACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT
CCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG
GTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG
GAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA
CAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG
GAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC
AAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00262</identifier>
        <name>Calreticulin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>proteinaceous extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>acrosomal vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>smooth endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>MHC class I peptide loading complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>polysome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>integrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>chaperone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>complement component C1q binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>zinc ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein binding involved in protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>unfolded protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ubiquitin protein ligase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>androgen receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>DNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>mRNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phagocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cortical actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chaperone-mediated protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lithium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ATF6-mediated unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiac muscle cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein maturation by protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell cycle arrest</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular senescence</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to testosterone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sequestering of calcium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of intracellular steroid hormone receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucocorticoid receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA replication</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of substrate adhesion-dependent cell spreading</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of retinoic acid receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptide antigen assembly with MHC class I protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular calcium ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dendritic cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein export from nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of translation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endoplasmic reticulum unfolded protein response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of meiotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein stabilization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="10">
      <id>BE0001011</id>
      <name>Calnexin</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>9359841</pubmed-id>
            <citation>Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P27824" source="Swiss-Prot">
    <name>Calnexin</name>
    <general-function>Poly(a) rna binding</general-function>
    <specific-function>Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.</specific-function>
    <gene-name>CANX</gene-name>
    <locus>5q35</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions>482-502</transmembrane-regions>
    <signal-regions>1-20</signal-regions>
    <theoretical-pi>4.21</theoretical-pi>
    <molecular-weight>67567.695</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:1473</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CANX</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L10284</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>186523</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P27824</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CALX_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IP90</synonym>
      <synonym>Major histocompatibility complex class I antigen-binding protein p88</synonym>
      <synonym>p90</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002013|Calnexin
MEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY
KAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL
VLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH
DKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL
ILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK
PDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC
ESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS
AIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER
PWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE
EEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016282|Calnexin (CANX)
ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT
CATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA
GAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC
AAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG
TCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT
GATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT
GTGTTGATGTCTCGGGCCAAGCATCATGCCATCTCTGCTAAACTGAACAAGCCCTTCCTG
TTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT
GGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT
GACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG
CACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG
AGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA
ATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA
AATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA
GACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG
CCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC
GAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG
GATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT
GAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA
GGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG
AAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT
GCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT
TGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT
GCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC
CCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC
TTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT
CAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG
GAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT
GGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG
AACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00262</identifier>
        <name>Calreticulin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>dendritic spine</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>myelin sheath</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>rough endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>smooth endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ribosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>ER-mitochondrion membrane contact site</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>melanosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of lumenal side of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>carbohydrate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>clathrin-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of peptide antigen via MHC class I</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein N-linked glycosylation via asparagine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chaperone-mediated protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>antigen processing and presentation of exogenous peptide antigen via MHC class II</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein folding in endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle endocytosis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="11">
      <id>BE0002110</id>
      <name>Prolow-density lipoprotein receptor-related protein 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>8344937</pubmed-id>
            <citation>Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, Christensen EI: Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem. 1993 Aug 5;268(22):16564-70.</citation>
          </article>
          <article>
            <pubmed-id>1378833</pubmed-id>
            <citation>Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, et al.: Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 Jul 25;267(21):14543-6.</citation>
          </article>
          <article>
            <pubmed-id>16303771</pubmed-id>
            <citation>Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006 Jan 27;281(4):2120-7. Epub 2005 Nov 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q07954" source="Swiss-Prot">
    <name>Prolow-density lipoprotein receptor-related protein 1</name>
    <general-function>Receptor activity</general-function>
    <specific-function>Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.</specific-function>
    <gene-name>LRP1</gene-name>
    <locus>12q13-q14</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>4420-4444</transmembrane-regions>
    <signal-regions>1-19</signal-regions>
    <theoretical-pi>5.02</theoretical-pi>
    <molecular-weight>504601.695</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6692</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LRP1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X13916</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>34339</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q07954</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LRP1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>A2MR</synonym>
      <synonym>Alpha-2-macroglobulin receptor</synonym>
      <synonym>APOER</synonym>
      <synonym>Apolipoprotein E receptor</synonym>
      <synonym>APR</synonym>
      <synonym>LRP-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1
MLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA
PEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC
QHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL
LQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE
TVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI
DDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK
LVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE
NYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN
DQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG
MDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG
IHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG
WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY
DRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT
LLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV
TCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF
KCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD
CGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF
KCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW
RCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC
ESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP
GEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES
CRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK
IYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT
LLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT
VDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT
LAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT
VSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL
DYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN
KKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG
QKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW
WADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL
CLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG
TSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY
WTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG
TERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS
VSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA
VANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL
NAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE
NVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD
ECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK
IERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI
PQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV
NSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS
NMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS
ATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY
FACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG
DGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD
REFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG
ENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH
INECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH
GSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV
ALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD
KGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR
SVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF
EDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG
CSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG
DHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC
TNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV
DGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ
FRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC
ADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ
CNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD
NCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP
KLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN
TKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV
RIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP
RGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW
GNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI
VAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH
QHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC
NLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT
GFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM
AADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH
CSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV
VFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT
NFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)
ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT
ATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT
ATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC
CCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG
GGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC
GGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC
CAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG
CTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC
AGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC
CTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG
CTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT
ACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG
ACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC
ATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC
CACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC
GATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG
GAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT
GACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG
CTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT
GTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC
CGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG
AATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC
CGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT
GCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC
GACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG
GCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG
AAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC
ATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC
CCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC
TACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC
ATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC
GATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG
ACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG
TGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG
AGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG
CCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC
GACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT
GAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT
CGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC
CTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG
CAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC
ACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC
ACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC
TGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG
GACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC
AAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT
GGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG
TTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC
TGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT
CAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT
GACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC
AAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC
GGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT
GGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG
CGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG
ACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC
AAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC
GAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG
CCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG
CTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT
GGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC
TGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC
AAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC
TGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG
CGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC
GCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG
ATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG
TATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG
GTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC
CTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC
CTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG
GCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC
GTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA
GCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC
CCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA
CTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC
CAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT
GAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC
GTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG
TTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT
CCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA
GACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG
CGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC
CACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT
AAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC
CTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT
GGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC
CAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC
TCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT
GCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG
TGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC
GTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC
CAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC
TGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG
AGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA
ATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG
ACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC
ATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG
ACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC
TGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC
GTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG
TACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC
ACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC
TACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC
CTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA
GTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC
AAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC
CAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG
GTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC
GCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC
CTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC
AATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC
TTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC
CACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA
AACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA
AGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC
GAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC
GAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG
GCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT
GGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG
ATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC
CACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG
GCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC
CCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT
CCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT
GTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG
AATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC
AGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC
TGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC
AACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC
AACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC
TCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT
GCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC
GAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG
GACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC
TTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC
TGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG
TGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG
GATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC
TGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT
GCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC
CGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC
CGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC
AGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC
GAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA
GAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG
GCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC
ATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG
ATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT
GCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT
GGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC
TGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC
AAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT
GCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC
AGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC
CTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC
AAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC
AGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC
TGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC
AGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT
GAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC
TCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT
GAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC
ACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC
TTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC
TGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC
TTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA
TGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG
GACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG
TGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG
GACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC
ACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA
GATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC
TCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG
GATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC
TGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT
GGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG
TTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT
TGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC
TCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC
GCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC
AAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC
GGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG
TGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG
GACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC
TTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC
AACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC
TGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC
TGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC
AAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC
ACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC
GGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC
ACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC
AAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC
CTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC
CGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC
ACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC
CACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC
AGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT
GTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT
GACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG
GGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG
CAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC
TGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT
GTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT
TACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC
AGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT
CAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC
CTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC
ACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT
AACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC
CGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT
CGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG
GGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC
ACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC
GACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG
GCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG
GTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT
GTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC
TGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA
CCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT
ATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG
GTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC
AACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG
CCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC
AACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC
CTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG
GACCCCTTGGCATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07645</identifier>
        <name>EGF_CA</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00058</identifier>
        <name>Ldl_recept_b</name>
      </pfam>
      <pfam>
        <identifier>PF12662</identifier>
        <name>cEGF</name>
      </pfam>
      <pfam>
        <identifier>PF16472</identifier>
        <name>DUF5050</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>dendrite</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>coated pit</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleolus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endocytic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipoprotein particle receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>apolipoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipoprotein transporter activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein complex binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>poly(A) RNA binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of lipid transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>receptor-mediated endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aorta morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron projection development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cholesterol transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoprotein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>beta-amyloid clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cholesterol efflux</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic cell clearance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of platelet-derived growth factor receptor-beta signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of actin cytoskeleton organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of phospholipase A2 activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoprotein transport</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-06-26">
  <drugbank-id primary="true">DB00032</drugbank-id>
  <drugbank-id>BTD00018</drugbank-id>
  <drugbank-id>BIOD00018</drugbank-id>
  <name>Menotropins</name>
  <description>Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women.  It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.</description>
  <cas-number>9002-68-0</cas-number>
  <unii>5Y9QQM372Q</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of female infertility</indication>
  <pharmacodynamics>Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.</pharmacodynamics>
  <mechanism-of-action>Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Human menopausal gonadotrophin</synonym>
    <synonym language="" coder="">Menotrophin</synonym>
    <synonym language="" coder="">Menotropin</synonym>
    <synonym language="" coder="">Menotropins (FSH;LH)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Menopur</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-7501</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA021663</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Menopur</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02283093</dpd-id>
      <started-marketing-on>2006-09-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>75 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Repronex</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02247790</dpd-id>
      <started-marketing-on>2003-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>75 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Repronex</name>
      <ingredients>Menotropins</ingredients>
    </mixture>
    <mixture>
      <name>Menopur</name>
      <ingredients>Menotropins</ingredients>
    </mixture>
    <mixture>
      <name>Menopur</name>
      <ingredients>Menotropins</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Ferring Pharmaceuticals Inc.</name>
      <url>http://www.ferring.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Menopur 75 unit vial</description>
      <cost currency="USD">93.85</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Repronex 75 unit vial</description>
      <cost currency="USD">93.85</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Repronex 5 75 unit Solution 1 Box Contains Five 1ml Vials</description>
      <cost currency="USD">488.04</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Fertility Agents</category>
      <mesh-id>D005299</mesh-id>
    </category>
    <category>
      <category>Fertility Agents, Female</category>
      <mesh-id>D005300</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropins</category>
      <mesh-id>D006062</mesh-id>
    </category>
    <category>
      <category>Gonadotropins, Pituitary</category>
      <mesh-id>D006065</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones</category>
      <mesh-id>D010907</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones, Anterior</category>
      <mesh-id>D010908</mesh-id>
    </category>
    <category>
      <category>Reproductive Control Agents</category>
      <mesh-id>D012102</mesh-id>
    </category>
    <category>
      <category>Sex Hormones and Modulators of the Genital System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>75 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G03GA02">
      <level code="G03GA">Gonadotropins</level>
      <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:18.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1FLZ</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00032.pdf?1265922809</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;AlphaChain (LH)
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
    <sequence format="FASTA">&gt;BetaChain (LH)
SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR
DVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF
L</sequence>
    <sequence format="FASTA">&gt;AlphaChain (FSH)
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
    <sequence format="FASTA">&gt;BetaChain (FSH)
NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET
VRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>55 °C</value>
      <source>Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.063</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.44</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>23390.3</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1014H1609N287O294S27</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7369</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X00264</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749406</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01229</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001027</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Menotropins</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108427</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/menotropins.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/menotropins.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000387</id>
      <name>Follicle-stimulating hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>14680547</pubmed-id>
            <citation>van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57.</citation>
          </article>
          <article>
            <pubmed-id>7872378</pubmed-id>
            <citation>Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P23945" source="Swiss-Prot">
    <name>Follicle-stimulating hormone receptor</name>
    <general-function>G-protein coupled peptide receptor activity</general-function>
    <specific-function>Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.</specific-function>
    <gene-name>FSHR</gene-name>
    <locus>2p21-p16</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>367-387
399-421
444-465
486-508
529-550
574-597
609-630</transmembrane-regions>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>7.19</theoretical-pi>
    <molecular-weight>78264.07</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3969</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FSHR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M65085</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182771</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>253</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>253</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P23945</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FSHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Follitropin receptor</synonym>
      <synonym>FSH-R</synonym>
      <synonym>LGR1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037007|Follicle-stimulating hormone receptor
MALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV
IQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP
NLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN
GIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN
LKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE
VDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM
GYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS
VDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK
VQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL
AFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP
LITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS
TVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018946|Follicle-stimulating hormone receptor (FSHR)
ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT
CGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT
CCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC
ATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT
GATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT
AGAATTGAAAAGGCCAACAACCTGCTCTACATCAACCCTGAGGCCTTCCAGAACCTTCCC
AACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG
ATTCATTCTCTCCAAAAAGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT
GAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT
GGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGAGCTGAATCTA
AGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA
GTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT
CTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG
CTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC
TGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA
GTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC
AGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA
GTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG
GGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC
ATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT
ATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA
GTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA
GGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG
ACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG
GTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT
GCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG
GATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG
GCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC
ATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT
GACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC
CTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT
GCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG
CTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC
ACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT
GGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF01462</identifier>
        <name>LRRNT</name>
      </pfam>
      <pfam>
        <identifier>PF13306</identifier>
        <name>LRR_5</name>
      </pfam>
      <pfam>
        <identifier>PF12369</identifier>
        <name>GnHR_trans</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>follicle-stimulating hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled peptide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>uterus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of protein kinase A signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of osteoclast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female gamete generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>follicle-stimulating hormone signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>primary ovarian follicle growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000134</id>
      <name>Lutropin-choriogonadotropic hormone receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>14680547</pubmed-id>
            <citation>van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57.</citation>
          </article>
          <article>
            <pubmed-id>7872378</pubmed-id>
            <citation>Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22888" source="Swiss-Prot">
    <name>Lutropin-choriogonadotropic hormone receptor</name>
    <general-function>Luteinizing hormone receptor activity</general-function>
    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.</specific-function>
    <gene-name>LHCGR</gene-name>
    <locus>2p21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>364-385
396-416
440-462
483-505
526-549
571-594
606-627</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>78642.01</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6585</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LHCGR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M73746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>903746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P22888</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LSHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>LCGR</synonym>
      <synonym>LGR2</synonym>
      <synonym>LH/CG-R</synonym>
      <synonym>LHR</synonym>
      <synonym>LHRHR</synonym>
      <synonym>LSH-R</synonym>
      <synonym>Luteinizing hormone receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor
MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
SKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)
ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG
CTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC
GCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT
GTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC
TCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG
TCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA
AATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT
GTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC
ATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA
CTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT
TCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG
GCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT
GGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA
TCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT
GCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT
TCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG
CTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA
CCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC
TTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT
CTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT
CTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC
CAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC
ACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC
ACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA
AGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG
CCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA
ACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC
ATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT
ACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC
TGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA
GTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA
TTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA
TTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC
TCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG
TCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF13306</identifier>
        <name>LRR_5</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>luteinizing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled peptide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to gonadotropin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cognition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>luteinizing hormone signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male genitalia development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation cycle process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inositol trisphosphate biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>uterus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-02-10">
  <drugbank-id primary="true">DB00033</drugbank-id>
  <drugbank-id>BTD00017</drugbank-id>
  <drugbank-id>BIOD00017</drugbank-id>
  <name>Interferon gamma-1b</name>
  <description>Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. &#13;
The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.</description>
  <cas-number>98059-61-1</cas-number>
  <unii>21K6M2I7AG</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>55526</pubmed-id>
        <citation>Kantoch M, Dobrowolska H, Jarzabek Z, Jankowski M, Sadowski W, Janicki P: [Distribution and characteristics of Poliovirus strains circulating in Poland in 1968-1972. Genetic variation of strains isolated in various secretion periods and clones isolated from vaccines]. Med Dosw Mikrobiol. 1975;27(4):353-63.</citation>
      </article>
      <article>
        <pubmed-id>3458</pubmed-id>
        <citation>Ormas P, Pompa G, Beretta C, Faustini R: [The effects of some polypeptides on the systemic blood pressure of sheep (author's transl)]. Folia Vet Lat. 1975 Jan-Mar;5(1):45-54.</citation>
      </article>
      <article>
        <pubmed-id>15978</pubmed-id>
        <citation>Selitrennikoff CP, Sonneborn DR: Alkaline phosphatase of Blastocladiella emersonii: partial purification and characterization. J Bacteriol. 1977 Apr;130(1):249-56.</citation>
      </article>
      <article>
        <pubmed-id>6180322</pubmed-id>
        <citation>Gray PW, Goeddel DV: Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859-63.</citation>
      </article>
      <article>
        <pubmed-id>1902591</pubmed-id>
        <citation>Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE: Three-dimensional structure of recombinant human interferon-gamma. Science. 1991 May 3;252(5006):698-702.</citation>
      </article>
      <article>
        <pubmed-id>11900986</pubmed-id>
        <citation>Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109.</citation>
      </article>
      <article>
        <pubmed-id>12401479</pubmed-id>
        <citation>Chesler DA, Reiss CS: The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002 Dec;13(6):441-54.</citation>
      </article>
      <article>
        <pubmed-id>15361241</pubmed-id>
        <citation>Dessein A, Kouriba B, Eboumbou C, Dessein H, Argiro L, Marquet S, Elwali NE, Rodrigues V, Li Y, Doumbo O, Chevillard C: Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev. 2004 Oct;201:180-90.</citation>
      </article>
      <article>
        <pubmed-id>15638726</pubmed-id>
        <citation>Joseph AM, Kumar M, Mitra D: Nef: "necessary and enforcing factor" in HIV infection. Curr HIV Res. 2005 Jan;3(1):87-94.</citation>
      </article>
      <article>
        <pubmed-id>16375755</pubmed-id>
        <citation>Copeland KF: Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem. 2005 Dec;5(12):1093-101.</citation>
      </article>
      <article>
        <pubmed-id>14525967</pubmed-id>
        <citation>Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004 Feb;75(2):163-89. Epub 2003 Oct 2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Irwin A. Braude, "Production of human IFN-gamma (immune) interferon." U.S. Patent US4376821, issued December, 1975.</synthesis-reference>
  <indication>Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.</indication>
  <pharmacodynamics>IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring.</pharmacodynamics>
  <mechanism-of-action>Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">IFN-gamma-1b</synonym>
    <synonym language="" coder="">Interferon gamma-1b, recombinant</synonym>
    <synonym language="" coder="">Interferon gamma-2a</synonym>
  </synonyms>
  <products>
    <product>
      <name>Actimmune</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75987-111</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103836</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Actimmune</name>
      <labeller>Hznp Usa, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42238-111</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 ug/.5mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103836</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Immukin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Actimmune</name>
      <ingredients>Interferon gamma-1b</ingredients>
    </mixture>
    <mixture>
      <name>Actimmune</name>
      <ingredients>Interferon gamma-1b</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>InterMune Inc.</name>
      <url>http://www.intermune.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Actimmune 2 million unit vial</description>
      <cost currency="USD">344.4</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors</category>
      <mesh-id>D065609</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inhibitors (weak)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Lymphokines</category>
      <mesh-id>D008222</mesh-id>
    </category>
    <category>
      <category>Macrophage-Activating Factors</category>
      <mesh-id>D016215</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 ug/.5mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1AU1</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00033.pdf?1265922805</fda-label>
  <patents>
    <patent>
      <number>6936695</number>
      <country>United States</country>
      <approved>2005-08-30</approved>
      <expires>2022-08-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6936694</number>
      <country>United States</country>
      <approved>2005-08-30</approved>
      <expires>2022-08-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The serum concentration of Tizanidine can be increased when it is combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00033 sequence
CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLF
KNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM
AELSPAAKTGKRKRSQMLFRGRRASQ</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C</value>
      <source>Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.823</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.54</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>17145.6</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C761H1206N214O225S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X13274</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164746386</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01579</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001286</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Interferon_gamma-1b</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201564</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/interferon-gamma-1b.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000711</id>
      <name>Interferon gamma receptor 1</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17251453</pubmed-id>
            <citation>Matsuda A, Ebihara N, Kumagai N, Fukuda K, Ebe K, Hirano K, Sotozono C, Tei M, Hasegawa K, Shimizu M, Tamari M, Namba K, Ohno S, Mizuki N, Ikezawa Z, Shirakawa T, Hamuro J, Kinoshita S: Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9.</citation>
          </article>
          <article>
            <pubmed-id>17618444</pubmed-id>
            <citation>Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-71. Epub 2007 Jul 6.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P15260" source="Swiss-Prot">
    <name>Interferon gamma receptor 1</name>
    <general-function>Interferon-gamma receptor activity</general-function>
    <specific-function>Receptor for interferon gamma. Two receptors bind one interferon gamma dimer.</specific-function>
    <gene-name>IFNGR1</gene-name>
    <locus>6q23-q24</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>246-266</transmembrane-regions>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>4.56</theoretical-pi>
    <molecular-weight>54404.07</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5439</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNGR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03143</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306915</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P15260</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INGR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CDw119</synonym>
      <synonym>IFN-gamma receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001418|Interferon gamma receptor 1
MALLFLLPLVMQGVSRAEMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFT
VEVKNYGVKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVGQKESAYAKSEEFA
VCRDGKIGPPKLDIRKEEKQIMIDIFHPSVFVNGDEQEVDYDPETTCYIRVYNVYVRMNG
SEIQYKILTQKEDDCDEIQCQLAIPVSSLNSQYCVSAEGVLHVWGVTTEKSKEVCITIFN
SSIKGSLWIPVVAALLLFLVLSLVFICFYIKKINPLKEKSIILPKSLISVVRSATLETKP
ESKYVSLITSYQPFSLEKEVVCEEPLSPATVPGMHTEDNPGKVEHTEELSSITEVVTTEE
NIPDVVPGSHLTPIERESSSPLSSNQSEPGSIALNSYHSRNCSESDHSRNGFDTDSSCLE
SHSSLSDSEFPPNNKGEIKTEGQELITVIKAPTSFGYDKPHVLVDLLVDDSGKESLIGYR
PTEDSKEFS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010499|Interferon gamma receptor 1 (IFNGR1)
ATGGCTCTCCTCTTTCTCCTACCCCTTGTCATGCAGGGTGTGAGCAGGGCTGAGATGGGC
ACCGCGGATCTGGGGCCGTCCTCAGTGCCTACACCAACTAATGTTACAATTGAATCCTAT
AACATGAACCCTATCGTATATTGGGAGTACCAGATCATGCCACAGGTCCCTGTTTTTACC
GTAGAGGTAAAGAACTATGGTGTTAAGAATTCAGAATGGATTGATGCCTGCATCAATATT
TCTCATCATTATTGTAATATTTCTGATCATGTTGGTGATCCATCAAATTCTCTTTGGGTC
AGAGTTAAAGCCAGGGTTGGACAAAAAGAATCTGCCTATGCAAAGTCAGAAGAATTTGCT
GTATGCCGAGATGGAAAAATTGGACCACCTAAACTGGATATCAGAAAGGAGGAGAAGCAA
ATCATGATTGACATATTTCACCCTTCAGTTTTTGTAAATGGAGACGAGCAGGAAGTCGAT
TATGATCCCGAAACTACCTGTTACATTAGGGTGTACAATGTGTATGTGAGAATGAACGGA
AGTGAGATCCAGTATAAAATACTCACGCAGAAGGAAGATGATTGTGACGAGATTCAGTGC
CAGTTAGCGATTCCAGTATCCTCACTGAATTCTCAGTACTGTGTTTCAGCAGAAGGAGTC
TTACATGTGTGGGGTGTTACAACTGAAAAGTCAAAAGAAGTTTGTATTACCATTTTCAAT
AGCAGTATAAAAGGTTCTCTTTGGATTCCAGTTGTTGCTGCTTTACTACTCTTTCTAGTG
CTTAGCCTGGTATTCATCTGTTTTTATATTAAGAAAATTAATCCATTGAAGGAAAAAAGC
ATAATATTACCCAAGTCCTTGATCTCTGTGGTAAGAAGTGCTACTTTAGAGACAAAACCT
GAATCAAAATATGTATCACTCATCACGTCATACCAGCCATTTTCCTTAGAAAAGGAGGTG
GTCTGTGAAGAGCCGTTGTCTCCAGCAACAGTTCCAGGCATGCATACCGAAGACAATCCA
GGAAAAGTGGAACATACAGAAGAACTTTCTAGTATAACAGAAGTGGTGACTACTGAAGAA
AATATTCCTGACGTGGTCCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCA
CCTTTAAGTAGTAACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCCAGA
AATTGTTCTGAGAGTGATCACTCCAGAAATGGTTTTGATACTGATTCCAGCTGTCTGGAA
TCACATAGCTCCTTATCTGACTCAGAATTTCCCCCAAATAATAAAGGTGAAATAAAAACA
GAAGGACAAGAGCTCATAACCGTAATAAAAGCCCCCACCTCCTTTGGTTATGATAAACCA
CATGTGCTAGTGGATCTACTTGTGGATGATAGCGGTAAAGAGTCCTTGATTGGTTATAGA
CCAACAGAAGATTCCAAAGAATTTTCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07140</identifier>
        <name>IFNGR1</name>
      </pfam>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interferon-gamma receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000467</id>
      <name>Interferon gamma receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17239631</pubmed-id>
            <citation>Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007 Jan;26(1):67-78.</citation>
          </article>
          <article>
            <pubmed-id>17618444</pubmed-id>
            <citation>Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-71. Epub 2007 Jul 6.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P38484" source="Swiss-Prot">
    <name>Interferon gamma receptor 2</name>
    <general-function>Interferon-gamma receptor activity</general-function>
    <specific-function>Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2.</specific-function>
    <gene-name>IFNGR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>248-268</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.35</theoretical-pi>
    <molecular-weight>37805.97</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5440</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNGR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U05875</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>463550</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P38484</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INGR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>AF-1</synonym>
      <synonym>IFN-gamma receptor 2</synonym>
      <synonym>IFNGT1</synonym>
      <synonym>Interferon gamma receptor accessory factor 1</synonym>
      <synonym>Interferon gamma transducer 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010328|Interferon gamma receptor 2
MRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRP
VVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELG
ALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYW
EKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMAD
ASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQ
PILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010329|Interferon gamma receptor 2 (IFNGR2)
ATGCGACCGACGCTGCTGTGGTCGCTGCTGCTGCTGCTCGGAGTCTTCGCCGCCGCCGCC
GCGGCCCCGCCAGACCCTCTTTCCCAGCTGCCCGCTCCTCAGCACCCGAAGATTCGCCTG
TACAACGCAGAGCAGGTCCTGAGTTGGGAGCCAGTGGCCCTGAGCAATAGCACGAGGCCT
GTTGTCTACCAAGTGCAGTTTAAATACACCGACAGTAAATGGTTCACGGCCGACATCATG
TCCATAGGGGTGAATTGTACACAGATCACAGCAACAGAGTGTGACTTCACTGCCGCCAGT
CCCTCAGCAGGCTTCCCAATGGATTTCAATGTCACTCTACGCCTTCGAGCTGAGCTGGGA
GCACTCCATTCTGCCTGGGTGACAATGCCTTGGTTTCAACACTATCGGAATGTGACTGTC
GGGCCTCCAGAAAACATTGAGGTGACCCCAGGAGAAGGCTCCCTCATCATCAGGTTCTCC
TCTCCCTTTGACATCGCTGATACCTCCACGGCCTTTTTTTGTTATTATGTCCATTACTGG
GAAAAAGGAGGAATCCAACAGGTCAAAGGCCCTTTCAGAAGCAACTCCATTTCATTGGAT
AACTTAAAACCCTCCAGAGTGTACTGTTTACAAGTCCAGGCACAACTGCTTTGGAACAAA
AGTAACATCTTTAGAGTCGGGCATTTAAGCAACATATCTTGCTACGAAACAATGGCAGAT
GCCTCCACTGAGCTTCAGCAAGTCATCCTGATCTCCGTGGGAACATTTTCGTTGCTGTCG
GTGCTGGCAGGAGCCTGTTTCTTCCTGGTCCTGAAATATAGAGGCCTGATTAAATACTGG
TTTCACACTCCACCAAGCATCCCATTACAGATAGAAGAGTATTTAAAAGACCCAACTCAG
CCCATCTTAGAGGCCTTGGACAAGGACAGCTCACCAAAGGATGACGTCTGGGACTCTGTG
TCCATTATCTCGTTTCCGGAAAAGGAGCAAGAAGATGTTCTCCAAACGCTTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interferon-gamma receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of interferon-gamma-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
    <name>Cytochrome P450 1A2</name>
    <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
    <gene-name>CYP1A2</gene-name>
    <locus>15q24</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>9.43</theoretical-pi>
    <molecular-weight>58293.76</molecular-weight>
    <chromosome-location>15</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2596</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP1A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z00036</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1319</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05177</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP1A2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.14.1</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYPIA2</synonym>
      <synonym>Cytochrome P(3)450</synonym>
      <synonym>Cytochrome P450 4</synonym>
      <synonym>Cytochrome P450-P3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>demethylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>electron carrier activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular respiration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>omega-hydroxylase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monocarboxylic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative deethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to immobilization stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to cadmium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>porphyrin-containing compound metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dibenzo-p-dioxin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>methylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epoxygenase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hydrogen peroxide biosynthetic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>weak</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00034</drugbank-id>
  <drugbank-id>BTD00095</drugbank-id>
  <drugbank-id>BTD00012</drugbank-id>
  <drugbank-id>BIOD00095</drugbank-id>
  <drugbank-id>BIOD00012</drugbank-id>
  <drugbank-id>DB00037</drugbank-id>
  <name>Interferon Alfa-2a, Recombinant</name>
  <description>Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.&#13;
&#13;
</description>
  <cas-number>76543-88-9</cas-number>
  <unii>47RRR83SK7</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.</indication>
  <pharmacodynamics>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacodynamics>
  <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
  <toxicity>Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.</toxicity>
  <metabolism/>
  <absorption>Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.</absorption>
  <half-life>The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).</half-life>
  <protein-binding/>
  <route-of-elimination>Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.</route-of-elimination>
  <volume-of-distribution>* 0.223 to 0.748 L/kg [healthy people]</volume-of-distribution>
  <clearance>* 2.14 - 3.62 mL/min/kg [healthy]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Interferon alfa-2a</synonym>
    <synonym language="" coder="">Interferon alfa-2a (recombinant)</synonym>
    <synonym language="" coder="">Interferon alfa-2a, recombinant</synonym>
    <synonym language="" coder="">Interferon alfa-2a,recombinant</synonym>
    <synonym language="" coder="">Interferon alpha-2a</synonym>
    <synonym language="" coder="">Interferon-alfa-2a</synonym>
    <synonym language="" coder="">Recombinant human interferon alfa-2a</synonym>
    <synonym language="" coder="">Recombinant human interferon-alfa-2a</synonym>
    <synonym language="" coder="">rIFN-alpha-2a</synonym>
    <synonym language="" coder="">SH-polypeptide-46</synonym>
  </synonyms>
  <products>
    <product>
      <name>Roferon A Soln Inj 6 Million</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00812498</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-26</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>6000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon A Sterile Pws 18m Unit/vial</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01912003</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>18000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon A Sterile Pws 3m Unit/vial</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01911988</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>3000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon A Sterile Pws 9m Unit/vial</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01911996</dpd-id>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>9000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A  Solution Inj. 9million I.U./0.9ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02019914</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-26</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>9000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Sol Inj 3million Iu/vial</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00812501</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>3000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Soln-liq Im Sc 4.5million I.u/ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217023</dpd-id>
      <started-marketing-on>1997-04-25</started-marketing-on>
      <ended-marketing-on>1999-11-02</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>4.5 m</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Soln-liq Im Sc 9million I.U./ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217058</dpd-id>
      <started-marketing-on>1997-04-29</started-marketing-on>
      <ended-marketing-on>2004-11-01</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>9 m</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Solution 18 Million I.U./3ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217066</dpd-id>
      <started-marketing-on>1997-01-15</started-marketing-on>
      <ended-marketing-on>2005-07-14</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>18 m</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Solution 3 Million I.U./ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217015</dpd-id>
      <started-marketing-on>1997-02-25</started-marketing-on>
      <ended-marketing-on>2005-07-14</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>3 m</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Solution 6 Million I.U./ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02217031</dpd-id>
      <started-marketing-on>1997-02-24</started-marketing-on>
      <ended-marketing-on>2000-07-27</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>6 m</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Roferon-A Solution Inj 36000000unit/ml</name>
      <labeller>Hoffmann La Roche</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00891002</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1997-06-18</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>36000000 unit</strength>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Roferon A</name>
      <company>Hoffmann-La Roche Inc</company>
    </international-brand>
    <international-brand>
      <name>Veldona</name>
      <company>Amarillo Biosciences</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Roferon A Sterile Pws 3m Unit/vial</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon A Sterile Pws 18m Unit/vial</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon A Sterile Pws 9m Unit/vial</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Solution Inj 36000000unit/ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A  Solution Inj. 9million I.U./0.9ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Solution 3 Million I.U./ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon A Soln Inj 6 Million</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Sol Inj 3million Iu/vial</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Soln-liq Im Sc 4.5million I.u/ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Solution 6 Million I.U./ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Soln-liq Im Sc 9million I.U./ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Roferon-A Solution 18 Million I.U./3ml</name>
      <ingredients>Interferon Alfa-2a, Recombinant</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>F Hoffmann La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
    <packager>
      <name>F Hoffmann-La Roche Ltd.</name>
      <url>http://www.roche.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Alfa Interferons</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interferon Type I</category>
      <mesh-id>D007370</mesh-id>
    </category>
    <category>
      <category>Interferons</category>
      <mesh-id>D007372</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>6000000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>18000000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>3000000 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>9000000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>9000000 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>3000000 unit</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>4.5 m</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>9 m</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>18 m</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>3 m</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>6 m</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>36000000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AB04">
      <level code="L03AB">Interferons</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1ITF</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00034.pdf?1265922797</fda-label>
  <patents>
    <patent>
      <number>2172664</number>
      <country>Canada</country>
      <approved>2000-10-03</approved>
      <expires>2016-03-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>The metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13141</drugbank-id>
      <name>Ambroxol acefyllinate</name>
      <description>The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon Alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Ribavirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00034 sequence
CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>100 mg/ml</value>
      <source/>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.336</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>5.99</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>19241.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C860H1353N227O255S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1746</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164779048</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01563</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000801</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/roferon.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/interferon-alfa-2a-solution.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000661</id>
      <name>Interferon alpha/beta receptor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>18230610</pubmed-id>
            <citation>Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. doi: 10.1074/jbc.M708502200. Epub 2008  Jan 29.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P17181" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 1</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.</specific-function>
    <gene-name>IFNAR1</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>437-457</transmembrane-regions>
    <signal-regions>1-27</signal-regions>
    <theoretical-pi>5.56</theoretical-pi>
    <molecular-weight>63524.81</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5432</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03171</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306914</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1723</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P17181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CRF2-1</synonym>
      <synonym>Cytokine receptor class-II member 1</synonym>
      <synonym>Cytokine receptor family 2 member 1</synonym>
      <synonym>IFN-R-1</synonym>
      <synonym>IFNAR</synonym>
      <synonym>Type I interferon receptor 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001318|Interferon alpha/beta receptor 1
MMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT
FSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF
TPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI
ENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ
NQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK
GIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP
VIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV
FSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE
YFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN
EDESESKTSEELQQDFV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)
ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG
TTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC
ATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT
TTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG
AATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT
AAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT
ACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG
GCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT
TTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT
GAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA
AAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT
ATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA
AATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG
TGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA
CCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA
GGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA
GAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA
TCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT
GTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT
GAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT
GTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT
TTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA
GTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC
TTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG
TATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA
AAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT
GATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT
GAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-1 beta secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-gamma production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>T cell activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000385</id>
      <name>Interferon alpha/beta receptor 2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15898717</pubmed-id>
            <citation>Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27.</citation>
          </article>
          <article>
            <pubmed-id>18230610</pubmed-id>
            <citation>Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. doi: 10.1074/jbc.M708502200. Epub 2008  Jan 29.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48551" source="Swiss-Prot">
    <name>Interferon alpha/beta receptor 2</name>
    <general-function>Type i interferon receptor activity</general-function>
    <specific-function>Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.</specific-function>
    <gene-name>IFNAR2</gene-name>
    <locus/>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>244-264</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.11</theoretical-pi>
    <molecular-weight>57758.24</molecular-weight>
    <chromosome-location>21</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5433</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IFNAR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L42243</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995300</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P48551</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>INAR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IFN-R-2</synonym>
      <synonym>IFNABR</synonym>
      <synonym>IFNARB</synonym>
      <synonym>Interferon alpha binding protein</synonym>
      <synonym>Type I interferon receptor 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000767|Interferon alpha/beta receptor 2
MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS
IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF
SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK
HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE
SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD
MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI
DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR
ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT
FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)
ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT
ATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT
TTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC
ATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG
GTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA
AGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC
AGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG
ATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA
GAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG
CATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA
ATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA
ATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA
TCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC
ATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG
AGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA
CTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG
GATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>type I interferon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of type I interferon-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to interferon-alpha</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>type I interferon signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="small molecule" created="2005-06-13" updated="2017-09-20">
  <drugbank-id primary="true">DB00035</drugbank-id>
  <drugbank-id>BTD00112</drugbank-id>
  <drugbank-id>BTD00061</drugbank-id>
  <drugbank-id>BIOD00112</drugbank-id>
  <drugbank-id>BIOD00061</drugbank-id>
  <name>Desmopressin</name>
  <description>Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.</description>
  <cas-number>16679-58-6</cas-number>
  <unii>ENR1LLB0FP</unii>
  <average-mass>1069.217</average-mass>
  <monoisotopic-mass>1068.426954962</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>11380629</pubmed-id>
        <citation>Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, "High purity desmopressin produced in large single batches." U.S. Patent US5674850, issued November, 1991.</synthesis-reference>
  <indication>Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia. </indication>
  <pharmacodynamics>Desmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting. </pharmacodynamics>
  <mechanism-of-action>Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by  deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis. </mechanism-of-action>
  <toxicity>Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations. </toxicity>
  <metabolism>Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes. </metabolism>
  <absorption>Minimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa. </absorption>
  <half-life>Oral t&lt;sub&gt;1/2&lt;/sub&gt;=1.5-2.5 hours. Intranasal t&lt;sub&gt;1/2&lt;/sub&gt;=3.3-3.5 hours. IV t&lt;sub&gt;1/2&lt;/sub&gt; is biphasic: initial t&lt;sub&gt;1/2&lt;/sub&gt;=7.8 minutes, terminal t&lt;sub&gt;1/2&lt;/sub&gt;=0.4-4 hours. </half-life>
  <protein-binding>50%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of chemical entities known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.</description>
    <direct-parent>Oligopeptides</direct-parent>
    <kingdom>Chemical entities</kingdom>
    <superclass>Organic compounds</superclass>
    <class>Organic acids and derivatives</class>
    <subclass>Carboxylic acids and derivatives</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Arginine and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Cyclic peptides</alternative-parent>
    <alternative-parent>Guanidines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imines</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Macrolactams</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>N-acylpyrrolidines</alternative-parent>
    <alternative-parent>Organic disulfides</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Proline and derivatives</alternative-parent>
    <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Alpha-oligopeptide</substituent>
    <substituent>Arginine or derivatives</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Cyclic alpha peptide</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Guanidine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imine</substituent>
    <substituent>Lactam</substituent>
    <substituent>Macrolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>N-acylpyrrolidine</substituent>
    <substituent>N-substituted-alpha-amino acid</substituent>
    <substituent>Organic disulfide</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Proline or derivatives</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
    <substituent>Pyrrolidine-2-carboxamide</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000044</drugbank-id>
      <name>Desmopressin acetate</name>
      <unii>1K12647SFC</unii>
      <cas-number>62288-83-9</cas-number>
      <inchikey>MLSVJHOYXJGGTR-IFHOVBQLSA-N</inchikey>
      <average-mass>1129.269</average-mass>
      <monoisotopic-mass>1128.448084334</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001154</drugbank-id>
      <name>Desmopressin acetate trihydrate</name>
      <unii>XB13HYU18U</unii>
      <cas-number>62357-86-2</cas-number>
      <inchikey>YNKFCNRZZPFMEX-XHPDKPNGSA-N</inchikey>
      <average-mass>1183.32</average-mass>
      <monoisotopic-mass>1182.479779327</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="" coder="">1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin</synonym>
    <synonym language="" coder="">1-deamino-8-D-arginine vasopressin</synonym>
    <synonym language="" coder="">1-Desamino-8-D-arginine vasopressin</synonym>
    <synonym language="" coder="">DDAVP</synonym>
    <synonym language="Spanish" coder="INN">Desmopresina</synonym>
    <synonym language="" coder="">Desmopressin</synonym>
    <synonym language="French" coder="INN">Desmopressine</synonym>
    <synonym language="Latin" coder="INN">Desmopressinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Apo-desmopressin</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284030</dpd-id>
      <started-marketing-on>2007-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-desmopressin</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284049</dpd-id>
      <started-marketing-on>2007-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2200</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1984-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2300</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1984-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2500</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1978-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.1 ug/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2400</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1978-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>.1 ug/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2600</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-2700</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0075-0016</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0075-0026</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1995-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0075-2451</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1984-03-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0075-2452</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1978-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp Inj 4mcg/ml</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00873993</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>4 mcg</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Melt</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284995</dpd-id>
      <started-marketing-on>2006-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>60 mcg</strength>
      <route>Sublingual</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Melt</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02285002</dpd-id>
      <started-marketing-on>2006-11-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>120 mcg</strength>
      <route>Sublingual</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Melt</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02285010</dpd-id>
      <started-marketing-on>2009-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>240 mcg</strength>
      <route>Sublingual</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Rhinal Tube</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0075-2450</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1978-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Ddavp Rhinyle</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00402516</dpd-id>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>0.1 mg</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Spray</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00836362</dpd-id>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength>10 mcg</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Tablets 0.1mg</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00824305</dpd-id>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ddavp Tablets 0.2mg</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00824143</dpd-id>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desmopressin</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346788</dpd-id>
      <started-marketing-on>2011-07-27</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desmopressin</name>
      <labeller>Meliapharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02346796</dpd-id>
      <started-marketing-on>2011-07-27</started-marketing-on>
      <ended-marketing-on>2014-06-25</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-084</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-01-12</started-marketing-on>
      <ended-marketing-on>2015-12-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077414</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-085</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2010-01-12</started-marketing-on>
      <ended-marketing-on>2015-12-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077414</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Sun Pharma Global FZE</labeller>
      <ndc-id/>
      <ndc-product-code>47335-788</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-12-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA078271</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-220</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-221</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4816</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-109</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-09-15</started-marketing-on>
      <ended-marketing-on>2018-11-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-120</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-09-15</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-161</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA077212</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-5020</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-5030</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-5040</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-5060</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55566-5061</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0257</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077414</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0258</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077414</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin acetate</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-5051</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA074888</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin acetate</name>
      <labeller>Teva Parenteral Medicines, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0703-5054</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA074888</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-604</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-08</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amerincan Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>68084-606</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-08</started-marketing-on>
      <ended-marketing-on>2017-03-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-101</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-201</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA019955</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Ncs Health Care Of Ky, Inc Dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-7549</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-01-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-275</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201831</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Glenmark Pharmaceuticals Inc.,Usa</labeller>
      <ndc-id/>
      <ndc-product-code>68462-276</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201831</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Blue Point Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>68001-325</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201831</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Blue Point Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>68001-326</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201831</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Sun Pharmaceutical Industries Limited</labeller>
      <ndc-id/>
      <ndc-product-code>62756-529</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2013-01-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA091280</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2464</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Actavis Pharma Company</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2465</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1129</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-07-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Blue Point Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>68001-233</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Blue Point Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>68001-234</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA076470</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Heritage</labeller>
      <ndc-id/>
      <ndc-product-code>23155-489</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207880</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Heritage</labeller>
      <ndc-id/>
      <ndc-product-code>23155-490</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207880</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-2265</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-08-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>ANDA075220</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7316</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-27</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7317</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-27</started-marketing-on>
      <ended-marketing-on>2017-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Prasco, Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>66993-025</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2014-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>10 ug/.1mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA021333</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5602</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-05-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA074830</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Bauch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-342</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>.1 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA074830</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-1281</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-899</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-901</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>4 ug/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1646</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.1 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Impax Generics</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1647</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-01-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0815</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-01-27</started-marketing-on>
      <ended-marketing-on>2017-02-23</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>10 ug/1</strength>
      <route>Nasal</route>
      <fda-application-number>ANDA076703</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Mylan Institutional</labeller>
      <ndc-id/>
      <ndc-product-code>51079-446</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>.2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA077122</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Acetate</name>
      <labeller>Amring Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69918-501</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2016-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>10 ug/.1mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA017922</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Desmopressin Spray</name>
      <labeller>Aa Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242465</dpd-id>
      <started-marketing-on>2000-08-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>10 mcg</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desmopressin Tablets</name>
      <labeller>Rainbow Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257696</dpd-id>
      <started-marketing-on>2005-02-18</started-marketing-on>
      <ended-marketing-on>2012-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Desmopressin Tablets</name>
      <labeller>Rainbow Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02257718</dpd-id>
      <started-marketing-on>2005-02-18</started-marketing-on>
      <ended-marketing-on>2012-08-03</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minirin</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02246500</dpd-id>
      <started-marketing-on>2003-01-15</started-marketing-on>
      <ended-marketing-on>2015-07-22</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Minirin</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238598</dpd-id>
      <started-marketing-on>2000-08-21</started-marketing-on>
      <ended-marketing-on>2005-08-02</ended-marketing-on>
      <dosage-form>Aerosol, metered</dosage-form>
      <strength>10 mcg</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nocdurna</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02397927</dpd-id>
      <started-marketing-on>2013-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>25 mcg</strength>
      <route>Sublingual</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nocdurna</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02431076</dpd-id>
      <started-marketing-on>2014-11-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>50 mcg</strength>
      <route>Sublingual</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Nu-desmopressin Spray</name>
      <labeller>Nu Pharm Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02336154</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>0.1 g</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octostim Liq Inj. 15mcg/ml</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024179</dpd-id>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength>15 mcg</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Octostim Spray</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237860</dpd-id>
      <started-marketing-on>1998-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength>150 mcg</strength>
      <route>Nasal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-desmopressin</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304368</dpd-id>
      <started-marketing-on>2008-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-desmopressin</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02304376</dpd-id>
      <started-marketing-on>2008-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Stimate</name>
      <labeller>Csl Behring</labeller>
      <ndc-id/>
      <ndc-product-code>0053-6871</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2011-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray, metered</dosage-form>
      <strength>1.5 mg/mL</strength>
      <route>Nasal</route>
      <fda-application-number>NDA020355</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-desmopressin</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287730</dpd-id>
      <started-marketing-on>2007-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.1 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-desmopressin</name>
      <labeller>Teva</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02287749</dpd-id>
      <started-marketing-on>2007-07-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>0.2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Adiuretin</name>
      <company>Ferring</company>
    </international-brand>
    <international-brand>
      <name>DesmoMelt</name>
      <company>Ferring</company>
    </international-brand>
    <international-brand>
      <name>Minirin</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Stimate</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Rhinal Tube</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Inj 4mcg/ml</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Rhinyle</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Octostim Liq Inj. 15mcg/ml</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Tablets 0.1mg</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Tablets 0.2mg</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Octostim Spray</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Spray</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Apo-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Apo-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Melt</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Melt</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Melt</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Nocdurna</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Nocdurna</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp Spray</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Minirin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Minirin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Tablets</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Tablets</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Nu-desmopressin Spray</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>PMS-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>PMS-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Ddavp</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Teva-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Teva-desmopressin</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Stimate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
    <mixture>
      <name>Desmopressin Acetate</name>
      <ingredients>Desmopressin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amerisource Health Services Corp.</name>
      <url>http://www.amerisourcebergen.com</url>
    </packager>
    <packager>
      <name>Apotex Inc.</name>
      <url>http://www.apotex.com</url>
    </packager>
    <packager>
      <name>Arcola Laboratories</name>
      <url/>
    </packager>
    <packager>
      <name>Bachem Inc.</name>
      <url>http://www.bachem.com</url>
    </packager>
    <packager>
      <name>Barr Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Bausch &amp; Lomb Inc.</name>
      <url>http://www.bausch.com</url>
    </packager>
    <packager>
      <name>CSL Behring LLC</name>
      <url>http://www.cslbehring.com</url>
    </packager>
    <packager>
      <name>Ferring Pharmaceuticals Inc.</name>
      <url>http://www.ferring.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Pharmacy Service Center</name>
      <url/>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Promex Medical Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Rechon Life Science AB</name>
      <url>http://www.rechon.com</url>
    </packager>
    <packager>
      <name>Sanofi-Aventis Inc.</name>
      <url>http://www.sanofi-aventis.com</url>
    </packager>
    <packager>
      <name>Sicor Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Sun Pharmaceutical Industries Ltd.</name>
      <url>http://www.sunpharma.com</url>
    </packager>
    <packager>
      <name>Teva Pharmaceutical Industries Ltd.</name>
      <url>http://www.tevapharm.com</url>
    </packager>
    <packager>
      <name>UDL Laboratories</name>
      <url>http://www.udllabs.com</url>
    </packager>
    <packager>
      <name>Watson Pharmaceuticals</name>
      <url>http://www.watson.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Sanofi aventis us llc</manufacturer>
    <manufacturer generic="true" url="">Bedford laboratories div ben venue laboratories inc</manufacturer>
    <manufacturer generic="true" url="">Hospira inc</manufacturer>
    <manufacturer generic="true" url="">Teva parenteral medicines inc</manufacturer>
    <manufacturer generic="false" url="">Ferring pharmaceuticals inc</manufacturer>
    <manufacturer generic="true" url="">Bausch and lomb pharmaceuticals inc</manufacturer>
    <manufacturer generic="false" url="">Apotex inc richmond hill</manufacturer>
    <manufacturer generic="false" url="">Csl behring llc</manufacturer>
    <manufacturer generic="true" url="">Apotex inc etobicoke site</manufacturer>
    <manufacturer generic="true" url="">Teva pharmaceuticals usa</manufacturer>
    <manufacturer generic="true" url="">Watson laboratories inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Apo-Desmopressin 10 mcg/dose Metered Dose Spray</description>
      <cost currency="USD">1.48</cost>
      <unit>dose</unit>
    </price>
    <price>
      <description>Ddavp 0.1 mg Tablet</description>
      <cost currency="USD">1.49</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Apo-Desmopressin 0.2 mg Tablet</description>
      <cost currency="USD">1.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Desmopressin 0.2 mg Tablet</description>
      <cost currency="USD">1.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Desmopressin 0.2 mg Tablet</description>
      <cost currency="USD">1.67</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ddavp 10 mcg/dose Metered Dose Spray</description>
      <cost currency="USD">2.13</cost>
      <unit>dose</unit>
    </price>
    <price>
      <description>Ddavp 0.2 mg Tablet</description>
      <cost currency="USD">2.98</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Desmopressin acetate 0.1 mg tablet</description>
      <cost currency="USD">3.08</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Desmopressin acetate 0.2 mg tablet</description>
      <cost currency="USD">4.44</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ddavp 0.1 mg tablet</description>
      <cost currency="USD">4.47</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Ddavp 0.2 mg tablet</description>
      <cost currency="USD">6.43</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Desmopressin ac 4 mcg/ml vial</description>
      <cost currency="USD">7.08</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Desmopressin ac 4 mcg/ml amp</description>
      <cost currency="USD">7.28</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Ddavp 4 mcg/ml</description>
      <cost currency="USD">11.33</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Octostim 150 mcg/dose Metered Dose Spray</description>
      <cost currency="USD">17.39</cost>
      <unit>dose</unit>
    </price>
    <price>
      <description>Ddavp 0.1 mg/ml Solution</description>
      <cost currency="USD">21.26</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Desmopressin 0.1 mg/ml spray</description>
      <cost currency="USD">39.6</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Ddavp 4 mcg/ml ampul</description>
      <cost currency="USD">43.27</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Ddavp 0.01% nasal spray</description>
      <cost currency="USD">50.76</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Stimate 1.5 mg/ml nasal spray</description>
      <cost currency="USD">334.2</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Apo-Desmopressin 0.1 mg Tablet</description>
      <cost currency="USD">0.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Novo-Desmopressin 0.1 mg Tablet</description>
      <cost currency="USD">0.83</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Pms-Desmopressin 0.1 mg Tablet</description>
      <cost currency="USD">0.83</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antidiuretic Agents</category>
      <mesh-id>D050034</mesh-id>
    </category>
    <category>
      <category>Arginine Vasopressin</category>
      <mesh-id>D001127</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Coagulants</category>
      <mesh-id>D003029</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Natriuretic Agents</category>
      <mesh-id>D045283</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Oligopeptides</category>
      <mesh-id>D009842</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary and Hypothalamic Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pituitary Hormones</category>
      <mesh-id>D010907</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones, Posterior</category>
      <mesh-id>D010909</mesh-id>
    </category>
    <category>
      <category>Posterior Pituitary Lobe Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Vasopressin and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasopressins</category>
      <mesh-id>D014667</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>4 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>.1 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>.2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>4 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Sublingual</route>
      <strength>120 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Sublingual</route>
      <strength>240 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Sublingual</route>
      <strength>60 mcg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength>.1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Nasal</route>
      <strength>0.1 mg</strength>
    </dosage>
    <dosage>
      <form>Aerosol, metered</form>
      <route>Nasal</route>
      <strength>10 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.1 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>0.2 mg</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>4 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>4 ug/mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>10 ug/1</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>10 ug/.1mL</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>10 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Sublingual</route>
      <strength>25 mcg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Sublingual</route>
      <strength>50 mcg</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>0.1 g</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>15 mcg</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Nasal</route>
      <strength>150 mcg</strength>
    </dosage>
    <dosage>
      <form>Spray, metered</form>
      <route>Nasal</route>
      <strength>1.5 mg/mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H01BA02">
      <level code="H01BA">Vasopressin and analogues</level>
      <level code="H01B">POSTERIOR PITUITARY LOBE HORMONES</level>
      <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:28.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00035.pdf?1265922804</fda-label>
  <patents>
    <patent>
      <number>7022340</number>
      <country>United States</country>
      <approved>2003-04-30</approved>
      <expires>2023-04-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5500413</number>
      <country>United States</country>
      <approved>1993-06-29</approved>
      <expires>2013-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2484724</number>
      <country>Canada</country>
      <approved>2007-01-16</approved>
      <expires>2023-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2486833</number>
      <country>Canada</country>
      <approved>2005-08-02</approved>
      <expires>2024-04-30</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9539302</number>
      <country>United States</country>
      <approved>2010-06-15</approved>
      <expires>2030-06-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7799761</number>
      <country>United States</country>
      <approved>2004-09-26</approved>
      <expires>2024-09-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7405203</number>
      <country>United States</country>
      <approved>2003-05-06</approved>
      <expires>2023-05-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7579321</number>
      <country>United States</country>
      <approved>2003-05-06</approved>
      <expires>2023-05-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00179</drugbank-id>
      <name>Masoprocol</name>
      <description>The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00210</drugbank-id>
      <name>Adapalene</name>
      <description>The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00337</drugbank-id>
      <name>Pimecrolimus</name>
      <description>The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00735</drugbank-id>
      <name>Naftifine</name>
      <description>The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05073</drugbank-id>
      <name>SRT501</name>
      <description>The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05173</drugbank-id>
      <name>PTC299</name>
      <description>The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of adverse effects can be increased when HMPL-004 is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06246</drugbank-id>
      <name>exisulind</name>
      <description>The risk or severity of adverse effects can be increased when exisulind is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08880</drugbank-id>
      <name>Teriflunomide</name>
      <description>The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08921</drugbank-id>
      <name>D-Limonene</name>
      <description>The risk or severity of adverse effects can be increased when D-Limonene is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11444</drugbank-id>
      <name>Orgotein</name>
      <description>The risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11687</drugbank-id>
      <name>E-6201</name>
      <description>The risk or severity of adverse effects can be increased when E6201 is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12160</drugbank-id>
      <name>Bucillamine</name>
      <description>The risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of adverse effects can be increased when Ebselen is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12618</drugbank-id>
      <name>Apocynin</name>
      <description>The risk or severity of adverse effects can be increased when Acetovanillone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12617</drugbank-id>
      <name>Mizoribine</name>
      <description>The risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Pethidine</name>
      <description>The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levomethadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl Acetate</name>
      <description>The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Heroin</name>
      <description>The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium</name>
      <description>The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.10e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-6.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>desmopressin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1069.217</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1068.426954962</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C46H64N14O12S2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NFLWUMRGJYTJIN-NXBWRCJVSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>435.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>279.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>106.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>11.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>-4.2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2155</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>19910</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20181</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>4450</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>16051933</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507014</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06944</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00291</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10481973</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50205291</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449237</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DNC000526</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Desmopressin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL376685</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/desmoprt.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/desmopressin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000293</id>
      <name>Vasopressin V2 receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>18761325</pubmed-id>
            <citation>Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.</citation>
          </article>
          <article>
            <pubmed-id>16333859</pubmed-id>
            <citation>Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30518" source="Swiss-Prot">
    <name>Vasopressin V2 receptor</name>
    <general-function>Vasopressin receptor activity</general-function>
    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.</specific-function>
    <gene-name>AVPR2</gene-name>
    <locus>Xq28</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>39-63
78-98
114-135
160-180
201-220
272-293
309-328</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.41</theoretical-pi>
    <molecular-weight>40278.57</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:897</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>AVPR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U04357</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>28418</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>368</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>368</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P30518</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>V2R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>ADHR</synonym>
      <synonym>Antidiuretic hormone receptor</synonym>
      <synonym>AVPR V2</synonym>
      <synonym>DIR</synonym>
      <synonym>DIR3</synonym>
      <synonym>Renal-type arginine vasopressin receptor</synonym>
      <synonym>V2R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000583|Vasopressin V2 receptor
MLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA
ALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM
VGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ
RNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP
SERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA
PLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT
ASSSLAKDTSS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010065|Vasopressin V2 receptor (AVPR2)
ATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC
AGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG
CTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG
GCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC
TTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG
GCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG
GTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC
ATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG
CTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG
CGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG
GGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT
ATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA
TCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC
CACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT
GTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA
CCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC
AACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC
TGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC
GCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vasopressin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hormone stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of systemic arterial blood pressure by vasopressin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of urine volume</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein ubiquitination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>renal water homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to peptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to cytokine</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>telencephalon development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>I-kappaB kinase/NF-kappaB signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hemostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interferon-gamma production</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0000165</id>
      <name>Vasopressin V1a receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10731046</pubmed-id>
            <citation>Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26.</citation>
          </article>
          <article>
            <pubmed-id>10594321</pubmed-id>
            <citation>Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.</citation>
          </article>
          <article>
            <pubmed-id>8957254</pubmed-id>
            <citation>Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32.</citation>
          </article>
          <article>
            <pubmed-id>15613460</pubmed-id>
            <citation>Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P37288" source="Swiss-Prot">
    <name>Vasopressin V1a receptor</name>
    <general-function>Vasopressin receptor activity</general-function>
    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.</specific-function>
    <gene-name>AVPR1A</gene-name>
    <locus>12q14-q15</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>53-76
89-110
126-147
169-190
219-239
294-313
332-351</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.67</theoretical-pi>
    <molecular-weight>46799.105</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:895</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>AVPR1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L25615</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>667068</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>366</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>366</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P37288</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>V1AR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Antidiuretic hormone receptor 1a</synonym>
      <synonym>AVPR V1a</synonym>
      <synonym>AVPR1</synonym>
      <synonym>V1aR</synonym>
      <synonym>Vascular/hepatic-type arginine vasopressin receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009979|Vasopressin V1a receptor
MRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV
TFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP
DWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV
LSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC
YNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY
IVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV
QSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0009980|Vasopressin V1a receptor (AVPR1A)
ATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT
CTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC
CCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG
ACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG
CGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG
GCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC
GACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC
ATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG
CAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG
CTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC
CGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG
ACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC
TACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG
CAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG
TCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC
ATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC
GTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT
AGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT
CAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT
ATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG
TGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF08983</identifier>
        <name>DUF1856</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vasopressin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase C binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>generation of precursor metabolites and energy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of systemic arterial blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maternal behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>grooming behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>myotube differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to corticosterone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of female receptivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to peptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transmission of nerve impulse</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>social behavior</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hormone stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>penile erection</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sperm ejaculation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of systemic arterial blood pressure by vasopressin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cellular pH reduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>telencephalon development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of glutamate secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood circulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of heart rate</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to water deprivation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of renal sodium excretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maternal aggressive behavior</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0000773</id>
      <name>Vasopressin V1b receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15613460</pubmed-id>
            <citation>Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85.</citation>
          </article>
          <article>
            <pubmed-id>14971638</pubmed-id>
            <citation>Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72.</citation>
          </article>
          <article>
            <pubmed-id>18655906</pubmed-id>
            <citation>Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. doi: 10.1016/S0079-6123(08)00440-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P47901" source="Swiss-Prot">
    <name>Vasopressin V1b receptor</name>
    <general-function>Vasopressin receptor activity</general-function>
    <specific-function>Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system.</specific-function>
    <gene-name>AVPR1B</gene-name>
    <locus>1q32</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>36-59
72-93
109-130
152-173
202-222
284-303
322-341</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.05</theoretical-pi>
    <molecular-weight>46970.345</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:896</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>AVPR1B</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D31833</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>563982</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>367</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>367</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P47901</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>V1BR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Antidiuretic hormone receptor 1b</synonym>
      <synonym>AVPR V1b</synonym>
      <synonym>AVPR V3</synonym>
      <synonym>AVPR3</synonym>
      <synonym>V1bR</synonym>
      <synonym>Vasopressin V3 receptor</synonym>
      <synonym>VPR3</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010547|Vasopressin V1b receptor
MDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG
QLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA
STYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG
SGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG
GGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV
QMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ
PRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE
TIIF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010548|Vasopressin V1b receptor (AVPR1B)
ATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC
AATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC
CTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC
CAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC
CTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC
CAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC
TCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG
CGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG
GCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC
TCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC
ACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC
CTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA
GGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG
GGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG
AAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC
CAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC
ACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC
TTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG
CCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG
ACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG
CCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG
ACCATCATCTTTTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF08983</identifier>
        <name>DUF1856</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein kinase C binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vasopressin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to peptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hormone stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of systemic arterial blood pressure by vasopressin</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="4">
      <id>BE0000017</id>
      <name>Prostaglandin G/H synthase 1</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15644490</pubmed-id>
            <citation>Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23219" source="Swiss-Prot">
    <name>Prostaglandin G/H synthase 1</name>
    <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
    <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.</specific-function>
    <gene-name>PTGS1</gene-name>
    <locus>9q32-q33.3</locus>
    <cellular-location>Microsome membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>7.39</theoretical-pi>
    <molecular-weight>68685.82</molecular-weight>
    <chromosome-location>9</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9604</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PTGS1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M31822</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>387018</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1375</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P23219</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PGH1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.99.1</synonym>
      <synonym>COX-1</synonym>
      <synonym>COX1</synonym>
      <synonym>Cyclooxygenase-1</synonym>
      <synonym>PGH synthase 1</synonym>
      <synonym>PGHS-1</synonym>
      <synonym>PHS 1</synonym>
      <synonym>Prostaglandin H2 synthase 1</synonym>
      <synonym>Prostaglandin-endoperoxide synthase 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036935|Prostaglandin G/H synthase 1
MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021254|Prostaglandin G/H synthase 1 (PTGS1)
ATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCGCTCCCC
GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC
CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC
ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA
CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG
TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCGCCTGGTACTCACAGTGCGCTCC
AACCTTATCCCCAGTCCCCCCACCTACAACTCAGCACATGACTACATCAGCTGGGAGTCT
TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA
CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC
CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT
GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC
AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG
TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG
TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC
CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT
GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC
ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC
AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT
GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCATGGAGTTC
AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG
TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC
CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC
CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG
CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC
GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG
GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT
ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT
CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG
GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT
GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03098</identifier>
        <name>An_peroxidase</name>
      </pfam>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>photoreceptor outer segment</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nuclear envelope</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peroxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>prostaglandin-endoperoxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>dioxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to corticosterone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of blood-brain barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to oxidative stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fatty acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of norepinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epinephrine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cyclooxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to organonitrogen compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="5">
      <id>BE0000262</id>
      <name>Prostaglandin G/H synthase 2</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>15644490</pubmed-id>
            <citation>Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35354" source="Swiss-Prot">
    <name>Prostaglandin G/H synthase 2</name>
    <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
    <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.</specific-function>
    <gene-name>PTGS2</gene-name>
    <locus>1q25.2-q25.3</locus>
    <cellular-location>Microsome membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>7.41</theoretical-pi>
    <molecular-weight>68995.625</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PTGS2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L15326</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>291988</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1376</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35354</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PGH2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.99.1</synonym>
      <synonym>COX-2</synonym>
      <synonym>COX2</synonym>
      <synonym>Cyclooxygenase-2</synonym>
      <synonym>PGH synthase 2</synonym>
      <synonym>PGHS-2</synonym>
      <synonym>PHS II</synonym>
      <synonym>Prostaglandin H2 synthase 2</synonym>
      <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021832|Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03098</identifier>
        <name>An_peroxidase</name>
      </pfam>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peroxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>prostaglandin-endoperoxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonate 15-lipoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryo implantation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fructose</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lithium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to UV</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fatty acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fever generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to fluid shear stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vascular endothelial growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of blood-brain barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to ATP</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to tumor necrosis factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to oxidative stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to vitamin D</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transforming growth factor beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>decidualization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to manganese ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nicotinamide metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>NAD metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cyclooxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of platelet-derived growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water-soluble vitamin metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00036</drugbank-id>
  <drugbank-id>BTD00006</drugbank-id>
  <drugbank-id>BIOD00006</drugbank-id>
  <name>Coagulation factor VIIa Recombinant Human</name>
  <description>Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.</description>
  <cas-number>102786-61-8</cas-number>
  <unii>AC71R787OV</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>2155</pubmed-id>
        <citation>Blackshear PJ, Holloway PA, Alberti KG: Factors regulating amino acid release from extrasplanchnic tissues in the rat. Interactions of alanine and glutamine. Biochem J. 1975 Sep;150(3):379-87.</citation>
      </article>
      <article>
        <pubmed-id>15328151</pubmed-id>
        <citation>Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24.</citation>
      </article>
      <article>
        <pubmed-id>10584732</pubmed-id>
        <citation>Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999 Nov 27;354(9193):1879.</citation>
      </article>
      <article>
        <pubmed-id>16418464</pubmed-id>
        <citation>O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8.</citation>
      </article>
      <article>
        <pubmed-id>15728810</pubmed-id>
        <citation>Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 Feb 24;352(8):777-85.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of hemorrhagic complications in hemophilia A and B</indication>
  <pharmacodynamics>Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.</pharmacodynamics>
  <mechanism-of-action>NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>* 121 ± 30 mL/kg [adults]&#13;
* 153 ± 29 mL/kg [children]&#13;
* 280 to 290 mL/kg [congenital Factor VII deficiency]</volume-of-distribution>
  <clearance>* 33 - 37 mL/h x kg [healthy]&#13;
* 1375 +/- 396 mL/hr [severe hemophilia A male children]&#13;
* 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children]&#13;
* 2767 +/- 385 mL/hr [severe hemophilia A men]&#13;
* 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Coagulation factor VIIa</synonym>
    <synonym language="" coder="">Coagulation factor VIIa (recombinant)</synonym>
    <synonym language="" coder="">Eptacog alfa</synonym>
    <synonym language="" coder="">Eptacog alfa (activated)</synonym>
    <synonym language="" coder="">rFVIIa</synonym>
  </synonyms>
  <products>
    <product>
      <name>Niastase</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239659</dpd-id>
      <started-marketing-on>1999-08-05</started-marketing-on>
      <ended-marketing-on>2013-07-22</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1.2 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239660</dpd-id>
      <started-marketing-on>1999-08-05</started-marketing-on>
      <ended-marketing-on>2013-07-22</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>2.4 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239661</dpd-id>
      <started-marketing-on>1999-08-05</started-marketing-on>
      <ended-marketing-on>2013-07-22</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>4.8 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417146</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>8 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02365669</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>8 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347113</dpd-id>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347121</dpd-id>
      <started-marketing-on>2010-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02347148</dpd-id>
      <started-marketing-on>2010-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417103</dpd-id>
      <started-marketing-on>2015-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417111</dpd-id>
      <started-marketing-on>2015-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Niastase RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02417138</dpd-id>
      <started-marketing-on>2015-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>5 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>NovoSeven RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7201</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103665</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovoSeven RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7202</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103665</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovoSeven RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7205</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103665</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovoSeven RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7208</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2012-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103665</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovoSeven RT</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7050</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-04-30</started-marketing-on>
      <ended-marketing-on>2015-10-31</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103665</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>NovoSeven</name>
      <company>Novo Nordisk</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Niastase RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>NovoSeven RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>NovoSeven RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>NovoSeven RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>NovoSeven RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>NovoSeven RT</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
    <mixture>
      <name>Novoseven</name>
      <ingredients>Coagulation factor VIIa Recombinant Human</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Novo Nordisk Inc.</name>
      <url>http://www.novonordisk.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Novoseven 1200 mcg vial</description>
      <cost currency="USD">1.64</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Novoseven 2400 mcg vial</description>
      <cost currency="USD">1.64</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Novoseven 4800 mcg vial</description>
      <cost currency="USD">1.64</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Factor VII</category>
      <mesh-id>D005167</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Endopeptidases</category>
      <mesh-id>D012697</mesh-id>
    </category>
    <category>
      <category>Serine Proteases</category>
      <mesh-id>D057057</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>1.2 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>2.4 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>4.8 mg</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>8 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>100 KIU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 KIU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>400 KIU</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 KIU</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02BD08">
      <level code="B02BD">Blood coagulation factors</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1DAN</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;DB00036 sequence
ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>58 °C</value>
      <source>Petersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.311</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>6.09</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>45079.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1972H3076N560O597S28</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13301</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C03378</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00172</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M13232</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748389</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P08709</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Factor_VII</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/novoseven.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000216</id>
      <name>Coagulation factor X</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>5969560</pubmed-id>
            <citation>Malinvaud G: [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)]. Transfusion (Paris). 1966;9(3):245-54.</citation>
          </article>
          <article>
            <pubmed-id>13801371</pubmed-id>
            <citation>BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86.</citation>
          </article>
          <article>
            <pubmed-id>13713641</pubmed-id>
            <citation>HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6.</citation>
          </article>
          <article>
            <pubmed-id>14227143</pubmed-id>
            <citation>GAERTNER H, CAEN J: [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X)]. Acta Physiol Pol. 1964 Mar-Apr;15:237-43.</citation>
          </article>
          <article>
            <pubmed-id>13621053</pubmed-id>
            <citation>DIDISHEIM P, LOEB J, BLATRIX C, SOULIER JP: Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med. 1959 Feb;53(2):322-30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00742" source="Swiss-Prot">
    <name>Coagulation factor X</name>
    <general-function>Serine-type endopeptidase activity</general-function>
    <specific-function>Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.</specific-function>
    <gene-name>F10</gene-name>
    <locus>13q34</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-31</signal-regions>
    <theoretical-pi>5.74</theoretical-pi>
    <molecular-weight>54731.255</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3528</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F10</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>K03194</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182841</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2359</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00742</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FA10_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.6</synonym>
      <synonym>Stuart factor</synonym>
      <synonym>Stuart-Prower factor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010204|Coagulation factor X
MGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE
TCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN
CELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR
KRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE
CKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE
AVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI
VSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG
GPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE
VITSSPLK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010205|Coagulation factor X (F10)
ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC
GGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG
GCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG
ACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC
TGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA
TGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC
TGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC
CACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC
GGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG
AAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG
AAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC
AACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA
TGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC
TGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA
GCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG
GCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC
TTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT
GCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT
GTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG
GAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG
AACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG
GGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA
GAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG
TGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG
GTCATAACGTCCTCTCCATTAAAGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, intrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002128</id>
      <name>Serine protease hepsin</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05981" source="Swiss-Prot">
    <name>Serine protease hepsin</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Plays an essential role in cell growth and maintenance of cell morphology. May mediate the activating cleavage of HGF and MST1/HGFL. Plays a role in the proteolytic processing of ACE2.</specific-function>
    <gene-name>HPN</gene-name>
    <locus>19q11-q13.2</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>24-44</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>7.66</theoretical-pi>
    <molecular-weight>45011.01</molecular-weight>
    <chromosome-location>19</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5155</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HPN</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M18930</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>306886</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05981</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>HEPS_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.106</synonym>
      <synonym>TMPRSS1</synonym>
      <synonym>Transmembrane protease serine 1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016689|Serine protease hepsin
MAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSAD
ARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCV
DEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSL
RYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYH
GGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQ
YYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCE
DSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016690|Serine protease hepsin (HPN)
ATGGCGCAGAAGGAGGGTGGCCGGACTGTGCCATGCTGCTCCAGACCCAAGGTGGCAGCT
CTCACTGCGGGGACCCTGCTACTTCTGACAGCCATCGGGGCGGCATCCTGGGCCATTGTG
GCTGTTCTCCTCAGGAGTGACCAGGAGCCGCTGTACCCAGTGCAGGTCAGCTCTGCGGAC
GCTCGGCTCATGGTCTTTGACAAGACGGAAGGGACGTGGCGGCTGCTGTGCTCCTCGCGC
TCCAACGCCAGGGTAGCCGGACTCAGCTGCGAGGAGATGGGCTTCCTCAGGGCACTGACC
CACTCCGAGCTGGACGTGCGAACGGCGGGCGCCAATGGCACGTCGGGCTTCTTCTGTGTG
GACGAGGGGAGGCTGCCCCACACCCAGAGGCTGCTGGAGGTCATCTCCGTGTGTGATTGC
CCCAGAGGCCGTTTCTTGGCCGCCATCTGCCAAGACTGTGGCCGCAGGAAGCTGCCCGTG
GACCGCATCGTGGGAGGCCGGGACACCAGCTTGGGCCGGTGGCCGTGGCAAGTCAGCCTT
CGCTATGATGGAGCACACCTCTGTGGGGGATCCCTGCTCTCCGGGGACTGGGTGCTGACA
GCCGCCCACTGCTTCCCGGAGCGGAACCGGGTCCTGTCCCGATGGCGAGTGTTTGCCGGT
GCCGTGGCCCAGGCCTCTCCCCACGGTCTGCAGCTGGGGGTGCAGGCTGTGGTCTACCAC
GGGGGCTATCTTCCCTTTCGGGACCCCAACAGCGAGGAGAACAGCAACGATATTGCCCTG
GTCCACCTCTCCAGTCCCCTGCCCCTCACAGAATACATCCAGCCTGTGTGCCTCCCAGCT
GCCGGCCAGGCCCTGGTGGATGGCAAGATCTGTACCGTGACGGGCTGGGGCAACACGCAG
TACTATGGCCAACAGGCCGGGGTACTCCAGGAGGCTCGAGTCCCCATAATCAGCAATGAT
GTCTGCAATGGCGCTGACTTCTATGGAAACCAGATCAAGCCCAAGATGTTCTGTGCTGGC
TACCCCGAGGGTGGCATTGATGCCTGCCAGGGCGACAGCGGTGGTCCCTTTGTGTGTGAG
GACAGCATCTCTCGGACGCCACGTTGGCGGCTGTGTGGCATTGTGAGTTGGGGCACTGGC
TGTGCCCTGGCCCAGAAGCCAGGCGTCTACACCAAAGTCAGTGACTTCCGGGAGTGGATC
TTCCAGGCCATAAAGACTCACTCCGAAGCCAGCGGCATGGTGACCCAGCTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
      <pfam>
        <identifier>PF09272</identifier>
        <name>Hepsin-SRCR</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuronal cell body</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell-cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-activated potassium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type exopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>potassium ion transmembrane transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of hepatocyte proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cholesterol homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epithelial to mesenchymal transition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation by host of viral transcription</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>basement membrane disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell shape</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cochlea morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of mechanical stimulus involved in sensory perception of sound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of alkaline phosphatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>pilomotor reflex</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of thyroid hormone generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of plasminogen activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to thyroid hormone</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000967</id>
      <name>Tissue factor pathway inhibitor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11772005</pubmed-id>
            <citation>Mine S, Yamazaki T, Miyata T, Hara S, Kato H: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002 Jan 8;41(1):78-85.</citation>
          </article>
          <article>
            <pubmed-id>7559599</pubmed-id>
            <citation>Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 1995 Oct 20;270(42):24800-4.</citation>
          </article>
          <article>
            <pubmed-id>8700900</pubmed-id>
            <citation>Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149-54.</citation>
          </article>
          <article>
            <pubmed-id>12974870</pubmed-id>
            <citation>Lee AY, Vlasuk GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003 Oct;254(4):313-21.</citation>
          </article>
          <article>
            <pubmed-id>11238112</pubmed-id>
            <citation>Hansen CB, Pyke C, Petersen LC, Rao LV: Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood. 2001 Mar 15;97(6):1712-20.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10646" source="Swiss-Prot">
    <name>Tissue factor pathway inhibitor</name>
    <general-function>Serine-type endopeptidase inhibitor activity</general-function>
    <specific-function>Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.</specific-function>
    <gene-name>TFPI</gene-name>
    <locus>2q32</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-28</signal-regions>
    <theoretical-pi>8.31</theoretical-pi>
    <molecular-weight>35014.835</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11760</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>TFPI</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J03225</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>180546</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P10646</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TFPI1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>EPI</synonym>
      <synonym>Extrinsic pathway inhibitor</synonym>
      <synonym>LACI</synonym>
      <synonym>Lipoprotein-associated coagulation inhibitor</synonym>
      <synonym>TFPI</synonym>
      <synonym>TFPI1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001925|Tissue factor pathway inhibitor
MIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADD
GPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQE
KPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPN
GFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG
KCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIF
VKNM</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010679|Tissue factor pathway inhibitor (TFPI)
ATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAAT
CTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACA
GATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGAT
GGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAA
GAATTTATATATGGGGGATGTGAAGGAAATCAGAATCGATTTGAAAGTCTGGAAGAGTGC
AAAAAAATGTGTACAAGAGATAATGCAAACAGGATTATAAAGACAACATTGCAACAAGAA
AAGCCAGATTTCTGCTTTTTGGAAGAAGATCCTGGAATATGTCGAGGTTATATTACCAGG
TATTTTTATAACAATCAGACAAAACAGTGTGAACGTTTCAAGTATGGTGGATGCCTGGGC
AATATGAACAATTTTGAGACACTGGAAGAATGCAAGAACATTTGTGAAGATGGTCCGAAT
GGTTTCCAGGTGGATAATTATGGAACCCAGCTCAATGCTGTGAATAACTCCCTGACTCCG
CAATCAACCAAGGTTCCCAGCCTTTTTGTTACAAAAGAAGGAACAAATGATGGTTGGAAG
AATGCGGCTCATATTTACCAAGTCTTTCTGAACGCCTTCTGCATTCATGCATCCATGTTC
TTTCTAGGATTGGATAGCATTTCATGCCTATGTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00014</identifier>
        <name>Kunitz_BPTI</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>anchored component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>organelle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase inhibitor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000403</id>
      <name>Vitamin K-dependent gamma-carboxylase</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>10901669</pubmed-id>
            <citation>Bouwman CA, Van Dam E, Fase KM, Koppe JG, Seinen W, Thijssen HH, Vermeer C, Van den Berg M: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere. 1999 Feb;38(3):489-505.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P38435" source="Swiss-Prot">
    <name>Vitamin K-dependent gamma-carboxylase</name>
    <general-function>Gamma-glutamyl carboxylase activity</general-function>
    <specific-function>Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.</specific-function>
    <gene-name>GGCX</gene-name>
    <locus>2p12</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions>61-81
114-134
137-157
293-313
362-382</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.1</theoretical-pi>
    <molecular-weight>87560.065</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4247</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GGCX</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M81592</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>184028</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P38435</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>VKGC_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>4.1.1.90</synonym>
      <synonym>Gamma-glutamyl carboxylase</synonym>
      <synonym>GC</synonym>
      <synonym>Peptidyl-glutamate 4-carboxylase</synonym>
      <synonym>Vitamin K gamma glutamyl carboxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000803|Vitamin K-dependent gamma-carboxylase
MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD
PASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT
IMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW
SVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP
FKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS
YVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH
QLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT
GELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR
IFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL
ENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM
YVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL
RRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV
TYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018949|Vitamin K-dependent gamma-carboxylase (GGCX)
ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC
AAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT
GAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC
CCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC
CAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC
TTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC
ATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG
TTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC
TCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG
TCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT
GCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT
GCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC
TTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG
CTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG
TTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC
TACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG
TCCTACTGCCCCCGAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT
GTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT
CAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT
CATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC
ATGATGGTGCACTCCCGCTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT
GGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT
GCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC
ACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG
ATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC
TGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG
AGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG
GAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG
ACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG
TTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG
TACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA
TTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT
CTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT
AGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA
TTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT
ATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG
ACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT
TCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF05090</identifier>
        <name>VKG_Carbox</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>gamma-glutamyl carboxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein modification process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000333</id>
      <name>Coagulation factor VII</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10388743</pubmed-id>
            <citation>Perera L, Darden TA, Pedersen LG: Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association. Biophys J. 1999 Jul;77(1):99-113.</citation>
          </article>
          <article>
            <pubmed-id>11735107</pubmed-id>
            <citation>Shapiro A: Inhibitor treatment: state of the art. Semin Hematol. 2001 Oct;38(4 Suppl 12):26-34.</citation>
          </article>
          <article>
            <pubmed-id>12525826</pubmed-id>
            <citation>Shapiro A: Inhibitor treatment: state of the art. Dis Mon. 2003 Jan;49(1):22-38.</citation>
          </article>
          <article>
            <pubmed-id>15907148</pubmed-id>
            <citation>Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161-77.</citation>
          </article>
          <article>
            <pubmed-id>16370916</pubmed-id>
            <citation>Rizoli SB, Chughtai T: The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther. 2006 Jan;6(1):73-81.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08709" source="Swiss-Prot">
    <name>Coagulation factor VII</name>
    <general-function>Serine-type peptidase activity</general-function>
    <specific-function>Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.</specific-function>
    <gene-name>F7</gene-name>
    <locus>13q34</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-20</signal-regions>
    <theoretical-pi>7.23</theoretical-pi>
    <molecular-weight>51593.465</molecular-weight>
    <chromosome-location>13</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3544</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F7</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M13232</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182801</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2363</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08709</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FA7_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>3.4.21.21</synonym>
      <synonym>Proconvertin</synonym>
      <synonym>Serum prothrombin conversion accelerator</synonym>
      <synonym>SPCA</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000663|Coagulation factor VII
MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR
ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016066|Coagulation factor VII (F7)
ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT
GCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG
CCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC
GCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG
CAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC
TGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC
TGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC
TGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG
TACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG
CTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT
CTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC
AAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG
ACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC
TGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG
CAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC
CACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC
CTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG
GTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTCCTC
AACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC
CCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC
AAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC
ATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC
TCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC
CTGCGAGCCCCATTTCCCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF00594</identifier>
        <name>Gla</name>
      </pfam>
      <pfam>
        <identifier>PF00089</identifier>
        <name>Trypsin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type peptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glycoprotein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>serine-type endopeptidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of platelet-derived growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to vitamin K</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>circadian rhythm</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estrogen</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-glutamic acid carboxylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ regeneration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukocyte chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of positive chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-translational protein modification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to growth hormone</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>proteolysis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0001178</id>
      <name>Tissue factor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>13713641</pubmed-id>
            <citation>HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6.</citation>
          </article>
          <article>
            <pubmed-id>1586032</pubmed-id>
            <citation>Rogers KS, Barton CL, Benson PA, Green RA: Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res. 1992 Apr;53(4):580-4.</citation>
          </article>
          <article>
            <pubmed-id>6658368</pubmed-id>
            <citation>Christensen NJ: Measurements of some blood clotting factors using a centrifugal analyser (Multistat III). Scand J Clin Lab Invest. 1983 Oct;43(6):521-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P13726" source="Swiss-Prot">
    <name>Tissue factor</name>
    <general-function>Protease binding</general-function>
    <specific-function>Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade.</specific-function>
    <gene-name>F3</gene-name>
    <locus>1p22-p21</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>252-274</transmembrane-regions>
    <signal-regions>1-32</signal-regions>
    <theoretical-pi>7.09</theoretical-pi>
    <molecular-weight>33067.3</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3541</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>F3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M16553</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>339504</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P13726</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TF_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Coagulation factor III</synonym>
      <synonym>TF</synonym>
      <synonym>Thromboplastin</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002343|Tissue factor
METPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPK
PVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGS
AGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFG
KDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVE
CMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021656|Tissue factor (F3)
ATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTC
CTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCA
GCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAA
CCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAA
TGCTTTTACACAACAGACACAGAGTGTGACCTCACCGACGAGATTGTGAAGGATGTGAAG
CAGACGTACTTGGCACGGGTCTTCTCCTACCCGGCAGGGAATGTGGAGAGCACCGGTTCT
GCTGGGGAGCCTCTGTATGAGAACTCCCCAGAGTTCACACCTTACCTGGAGACAAACCTC
GGACAGCCAACAATTCAGAGTTTTGAACAGGTGGGAACAAAAGTGAATGTGACCGTAGAA
GATGAACGGACTTTAGTCAGAAGGAACAACACTTTCCTAAGCCTCCGGGATGTTTTTGGC
AAGGACTTAATTTATACACTTTATTATTGGAAATCTTCAAGTTCAGGAAAGAAATATTCT
ACATCATTGGAGCTGTGGTATTTGTGGTCATCATCCTTGTCATCATCCTGGCTATATCTC
TACACAAGTGTAGAAAGGCAGGAGTGGGGCAGAGCTGGAAGGAGAACTCCCCACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01108</identifier>
        <name>Tissue_fac</name>
      </pfam>
      <pfam>
        <identifier>PF09294</identifier>
        <name>Interfer-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intrinsic component of external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protease binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to low-density lipoprotein particle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation, extrinsic pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fluid shear stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of positive chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to temperature stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of platelet-derived growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>aging</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of blood coagulation via clotting cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hydrogen peroxide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of plasma proteins involved in acute inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of endothelial cell proliferation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00038</drugbank-id>
  <drugbank-id>BTD00021</drugbank-id>
  <drugbank-id>BIOD00021</drugbank-id>
  <name>Oprelvekin</name>
  <description>Oprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.&#13;
&#13;
The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls.&#13;
&#13;
In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.</description>
  <cas-number>145941-26-0</cas-number>
  <unii>O14Q7A13PT</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>Increases reduced platelet levels due to chemotherapy</indication>
  <pharmacodynamics>Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis</pharmacodynamics>
  <mechanism-of-action>Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Absolute bioavailability is over 80%.</absorption>
  <half-life>6.9 +/- 1.7 hrs</half-life>
  <protein-binding/>
  <route-of-elimination>The kidney is the primary route of elimination. The amount of intact Neumega in urine was low, indicating that the molecule was metabolized before excretion.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Adipogenesis inhibitory factor</synonym>
    <synonym language="" coder="">AGIF</synonym>
    <synonym language="" coder="">IL-11</synonym>
    <synonym language="" coder="">Interleukin-11 precursor</synonym>
  </synonyms>
  <products>
    <product>
      <name>Neumega</name>
      <labeller>Wyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>58394-004</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1997-11-01</started-marketing-on>
      <ended-marketing-on>2017-04-30</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA103694</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Neumega</name>
      <ingredients>Oprelvekin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Wyeth Pharmaceuticals</name>
      <url>http://www.wyeth.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Neumega 5 mg vial</description>
      <cost currency="USD">352.9</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interleukins</category>
      <mesh-id>D007378</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AC02">
      <level code="L03AC">Interleukins</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00038.pdf?1265922806</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Oprelvekin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;DB00038 sequence
GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSA
GALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQL
LMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.070</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>11.16</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>19047.2</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C854H1411N253O235S2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M57765</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164747991</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P20809</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001287</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Oprelvekin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201573</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/oprelvek.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/oprelvekin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000416</id>
      <name>Interleukin-11 receptor subunit alpha</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>11012177</pubmed-id>
            <citation>Nandurkar HH, Robb L, Begley CG: The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16 Suppl 2:53-65.</citation>
          </article>
          <article>
            <pubmed-id>11570967</pubmed-id>
            <citation>Li R, Hartley L, Robb L: Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period. Reproduction. 2001 Oct;122(4):593-600.</citation>
          </article>
          <article>
            <pubmed-id>8637716</pubmed-id>
            <citation>Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG: The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene. 1996 Feb 1;12(3):585-93.</citation>
          </article>
          <article>
            <pubmed-id>8676079</pubmed-id>
            <citation>Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581-91.</citation>
          </article>
          <article>
            <pubmed-id>9310465</pubmed-id>
            <citation>Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997 Sep 15;90(6):2148-59.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q14626" source="Swiss-Prot">
    <name>Interleukin-11 receptor subunit alpha</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number.</specific-function>
    <gene-name>IL11RA</gene-name>
    <locus>9p13</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>371-391</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>7.91</theoretical-pi>
    <molecular-weight>45221.925</molecular-weight>
    <chromosome-location>9</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5967</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL11RA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>Z38102</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>995654</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q14626</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>I11RA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IL-11 receptor subunit alpha</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000829|Interleukin-11 receptor subunit alpha
MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWF
RDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSC
QAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARC
VVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASW
TYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD
AGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHR
DSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAP
NL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016088|Interleukin-11 receptor subunit alpha (IL11RA)
ATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTG
TCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCA
GGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTT
CGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTC
CTGGCCCAGGCAGACAGCACTGATGAGGGCACCTACATCTGCCAGACCCTGGATGGTGCA
CTTGGGGGCACAGTGACCCTGCAGCTGGGCTACCCTCCAGCCCGCCCTGTTGTCTCCTGC
CAAGCAGCCGACTATGAGAACTTCTCTTGCACTTGGAGTCCCAGCCAGATCAGCGGTTTA
CCCACCCGCTACCTCACCTCCTACAGGAAGAAGACAGTCCTAGGAGCTGATAGCCAGAGG
AGGAGTCCATCCACAGGGCCCTGGCCATGCCCACAGGATCCCCTAGGGGCTGCCCGCTGT
GTTGTCCACGGGGCTGAGTTCTGGAGCCAGTACCGGATTAATGTGACTGAGGTGAACCCA
CTGGGTGCCAGCACACGCCTGCTGGATGTGAGCTTGCAGAGCATCTTGCGCCCTGACCCA
CCCCAGGGCCTGCGGGTAGAGTCAGTACCAGGTTACCCCCGACGCCTGCGAGCCAGCTGG
ACATACCCTGCCTCCTGGCCGTGCCAGCCCCACTTCCTGCTCAAGTTCCGTTTGCAGTAC
CGTCCGGCGCAGCATCCAGCCTGGTCCACGGTGGAGCCAGCTGGACTGGAGGAGGTGATC
ACAGATGCTGTGGCTGGGCTGCCCCATGCTGTACGAGTCAGTGCCCGGGACTTTCTAGAT
GCTGGCACCTGGAGCACCTGGAGCCCGGAGGCCTGGGGAACTCCGAGCACTGGGACCATA
CCAAAGGAGATACCAGCATGGGGCCAGCTACACACGCAGCCAGAGGTGGAGCCTCAGGTG
GACAGCCCTGCTCCTCCAAGGCCCTCCCTCCAACCACACCCTCGGCTACTTGATCACAGG
GACTCTGTGGAGCAGGTAGCTGTGCTGGCGTCTTTGGGAATCCTTTCTTTCCTGGGACTG
GTGGCTGGGGCCCTGGCACTGGGGCTCTGGCTGAGGCTGAGACGGGGTGGGAAGGATGGA
TCCCCAAAGCCTGGGTTCTTGGCCTCAGTGATTCCAGTGGACAGGCGTCCAGGAGCTCCA
AACCTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>signal transducer activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryo implantation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>head development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>developmental process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00039</drugbank-id>
  <drugbank-id>BTD00042</drugbank-id>
  <drugbank-id>BIOD00042</drugbank-id>
  <name>Palifermin</name>
  <description>Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.</description>
  <cas-number>162394-19-6</cas-number>
  <unii>9YXF283GP1</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of oral mucositis associated with chemotherapy and radiation therapy.</indication>
  <pharmacodynamics>Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.</pharmacodynamics>
  <mechanism-of-action>Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>Elimination half-life: 4.5 hours (range: 3.3-5.7 hours)</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">FGF-7</synonym>
    <synonym language="" coder="">Fibroblast growth factor- 7</synonym>
    <synonym language="" coder="">HBGF-7</synonym>
    <synonym language="" coder="">Keratinocyte growth factor precursor</synonym>
    <synonym language="" coder="">KGF</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kepivance</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code>66658-112</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2009-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>6.25 mg/1.2mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125103</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kepivance</name>
      <labeller>SWEDISH ORPHAN BIOVITRUM AB (PUBL)</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02274221</dpd-id>
      <started-marketing-on>2006-03-14</started-marketing-on>
      <ended-marketing-on>2016-01-30</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>6.25 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kepivance</name>
      <ingredients>Palifermin</ingredients>
    </mixture>
    <mixture>
      <name>Kepivance</name>
      <ingredients>Palifermin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Amgen Inc.</name>
      <url>http://www.amgen.com</url>
    </packager>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>BioVitrum AB</name>
      <url>http://www.biovitrum.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Kepivance 6.25 mg vial</description>
      <cost currency="USD">1650.0</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Detoxifying Agents for Antineoplastic Treatment</category>
      <mesh-id/>
    </category>
    <category>
      <category>Fibroblast Growth Factors</category>
      <mesh-id>D005346</mesh-id>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>6.25 mg/1.2mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>6.25 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V03AF08">
      <level code="V03AF">Detoxifying agents for antineoplastic treatment</level>
      <level code="V03A">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V03">ALL OTHER THERAPEUTIC PRODUCTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>84:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1QQK</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00039.pdf?1265922805</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The serum concentration of Palifermin can be increased when it is combined with Heparin.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Palifermin sequence
SYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVE
SEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPV
RGKKTKKEQKTAHFLPMAIT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.650</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.47</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>16192.7</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C721H1142N202O204S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>17147</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M60828</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164744014</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P21781</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001026</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Palifermin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201821</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/kepivance.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/palifermin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000748</id>
      <name>Fibroblast growth factor receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17728847</pubmed-id>
            <citation>Beaven AW, Shea TC: Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc). 2007 Jul;43(7):461-73.</citation>
          </article>
          <article>
            <pubmed-id>16390600</pubmed-id>
            <citation>Radtke ML, Kolesar JM: Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 2005 Sep;11(3):121-5.</citation>
          </article>
          <article>
            <pubmed-id>16854582</pubmed-id>
            <citation>Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):24-33. Epub 2006 Jul 18.</citation>
          </article>
          <article>
            <pubmed-id>7499435</pubmed-id>
            <citation>Patrie KM, Kudla AJ, Olwin BB, Chiu IM: Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors. J Biol Chem. 1995 Dec 1;270(48):29018-24.</citation>
          </article>
          <article>
            <pubmed-id>9056643</pubmed-id>
            <citation>Cardoso WV, Itoh A, Nogawa H, Mason I, Brody JS: FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium. Dev Dyn. 1997 Mar;208(3):398-405.</citation>
          </article>
          <article>
            <pubmed-id>10593896</pubmed-id>
            <citation>Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8.</citation>
          </article>
          <article>
            <pubmed-id>17456767</pubmed-id>
            <citation>Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol. 2007 May;170(5):1618-28.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P21802" source="Swiss-Prot">
    <name>Fibroblast growth factor receptor 2</name>
    <general-function>Protein tyrosine kinase activity</general-function>
    <specific-function>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.</specific-function>
    <gene-name>FGFR2</gene-name>
    <locus>10q26</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>378-398</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>5.68</theoretical-pi>
    <molecular-weight>92024.29</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3689</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGFR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X52832</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31374</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1809</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P21802</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FGFR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>BEK</synonym>
      <synonym>FGFR-2</synonym>
      <synonym>K-sam</synonym>
      <synonym>Keratinocyte growth factor receptor</synonym>
      <synonym>KGFR</synonym>
      <synonym>KSAM</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001492|Fibroblast growth factor receptor 2
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV
RCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF
MVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI
NHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK
YGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL
PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK
RIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK
LTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM
IGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF
KDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT
TNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH
RMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS
PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010527|Fibroblast growth factor receptor 2 (FGFR2)
ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTG
GCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC
AAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTG
CGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGG
CCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA
GACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTC
ATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCG
GAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA
AAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCA
GCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAG
GAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT
GTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAATACGGGTCCATC
AATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCC
GGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTT
TACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAA
TACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACG
GACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATAT
ACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTG
CCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATT
TACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATG
AAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAA
CGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCC
AACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTG
GCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAG
CTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCA
GTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAA
GATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATG
ATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTC
TATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGG
CCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTC
AAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAA
AAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATG
AAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACC
ACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATAC
ACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGG
GGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACAC
AGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGG
CATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATT
CTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCA
CCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCA
GACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAA
ACATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>excitatory synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell cortex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bounded vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>morphogenesis of embryonic epithelium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smooth muscle cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bud elongation involved in lung branching</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial to mesenchymal transition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>limb bud formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>pyramidal neuron development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of canonical Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of smoothened signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell fate commitment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in hemopoiesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>in utero embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung lobe morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>reproductive structure development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>coronal suture morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in mammary gland specification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung-associated mesenchyme development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>odontogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>squamous basal epithelial stem cell differentiation involved in prostate gland acinus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostate epithelial cord elongation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mammary gland bud formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epithelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic cranial skeleton morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic organ morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostate gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membranous septum morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ureteric bud development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>otic vesicle formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell fate commitment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branch elongation involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mesenchymal cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ventricular zone neuroblast division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic organ development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>outflow tract septum morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching involved in labyrinthine layer morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mesenchymal cell differentiation involved in lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic pattern specification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cardiac muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of branching involved in prostate gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair follicle morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of morphogenesis of a branching structure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching involved in prostate gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mesenchymal cell proliferation involved in lung development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endodermal digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ventricular cardiac muscle tissue morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lacrimal gland development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuromuscular junction development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal system morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of osteoblast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mesodermal cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermis morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of epithelial cell proliferation involved in lung morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lateral sprouting from an epithelium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of multicellular organism growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>midbrain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of osteoblast proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching morphogenesis of a nerve</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial cell proliferation involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mesenchymal cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung alveolus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lens fiber cell development</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002129</id>
      <name>Neuropilin-1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10821861</pubmed-id>
            <citation>Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7.</citation>
          </article>
          <article>
            <pubmed-id>9094999</pubmed-id>
            <citation>Friedl A, Chang Z, Tierney A, Rapraeger AC: Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol. 1997 Apr;150(4):1443-55.</citation>
          </article>
          <article>
            <pubmed-id>9890894</pubmed-id>
            <citation>Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O14786" source="Swiss-Prot">
    <name>Neuropilin-1</name>
    <general-function>Vascular endothelial growth factor-activated receptor activity</general-function>
    <specific-function>The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis.The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. It may also induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity.</specific-function>
    <gene-name>NRP1</gene-name>
    <locus>10p12</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>857-879</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>5.71</theoretical-pi>
    <molecular-weight>103133.62</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:8004</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>NRP1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF018956</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>2407641</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O14786</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>NRP1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>NRP</synonym>
      <synonym>Vascular endothelial cell growth factor 165 receptor</synonym>
      <synonym>VEGF165R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037165|Neuropilin-1
MERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQA
PDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLF
IKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFVP
KMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSS
GILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTN
WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKI
DVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFE
VYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSY
INEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSF
EGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLV
DECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTF
CHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAH
CMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVI
FEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGD
KNISRKPGNVLKTLDPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYN
FELVDGVKLKKDKLNTQSTYSEA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021319|Neuropilin-1 (NRP1)
ATGGAGAGGGGGCTGCCGCTCCTCTGCGCCGTGCTCGCCCTCGTCCTCGCCCCGGCCGGC
GCTTTTCGCAACGATAAATGTGGCGATACTATAAAAATTGAAAGCCCCGGGTACCTTACA
TCTCCTGGTTATCCTCATTCTTATCACCCAAGTGAAAAATGCGAATGGCTGATTCAGGCT
CCGGACCCATACCAGAGAATTATGATCAACTTCAACCCTCACTTCGATTTGGAGGACAGA
GACTGCAAGTATGACTACGTGGAAGTCTTCGATGGAGAAAATGAAAATGGACATTTTAGG
GGAAAGTTCTGTGGAAAGATAGCCCCTCCTCCTGTTGTGTCTTCAGGGCCATTTCTTTTT
ATCAAATTTGTCTCTGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAATT
TTCAAGAGAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCC
CCCGGATTCCCTGAAAAATATCCCAACAGCCTTGAATGCACTTATATTGTCTTTGCGCCA
AAGATGTCAGAGATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCT
CCAGGGGGGATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTT
GGCCCTCACATTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCG
GGCATTCTCTCCATGGTTTTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCA
AACTACAGTGTCTTGCAGAGCAGTGTCTCAGAAGATTTCAAATGTATGGAAGCTCTGGGC
ATGGAATCAGGAGAAATTCATTCTGACCAGATCACAGCTTCTTCCCAGTATAGCACCAAC
TGGTCTGCAGAGCGCTCCCGCCTGAACTACCCTGAGAATGGGTGGACTCCCGGAGAGGAT
TCCTACCGAGAGTGGATACAGGTAGACTTGGGCCTTCTGCGCTTTGTCACGGCTGTCGGG
ACACAGGGCGCCATTTCAAAAGAAACCAAGAAGAAATATTATGTCAAGACTTACAAGATC
GACGTTAGCTCCAACGGGGAAGACTGGATCACCATAAAAGAAGGAAACAAACCTGTTCTC
TTTCAGGGAAACACCAACCCCACAGATGTTGTGGTTGCAGTATTCCCCAAACCACTGATA
ACTCGATTTGTCCGAATCAAGCCTGCAACTTGGGAAACTGGCATATCTATGAGATTTGAA
GTATACGGTTGCAAGATAACAGATTATCCTTGCTCTGGAATGTTGGGTATGGTGTCTGGA
CTTATTTCTGACTCCCAGATCACATCATCCAACCAAGGGGACAGAAACTGGATGCCTGAA
AACATCCGCCTGGTAACCAGTCGCTCTGGCTGGGCACTTCCACCCGCACCTCATTCCTAC
ATCAATGAGTGGCTCCAAATAGACCTGGGGGAGGAGAAGATCGTGAGGGGCATCATCATT
CAGGGTGGGAAGCACCGAGAGAACAAGGTGTTCATGAGGAAGTTCAAGATCGGGTACAGC
AACAACGGCTCGGACTGGAAGATGATCATGGATGACAGCAAACGCAAGGCGAAGTCTTTT
GAGGGCAACAACAACTATGATACACCTGAGCTGCGGACTTTTCCAGCTCTCTCCACGCGA
TTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTCAGAATGGAGCTG
CTGGGCTGTGAAGTGGAAGCCCCTACAGCTGGACCGACCACTCCCAACGGGAACTTGGTG
GATGAATGTGATGACGACCAGGCCAACTGCCACAGTGGAACAGGTGATGACTTCCAGCTC
ACAGGTGGCACCACTGTGCTGGCCACAGAAAAGCCCACGGTCATAGACAGCACCATACAA
TCAGGTATCAAATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00754</identifier>
        <name>F5_F8_type_C</name>
      </pfam>
      <pfam>
        <identifier>PF00629</identifier>
        <name>MAM</name>
      </pfam>
      <pfam>
        <identifier>PF00431</identifier>
        <name>CUB</name>
      </pfam>
      <pfam>
        <identifier>PF11980</identifier>
        <name>DUF3481</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>semaphorin receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>early endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neurofilament</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sorting endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>axon</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>semaphorin receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>coreceptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vascular endothelial growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vascular endothelial growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonal fasciculation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ganglion morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toxin transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of extrinsic apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>semaphorin-plexin signaling pathway involved in neuron projection guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>gonadotrophin-releasing hormone neuronal migration to the hypothalamus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet-derived growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell migration involved in sprouting angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory neuron axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>patterning of blood vessels</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of axon extension involved in axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>commissural neuron axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sympathetic neuron projection extension</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of endothelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis involved in coronary vascular morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neural crest cell migration involved in autonomic nervous system development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinal ganglion cell axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sympathetic neuron projection guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon extension involved in axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>otic placode formation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>trigeminal ganglion development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branchiomotor neuron axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hepatocyte growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retina vasculature morphogenesis in camera-type eye</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nerve development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>trigeminal nerve structural organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>coronary artery morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell-cell signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dendrite development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of retinal ganglion cell axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of endothelial cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>VEGF-activated neuropilin signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>dichotomous subdivision of terminal units involved in salivary gland branching</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>semaphorin-plexin signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>artery morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization to early endosome</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>VEGF-activated neuropilin signaling pathway involved in axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to vascular endothelial growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endothelial tip cell fate specification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sympathetic ganglion development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of axon extension involved in axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of retinal ganglion cell axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ventral trunk neural crest cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sprouting angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>facial nerve structural organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis involved in innervation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>renal artery morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vestibulocochlear nerve structural organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>facioacoustic ganglion development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hepatocyte growth factor stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endothelial cell chemotaxis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>semaphorin-plexin signaling pathway involved in axon guidance</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002131</id>
      <name>Fibroblast growth factor receptor 1</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11714710</pubmed-id>
            <citation>Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem. 2002 Jan 25;277(4):2444-53. Epub 2001 Nov 19.</citation>
          </article>
          <article>
            <pubmed-id>10950949</pubmed-id>
            <citation>Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6.</citation>
          </article>
          <article>
            <pubmed-id>11091737</pubmed-id>
            <citation>Matsubara A, Yasumoto H, Usui T: Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor. Breast Cancer. 1999 Oct 25;6(4):320-324.</citation>
          </article>
          <article>
            <pubmed-id>10212269</pubmed-id>
            <citation>Lu W, Luo Y, Kan M, McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999 Apr 30;274(18):12827-34.</citation>
          </article>
          <article>
            <pubmed-id>9890894</pubmed-id>
            <citation>Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11362" source="Swiss-Prot">
    <name>Fibroblast growth factor receptor 1</name>
    <general-function>Protein tyrosine kinase activity</general-function>
    <specific-function>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation.</specific-function>
    <gene-name>FGFR1</gene-name>
    <locus>8p11.2-p11.1</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>377-397</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>6.14</theoretical-pi>
    <molecular-weight>91866.935</molecular-weight>
    <chromosome-location>8</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3688</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGFR1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X51803</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31368</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1808</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P11362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FGFR1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>Basic fibroblast growth factor receptor 1</synonym>
      <synonym>bFGF-R-1</synonym>
      <synonym>BFGFR</synonym>
      <synonym>CEK</synonym>
      <synonym>FGFBR</synonym>
      <synonym>FGFR-1</synonym>
      <synonym>FLG</synonym>
      <synonym>FLT-2</synonym>
      <synonym>FLT2</synonym>
      <synonym>Fms-like tyrosine kinase 2</synonym>
      <synonym>HBGFR</synonym>
      <synonym>N-sam</synonym>
      <synonym>Proto-oncogene c-Fgr</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004180|Fibroblast growth factor receptor 1
MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD
VQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD
ALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS
SGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN
HTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI
GPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE
ALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS
IPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL
GKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK
HKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL
VSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG
RLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD
KPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF
PDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021960|Fibroblast growth factor receptor 1 (FGFR1)
ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC
GCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTG
GAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGAT
GTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGC
ATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCT
TGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGAT
GCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAA
ACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAG
ATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCC
AGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGAC
CACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTG
GTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAAC
CACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGG
TTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTAC
AGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATT
GGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGAC
AAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACG
TGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAA
GCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTAT
TGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAG
AGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGC
ATCCCTCTGCGCAGACAGGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTT
CTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAG
TATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTAGGCAAA
CCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTGGACAAG
GACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCAACAGAG
AAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAGCATAAG
AATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATCGTGGAG
TATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGGCTGGAA
TACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTGGTGTCC
TGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATACACCGA
GACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCAGACTTT
GGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTG
CCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGAT
GTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCC
GGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCC
AGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCA
CAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGACCTCC
AACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTTCCCGAC
ACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGCTGCCC
GAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGC
TGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>receptor complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bounded vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>identical protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of lateral mesodermal cell fate specification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cardiac muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>organ induction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>middle ear morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron projection development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mesenchymal cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chordate embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ureteric bud development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>in utero embryonic development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal system morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>auditory receptor cell development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ventricular zone neuroblast division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>motogenic signaling involved in postnatal olfactory bulb interneuron migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of sound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>branching involved in salivary gland morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>transcription, DNA-templated</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>outer ear morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal system development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell maturation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>paraxial mesoderm development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lung-associated mesenchyme development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of osteoblast differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of extrinsic apoptotic signaling pathway in absence of ligand</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>mesenchymal cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic limb morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>stem cell population maintenance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAP kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>midbrain development</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0001203</id>
      <name>Fibroblast growth factor receptor 4</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>7526860</pubmed-id>
            <citation>Imagawa W, Cunha GR, Young P, Nandi S: Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1165-9.</citation>
          </article>
          <article>
            <pubmed-id>10950949</pubmed-id>
            <citation>Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6.</citation>
          </article>
          <article>
            <pubmed-id>9755102</pubmed-id>
            <citation>Sannes PL, Khosla J, Li CM, Pagan I: Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Am J Physiol. 1998 Oct;275(4 Pt 1):L701-8.</citation>
          </article>
          <article>
            <pubmed-id>9843417</pubmed-id>
            <citation>Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL: The glycine box: a determinant of specificity for fibroblast growth factor. Biochemistry. 1998 Nov 24;37(47):16506-15.</citation>
          </article>
          <article>
            <pubmed-id>11149756</pubmed-id>
            <citation>Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P22455" source="Swiss-Prot">
    <name>Fibroblast growth factor receptor 4</name>
    <general-function>Protein tyrosine kinase activity</general-function>
    <specific-function>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.</specific-function>
    <gene-name>FGFR4</gene-name>
    <locus>5q35.1-qter</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>370-390</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>6.81</theoretical-pi>
    <molecular-weight>87953.535</molecular-weight>
    <chromosome-location>5</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3691</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGFR4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X57205</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31372</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1811</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P22455</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FGFR4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>FGFR-4</synonym>
      <synonym>JTK2</synonym>
      <synonym>TKF</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002393|Fibroblast growth factor receptor 4
MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRA
ERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDS
LTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTP
TIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLD
VLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFP
YVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTA
AAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSL
ESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQ
VVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVC
TQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGM
QYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEA
LFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYG
LMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDS
VFSHDPLPLGSSSFPFGSGVQT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021287|Fibroblast growth factor receptor 4 (FGFR4)
ATGCGGCTGCTGCTGGCCCTGTTGGGGGTCCTGCTGAGTGTGCCTGGGCCTCCAGTCTTG
TCCCTGGAGGCCTCTGAGGAAGTGGAGCTTGAGCCCTGCCTGGCTCCCAGCCTGGAGCAG
CAAGAGCAGGAGCTGACAGTAGCCCTTGGGCAGCCTGTGCGTCTGTGCTGTGGGCGGGCT
GAGCGTGGTGGCCACTGGTACAAGGAGGGCAGTCGCCTGGCACCTGCTGGCCGTGTACGG
GGCTGGAGGGGCCGCCTAGAGATTGCCAGCTTCCTACCTGAGGATGCTGGCCGCTACCTC
TGCCTGGCACGAGGCTCCATGATCGTCCTGCAGAATCTCACCTTGATTACAGGTGACTCC
TTGACCTCCAGCAACGATGATGAGGACCCCAAGTCCCATAGGGACCCCTCGAATAGGCAC
AGTTACCCCCAGCAAGCACCCTACTGGACACACCCCCAGCGCATGGAGAAGAAACTGCAT
GCAGTACCTGCGGGGAACACCGTCAAGTTCCGCTGTCCAGCTGCAGGCAACCCCACGCCC
ACCATCCGCTGGCTTAAGGATGGACAGGCCTTTCATGGGGAGAACCGCATTGGAGGCATT
CGGCTGCGCCATCAGCACTGGAGTCTCGTGATGGAGAGCGTGGTGCCCTCGGACCGCGGC
ACATACACCTGCCTGGTAGAGAACGCTGTGGGCAGCATCCGCTATAACTACCTGCTAGAT
GTGCTGGAGCGGTCCCCGCACCGGCCCATCCTGCAGGCCGGGCTCCCGGCCAACACCACA
GCCGTGGTGGGCAGCGACGTGGAGCTGCTGTGCAAGGTGTACAGCGATGCCCAGCCCCAC
ATCCAGTGGCTGAAGCACATCGTCATCAACGGCAGCAGCTTCGGAGCCGACGGTTTCCCC
TATGTGCAAGTCCTAAAGACTGCAGACATCAATAGCTCAGAGGTGGAGGTCCTGTACCTG
CGGAACGTGTCAGCCGAGGACGCAGGCGAGTACACCTGCCTCGCAGGCAATTCCATCGGC
CTCTCCTACCAGTCTGCCTGGCTCACGGTGCTGCCAGAGGAGGACCCCACATGGACCGCA
GCAGCGCCCGAGGCCAGTTCTCCCTGGAGTCAGGCTCTTCCGGCAAGTCAAGCTCATCCC
TGGTACGAGGCGTGCGTCTCTCCTCCAGCGGCCCCGCCTTGCTCGCCGGCCTCGCTGGTG
CTTGGGAAGCCCCTAGGCGAGGGCTGCTTTGGCCAGGTAGTACGTGCAGAGGCCTTTGGC
ATGGACCCTGCCCGGCCTGACCAAGCCAGCACTGTGGCCGTCAAGATGCTCAAAGACAAC
GCCTCTGACAAGGACCTGGCCGACCTGGTCTCGGAGATGGAGGTGATGAAGCTGATCGGC
CGACACAAGAACATCATCAACCTGCTTGGTGTCTGCACCCAGGAAGGGCCCCTGTACGTG
ATCGTGGAGTGCGCCGCCAAGGGAAACCTGCGGGAGTTCCTGCGGGCCCGGCGCCCCCCA
GGCCCCGACCTCAGCCCCGACGGTCCTCGGAGCAGTGAGGGGCCGCTCTCCTTCCCAGTC
CTGGTCTCCTGCGCCTACCAGGTGGCCCGAGGCATGCAGTATCTGGAGTCCCGGAAGTGT
ATCCACCGGGACCTGGCTGCCCGCAATGTGCTGGTGACTGAGGACAATGTGATGAAGATT
GCTGACTTTGGGCTGGCCCGCGGCGTCCACCACATTGACTACTATAAGAAAACCAGCAAC
GGCCGCCTGCCTGTGAAGTGGATGGCGCCCGAGGCCTTGTTTGACCGGGTGTACACACAC
CAGAGTGACGTGTGGTCTTTTGGGATCCTGCTATGGGAGATCTTCACCCTCGGGGGCTCC
CCGTATCCTGGCATCCCGGTGGAGGAGCTGTTCTCGCTGCTGCGGGAGGGACATCGGATG
GACCGACCCCCACACTGCCCCCCAGAGCTGTACGGGCTGATGCGTGAGTGCTGGCACGCA
GCGCCCTCCCAGAGGCCTACCTTCAAGCAGCTGGTGGAGGCGCTGGACAAGGTCCTGCTG
GCCGTCTCTGAGGAGTACCTCGACCTCCGCCTGACCTTCGGACCCTATTCCCCCTCTGGT
GGGGACGCCAGCAGCACCTGCTCCTCCAGCGATTCTGTCTTCAGCCACGACCCCCTGCCA
TTGGGATCCAGCTCCTTCCCCTTCGGGTCTGGGGTGCAGACATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heparin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of bile acid biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of proteolysis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of DNA biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of metalloenzyme activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cholesterol homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphate ion homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of lipid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002133</id>
      <name>Fibroblast growth factor receptor 3</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>11422746</pubmed-id>
            <citation>Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF: Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 2001 Jul;60(1):147-55.</citation>
          </article>
          <article>
            <pubmed-id>11149756</pubmed-id>
            <citation>Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53.</citation>
          </article>
          <article>
            <pubmed-id>10821861</pubmed-id>
            <citation>Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7.</citation>
          </article>
          <article>
            <pubmed-id>7890137</pubmed-id>
            <citation>Launay C, Fromentoux V, Thery C, Shi DL, Boucaut JC: Comparative analysis of the tissue distribution of three fibroblast growth factor receptor mRNAs during amphibian morphogenesis. Differentiation. 1994 Dec;58(2):101-11.</citation>
          </article>
          <article>
            <pubmed-id>7680555</pubmed-id>
            <citation>Mummery CL, van Rooyen M, Bracke M, van den Eijnden-van Raaij J, van Zoelen EJ, Alitalo K: Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours. Biochem Biophys Res Commun. 1993 Feb 26;191(1):188-95.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P22607" source="Swiss-Prot">
    <name>Fibroblast growth factor receptor 3</name>
    <general-function>Protein tyrosine kinase activity</general-function>
    <specific-function>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.</specific-function>
    <gene-name>FGFR3</gene-name>
    <locus>4p16.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>376-396</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>5.73</theoretical-pi>
    <molecular-weight>87708.905</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3690</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FGFR3</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M58051</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>182569</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1810</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P22607</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FGFR3_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>2.7.10.1</synonym>
      <synonym>FGFR-3</synonym>
      <synonym>JTK4</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004184|Fibroblast growth factor receptor 3
MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS
CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH
FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG
NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT
YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE
EELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK
RQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE
GCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN
LLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW
MAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT
HDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS
SSSGDDSVFAHDLLPPAPPSSGGSRT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021674|Fibroblast growth factor receptor 3 (FGFR3)
ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCC
TCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGC
CCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCTGAGC
TGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
CTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCC
CACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCAC
TTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGGAGGACGAG
GCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGATGGAC
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGC
AACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGC
ATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAAAGCGTGGTGCCC
TCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCG
GCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGAC
GCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAATGGCAGCAAGGTGGGCCCG
GACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTAACACCACCGACAAGGAG
CTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTG
GCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAG
GAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGG
GTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGC
CCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAG
CGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATC
GCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCT
GCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAG
GGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCC
AAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCG
GACCTGGTGTCTGAGATGGAGATGATGAAGATGATCGGGAAACACAAAAACATCATCAAC
CTGCTGGGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAG
GGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGAC
ACCTGCAAGCCGCCCGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAG
GTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCC
CGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGG
GACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGG
ATGGCGCCTGAGGCCTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTT
GGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTG
GAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACA
CACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACC
TTCAAGCAGCTGGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGACGAGTAC
CTGGACCTGTCGGCGCCTTTCGAGCAGTACTCCCCGGGTGGCCAGGACACCCCCAGCTCC
AGCTCCTCAGGGGACGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGC
AGTGGGGGCTCGCGGACGTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF07714</identifier>
        <name>Pkinase_Tyr</name>
      </pfam>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>transport vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor-activated receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein tyrosine kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>fibroblast growth factor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>ATP binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein autophosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>substantia nigra development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>somatic stem cell population maintenance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cochlea development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endochondral ossification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>digestive tract morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to axon injury</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of canonical Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alveolar secondary septum development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of astrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lens morphogenesis in camera-type eye</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smoothened signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>skeletal system development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone maturation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of endothelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epithelial cell fate commitment</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lens fiber cell development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axonogenesis involved in innervation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of protein ubiquitination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor apoptotic signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of mitotic nuclear division</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>central nervous system myelination</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inner ear receptor cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phospholipase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>forebrain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of developmental growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of neuron apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>morphogenesis of an epithelium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>JAK-STAT cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of tyrosine phosphorylation of Stat1 protein</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of ERK1 and ERK2 cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondrocyte proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of phosphatidylinositol 3-kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endochondral bone developmental growth</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of tyrosine phosphorylation of Stat3 protein</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0001031</id>
      <name>Basement membrane-specific heparan sulfate proteoglycan core protein</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>10593896</pubmed-id>
            <citation>Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8.</citation>
          </article>
          <article>
            <pubmed-id>9788974</pubmed-id>
            <citation>Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV: Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998 Oct 15;102(8):1599-608.</citation>
          </article>
          <article>
            <pubmed-id>16989989</pubmed-id>
            <citation>Iwabuchi T, Goetinck PF: Syndecan-4 dependent FGF stimulation of mouse vibrissae growth. Mech Dev. 2006 Nov;123(11):831-41. Epub 2006 Aug 12.</citation>
          </article>
          <article>
            <pubmed-id>14753849</pubmed-id>
            <citation>Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, Nakanishi T, Kajiyama G, Chayama K, Okamoto T: Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):321-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P98160" source="Swiss-Prot">
    <name>Basement membrane-specific heparan sulfate proteoglycan core protein</name>
    <general-function>Protein c-terminus binding</general-function>
    <specific-function>Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.</specific-function>
    <gene-name>HSPG2</gene-name>
    <locus>1p36.1-p34</locus>
    <cellular-location>Secreted</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>6.49</theoretical-pi>
    <molecular-weight>468826.45</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:5273</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>HSPG2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X62515</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>29470</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P98160</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PGBM_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>HSPG</synonym>
      <synonym>Perlecan</synonym>
      <synonym>PLC</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010721|Basement membrane-specific heparan sulfate proteoglycan core protein
MGWRAAGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDML
ADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLE
SEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTS
PQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLG
ISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPR
DYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCP
TKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASR
GQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCE
AMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQI
RLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPE
QFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALNQR
QVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHAT
SHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCNCNGHASSCDPVYGHC
LNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCD
ACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVG
RLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAAS
THTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPG
STPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMA
LAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDC
DTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQR
GTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQG
QPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPD
GCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGA
QLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGN
NIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSV
PLAASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHC
ELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNP
ENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVE
VHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSD
AGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSP
AYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQAS
GTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRL
PAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAA
GVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQV
VVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGS
RLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSS
SHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHV
VGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYK
RGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGST
QPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPA
DSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLV
AGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTI
QQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQI
VGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPT
VVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANN
NIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTW
HKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHV
PAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRL
NQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQ
TLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPE
QEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRN
QELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEG
PVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDA
GTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPA
PTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPY
ATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDS
GRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFH
CAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQ
LVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVV
RIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASG
YPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPE
RVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQ
PDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVN
GTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAH
GISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCV
NRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPL
APDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAER
LNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEV
SVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLC
EHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPG
QYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFI
SLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSP
GPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRA
QAGANTRPCPS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010722|Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2)
ATGGGGTGGCGGGCGGCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTG
GCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACC
GTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTG
GCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAG
ATGGTTTATTTCCGAGCCCTGGTGAATTTCACTCGCTCCATCGAGTACAGCCCTCAGCTG
GAGGATGCAGGCTCCAGAGAGTTCCGAGAGGTGTCCGAGGCTGTGGTAGACACGCTGGAG
TCGGAGTACTTGAAAATTCCCGGAGACCAGGTTGTCAGTGTGGTGTTCATCAAGGAGCTG
GATGGCTGGGTTTTTGTGGAGCTGGATGTGGGCTCGGAAGGGAATGCGGATGGGGCTCAG
ATTCAGGAGATGCTGCTCAGGGTCATCTCCAGCGGCTCTGTGGCCTCCTACGTCACCTCT
CCCCAGGGATTCCAGTTCCGACGCCTGGGCACAGTGCCCCAGTTCCCAAGAGCCTGCACG
GAGGCCGAGTTTGCCTGCCACAGCTACAATGAGTGTGTGGCCCTGGAGTATCGCTGTGAC
CGGCGGCCCGACTGCAGGGACATGTCTGATGAGCTCAATTGTGAGGAGCCAGTCCTGGGT
ATCAGCCCCACATTCTCTCTCCTTGTGGAGACGACATCTTTACCGCCCCGGCCAGAGACA
ACCATCATGCGACAGCCACCAGTCACCCACGCTCCTCAGCCCCTGCTTCCCGGTTCCGTC
AGGCCCCTGCCCTGTGGGCCCCAGGAGGCCGCATGCCGCAATGGGCACTGCATCCCCAGA
GACTACCTCTGCGACGGACAGGAGGACTGCGAGGACGGCAGCGATGAGCTAGACTGTGGC
CCCCCGCCACCCTGTGAGCCCAACGAGTTCCCCTGCGGGAATGGACATTGTGCCCTCAAG
CTGTGGCGCTGCGATGGTGACTTTGACTGTGAGGACCGAACTGATGAAGCCAACTGCCCC
ACCAAGCGTCCTGAGGAAGTGTGCGGGCCCACACAGTTCCGATGCGTCTCTACCAACATG
TGCATCCCAGCCAGCTTCCACTGTGACGAGGAGAGCGACTGTCCTGACCGGAGCGACGAG
TTTGGCTGCATGCCCCCCCAGGTGGTGACACCTCCCCGGGAGTCCATCCAGGCTTCCCGG
GGCCAGACAGTGACCTTCACCTGCGTGGCCATTGGCGTCCCCACCCCCATCATCAATTGG
AGGCTCAACTGGGGCCACATCCCCTCTCATCCCAGGGTGACAGTGACCAGCGAGGGTGGC
CGTGGCACACTGATCATCCGTGATGTGAAGGAGTCAGACCAGGGTGCCTACACCTGTGAG
GCCATGAACGCCCGGGGCATGGTGTTTGGCATTCCTGACGGTGTCCTTGAGCTCGTCCCA
CAACGAGCAGGCCCCTGCCCTGACGGCCACTTCTACCTGGAGCACAGCGCCGCCTGCCTG
CCCTGCTTCTGCTTTGGCATCACCAGCGTGTGCCAGAGCACCCGCCGCTTCCGGGACCAG
ATCAGGCTGCGCTTTGACCAACCCGATGACTTCAAGGGTGTGAATGTGACAATGCCTGCG
CAGCCCGGCACGCCACCCCTCTCCTCCACGCAGCTGCAGATCGACCCATCCCTGCACGAG
TTCCAGCTAGTCGACCTGTCCCGCCGCTTCCTCGTCCACGACTCCTTCTGGGCTCTGCCT
GAACAGTTCCTGGGCAACAAGGTGGACTCCTATGGCGGCTCCCTGCGTTACAACGTGCGC
TACGAGTTGGCCCGTGGCATGCTGGAGCCAGTGCAGCGGCCGGACGTGGTCCTCATGGGT
GCCGGGTACCGCCTCCTCTCCCGAGGCCACACACCCACCCAACCTGGTGCTCTGAACCAG
CGCCAGGTCCAGTTCTCTGAGGAGCACTGGGTCCATGAGTCTGGCCGGCCGGTGCAGCGC
GCGGAGCTGCTGCAGGTGCTGCAGAGCCTGGAGGCCGTGCTCATCCAGACCGTGTACAAC
ACCAAGATGGCCAGCGTGGGACTTAGCGACATCGCCATGGATACCACCGTCACCCATGCC
ACCAGCCATGGCCGTGCCCACAGTGTGGAGGAGTGCAGATGCCCCATTGGCTATTCTGGC
TTGTCCTGCGAGAGCTGTGATGCCCACTTCACTCGGGTGCCTGGTGGGCCCTACCTGGGC
ACCTGCTCTGGTTGCAATTGCAATGGCCATGCCAGCTCCTGTGACCCTGTGTATGGCCAC
TGCCTGAATTGCCAGCACAACACGGAGGGGCCACAGTGCAACAAGTGCAAGGCTGGCTTC
TTTGGGGACGCCATGAAGGCCACGGCCACTTCCTGCCGGCCCTGCCCTTGCCCATACATC
GATGCCTCCCGCAGATTCTCAGACACTTGCTTCCTGGACACGGATGGCCAAGCCACATGT
GACGCCTGTGCCCCAGGCTACACTGGCCGCCGCTGTGAGAGCTGTGCCCCCGGATACGAG
GGCAACCCCATCCAGCCCGGCGGGAAGTGCAGGCCCGTCAACCAGGAGATTGTGCGCTGT
GACGAGCGTGGCAGCATGGGGACCTCCGGGGAGGCCTGCCGCTGTAAGAACAATGTGGTG
GGGCGCTTGTGCAATGAATGTGCTGACGGCTCTTTCCACCTGAGTACCCGAAACCCCGAT
GGCTGCCTCAAGTGCTTCTGCATGGGTGTCAGTCGCCACTGCACCAGCTCTTCATGGAGC
CGTGCCCAGTTGCATGGGGCCTCTGAGGAGCCTGGTCACTTCAGCCTGACCAACGCCGCA
AGCACCCACACCACCAACGAGGGCATCTTCTCCCCCACGCCCGGGGAACTGGGATTCTCC
TCCTTCCACAGACTCTTATCTGGACCCTACTTCTGGAGCCTCCCTTCACGCTTCCTGGGG
GACAAGGTGACCTCCTATGGAGGAGAGCTGCGCTTCACAGTGACCCAGAGGTCCCAGCCG
GGCTCCACACCCCTGCACGGGCAGCCGTTGGTGGTGCTGCAAGGTAACAACATCATCCTA
GAGCACCATGTGGCCCAGGAGCCCAGCCCCGGCCAGCCCAGCACCTTCATTGTGCCTTTC
CGGGAGCAAGCATGGCAGCGGCCCGATGGGCAGCCAGCCACACGGGAGCACCTGCTGATG
GCACTGGCAGGCATCGACACCCTCCTGATCCGAGCATCCTACGCCCAGCAGCCCGCTGAG
AGCAGGGTCTCTGGCATCAGCATGGACGTGGCTGTGCCCGAGGAAACCGGCCAGGACCCC
GCGCTGGAAGTGGAACAGTGCTCCTGCCCACCCGGGTACCGTGGGCCGTCCTGCCAGGAC
TGTGACACAGGCTACACACGCACGCCCAGTGGCCTCTACCTGGGTACCTGTGAACGCTGC
AGCTGCCATGGCCACTCAGAGGCCTGCGAGCCAGAAACAGGTGCCTGCCAGGGCTGCCAG
CATCACACGGAGGGCCCTCGGTGTGAGCAGTGCCAGCCAGGATACTACGGGGACGCCCAG
CGGGGGACACCACAGGACTGCCAGCTGTGCCCCTGCTACGGAGACCCTGCTGCCGGCCAG
GCTGCCCACACTTGTTTTCTGGACACAGACGGCCACCCCACCTGTGATGCGTGCTCCCCA
GGCCACAGTGGGCGTCACTGTGAGAGGTGCGCCCCTGGCTACTATGGCAACCCCAGCCAG
GGCCAGCCATGCCAGAGAGACAGCCAGGTGCCAGGGCCCATAGGCTGCAACTGTGACCCC
CAAGGCAGCGTCAGCAGCCAGTGTGATGCTGCTGGTCAGTGCCAGTGCAAGGCCCAGGTG
GAAGGCCTCACTTGCAGCCACTGCCGGCCCCACCACTTCCACCTGAGTGCCAGCAACCCA
GACGGCTGCCTGCCCTGCTTCTGTATGGGCATCACCCAGCAGTGCGCCAGCTCTGCCTAC
ACACGCCACCTGATCTCCACCCACTTTGCCCCTGGGGACTTCCAAGGCTTTGCCCTGGTG
AACCCACAGCGAAACAGCCGCCTGACAGGAGAATTCACTGTGGAACCCGTGCCCGAGGGT
GCCCAGCTCTCTTTTGGCAACTTTGCCCAACTCGGCCATGAGTCCTTCTACTGGCAGCTG
CCGGAGACATACCAGGGAGACAAGGTGGCGGCCTACGGTGGGAAGTTGCGATACACCCTC
TCCTACACAGCAGGCCCACAGGGCAGCCCACTCTCTGACCCCGATGTGCAGATCACGGGC
AACAACATCATGCTAGTGGCCTCCCAGCCAGCGCTGCAGGGCCCTGAGAGGAGGAGCTAC
GAGATCATGTTCCGAGAGGAATTCTGGCGCCGGCCCGATGGGCAGCCGGCCACACGCGAG
CACCTCCTGATGGCACTGGCCGACCTGGATGAGCTCCTGATCCGGGCCACGTTCTCCTCC
GTGCCGCTGGCGGCCAGCATCAGCGCAGTCAGCCTGGAGGTCGCCCAGCCGGGGCCCTCA
AACAGACCCCGCGCCCTCGAGGTGGAGGAGTGCCGCTGCCCGCCAGGCTACATCGGTCTG
TCCTGCCAGGACTGTGCCCCCGGCTACACGCGCACCGGGAGTGGGCTCTACCTCGGCCAC
TGCGAGCTATGTGAATGCAATGGCCACTCAGACCTGTGCCACCCAGAGACTGGGGCCTGC
TCGCAATGCCAGCACAACGCCGCAGGGGAGTTCTGCGAGCTTTGTGCCCCTGGCTACTAC
GGAGATGCCACAGCCGGGACGCCTGAGGACTGCCAGCCCTGTGCCTGCCCACTGACCAAC
CCAGAGAACATGTTTTCCCGCACCTGTGAGAGCCTGGGAGCCGGCGGGTACCGCTGCACG
GCCTGCGAACCCGGCTACACTGGCCAGTACTGTGAGCAGTGTGGCCCAGGTTACGTGGGT
AACCCCAGTGTGCAAGGGGGCCAGTGCCTGCCAGAGACAAACCAAGCCCCACTGGTGGTC
GAGGTCCATCCTGCTCGAAGCATAGTGCCCCAAGGTGGCTCCCACTCCCTGCGGTGTCAG
GTCAGTGGGAGCCCACCCCACTACTTCTATTGGTCCCGTGAGGATGGGCGGCCTGTGCCC
AGCGGCACCCAGCAGCGACATCAAGGCTCCGAGCTCCACTTCCCCAGCGTCCAGCCCTCG
GATGCTGGGGTCTACATTTGCACCTGCCGTAATCTCCACCAATCCAATACCAGCCGGGCA
GAGCTGCTGGTCACTGAGGCTCCAAGCAAGCCCATCACAGTGACTGTGGAGGAGCAGCGG
AGCCAGAGCGTGCGCCCCGGAGCTGACGTCACCTTCATCTGCACAGCCAAAAGCAAGTCC
CCAGCCTATACCCTGGTGTGGACCCGCCTGCACAACGGGAAACTGCCCACCCGAGCCATG
GATTTCAATGGCATCCTGACCATTCGCAACGTCCAGCTGAGTGATGCAGGCACCTACGTG
TGCACCGGCTCCAACATGTTTGCCATGGACCAGGGCACAGCCACTCTACATGTGCAGGCC
TCGGGCACCTTGTCCGCCCCCGTGGTCTCCATCCATCCGCCACAGCTCACAGTGCAGCCC
GGGCAACTGGCGGAGTTCCGCTGCAGCGCCACAGGGAGCCCCACGCCCACCCTCGAGTGG
ACAGGGGGCCCCGGCGGCCAGCTCCCTGCGAAGGCACAAATCCACGGCGGCATCCTGCGC
CTGCCAGCTGTCGAGCCCACGGATCAGGCCCAGTACTTGTGCCGAGCCCACAGCAGCGCT
GGGCAGCAGGTGGCCAGGGCTGTGCTCCACGTGCATGGGGGCGGTGGGCCCAGAGTCCAA
GTGAGCCCAGAGAGGACCCAGGTCCACGCAGGCCGCACCGTCAGGCTGTACTGCAGGGCT
GCAGGCGTGCCTAGCGCCACCATCACCTGGAGGAAGGAAGGGGGCAGCCTCCCACCACAG
GCCCGGTCAGAGCGCACAGACATCGCGACACTGCTCATCCCAGCCATCACGACTGCTGAC
GCCGGCTTCTACCTCTGCGTGGCCACCAGCCCTGCAGGCACTGCCCAGGCCCGGATCCAA
GTGGTTGTCCTTTCAGCCTCAGATGCCAGCCCACCGCCGGTCAAGATTGAGTCCTCATCG
CCTTCTGTGACAGAAGGGCAAACACTCGACCTCAACTGTGTGGTGGCAGGGTCAGCCCAT
GCCCAGGTCACCTGGTACAGGCGAGGGGGTAGCCTGCCTCCCCACACCCAGGTGCACGGC
TCCCGTCTGCGGCTCCCCCAGGTCTCACCAGCTGATTCTGGAGAATATGTGTGCCGTGTG
GAGAATGGATCGGGCCCCAAGGAGGCCTCCATTACTGTGTCTGTGCTCCACGGCACCCAT
TCTGGCCCCAGCTACACCCCAGTGCCCGGCAGCACCCGGCCCATCCGCATCGAGCCCTCC
TCCTCACACGTGGCGGAAGGGCAGACCCTGGATCTGAACTGCGTGGTGCCCGGGCAGGCC
CACGCCCAGGTCACGTGGCACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGACCCAC
GGCTCGCTGCTGCGGCTGCACCAGGTGACCCCGGCCGACTCAGGCGAGTATGTGTGCCAT
GTGGTGGGCACCTCCGGCCCCCTAGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCTGTC
ATCCCTGGACCCATCCCACCTGTCAGGATCGAGTCTTCATCCTCCACAGTGGCCGAGGGC
CAGACCCTGGATCTGAGCTGCGTGGTGGCAGGGCAGGCCCACGCCCAGGTCACATGGTAC
AAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGGTTCGTGGCTCCCGCCTGTACATCTTC
CAGGCCTCACCTGCCGATGCGGGACAGTACGTCTGCCGGGCCAGCAACGGCATGGAGGCC
TCCATCACGGTCACAGTAACTGGGACCCAGGGGGCCAACTTAGCCTACCCTGCCGGCAGC
ACCCAGCCCATCCGCATCGAGCCCTCCTCCTCGCAAGTGGCGGAAGGGCAGACCCTGGAT
CTGAACTGCGTGGTGCCCGGGCAGTCCCATGCCCAGGTCACGTGGCACAAGCGTGGGGGC
AGCCTCCCTGTCCGGCACCAGACCCACGGCTCCCTGCTGAGACTCTACCAAGCGTCCCCC
GCCGACTCGGGCGAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCTCTAGAGGCCTCT
GTCCTGGTCACCATTGAGCCTGCGGGCTCAGTGCCTGCACTTGGGGTCACCCCCACGGTC
CGGATCGAGTCATCGTCTTCGCAAGTGGCCGAGGGGCAGACCCTGGACCTGAACTGCCTC
GTTGCTGGTCAGGCCCATGCCCAGGTCACGTGGCACAAGCGCGGGGGCAGCCTCCCGGCC
CGGCACCAGGTGCATGGCTCGAGGCTACGCCTGCTCCAGGTGACCCCAGCTGATTCAGGG
GAGTACGTGTGCCGTGTGGTCGGCAGCTCAGGTACCCAGGAAGCCTCAGTCCTTGTCACC
ATCCAGCAGCGCCTTAGTGGCTCCCACTCCCAGGGTGTGGCGTACCCCGTCCGCATCGAG
TCCTCCTCAGCCTCCCTGGCCAATGGACACACCCTGGACCTCAACTGCCTGGTTGCCAGC
CAGGCTCCCCACACCATCACCTGGTATAAGCGTGGAGGCAGCTTACCCAGCCGGCACCAG
ATCGTGGGCTCCCGGCTGCGGATCCCTCAGGTGACTCCGGCAGACTCGGGCGAGTACGTG
TGTCACGTCAGTAACGGTGCAGGCTCCCGGGAGACCTCGCTCATCGTCACCATCCAGGGC
AGCGGTTCCTCCCACGTGCCCAGCGTCTCCCCACCGATCAGGATCGAGTCGTCTTCCCCC
ACGGTGGTGGAAGGGCAGACCTTGGATCTGAACTGCGTGGTCGCCAGGCAGCCCCAGGCT
ATCATCACATGGTACAAGCGTGGGGGCAGCCTTCCCTCCCGACACCAGACCCATGGCTCC
CACCTGCGGTTGCACCAAATGTCTGTGGCTGACTCGGGCGAGTATGTGTGCCGGGCCAAC
AACAACATCGATGCCCTGGAGGCCTCCATCGTCATCTCCGTCTCCCCTAGCGCCGGCAGC
CCCTCCGCCCCTGGCAGCTCCATGCCCATCAGAATTGAGTCATCCTCCTCACACGTGGCC
GAAGGGGAGACCCTGGATCTGAACTGCGTGGTCCCCGGGCAGGCCCATGCCCAGGTCACT
TGGCACAAGCGTGGGGGCAGCCTCCCCAGTCACCATCAGACCCGCGGCTCACGGCTGCGG
CTGCACCATGTGTCCCCGGCCGACTCGGGTGAATACGTGTGCCGGGTGATGGGCAGCTCT
GGCCCCCTGGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCTGGCTCAAGTGCTGTCCAC
GTCCCCGCCCCAGGTGGAGCCCCACCCATCCGCATCGAGCCCTCCTCCTCCCGAGTGGCA
GAAGGGCAGACCCTGGATCTGAAGTGCGTGGTGCCCGGGCAGGCCCACGCCCAGGTCACG
TGGCACAAGCGTGGAGGAAACCTCCCTGCCCGGCACCAGGTCCACGGCCCACTGCTGAGG
CTGAACCAGGTGTCCCCGGCTGACTCTGGCGAGTACTCGTGCCAAGTGACCGGAAGCTCA
GGCACCCTGGAGGCATCTGTCCTGGTCACAATTGAGCCCTCCAGCCCAGGACCCATTCCT
GCTCCAGGACTGGCCCAGCCCATCTACATCGAGGCCTCCTCTTCACACGTGACTGAAGGG
CAGACTCTGGATCTGAACTGTGTGGTGCCCGGGCAGGCCCATGCCCAGGTCACGTGGTAC
AAGCGCGGGGGCAGCCTCCCCGCCCGGCACCAGACCCATGGCTCCCAGCTGCGGCTCCAC
CTCGTCTCCCCTGCCGACTCAGGCGAGTATGTGTGTCGTGCAGCCAGCGGCCCAGGCCCT
GAGCAAGAAGCCTCCTTCACAGTCACCGTCCCGCCCAGTGAGGGGTCTTCCTACCGCCTT
AGGAGCCCGGTCATCTCCATCGACCCGCCCAGCAGCACCGTGCAGCAGGGCCAGGATGCC
AGCTTCAAGTGCCTCATCCATGACGGGGCAGCCCCCATCAGCCTCGAGTGGAAGACCCGG
AACCAGGAGCTGGAGGACAACGTCCACATCAGTCCCAATGGCTCCATCATCACCATCGTG
GGCACCCGGCCCAGCAACCACGGTACCTACCGCTGCGTGGCCTCCAATGCCTACGGTGTG
GCCCAGAGTGTGGTGAACCTCAGTGTGCACGGGCCCCCTACAGTGTCCGTGCTCCCCGAG
GGCCCCGTGTGGGTGAAAGTGGGAAAGGCTGTCACCCTGGAGTGTGTCAGTGCCGGGGAG
CCCCGCTCCTCTGCTCGTTGGACCCGGATCAGCAGCACCCCTGCCAAGTTGGAGCAGCGG
ACATATGGGCTCATGGACAGCCACGCGGTGCTGCAGATTTCATCAGCTAAACCATCAGAT
GCGGGCACTTATGTGTGCCTTGCTCAGAATGCACTAGGCACAGCACAGAAGCAGGTGGAG
GTGATCGTGGACACGGGCGCCATGGCCCCAGGGGCCCCTCAGGTCCAAGCTGAAGAAGCT
GAGCTGACTGTGGAGGCTGGACACACGGCCACCTTGCGCTGCTCAGCCACAGGCAGCCCC
GCGCCCACCATCCACTGGTCCAAGCTGCGTTCCCCACTGCCCTGGCAGCACCGGCTGGAA
GGTGACACACTCATCATACCCCGGGTAGCCCAGCAGGACTCGGGCCAGTACATCTGCAAT
GCCACTAGCCCTGCTGGGCACGCTGAGGCCACCATCATCCTGCACGTGGAGAGCCCACCA
TATGCCACCACGGTCCCAGAGCACGCTTCGGTGCAGGCAGGGGAGACGGTGCAGCTCCAG
TGCCTGGCTCACGGGACACCCCCACTCACCTTCCAGTGGAGCCGCGTGGGCAGCAGCCTT
CCTGGGAGGGCGACCGCCAGGAACGAGCTGCTGCACTTTGAGCGTGCAGCCCCTGAGGAC
TCAGGCCGCTACCGCTGCCGGGTCACCAACAAGGTGGGCTCAGCCGAGGCCTTTGCCCAG
CTGCTCGTCCAAGGCCCTCCCGGCTCTCTCCCTGCCACCTCCATCCCAGCAGGGTCCACG
CCCACCGTGCAGGTCACGCCTCAGCTAGAGACCAAGAGCATTGGGGCCAGCGTTGAGTTC
CACTGTGCTGTGCCCAGCGACCGGGGTACCCAGCTCCGTTGGTTCAAGGAAGGGGGTCAG
CTGCCTCCGGGTCACAGCGTGCAGGATGGGGTGCTCCGAATCCAGAACTTGGACCAGAGC
TGCCAAGGGACGTATATATGCCAGGCCCATGGACCTTGGGGGAAGGCCCAGGCCAGTGCC
CAGCTGGTTATCCAAGCCCTGCCCTCGGTGCTCATCAACATCCGGACCTCTGTGCAGACC
GTGGTGGTTGGCCACGCCGTGGAGTTCGAATGCCTGGCACTGGGTGACCCCAAGCCTCAG
GTGACATGGAGCAAAGTTGGAGGGCACCTGCGGCCAGGCATTGTGCAGAGCGGAGGTGTC
GTCAGGATCGCCCACGTAGAGCTGGCTGATGCGGGACAGTATCGCTGCACTGCCACCAAC
GCAGCTGGCACCACACAATCCCACGTCCTGCTGCTTGTGCAAGCCTTGCCCCAGATCTCA
ATGCCCCAAGAAGTCCGTGTGCCTGCTGGTTCTGCAGCTGTCTTCCCCTGCATAGCCTCA
GGCTACCCCACTCCTGACATCAGCTGGAGCAAGCTGGATGGCAGCCTGCCACCTGACAGC
CGCCTGGAGAACAACATGCTGATGCTGCCCTCAGTCCGACCCCAGGACGCAGGTACCTAC
GTCTGCACCGCCACTAACCGCCAGGGCAAGGTCAAAGCCTTTGCCCACCTGCAGGTGCCA
GAGCGGGTGGTGCCCTACTTCACGCAGACCCCCTACTCCTTCCTACCGCTGCCCACCATC
AAGGATGCCTACAGGAAGTTCGAGATCAAGATCACCTTCCGGCCCGACTCAGCCGATGGG
ATGCTGCTGTACAATGGGCAGAAGCGAGTCCCAGGGAGCCCCACCAACCTGGCCAACCGG
CAGCCCGACTTCATCTCCTTCGGCCTCGTGGGGGGAAGGCCCGAGTTCCGGTTCGATGCA
GGCTCAGGCATGGCCACCATCCGCCATCCCACACCACTGGCCCTGGGCCATTTCCACACC
GTGACCCTGCTGCGCAGCCTCACCCAGGGCTCCCTGATTGTGGGTGACCTGGCCCCGGTC
AATGGGACCTCCCAGGGCAAGTTCCAGGGCCTGGATCTGAACGAGGAACTCTACCTGGGT
GGCTATCCTGACTATGGTGCCATCCCCAAGGCGGGGCTGAGCAGCGGCTTCATAGGCTGT
GTCCGGGAGCTGCGCATCCAGGGCGAGGAGATCGTCTTCCATGACCTCAACCTCACGGCG
CACGGCATCTCCCACTGCCCCACCTGTCGGGACCGGCCCTGCCAGAATGGCGGTCAGTGC
CATGACTCTGAGAGCAGCAGCTACGTGTGCGTCTGCCCAGCTGGCTTCACCGGGAGCCGC
TGTGAGCACTCGCAGGCCCTGCACTGCCATCCAGAGGCCTGTGGGCCCGACGCCACCTGT
GTGAACCGGCCTGACGGTCGAGGCTACACCTGCCGCTGCCACCTGGGCCGCTCGGGGTTG
CGGTGTGAGGAAGGTGTGACAGTGACCACCCCCTCGCTGTCGGGTGCTGGCTCCTACCTG
GCACTGCCCGCCCTCACCAACACACACCACGAGCTACGCCTGGACGTGGAGTTCAAGCCA
CTCGCCCCTGACGGGGTCCTGCTGTTCAGCGGGGGGAAGAGCGGGCCTGTGGAGGACTTC
GTGTCCCTGGCGATGGTGGGCGGCCACCTGGAGTTCCGCTATGAGTTGGGGTCAGGGCTG
GCCGTTCTGCGGAGCGCCGAGCCGCTGGCCCTGGGCCGCTGGCACCGTGTGTCTGCAGAG
CGTCTCAACAAGGACGGCAGCCTGCGGGTGAATGGTGGACGCCCTGTGCTGCGCTCCTCG
CCCGGCAAGAGCCAGGGCCTCAACCTGCACACCCTGCTCTACCTGGGGGGTGTGGAGCCT
TCCGTGCCACTGTCCCCGGCCACCAACATGAGCGCTCACTTCCGCGGCTGTGTGGGCGAG
GTGTCAGTGAATGGCAAACGGCTGGACCTCACCTACAGTTTCCTAGGCAGCCAGGGCATC
GGGCAATGCTATGATAGCTCCCCATGTGAGCGCCAGCCTTGCCAACATGGTGCCACGTGC
ATGCCCGCTGGCGAGTATGAGTTCCAGTGCCTGTGTCGAGATGGATTCAAAGGAGACCTG
TGTGAGCACGAGGAGAACCCCTGCCAGCTCCGTGAACCCTGTCTGCATGGGGGCACCTGC
CAGGGCACCCGCTGCCTCTGCCTCCCTGGCTTCTCTGGCCCACGCTGCCAACAAGGCTCT
GGACATGGCATAGCAGAGTCCGACTGGCATCTTGAAGGCAGCGGGGGCAATGATGCCCCT
GGGCAGTACGGAGCCTATTTCCACGATGATGGCTTCCTCGCCTTCCCTGGCCATGTCTTC
TCCAGGAGCCTGCCCGAGGTGCCCGAGACCATCGAGCTGGAGGTTCGGACCAGCACAGCC
AGTGGCCTCCTGCTCTGGCAGGGTGTGGAGGTGGGAGAGGCCGGCCAAGGCAAGGACTTC
ATCAGCCTCGGGCTTCAAGACGGGCACCTTGTCTTCAGGTACCAGCTGGGTAGTGGGGAG
GCCCGCCTGGTCTCTGAGGACCCCATCAATGACGGCGAGTGGCACCGGGTGACAGCACTG
CGGGAGGGCCGCAGAGGTTCCATCCAAGTCGACGGTGAGGAGCTGGTCAGCGGCCGGTCC
CCAGGTCCCAACGTGGCAGTCAACGCCAAGGGCAGCGTCTACATCGGCGGAGCCCCTGAC
GTGGCCACGCTGACCGGGGGCAGATTCTCCTCAGGCATCACAGGCTGTGTCAAGAACCTG
GTGCTGCACTCGGCCCGACCCGGCGCCCCGCCCCCACAGCCCCTGGACCTGCAGCACCGC
GCCCAGGCCGGGGCCAACACACGCCCCTGCCCCTCGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00047</identifier>
        <name>ig</name>
      </pfam>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
      <pfam>
        <identifier>PF07679</identifier>
        <name>I-set</name>
      </pfam>
      <pfam>
        <identifier>PF00057</identifier>
        <name>Ldl_recept_a</name>
      </pfam>
      <pfam>
        <identifier>PF00054</identifier>
        <name>Laminin_G_1</name>
      </pfam>
      <pfam>
        <identifier>PF00052</identifier>
        <name>Laminin_B</name>
      </pfam>
      <pfam>
        <identifier>PF00053</identifier>
        <name>Laminin_EGF</name>
      </pfam>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>basal lamina</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>focal adhesion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>lysosomal lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular matrix</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular region</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein C-terminus binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phototransduction, visible light</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoprotein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondrocyte differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>carbohydrate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brain development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chondroitin sulfate metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryonic skeletal system morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cartilage development involved in endochondral bone morphogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>endochondral ossification</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycosaminoglycan biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix disassembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>retinoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>extracellular matrix organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein localization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiac muscle tissue development</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00040</drugbank-id>
  <drugbank-id>BTD00057</drugbank-id>
  <drugbank-id>BIOD00057</drugbank-id>
  <name>Glucagon recombinant</name>
  <description>29 residue peptide hormone. Glucagon is synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons</description>
  <cas-number>16941-32-5</cas-number>
  <unii>76LA80IG2G</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>10234590</pubmed-id>
        <citation>White CM: A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999 May;39(5):442-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of severe hypoglycemia, also used in gastrointestinal imaging</indication>
  <pharmacodynamics>Used in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.</pharmacodynamics>
  <mechanism-of-action>Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>* 0.25 L/kg</volume-of-distribution>
  <clearance>* 13.5  mL/min/kg [Adults with IV 1 mg]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001413</drugbank-id>
      <name>Glucagon hydrochloride</name>
      <unii>1H87NVF4DB</unii>
      <cas-number>19179-82-9</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="" coder="">Glucagon</synonym>
    <synonym language="" coder="">Glucagon (recombinant dna origin)</synonym>
    <synonym language="" coder="">Glucagon, human</synonym>
    <synonym language="" coder="">Glucagon, porcine</synonym>
    <synonym language="" coder="">Glucagone</synonym>
    <synonym language="" coder="">Glucagonum</synonym>
  </synonyms>
  <products>
    <product>
      <name>GlucaGen</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0053</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GlucaGen</name>
      <labeller>Bedford Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>55390-004</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-06-22</started-marketing-on>
      <ended-marketing-on>2017-01-19</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>GlucaGen</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0260</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02333619</dpd-id>
      <started-marketing-on>2010-01-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>GlucaGen HypoKit</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-7065</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-06-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020918</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagen Hypokit</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02333627</dpd-id>
      <started-marketing-on>2009-12-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8031</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020928</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-8031</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020928</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0639</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-03-01</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020928</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-596</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1 mg/mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>NDA201849</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243297</dpd-id>
      <started-marketing-on>2002-05-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5070</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2004-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA020928</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-593</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA201849</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code>63323-594</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>NDA201849</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Glucagon Ampoule 666 1mg</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00015377</dpd-id>
      <started-marketing-on>1961-12-31</started-marketing-on>
      <ended-marketing-on>2002-05-27</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>GlucaGen HypoKit</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>GlucaGen</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>GlucaGen</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>GlucaGen</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon Ampoule 666 1mg</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagen</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagen Hypokit</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
    <mixture>
      <name>Glucagon</name>
      <ingredients>Glucagon recombinant</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bedford Labs</name>
      <url>http://www.bedfordlabs.com</url>
    </packager>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Novo Nordisk Inc.</name>
      <url>http://www.novonordisk.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Eli lilly and co</manufacturer>
    <manufacturer generic="false" url="">Novo nordisk pharmaceuticals inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Glucagen 1 mg vial</description>
      <cost currency="USD">84.0</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Glucagon 1 mg/vial</description>
      <cost currency="USD">94.98</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Glucagon 1 mg emergency kit</description>
      <cost currency="USD">119.28</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>Glucagen 1 mg hypokit</description>
      <cost currency="USD">120.36</cost>
      <unit>kit</unit>
    </price>
    <price>
      <description>GlucaGen HypoKit 1 mg Solution Box</description>
      <cost currency="USD">123.72</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Glucagon Emergency 1 mg Kit Box</description>
      <cost currency="USD">124.05</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>Glucagon 1 mg kit</description>
      <cost currency="USD">128.34</cost>
      <unit>kit</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Agents</category>
      <mesh-id>D005765</mesh-id>
    </category>
    <category>
      <category>Gastrointestinal Hormones</category>
      <mesh-id>D005768</mesh-id>
    </category>
    <category>
      <category>Glycogenolytic Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Pancreatic Hormones</category>
      <mesh-id>D010187</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proglucagon</category>
      <mesh-id>D052336</mesh-id>
    </category>
    <category>
      <category>Protein Precursors</category>
      <mesh-id>D011498</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intramuscular</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>1 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>1 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="H04AA01">
      <level code="H04AA">Glycogenolytic hormones</level>
      <level code="H04A">GLYCOGENOLYTIC HORMONES</level>
      <level code="H04">PANCREATIC HORMONES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:22.12</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1GCN</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00040.pdf?1265922805</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The risk or severity of adverse effects can be increased when Trospium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Benzatropine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium bromide</name>
      <description>The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Ethopropazine</name>
      <description>The risk or severity of adverse effects can be increased when Ethopropazine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine Triethiodide</name>
      <description>The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine Methylbromide</name>
      <description>The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of adverse effects can be increased when Atropine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The risk or severity of adverse effects can be increased when Methantheline is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of adverse effects can be increased when Tolterodine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Pentolinium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The risk or severity of adverse effects can be increased when Tiotropium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of adverse effects can be increased when Solifenacin is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Hexamethonium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The risk or severity of adverse effects can be increased when Dexetimide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of adverse effects can be increased when Benactyzine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Scopolamine butylbromide</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The risk or severity of adverse effects can be increased when Metixene is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Umeclidinium is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The risk or severity of adverse effects can be increased when Propiverine is combined with Glucagon recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Glucagon recombinant may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Glucagon for Injection Sequence 
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-1.197</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>9.52</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>3767.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C165H249N49O51S1</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12072</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11363</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C01501</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00116</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>AF529185</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164779052</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>Q8MJ25</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001037</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Glucagon_recombinant</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL266481</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/gluca.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/glucagon.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000527</id>
      <name>Glucagon receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17462598</pubmed-id>
            <citation>Katayama T, Shimamoto S, Oda H, Nakahara K, Kangawa K, Murakami N: Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. Epub 2007 Apr 9.</citation>
          </article>
          <article>
            <pubmed-id>17620721</pubmed-id>
            <citation>Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F: Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601. Epub 2007 Jun 15.</citation>
          </article>
          <article>
            <pubmed-id>17623014</pubmed-id>
            <citation>Li XC, Zhuo JL: Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. Clin Sci (Lond). 2007 Aug;113(4):183-93.</citation>
          </article>
          <article>
            <pubmed-id>17534934</pubmed-id>
            <citation>Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49.</citation>
          </article>
          <article>
            <pubmed-id>17479245</pubmed-id>
            <citation>Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, Ahren B: Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia. 2007 Jul;50(7):1453-62. Epub 2007 May 4.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <pubmed-id>8020989</pubmed-id>
            <citation>Menzel S, Stoffel M, Espinosa R 3rd, Fernald AA, Le Beau MM, Bell GI: Localization of the glucagon receptor gene to human chromosome band 17q25. Genomics. 1994 Mar 15;20(2):327-8.</citation>
          </article>
          <article>
            <pubmed-id>12529935</pubmed-id>
            <citation>Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.</citation>
          </article>
          <article>
            <pubmed-id>8144028</pubmed-id>
            <citation>Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.: The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994 Mar 25;140(2):203-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P47871" source="Swiss-Prot">
    <name>Glucagon receptor</name>
    <general-function>Peptide hormone binding</general-function>
    <specific-function>G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.</specific-function>
    <gene-name>GCGR</gene-name>
    <locus>17q25</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>137-161
174-198
226-249
264-285
304-326
351-369
382-402</transmembrane-regions>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>8.83</theoretical-pi>
    <molecular-weight>54008.44</molecular-weight>
    <chromosome-location>17</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4192</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GCGR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U03469</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>439690</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>251</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>251</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P47871</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GLR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GL-R</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016117|Glucagon receptor
MPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNR
TFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQ
CQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANL
FASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYC
WLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDN
MGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGV
HEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRL
GKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016118|Glucagon receptor (GCGR)
ATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAG
CCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGT
GACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGA
ACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCC
TGCCCCTGGTACCTGCCTTGGCACCACAAAGTGCAACACCGCTTCGTGTTCAAGAGATGC
GGGCCCGACGGTCAGTGGGTGCGTGGACCCCGGGGGCAGCCTTGGCGTGATGCCTCCCAG
TGCCAGATGGATGGCGAGGAGATTGAGGTCCAGAAGGAGGTGGCCAAGATGTACAGCAGC
TTCCAGGTGATGTACACAGTGGGCTACAGCCTGTCCCTGGGGGCCCTGCTCCTCGCCTTG
GCCATCCTGGGGGGCCTCAGCAAGCTGCACTGCACCCGCAATGCCATCCACGCGAATCTG
TTTGCGTCCTTCGTGCTGAAAGCCAGCTCCGTGCTGGTCATTGATGGGCTGCTCAGGACC
CGCTACAGCCAGAAAATTGGCGACGACCTCAGTGTCAGCACCTGGCTCAGTGATGGAGCG
GTGGCTGGCTGCCGTGTGGCCGCGGTGTTCATGCAATATGGCATCGTGGCCAACTACTGC
TGGCTGCTGGTGGAGGGCCTGTACCTGCACAACCTGCTGGGCCTGGCCACCCTCCCCGAG
AGGAGCTTCTTCAGCCTCTACCTGGGCATCGGCTGGGGTGCCCCCATGCTGTTCGTCGTC
CCCTGGGCAGTGGTCAAGTGTCTGTTCGAGAACGTCCAGTGCTGGACCAGCAATGACAAC
ATGGGCTTCTGGTGGATCCTGCGGTTCCCCGTCTTCCTGGCCATCCTGATCAACTTCTTC
ATCTTCGTCCGCATCGTTCAGCTGCTCGTGGCCAAGCTGCGGGCACGGCAGATGCACCAC
ACAGACTACAAGTTCCGGCTGGCCAAGTCCACGCTGACCCTCATCCCTCTGCTGGGCGTC
CACGAAGTGGTCTTCGCCTTCGTGACGGACGAGCACGCCCAGGGCACCCTGCGCTCCGCC
AAGCTCTTCTTCGACCTCTTCCTCAGCTCCTTCCAGGGCCTGCTGGTGGCTGTCCTCTAC
TGCTTCCTCAACAAGGAGGTGCAGTCGGAGCTGCGGCGGCGTTGGCACCGCTGGCGCCTG
GGCAAAGTGCTATGGGAGGAGCGGAACACCAGCAACCACAGGGCCTCATCTTCGCCCGGC
CACGGCCCTCCCAGCAAGGAGCTGCAGTTTGGGAGGGGTGGTGGCAGCCAGGATTCATCT
GCGGAGACCCCCTTGGCTGGTGGCCTCCCTAGATTGGCTGAGAGCCCCTTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>guanyl-nucleotide exchange factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glucagon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptide hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to nutrient</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glucose homeostasis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to glucagon stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to starvation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of glycogen metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>generation of precursor metabolites and energy</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of GTPase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002134</id>
      <name>Glucagon-like peptide 2 receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>11212269</pubmed-id>
            <citation>Boushey RP, Yusta B, Drucker DJ: Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001 Jan 15;61(2):687-93.</citation>
          </article>
          <article>
            <pubmed-id>9990065</pubmed-id>
            <citation>Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A: Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1569-73.</citation>
          </article>
          <article>
            <pubmed-id>15817468</pubmed-id>
            <citation>Estall JL, Koehler JA, Yusta B, Drucker DJ: The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. J Biol Chem. 2005 Jun 10;280(23):22124-34. Epub 2005 Apr 6.</citation>
          </article>
          <article>
            <pubmed-id>12529935</pubmed-id>
            <citation>Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O95838" source="Swiss-Prot">
    <name>Glucagon-like peptide 2 receptor</name>
    <general-function>Glucagon receptor activity</general-function>
    <specific-function>This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.</specific-function>
    <gene-name>GLP2R</gene-name>
    <locus>17p13.3</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>174-198
211-235
262-285
300-321
340-362
387-405
418-438</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>9.03</theoretical-pi>
    <molecular-weight>63000.84</molecular-weight>
    <chromosome-location>17</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4325</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GLP2R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF105367</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>4324491</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>250</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>250</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O95838</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GLP2R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GLP-2 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011545|Glucagon-like peptide 2 receptor
MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS
IKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS
YLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL
MYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS
KRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW
PRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK
ILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI
QLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK
LSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM
ANTMEEILEESEI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011546|Glucagon-like peptide 2 receptor (GLP2R)
ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGC
GTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCAC
AGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCC
ATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAA
CAGGCATGTCTGAGAGACTTACTCAAGGAACCTTCTGGCATATTTTGTAACGGGACATTT
GATCAGTACGTGTGTTGGCCTCATTCTTCTCCTGGAAATGTCTCTGTACCCTGCCCTTCA
TACTTACCTTGGTGGAGTGAAGAGAGCTCAGGAAGGGCCTACAGACACTGCTTGGCTCAG
GGGACTTGGCAGACGATAGAGAACGCCACGGATATTTGGCAGGATGACTCCGAATGCTCC
GAGAACCACAGCTTCAAGCAAAACGTGGATCGTTATGCCTTGCTGTCAACCTTGCAGCTG
ATGTACACCGTGGGATACTCCTTCTCTCTTATCTCCCTCTTCCTGGCTCTCACCCTCCTC
TTGTTTCTTCGAAAACTCCACTGCACGCGCAACTACATCCACATGAACTTGTTTGCTTCT
TTCATCCTGAGAACCCTGGCTGTACTGGTGAAGGACGTCGTCTTCTACAACTCTTACTCC
AAGAGGCCTGACAATGAGAATGGGTGGATGTCCTACCTGTCAGAGATGTCCACCTCCTGC
CGCTCAGTCCAGGTTCTCTTGCATTACTTTGTGGGTGCCAATTACTTATGGCTGCTGGTT
GAAGGCCTCTACCTCCACACGCTGCTGGAGCCCACAGTGCTTCCTGAGAGGCGGCTGTGG
CCCAGATACCTGCTGTTGGGTTGGGCCTTCCCTGTGCTATTTGTTGTACCCTGGGGTTTC
GCCCGTGCACACCTGGAGAACACAGGGTGCTGGACAACAAATGGGAATAAGAAAATCTGG
TGGATCATCCGAGGACCCATGATGCTCTGTGTAACAGTCAATTTCTTCATCTTCCTGAAA
ATTCTCAAGCTTCTCATTTCTAAGCTCAAAGCTCATCAAATGTGCTTCAGAGATTATAAA
TACAGATTGGCAAAATCAACACTGGTCCTCATTCCTTTATTGGGCGTTCATGAGATCCTC
TTCTCTTTCATCACTGATGATCAAGTTGAAGGATTTGCAAAACTTATACGACTTTTCATT
CAGTTGACACTGAGCTCCTTTCATGGGTTCCTGGTGGCCTTGCAGTATGGTTTTGCCAAT
GGAGAGGTGAAGGCTGAGCTGCGGAAATACTGGGTCCGCTTCTTGCTAGCCCGCCACTCA
GGCTGCAGAGCCTGTGTCCTGGGGAAGGACTTCCGGTTCCTAGGAAAATGTCCCAAGAAG
CTCTCGGAAGGAGATGGCGCTGAGAAGCTTCGGAAGCTGCAGCCCTCACTTAACAGTGGG
CGGCTCCTACATCTAGCCATGCGAGGTCTTGGGGAGCTGGGCGCCCAGCCCCAACAGGAC
CATGCACGCTGGCCCCGGGGCAGCAGCCTGTCCGAGTGCAGTGAGGGGGATGTCACCATG
GCCAACACCATGGAGGAGATTCTGGAAGAGAGTGAGATCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glucagon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000857</id>
      <name>Glucagon-like peptide 1 receptor</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17475961</pubmed-id>
            <citation>Korner M, Stockli M, Waser B, Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007 May;48(5):736-43.</citation>
          </article>
          <article>
            <pubmed-id>17498508</pubmed-id>
            <citation>Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57.</citation>
          </article>
          <article>
            <pubmed-id>17534934</pubmed-id>
            <citation>Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49.</citation>
          </article>
          <article>
            <pubmed-id>12529935</pubmed-id>
            <citation>Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P43220" source="Swiss-Prot">
    <name>Glucagon-like peptide 1 receptor</name>
    <general-function>Transmembrane signaling receptor activity</general-function>
    <specific-function>This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.</specific-function>
    <gene-name>GLP1R</gene-name>
    <locus>6p21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>140-164
177-201
228-251
266-287
306-328
353-371
384-404</transmembrane-regions>
    <signal-regions>1-23</signal-regions>
    <theoretical-pi>8.19</theoretical-pi>
    <molecular-weight>53025.22</molecular-weight>
    <chromosome-location>6</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4324</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>GLP1R</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>U01104</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>405082</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>249</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>249</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P43220</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GLP1R_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>GLP-1 receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010605|Glucagon-like peptide 1 receptor
MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDL
FCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPW
RDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIH
LNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAAN
YYWLLVEGVYLYTLLAFSVLSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRN
SNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLL
GTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERW
RLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010606|Glucagon-like peptide 1 receptor (GLP1R)
ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGG
GCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGA
GAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTG
TTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTC
GTGAATGTCAGCTGCCCCTGGTACCTGCCCTGGGCCAGCAGTGTGCCGCAGGGCCACGTG
TACCGGTTCTGCACAGCTGAAGGCCTCTGGCTGCAGAAGGACAACTCCAGCCTGCCCTGG
AGGGACTTGTCGGAGTGCGAGGAGTCCAAGCGAGGGGAAAGAAGCTCCCCGGAGGAGCAG
CTCCTGTTCCTCTACATCATCTACACGGTGGGCTACGCACTCTCCTTCTCTGCTCTGGTT
ATCGCCTCTGCGATCCTCCTCGGCTTCAGACACCTGCACTGCACCAGGAACTACATCCAC
CTGAACCTGTTTGCATCCTTCATCCTGCGAGCATTGTCCGTCTTCATCAAGGACGCAGCC
CTGAAGTGGATGTATAGCACAGCCGCCCAGCAGCACCAGTGGGATGGGCTCCTCTCCTAC
CAGGACTCTCTGAGCTGCCGCCTGGTGTTTCTGCTCATGCAGTACTGTGTGGCGGCCAAT
TACTACTGGCTCTTGGTGGAGGGCGTGTACCTGTACACACTGCTGGCCTTCTCGGTCTTA
TCTGAGCAATGGATCTTCAGGCTCTACGTGAGCATAGGCTGGGGTGTTCCCCTGCTGTTT
GTTGTCCCCTGGGGCATTGTCAAGTACCTCTATGAGGACGAGGGCTGCTGGACCAGGAAC
TCCAACATGAACTACTGGCTCATTATCCGGCTGCCCATTCTCTTTGCCATTGGGGTGAAC
TTCCTCATCTTTGTTCGGGTCATCTGCATCGTGGTATCCAAACTGAAGGCCAATCTCATG
TGCAAGACAGACATCAAATGCAGACTTGCCAAGTCCACGCTGACACTCATCCCCCTGCTG
GGGACTCATGAGGTCATCTTTGCCTTTGTGATGGACGAGCACGCCCGGGGGACCCTGCGC
TTCATCAAGCTGTTTACAGAGCTCTCCTTCACCTCCTTCCAGGGGCTGATGGTGGCCATA
TTATACTGCTTTGTCAACAATGAGGTCCAGCTGGAATTTCGGAAGAGCTGGGAGCGCTGG
CGGCTTGAGCACTTGCACATCCAGAGGGACAGCAGCATGAAGCCCCTCAAGTGTCCCACC
AGCAGCCTGAGCAGTGGAGCCACGGCGGGCAGCAGCATGTACACAGCCACTTGCCAGGCC
TCCTGCAGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00002</identifier>
        <name>7tm_2</name>
      </pfam>
      <pfam>
        <identifier>PF02793</identifier>
        <name>HRM</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>glucagon receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning or memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytosolic calcium ion concentration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of heart contraction</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00041</drugbank-id>
  <drugbank-id>BTD00082</drugbank-id>
  <drugbank-id>BIOD00082</drugbank-id>
  <name>Aldesleukin</name>
  <description>Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.</description>
  <cas-number>110942-02-4</cas-number>
  <unii>M89N0Q7EQR</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference>Hans-Ake Fabricius, Roland Stahn, "Serum-free and mitogen-free T-cell growth factor and process for making same." U.S. Patent US4464355, issued May, 1971.</synthesis-reference>
  <indication>For treatment of adults with metastatic renal cell carcinoma.</indication>
  <pharmacodynamics>Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.</pharmacodynamics>
  <mechanism-of-action>Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>13 min-85 min</half-life>
  <protein-binding/>
  <route-of-elimination>The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.</route-of-elimination>
  <volume-of-distribution>0.18 l/kg</volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">125-L-serine-2-133-interleukin 2 (human reduced)</synonym>
    <synonym language="" coder="">Interleukin-2 aldesleukin</synonym>
    <synonym language="" coder="">Interleukin-2(2-133),125-ser</synonym>
    <synonym language="" coder="">Recombinant interleukin-2 human</synonym>
  </synonyms>
  <products>
    <product>
      <name>Proleukin</name>
      <labeller>Prometheus Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>65483-116</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1992-05-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1.1 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103293</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Proleukin</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0495</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1992-05-06</started-marketing-on>
      <ended-marketing-on>2017-04-15</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>1.1 mg/mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA103293</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Proleukin</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02130181</dpd-id>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>22000000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Proleukin</name>
      <ingredients>Aldesleukin</ingredients>
    </mixture>
    <mixture>
      <name>Proleukin</name>
      <ingredients>Aldesleukin</ingredients>
    </mixture>
    <mixture>
      <name>Proleukin</name>
      <ingredients>Aldesleukin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
    <packager>
      <name>Chiron Corp.</name>
      <url>http://www.chiron.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Prometheus Laboratories Inc.</name>
      <url>http://www.prometheuslabs.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Proleukin 22000000 unit Solution Vial</description>
      <cost currency="USD">976.66</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Proleukin 22 million unit vial</description>
      <cost currency="USD">1092.34</cost>
      <unit>each</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-HIV Agents</category>
      <mesh-id>D019380</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Retroviral Agents</category>
      <mesh-id>D044966</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2E1 Inhibitors</category>
      <mesh-id>D065691</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inhibitors</category>
      <mesh-id>D065692</mesh-id>
    </category>
    <category>
      <category>Cytokines</category>
      <mesh-id>D016207</mesh-id>
    </category>
    <category>
      <category>Hypotensive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Intercellular Signaling Peptides and Proteins</category>
      <mesh-id>D036341</mesh-id>
    </category>
    <category>
      <category>Interleukins</category>
      <mesh-id>D007378</mesh-id>
    </category>
    <category>
      <category>Lymphokines</category>
      <mesh-id>D008222</mesh-id>
    </category>
    <category>
      <category>Myelosuppressive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>1.1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>1.1 mg/mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>22000000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AC01">
      <level code="L03AC">Interleukins</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3INK</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of adverse effects can be increased when Metamizole is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of Bcg can be decreased when used in combination with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>Diflorasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>Alclometasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>Medrysone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>Amcinonide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>Fluorometholone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>Beclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>Betamethasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>Desoximetasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>Triamcinolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>Prednisone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>Estrone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>Flumethasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>Fludrocortisone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>Clocortolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>Flurandrenolide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>Prednisolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>Rimexolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>Methylprednisolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>Clobetasol propionate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>Fluocinonide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>Prednicarbate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Budesonide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>Dexamethasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>Cortisone acetate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>Paramethasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>Ciclesonide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01536</drugbank-id>
      <name>Androstenedione</name>
      <description>4-Androstenedione may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01708</drugbank-id>
      <name>Prasterone</name>
      <description>Prasterone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02187</drugbank-id>
      <name>Equilin</name>
      <description>Equilin may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02789</drugbank-id>
      <name>Pregnenolone</name>
      <description>Pregnenolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03515</drugbank-id>
      <name>Equilenin</name>
      <description>Equilenin may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>Aldosterone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>dehydroepiandrosterone sulfate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06780</drugbank-id>
      <name>Desoxycorticosterone acetate</name>
      <description>Desoxycorticosterone acetate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>Difluprednate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>Fluprednidene may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>Fluocortolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>Difluocortolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>Fluprednisolone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>Dexamethasone isonicotinate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>Melengestrol may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>Flunisolide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>Fluticasone Propionate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>Mometasone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>Fluticasone furoate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Tixocortol may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>Clobetasol may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone Acetonide</name>
      <description>Fluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01134</drugbank-id>
      <name>Desoxycorticosterone Pivalate</name>
      <description>Desoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01434</drugbank-id>
      <name>19-norandrostenedione</name>
      <description>19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01456</drugbank-id>
      <name>5-androstenedione</name>
      <description>5-androstenedione may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04870</drugbank-id>
      <name>Oleoyl-estrone</name>
      <description>Oleoyl estrone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05107</drugbank-id>
      <name>16-Bromoepiandrosterone</name>
      <description>16-Bromoepiandrosterone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05212</drugbank-id>
      <name>HE3286</name>
      <description>HE3286 may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05402</drugbank-id>
      <name>ME-609</name>
      <description>ME-609 may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05410</drugbank-id>
      <name>NCX 1022</name>
      <description>NCX 1022 may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06157</drugbank-id>
      <name>Istaroxime</name>
      <description>Istaroxime may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06250</drugbank-id>
      <name>fluasterone</name>
      <description>fluasterone may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Formestane may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12081</drugbank-id>
      <name>Anecortave</name>
      <description>Anecortave may decrease the antineoplastic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00072</drugbank-id>
      <name>Trastuzumab</name>
      <description>Trastuzumab may increase the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon Alfa-2a, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon Alfa-2b, Recombinant</name>
      <description>The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>Digoxin may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>Acetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>Deslanoside may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>Ouabain may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>Digitoxin may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>Anvirzel may decrease the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00965</drugbank-id>
      <name>Ethiodized oil</name>
      <description>The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01362</drugbank-id>
      <name>Iohexol</name>
      <description>The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04711</drugbank-id>
      <name>Iodipamide</name>
      <description>The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08947</drugbank-id>
      <name>Iopamidol</name>
      <description>The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>Bevacizumab may increase the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>Cyclophosphamide may increase the cardiotoxic activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00521</drugbank-id>
      <name>Carteolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide Dinitrate</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00964</drugbank-id>
      <name>Apraclonidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide Mononitrate</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01210</drugbank-id>
      <name>Levobunolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01214</drugbank-id>
      <name>Metipranolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Desflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fenoldopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fimasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indoramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isocarboxazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moxonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nabilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pramipexole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rasagiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Remifentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropinirole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sacubitril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sevoflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Sodium Nitrite</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sodium Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolcapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>Aripiprazole may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Nicorandil may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Methohexital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>Thiopental may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Primidone may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Methylphenobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Phenobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Amobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Barbital may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Barbexaclone may increase the hypotensive activities of Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Aldesleukin may increase the orthostatic hypotensive activities of Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>Aldesleukin may increase the orthostatic hypotensive activities of Levodopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Aldesleukin may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Aldesleukin sequence
MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
RWITFCQSIISTLT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.192</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.31</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>15314.8</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C690H1115N177O202S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>278</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M11144</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448081</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P60569</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001099</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Aldesleukin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201438</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/aldesleukin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/aldesleukin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000651</id>
      <name>Interleukin-2 receptor subunit beta</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>16477002</pubmed-id>
            <citation>Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13.</citation>
          </article>
          <article>
            <pubmed-id>16542139</pubmed-id>
            <citation>Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8.</citation>
          </article>
          <article>
            <pubmed-id>16569767</pubmed-id>
            <citation>Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28.</citation>
          </article>
          <article>
            <pubmed-id>16596189</pubmed-id>
            <citation>Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6.</citation>
          </article>
          <article>
            <pubmed-id>16617454</pubmed-id>
            <citation>Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14784" source="Swiss-Prot">
    <name>Interleukin-2 receptor subunit beta</name>
    <general-function>Interleukin-2 receptor activity</general-function>
    <specific-function>Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.</specific-function>
    <gene-name>IL2RB</gene-name>
    <locus>22q13|22q13.1</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>241-265</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>4.68</theoretical-pi>
    <molecular-weight>61116.59</molecular-weight>
    <chromosome-location>22</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6009</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RB</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M26062</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>307048</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P14784</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>High affinity IL-2 receptor subunit beta</synonym>
      <synonym>IL-2 receptor subunit beta</synonym>
      <synonym>p70-75</synonym>
      <synonym>p75</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016166|Interleukin-2 receptor subunit beta
MAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ
VHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA
IQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE
APLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT
IPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV
QKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT
NQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT
FPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP
DLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ
ELQGQDPTHLV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)
ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT
ACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG
AGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA
GTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT
CAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA
GTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC
ATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT
GTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC
TTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG
GCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA
GACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG
AGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC
ATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA
GTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT
AACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC
CAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT
GAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG
GACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC
AACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG
TACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC
ACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC
TTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC
CCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA
GAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA
GACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC
CCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG
GAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA
GAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG</gene-sequence>
    <pfams>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-2-mediated signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0000658</id>
      <name>Interleukin-2 receptor subunit alpha</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17216565</pubmed-id>
            <citation>Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11.</citation>
          </article>
          <article>
            <pubmed-id>16767920</pubmed-id>
            <citation>Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43.</citation>
          </article>
          <article>
            <pubmed-id>17530023</pubmed-id>
            <citation>Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703.</citation>
          </article>
          <article>
            <pubmed-id>17584597</pubmed-id>
            <citation>Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2.</citation>
          </article>
          <article>
            <pubmed-id>16864089</pubmed-id>
            <citation>Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <pubmed-id>10207608</pubmed-id>
            <citation>Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P01589" source="Swiss-Prot">
    <name>Interleukin-2 receptor subunit alpha</name>
    <general-function>Interleukin-2 receptor activity</general-function>
    <specific-function>Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.</specific-function>
    <gene-name>IL2RA</gene-name>
    <locus>10p15-p14</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>241-259</transmembrane-regions>
    <signal-regions>1-21</signal-regions>
    <theoretical-pi>6.49</theoretical-pi>
    <molecular-weight>30818.915</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6008</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RA</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X01057</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>33813</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1695</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01589</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>IL-2 receptor subunit alpha</synonym>
      <synonym>p55</synonym>
      <synonym>TAC antigen</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha
MDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS
GSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS
LPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP
QLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ
VAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)
ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG
GCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC
TACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC
GGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT
CAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA
CAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC
CTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT
CATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC
AGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC
CAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG
GCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT
CAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG
GTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC
TGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00084</identifier>
        <name>Sushi</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>drug binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of T cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of T cell tolerance induction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Notch signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of T cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation-induced cell death of T cells</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of defense response to virus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of activated T cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of T cell homeostatic proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response to antigenic stimulus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002102</id>
      <name>Cytokine receptor common subunit gamma</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>16477002</pubmed-id>
            <citation>Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13.</citation>
          </article>
          <article>
            <pubmed-id>17598841</pubmed-id>
            <citation>Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5.</citation>
          </article>
          <article>
            <pubmed-id>17635814</pubmed-id>
            <citation>Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71.</citation>
          </article>
          <article>
            <pubmed-id>17083048</pubmed-id>
            <citation>Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23.</citation>
          </article>
          <article>
            <pubmed-id>17363735</pubmed-id>
            <citation>Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P31785" source="Swiss-Prot">
    <name>Cytokine receptor common subunit gamma</name>
    <general-function>Interleukin-2 binding</general-function>
    <specific-function>Common subunit for the receptors for a variety of interleukins.</specific-function>
    <gene-name>IL2RG</gene-name>
    <locus>Xq13.1</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>263-283</transmembrane-regions>
    <signal-regions>1-22</signal-regions>
    <theoretical-pi>6.31</theoretical-pi>
    <molecular-weight>42286.68</molecular-weight>
    <chromosome-location>X</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6010</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>IL2RG</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D11086</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>219890</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P31785</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>IL2RG_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>gammaC</synonym>
      <synonym>IL-2 receptor subunit gamma</synonym>
      <synonym>IL-2R subunit gamma</synonym>
      <synonym>IL-2RG</synonym>
      <synonym>Interleukin-2 receptor subunit gamma</synonym>
      <synonym>p64</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004122|Cytokine receptor common subunit gamma
MLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV
QCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK
EIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN
HCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW
SHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV
TEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP
PCYTLKPET</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)
ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA
GTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC
TTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT
CAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC
CAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG
AAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG
GAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA
CAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA
ACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC
CACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA
TCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG
TTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG
AGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG
GAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT
TTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT
ACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT
CTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG
GCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC
CCATGTTACACCCTAAAGCCTGAAACCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00041</identifier>
        <name>fn3</name>
      </pfam>
      <pfam>
        <identifier>PF09240</identifier>
        <name>IL6Ra-bind</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>cytokine receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>interleukin-2 binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>insulin receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small GTPase mediated signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotrophin TRK receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>axon guidance</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Ras protein signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epidermal growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vascular endothelial growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>viral process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-2-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of MAPKK activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-4-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>fibroblast growth factor receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-7-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0000262</id>
      <name>Prostaglandin G/H synthase 2</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10823885</pubmed-id>
            <citation>Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000 Jun;74(12):5740-5.</citation>
          </article>
          <article>
            <pubmed-id>18209082</pubmed-id>
            <citation>Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil RW, Coito AJ: Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008 Feb 1;180(3):1843-53.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35354" source="Swiss-Prot">
    <name>Prostaglandin G/H synthase 2</name>
    <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
    <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.</specific-function>
    <gene-name>PTGS2</gene-name>
    <locus>1q25.2-q25.3</locus>
    <cellular-location>Microsome membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions>1-17</signal-regions>
    <theoretical-pi>7.41</theoretical-pi>
    <molecular-weight>68995.625</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9605</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PTGS2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>L15326</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>291988</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1376</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P35354</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PGH2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.99.1</synonym>
      <synonym>COX-2</synonym>
      <synonym>COX2</synonym>
      <synonym>Cyclooxygenase-2</synonym>
      <synonym>PGH synthase 2</synonym>
      <synonym>PGHS-2</synonym>
      <synonym>PHS II</synonym>
      <synonym>Prostaglandin H2 synthase 2</synonym>
      <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021832|Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF03098</identifier>
        <name>An_peroxidase</name>
      </pfam>
      <pfam>
        <identifier>PF00008</identifier>
        <name>EGF</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum lumen</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>caveola</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peroxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>prostaglandin-endoperoxide synthase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonate 15-lipoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>metal ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vasoconstriction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>embryo implantation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fructose</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lithium ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to UV</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucocorticoid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to hypoxia</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to fatty acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to lipopolysaccharide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic transmission, glutamatergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>memory</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to mechanical stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fever generation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>sensory perception of pain</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to fluid shear stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to drug</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of vascular endothelial growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to estradiol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>brown fat cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>maintenance of blood-brain barrier</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of calcium ion transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to ATP</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to tumor necrosis factor</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to oxidative stress</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipoxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of synaptic plasticity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of smooth muscle contraction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to vitamin D</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transforming growth factor beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of blood pressure</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of synaptic transmission, dopaminergic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>decidualization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>movement of cell or subcellular component</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to manganese ion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nicotinamide metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hair cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>NAD metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cyclooxygenase pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>learning</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of fibroblast growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of cell cycle</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of prostaglandin biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>bone mineralization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of platelet-derived growth factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>water-soluble vitamin metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="2">
      <id>BE0000657</id>
      <name>Cytosolic phospholipase A2</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>8536274</pubmed-id>
            <citation>Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother. 1995 Nov;41(5):287-92.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P47712" source="Swiss-Prot">
    <name>Cytosolic phospholipase A2</name>
    <general-function>Phospholipase a2 activity</general-function>
    <specific-function>Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.</specific-function>
    <gene-name>PLA2G4A</gene-name>
    <locus>1q25</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>5.03</theoretical-pi>
    <molecular-weight>85238.2</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:9035</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>PLA2G4A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M72393</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>190007</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1424</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P47712</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>PA24A_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>CPLA2</synonym>
      <synonym>Phospholipase A2 group IVA</synonym>
      <synonym>PLA2G4</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010456|Cytosolic phospholipase A2
MSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT
RHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV
PFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG
LHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH
PDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG
ETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG
TFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE
LENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN
TREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV
KSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN
KLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYRAPGVPRETE
EEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR
QNPSRCSVSLSNVEARRFFNKEFLSKPKA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010457|Cytosolic phospholipase A2 (PLA2G4A)
ATGTCATTTATAGATCCTTACCAGCACATTATAGTGGAGCACCAGTATTCCCACAAGTTT
ACGGTAGTGGTGTTACGTGCCACCAAAGTGACAAAGGGGGCCTTTGGTGACATGCTTGAT
ACTCCAGATCCCTATGTGGAACTTTTTATCTCTACAACCCCTGACAGCAGGAAGAGAACA
AGACATTTCAATAATGACATAAACCCTGTGTGGAATGAGACCTTTGAATTTATTTTGGAT
CCTAATCAGGAAAATGTTTTGGAGATTACGTTAATGGATGCCAATTATGTCATGGATGAA
ACTCTAGGGACAGCAACATTTACTGTATCTTCTATGAAGGTGGGAGAAAAGAAAGAAGTT
CCTTTTATTTTCAACCAAGTCACTGAAATGGTTCTAGAAATGTCTCTTGAAGTTTGCTCA
TGCCCAGACCTACGATTTAGTATGGCTCTGTGTGATCAGGAGAAGACTTTCAGACAACAG
AGAAAAGAACACATAAGGGAGAGCATGAAGAAACTCTTGGGTCCAAAGAATAGTGAAGGA
TTGCATTCTGCACGTGATGTGCCTGTGGTAGCCATATTGGGTTCAGGTGGGGGTTTCCGA
GCCATGGTGGGATTCTCTGGTGTGATGAAGGCATTATACGAATCAGGAATTCTGGATTGT
GCTACCTACGTTGCTGGTCTTTCTGGCTCCACCTGGTATATGTCAACCTTGTATTCTCAC
CCTGATTTTCCAGAGAAAGGGCCAGAGGAGATTAATGAAGAACTAATGAAAAATGTTAGC
CACAATCCCCTTTTACTTCTCACACCACAGAAAGTTAAAAGATATGTTGAGTCTTTATGG
AAGAAGAAAAGCTCTGGACAACCTGTCACCTTTACTGATATCTTTGGGATGTTAATAGGA
GAAACACTAATTCATAATAGAATGAATACTACTCTGAGCAGTTTGAAGGAAAAAGTTAAT
ACTGCACAATGCCCTTTACCTCTTTTCACCTGTCTTCATGTCAAACCTGACGTTTCAGAG
CTGATGTTTGCAGATTGGGTTGAATTTAGTCCATACGAAATTGGCATGGCTAAATATGGT
ACTTTTATGGCTCCCGACTTATTTGGAAGCAAATTTTTTATGGGAACAGTCGTTAAGAAG
TATGAAGAAAACCCCTTGCATTTCTTAATGGGTGTCTGGGGCAGTGCCTTTTCCATATTG
TTCAACAGAGTTTTGGGCGTTTCTGGTTCACAAAGCAGAGGCTCCACAATGGAGGAAGAA
TTAGAAAATATTACCACAAAGCATATTGTGAGTAATGATAGCTCGGACAGTGATGATGAA
TCACACGAACCCAAAGGCACTGAAAATGAAGATGCTGGAAGTGACTATCAAAGTGATAAT
CAAGCAAGTTGGATTCATCGTATGATAATGGCCTTGGTGAGTGATTCAGCTTTATTCAAT
ACCAGAGAAGGACGTGCTGGGAAGGTACACAACTTCATGCTGGGCTTGAATCTCAATACA
TCTTATCCACTGTCTCCTTTGAGTGACTTTGCCACACAGGACTCCTTTGATGATGATGAA
CTGGATGCAGCTGTAGCAGATCCTGATGAATTTGAGCGAATATATGAGCCTCTGGATGTC
AAAAGTAAAAAGATTCATGTAGTGGACAGTGGGCTCACATTTAACCTGCCGTATCCCTTG
ATACTGAGACCTCAGAGAGGGGTTGATCTCATAATCTCCTTTGACTTTTCTGCAAGGCCA
AGTGACTCTAGTCCTCCGTTCAAGGAACTTCTACTTGCAGAAAAGTGGGCTAAAATGAAC
AAGCTCCCCTTTCCAAAGATTGATCCTTATGTGTTTGATCGGGAAGGGCTGAAGGAGTGC
TATGTCTTTAAACCCAAGAATCCTGATATGGAGAAAGATTGCCCAACCATCATCCACTTT
GTTCTGGCCAACATCAACTTCAGAAAGTACAAGGCTCCAGGTGTTCCAAGGGAAACTGAG
GAAGAGAAAGAAATCGCTGACTTTGATATTTTTGATGACCCAGAATCACCATTTTCAACC
TTCAATTTTCAATATCCAAATCAAGCATTCAAAAGACTACATGATCTTATGCACTTCAAT
ACTCTGAACAACATTGATGTGATAAAAGAAGCCATGGTTGAAAGCATTGAATATAGAAGA
CAGAATCCATCTCGTTGCTCTGTTTCCCTTAGTAATGTTGAGGCAAGAAGATTTTTCAAC
AAGGAGTTTCTAAGTAAACCCAAAGCATAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00168</identifier>
        <name>C2</name>
      </pfam>
      <pfam>
        <identifier>PF01735</identifier>
        <name>PLA2_B</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>mitochondrial inner membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic membrane-bounded vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lysophospholipase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent phospholipase A2 activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipase A2 activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cardiolipin acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glycerophospholipid biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to antibiotic</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>icosanoid biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidic acid biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>icosanoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylcholine acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylethanolamine acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>platelet activating factor biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylglycerol acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylinositol acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phosphatidylserine acyl-chain remodeling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>arachidonic acid metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="3">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10086330</pubmed-id>
            <citation>Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4.</citation>
          </article>
          <article>
            <pubmed-id>14977871</pubmed-id>
            <citation>Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004 Mar;32(3):359-63.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
    <name>Cytochrome P450 3A4</name>
    <general-function>Vitamin d3 25-hydroxylase activity</general-function>
    <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
    <gene-name>CYP3A4</gene-name>
    <locus>7q21.1</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions>2-22</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.25</theoretical-pi>
    <molecular-weight>57342.67</molecular-weight>
    <chromosome-location>7</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2637</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>CYP3A4</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M18907</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1337</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P08684</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP3A4_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
      <synonym>1.14.13.-</synonym>
      <synonym>Albendazole monooxygenase</synonym>
      <synonym>Albendazole sulfoxidase</synonym>
      <synonym>Cholesterol 25-hydroxylase</synonym>
      <synonym>CYP3A3</synonym>
      <synonym>CYPIIIA3</synonym>
      <synonym>CYPIIIA4</synonym>
      <synonym>Cytochrome P450 3A3</synonym>
      <synonym>Cytochrome P450 HLp</synonym>
      <synonym>Cytochrome P450 NF-25</synonym>
      <synonym>Cytochrome P450-PCN1</synonym>
      <synonym>Nifedipine oxidase</synonym>
      <synonym>Quinine 3-monooxygenase</synonym>
      <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vitamin D 24-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>testosterone 6-beta-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>vitamin D3 25-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>aromatase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>albendazole monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>caffeine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>quinine 3-monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidative demethylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>androgen metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcitriol biosynthetic process from calciol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vitamin D metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>alkaloid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug catabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="4">
      <id>BE0002204</id>
      <name>Xanthine dehydrogenase/oxidase</name>
      <organism>Human</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>8032542</pubmed-id>
            <citation>Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.: Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P47989" source="Swiss-Prot">
    <name>Xanthine dehydrogenase/oxidase</name>
    <general-function>Xanthine oxidase activity</general-function>
    <specific-function>Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).</specific-function>
    <gene-name>XDH</gene-name>
    <locus>2p23.1</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>7.7</theoretical-pi>
    <molecular-weight>146422.99</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:12805</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>XDH</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D11456</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>10336525</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>2646</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P47989</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>XDH_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>XDHA</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011593|Xanthine dehydrogenase/oxidase
MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
GVPENCKPWSVRV</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011594|Xanthine dehydrogenase/oxidase (XDH)
ATGACAGCAGACAAATTGGTTTTCTTTGTGAATGGCAGAAAGGTGGTGGAGAAAAATGCA
GATCCAGAGACAACCCTTTTGGCCTACCTGAGAAGAAAGTTGGGGCTGAGTGGAACCAAG
CTCGGCTGTGGAGAGGGGGGCTGCGGGGCTTGCACAGTGATGCTCTCCAAGTATGATCGT
CTGCAGAACAAGATCGTCCACTTTTCTGCCAATGCCTGCCTGGCCCCCATCTGCTCCTTG
CACCATGTTGCAGTGACAACTGTGGAAGGAATAGGAAGCACCAAGACGAGGCTGCATCCT
GTGCAGGAGAGAATTGCCAAAAGCCACGGCTCCCAGTGCGGGTTCTGCACCCCTGGCATC
GTCATGAGTATGTACACACTGCTCCGGAATCAGCCCGAGCCCACCATGGAGGAGATTGAG
AATGCCTTCCAAGGAAATCTGTGCCGCTGCACAGGCTACAGACCCATCCTCCAGGGCTTC
CGGACCTTTGCCAGGGATGGTGGATGCTGTGGAGGAGATGGGAATAATCCAAATTGCTGC
ATGAACCAGAAGAAAGACCACTCAGTCAGCCTCTCGCCATCTTTATTCAAACCAGAGGAG
TTCACGCCCCTGGATCCAACCCAGGAGCCCATTTTTCCCCCAGAGTTGCTGAGGCTGAAA
GACACTCCTCGGAAGCAGCTGCGATTTGAAGGGGAGCGTGTGACGTGGATACAGGCCTCA
ACCCTCAAGGAGCTGCTGGACCTCAAGGCTCAGCACCCTGACGCCAAGCTGGTCGTGGGG
AACACGGAGATTGGCATTGAGATGAAGTTCAAGAATATGCTGTTTCCTATGATTGTCTGC
CCAGCCTGGATCCCTGAGCTGAATTCGGTAGAACATGGACCCGACGGTATCTCCTTTGGA
GCTGCTTGCCCCCTGAGCATTGTGGAAAAAACCCTGGTGGATGCTGTTGCTAAGCTTCCT
GCCCAAAAGACAGAGGTGTTCAGAGGGGTCCTGGAGCAGCTGCGCTGGTTTGCTGGGAAG
CAAGTCAAGTCTGTGGCGTCCGTTGGAGGGAACATCATCACTGCCAGCCCCATCTCCGAC
CTCAACCCCGTGTTCATGGCCAGTGGGGCCAAGCTGACACTTGTGTCCAGAGGCACCAGG
AGAACTGTCCAGATGGACCACACCTTCTTCCCTGGCTACAGAAAGACCCTGCTGAGCCCG
GAGGAGATACTGCTCTCCATAGAGATCCCCTACAGCAGGGAGGGGGAGTATTTCTCAGCA
TTCAAGCAGGCCTCCCGGAGAGAAGATGACATTGCCAAGGTAACCAGTGGCATGAGAGTT
TTATTCAAGCCAGGAACCACAGAGGTACAGGAGCTGGCCCTTTGCTATGGTGGAATGGCC
AACAGAACCATCTCAGCCCTCAAGACCACTCAGAGGCAGCTTTCCAAGCTCTGGAAGGAG
GAGCTGCTGCAGGACGTGTGTGCAGGACTGGCAGAGGAGCTGCATCTGCCTCCCGATGCC
CCTGGTGGCATGGTGGACTTCCGGTGCACCCTCACCCTCAGCTTCTTCTTCAAGTTCTAC
CTGACAGTCCTTCAGAAGCTGGGCCAAGAGAACCTGGAAGACAAGTGTGGTAAACTGGAC
CCCACTTTCGCCAGTGCAACTTTACTGTTTCAGAAAGACCCCCCAGCCGATGTCCAGCTC
TTCCAAGAGGTGCCCAAGGGTCAGTCTGAGGAGGACATGGTGGGCCGGCCCCTGCCCCAC
CTGGCAGCGGACATGCAGGCCTCTGGTGAGGCCGTGTACTGTGACGACATTCCTCGCTAC
GAGAATGAGCTGTCTCTCCGGCTGGTCACCAGCACCCGGGCCCACGCCAAGATCAAGTCC
ATAGATACATCAGAAGCTAAGAAGGTTCCAGGGTTTGTTTGTTTCATTTCCGCTGATGAT
GTTCCTGGGAGTAACATAACTGGAATTTGTAATGATGAGACAGTCTTTGCGAAGGATAAG
GTTACTTGTGTTGGGCATATCATTGGTGCTGTGGTTGCTGACACCCCGGAACACACACAG
AGAGCTGCCCAAGGGGTGAAAATCACCTATGAAGAACTACCAGCCATTATCACAATTGAG
GATGCTATAAAGAACAACTCCTTTTATGGACCTGAGCTGAAGATCGAGAAAGGGGACCTA
AAGAAGGGGTTTTCCGAAGCAGATAATGTTGTGTCAGGGGAGATATACATCGGTGGCCAA
GAGCACTTCTACCTGGAGACTCACTGCACCATTGCTGTTCCAAAAGGCGAGGCAGGGGAG
ATGGAGCTCTTTGTGTCTACACAGAACACCATGAAGACCCAGAGCTTTGTTGCAAAAATG
TTGGGGGTTCCAGCAAACCGGATTGTGGTTCGAGTGAAGAGAATGGGAGGAGGCTTTGGA
GGCAAGGAGACCCGGAGCACTGTGGTGTCCACGGCAGTGGCCCTGGCTGCATATAAGACC
GGCCGCCCTGTGCGATGCATGCTGGACCGTGATGAGGACATGCTGATAACTGGTGGCAGA
CATCCCTTCCTGGCCAGATACAAGGTTGGCTTCATGAAGACTGGGACAGTTGTGGCTCTT
GAGGTGGACCACTTCAGCAATGTGGGGAACACCCAGGATCTCTCTCAGAGTATTATGGAA
CGAGCTTTATTCCACATGGACAACTGCTATAAAATCCCCAACATCCGGGGCACTGGGCGG
CTGTGCAAAACCAACCTTCCCTCCAACACGGCCTTCCGGGGCTTTGGGGGGCCCCAGGGG
ATGCTCATTGCCGAGTGCTGGATGAGTGAAGTTGCAGTGACCTGTGGGATGCCTGCAGAG
GAGGTGCGGAGAAAAAACCTGTACAAAGAAGGGGACCTGACACACTTCAACCAGAAGCTT
GAGGGTTTCACCTTGCCCAGATGCTGGGAAGAATGCCTAGCAAGCTCTCAGTATCATGCT
CGGAAGAGTGAGGTTGACAAGTTCAACAAGGAGAATTGTTGGAAAAAGAGAGGATTGTGC
ATAATTCCCACCAAGTTTGGAATAAGCTTTACAGTTCCTTTTCTGAATCAGGCAGGAGCC
CTACTTCATGTGTACACAGATGGCTCTGTGCTGCTGACCCACGGGGGGACTGAGATGGGC
CAAGGCCTTCATACCAAAATGGTCCAGGTGGCCAGTAGAGCTCTGAAAATCCCCACCTCT
AAGATTTATATCAGCGAGACAAGCACTAACACTGTGCCCAACACCTCTCCCACGGCTGCC
TCTGTCAGCGCTGACCTCAATGGACAGGCCGTCTATGCGGCTTGTCAGACCATCTTGAAA
AGGCTGGAACCCTACAAGAAGAAGAATCCCAGTGGCTCCTGGGAAGACTGGGTCACAGCT
GCCTACATGGACACAGTGAGCTTGTCTGCCACTGGGTTTTATAGAACACCCAATCTGGGC
TACAGCTTTGAGACTAACTCAGGGAACCCCTTCCACTACTTCAGCTATGGGGTGGCTTGC
TCTGAAGTAGAAATCGACTGCCTAACAGGAGATCATAAGAACCTCCGCACAGATATTGTC
ATGGATGTTGGCTCCAGTCTAAACCCTGCCATTGATATTGGACAGGTGGAAGGGGCATTT
GTCCAGGGCCTTGGCCTCTTCACCCTAGAGGAGCTACACTATTCCCCCGAGGGGAGCCTG
CACACCCGTGGCCCTAGCACCTACAAGATCCCGGCATTTGGCAGCATCCCCATTGAGTTC
AGGGTGTCCCTGCTCCGCGACTGCCCCAACAAGAAGGCCATCTATGCATCGAAGGCTGTT
GGAGAGCCGCCCCTCTTCCTGGCTGCTTCTATCTTCTTTGCCATCAAAGATGCCATCCGT
GCAGCTCGAGCTCAGCACACAGGTAATAACGTGAAGGAACTCTTCCGGCTAGACAGCCCT
GCCACCCCGGAGAAGATCCGCAATGCCTGCGTGGACAAGTTCACCACCCTGTGTGTCACT
GGTGTCCCAGAAAACTGCAAACCCTGGTCTGTGAGGGTCTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00111</identifier>
        <name>Fer2</name>
      </pfam>
      <pfam>
        <identifier>PF01315</identifier>
        <name>Ald_Xan_dh_C</name>
      </pfam>
      <pfam>
        <identifier>PF02738</identifier>
        <name>Ald_Xan_dh_C2</name>
      </pfam>
      <pfam>
        <identifier>PF01799</identifier>
        <name>Fer2_2</name>
      </pfam>
      <pfam>
        <identifier>PF03450</identifier>
        <name>CO_deh_flav_C</name>
      </pfam>
      <pfam>
        <identifier>PF00941</identifier>
        <name>FAD_binding_5</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular space</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>sarcoplasmic reticulum</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>peroxisome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>2 iron, 2 sulfur cluster binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein homodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>molybdopterin cofactor binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on CH-OH group of donors</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>xanthine dehydrogenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on the aldehyde or oxo group of donors</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>flavin adenine dinucleotide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>xanthine oxidase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>electron carrier activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xanthine catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell differentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of endothelial cell proliferation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of reactive oxygen species metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>nucleobase-containing small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>purine nucleobase metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>purine nucleotide catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of protein kinase B signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vascular endothelial growth factor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lactation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of vasculogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of p38MAPK cascade</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
    <enzyme position="5">
      <id>BE0003533</id>
      <name>Cytochrome P450 2E1</name>
      <organism>Human</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>10086330</pubmed-id>
            <citation>Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05181" source="Swiss-Prot">
    <name>Cytochrome P450 2E1</name>
    <general-function>Steroid hydroxylase activity</general-function>
    <specific-function>Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.</specific-function>
    <gene-name>CYP2E1</gene-name>
    <locus>10q24.3-qter</locus>
    <cellular-location>Endoplasmic reticulum membrane</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>8.22</theoretical-pi>
    <molecular-weight>56848.42</molecular-weight>
    <chromosome-location>10</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:2631</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>J02625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>181360</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>1330</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P05181</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>CP2E1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>1.14.13.-</synonym>
      <synonym>4-nitrophenol 2-hydroxylase</synonym>
      <synonym>CYP2E</synonym>
      <synonym>CYPIIE1</synonym>
      <synonym>Cytochrome P450-J</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012460|Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0012461|Cytochrome P450 2E1 (CYP2E1)
ATGTCTGCCCTCGGAGTCACCGTGGCCCTGCTGGTGTGGGCGGCCTTCCTCCTGCTGGTG
TCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGCCCTTTCCCGCTTCCC
ATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCTTCACCCGGTTG
GCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCATGGTGGTGATG
CACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGTTCTCGGGCAGA
GGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTAATAATGGACCT
ACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATGGGATGGGGAAA
CAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAGCACTCAGGAAG
ACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCTGCAACGTCATA
GCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCTGATG
TATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGCTTTACAATAAT
TTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAAAAAATGTGGCT
GAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTCTGGACCCCAAC
TGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAAAGCACAGTGCA
GAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGTTCTTTGCGGGG
ACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGAAATACCCTGAG
ATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCCGAATCCCTGCC
ATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGGTTC
ATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCATTTTCAGAGGA
TACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTTTGTATGACAAC
CAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATGAAAATGGAAAG
TTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGTGTGCTGGAGAA
GGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGCATTTTAATTTG
AAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTGGGTTTGGCTGT
ATCCCACCACGTTACAAACTCTGTGTCATTCCCCGCTCATGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00067</identifier>
        <name>p450</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>Golgi membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intrinsic component of endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrion</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endoplasmic reticulum membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>monooxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>arachidonic acid epoxygenase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxygen binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>steroid hydroxylase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>enzyme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>oxidoreductase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>iron ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>oxidation-reduction process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>steroid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>heterocycle metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>monoterpenoid metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>xenobiotic metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>drug metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to ethanol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to organonitrogen compound</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>triglyceride metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>epoxygenase P450 pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exogenous drug catabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to ozone</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00042</drugbank-id>
  <drugbank-id>BTD00070</drugbank-id>
  <drugbank-id>BIOD00070</drugbank-id>
  <name>Botulinum Toxin Type B</name>
  <description>Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.</description>
  <cas-number>93384-44-2</cas-number>
  <unii>0Y70779M1F</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>15907915</pubmed-id>
        <citation>Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9.</citation>
      </article>
      <article>
        <pubmed-id>10534247</pubmed-id>
        <citation>Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8.</citation>
      </article>
      <article>
        <pubmed-id>15839401</pubmed-id>
        <citation>Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8.</citation>
      </article>
      <article>
        <pubmed-id>15887434</pubmed-id>
        <citation>Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66.</citation>
      </article>
      <article>
        <pubmed-id>15928517</pubmed-id>
        <citation>Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.</indication>
  <pharmacodynamics>Botulinum Toxin Type B inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.</pharmacodynamics>
  <mechanism-of-action>Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.</mechanism-of-action>
  <toxicity>One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.</toxicity>
  <metabolism/>
  <absorption>Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Botulinum neurotoxin type B precursor</synonym>
    <synonym language="" coder="">BTX-B</synonym>
    <synonym language="" coder="">RimabotulinumtoxinB</synonym>
  </synonyms>
  <products>
    <product>
      <name>Myobloc</name>
      <labeller>Solstice Neurosciences</labeller>
      <ndc-id/>
      <ndc-product-code>10454-710</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>2500 [USP'U]/.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103846</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myobloc</name>
      <labeller>Solstice Neurosciences</labeller>
      <ndc-id/>
      <ndc-product-code>10454-711</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>5000 [USP'U]/mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103846</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myobloc</name>
      <labeller>Solstice Neurosciences</labeller>
      <ndc-id/>
      <ndc-product-code>10454-712</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2000-12-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>10000 [USP'U]/2mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>BLA103846</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myobloc</name>
      <labeller>Solstice Neurosciences</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02252295</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5000 unit</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Neurobloc</name>
      <company>Solstice Neurosciences</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Myobloc</name>
      <ingredients>Botulinum Toxin Type B</ingredients>
    </mixture>
    <mixture>
      <name>Myobloc</name>
      <ingredients>Botulinum Toxin Type B</ingredients>
    </mixture>
    <mixture>
      <name>Myobloc</name>
      <ingredients>Botulinum Toxin Type B</ingredients>
    </mixture>
    <mixture>
      <name>Myobloc</name>
      <ingredients>Botulinum Toxin Type B</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Solstice Neurosciences</name>
      <url>http://www.solsticeneuro.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Myobloc 2500 unit/0.5 ml vial</description>
      <cost currency="USD">299.4</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Myobloc 10000 unit/2ml Solution 2ml Vial</description>
      <cost currency="USD">1245.5</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acetylcholine Release Inhibitors</category>
      <mesh-id>D065087</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Amphibian Venoms</category>
      <mesh-id>D000664</mesh-id>
    </category>
    <category>
      <category>Anti-Dyskinesia Agents</category>
      <mesh-id>D018726</mesh-id>
    </category>
    <category>
      <category>Bacterial Proteins</category>
      <mesh-id>D001426</mesh-id>
    </category>
    <category>
      <category>Bacterial Toxins</category>
      <mesh-id>D001427</mesh-id>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Bodily Secretions</category>
      <mesh-id>D012634</mesh-id>
    </category>
    <category>
      <category>Botulinum Toxins</category>
      <mesh-id>D001905</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cholinergic Agents</category>
      <mesh-id>D018678</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Endopeptidases</category>
      <mesh-id>D010450</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Fluids and Secretions</category>
      <mesh-id>D005441</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Membrane Transport Modulators</category>
      <mesh-id>D049990</mesh-id>
    </category>
    <category>
      <category>Metalloendopeptidases</category>
      <mesh-id>D008666</mesh-id>
    </category>
    <category>
      <category>Metalloproteases</category>
      <mesh-id>D045726</mesh-id>
    </category>
    <category>
      <category>Molecular Mechanisms of Pharmacological Action</category>
      <mesh-id>D045504</mesh-id>
    </category>
    <category>
      <category>Muscle Relaxants</category>
      <mesh-id/>
    </category>
    <category>
      <category>Muscle Relaxants, Peripherally Acting Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Musculo-Skeletal System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotoxins</category>
      <mesh-id>D009498</mesh-id>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
    <category>
      <category>Toxins, Biological</category>
      <mesh-id>D014118</mesh-id>
    </category>
    <category>
      <category>Venoms</category>
      <mesh-id>D014688</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>10000 [USP'U]/2mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>2500 [USP'U]/.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>5000 [USP'U]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular</route>
      <strength>5000 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="M03AX01">
      <level code="M03AX">Other muscle relaxants, peripherally acting agents</level>
      <level code="M03A">MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS</level>
      <level code="M03">MUSCLE RELAXANTS</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1F82</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00042.pdf?1265922805</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum Toxin Type A</name>
      <description>Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Succinylcholine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine Iodide</name>
      <description>Metocurine Iodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine Triethiodide</name>
      <description>Gallamine Triethiodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium besylate</name>
      <description>Cisatracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Rocuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Atracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium chloride</name>
      <description>Doxacurium chloride may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Tubocurarine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Mivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>Decamethonium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Metocurine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Pancuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Pipecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Vecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>Domoic Acid may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Rapacuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Pyrantel may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>Neosaxitoxin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>Trospium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium bromide</name>
      <description>Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Ethopropazine</name>
      <description>Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine Methylbromide</name>
      <description>Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>Atropine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Propantheline may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>Biperiden may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Quinidine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Methantheline may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Scopolamine butylbromide</name>
      <description>Scopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>Metixene may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>Homatropine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Propiverine may increase the anticholinergic activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00919</drugbank-id>
      <name>Spectinomycin</name>
      <description>Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01578</drugbank-id>
      <name>Metrizamide</name>
      <description>Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06810</drugbank-id>
      <name>Plicamycin</name>
      <description>Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11617</drugbank-id>
      <name>Aclarubicin</name>
      <description>Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00385</drugbank-id>
      <name>Valrubicin</name>
      <description>Valrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>GENTAMICIN C1A</name>
      <description>GENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04978</drugbank-id>
      <name>SP1049C</name>
      <description>SP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06013</drugbank-id>
      <name>INNO-206</name>
      <description>INNO-206 may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06263</drugbank-id>
      <name>Amrubicin</name>
      <description>Amrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>annamycin</name>
      <description>annamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11616</drugbank-id>
      <name>Pirarubicin</name>
      <description>Pirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11618</drugbank-id>
      <name>Zorubicin</name>
      <description>Zorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Botulinum neurotoxin type B - Clostridium botulinum
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>150804.0</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12854</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02735</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>M81186</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164747061</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P10844</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001272</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Botulinum_toxin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201569</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/botulinumtoxin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/botulinum-toxin-type-b.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002137</id>
      <name>Vesicle-associated membrane protein 2</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>14573702</pubmed-id>
            <citation>Liu W, Montana V, Chapman ER, Mohideen U, Parpura V: Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13621-5. Epub 2003 Oct 22.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P63027" source="Swiss-Prot">
    <name>Vesicle-associated membrane protein 2</name>
    <general-function>Syntaxin-1 binding</general-function>
    <specific-function>Involved in the targeting and/or fusion of transport vesicles to their target membrane. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1.</specific-function>
    <gene-name>VAMP2</gene-name>
    <locus>17p13.1</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions>95-114</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.48</theoretical-pi>
    <molecular-weight>12662.585</molecular-weight>
    <chromosome-location>17</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:12643</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>VAMP2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M36205</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>338632</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P63027</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>VAMP2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>SYB2</synonym>
      <synonym>Synaptobrevin-2</synonym>
      <synonym>VAMP-2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016692|Vesicle-associated membrane protein 2
MSATAATAPPAAPAGEGGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL
SELDDRADALQAGASQFETSAAKLKRKYWWKNLKMMIILGVICAIILIIIIVYFST</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016693|Vesicle-associated membrane protein 2 (VAMP2)
ATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCT
GCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGAT
GAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTG
TCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGC
GCAGCCAAGCTCAAGCGCAAATACTGGTGGAAAAACCTCAAGATGATGATCATCTTGGGA
GTGATTTGCGCCATCATCCTCATCATCATCATAGTTTACTTCAGCACTTAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00957</identifier>
        <name>Synaptobrevin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>clathrin-sculpted monoamine transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>trans-Golgi network</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>terminal bouton</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-sculpted glutamate transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>storage vacuole</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synapse</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptobrevin 2-SNAP-25-syntaxin-1a complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>extracellular exosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>zymogen granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasmic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>neuron projection terminus</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>perinuclear region of cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>clathrin-coated vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>secretory granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>SNARE complex</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calmodulin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>SNAP receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein self-association</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>SNARE binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>syntaxin-1 binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent protein binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>syntaxin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular protein metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vesicle fusion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to glucose</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>glutamate secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane organization</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>neurotransmitter secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>membrane fusion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium ion-dependent exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>small molecule metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>energy reserve metabolic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic transmission</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of insulin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>long-term synaptic potentiation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Golgi to plasma membrane protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of intracellular protein transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>eosinophil degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of delayed rectifier potassium channel activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>post-Golgi vesicle-mediated transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to insulin stimulus</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="2">
      <id>BE0002136</id>
      <name>Vesicle-associated membrane protein 1</name>
      <organism>Human</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P23763" source="Swiss-Prot">
    <name>Vesicle-associated membrane protein 1</name>
    <general-function>Snare binding</general-function>
    <specific-function>Involved in the targeting and/or fusion of transport vesicles to their target membrane.</specific-function>
    <gene-name>VAMP1</gene-name>
    <locus>12p</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions>97-116</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>6.59</theoretical-pi>
    <molecular-weight>12901.815</molecular-weight>
    <chromosome-location>12</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:12642</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>VAMP1</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M36200</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>338625</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P23763</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>VAMP1_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>SYB1</synonym>
      <synonym>Synaptobrevin-1</synonym>
      <synonym>VAMP-1</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004190|Vesicle-associated membrane protein 1
MSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQ
KLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0016691|Vesicle-associated membrane protein 1 (VAMP1)
ATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGT
CCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAA
GTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAG
AAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAG
AGCAGTGCTGCCAAGCTAAAGAGGAAGTATTGGTGGAAAAACTGCAAGATGATGATCATG
CTGGGAGCCATCTGTGCCATCATCGTGGTAGTTATTGTAAGAAGAGGCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00957</identifier>
        <name>Synaptobrevin</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>SNARE complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>specific granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>tertiary granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>mitochondrial outer membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>terminal bouton</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>SNAP receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>SNARE binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>SNARE complex assembly</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vesicle fusion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>exocytosis</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target position="3">
      <id>BE0002138</id>
      <name>Synaptotagmin-2</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>19576489</pubmed-id>
            <citation>Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins]. Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6. doi: 10.1016/S0151-9638(09)74531-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q8N9I0" source="Swiss-Prot">
    <name>Synaptotagmin-2</name>
    <general-function>Syntaxin binding</general-function>
    <specific-function>Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003).</specific-function>
    <gene-name>SYT2</gene-name>
    <locus>1q32.1</locus>
    <cellular-location>Cytoplasmic vesicle</cellular-location>
    <transmembrane-regions>63-83</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>8.12</theoretical-pi>
    <molecular-weight>46871.95</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11510</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>SYT2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AK090672</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>21748879</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q8N9I0</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>SYT2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Synaptotagmin II</synonym>
      <synonym>SytII</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011549|Synaptotagmin-2
MRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKIPL
PPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQDDDDA
ETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGTSDPYVK
VFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRFSKHDIIGE
VKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKM
DVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFEQIQKVQVVVTVL
DYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011550|Synaptotagmin-2 (SYT2)
ATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCC
ACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGCCAG
GAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTA
CCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGC
TTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAGAAGGAGAAGGGCAAA
GGCATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTCAGGATGACGACGACGCA
GAGACAGGCCTGACTGAGGGGGAAGGTGAAGGGGAGGAGGAGAAAGAGCCAGAGAACCTG
GGCAAACTGCAGTTTTCCCTGGACTATGATTTTCAGGCTAATCAGCTTACTGTGGGCGTT
CTGCAGGCTGCTGAACTGCCTGCCCTGGACATGGGAGGCACCTCAGACCCTTATGTCAAG
GTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGAGACCAAAGTCCATCGGAAGACACTG
AACCCTGCCTTCAATGAAACCTTCACCTTCAAGGTGCCATACCAGGAGCTTGGGGGCAAA
ACTCTGGTGATGGCCATCTATGACTTTGACCGCTTCTCCAAACATGACATCATTGGAGAG
GTAAAGGTGCCTATGAACACAGTGGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTG
CAAGGCGGGGAAAAGGAGGAGCCGGAGAAGCTGGGCGACATCTGCACCTCCCTGCGCTAT
GTGCCCACGGCCGGGAAGCTCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATG
GACGTGGGCGGCCTTTCAGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGG
CTCAAGAAGAAGAAGACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCC
TTCAGCTTTGAGATCCCCTTCGAGCAGATTCAGAAAGTCCAGGTAGTGGTCACCGTGCTG
GACTATGACAAGCTGGGCAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCC
ACGGGCACAGAGCTGCGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCC
CAGTGGCACTCGCTCAAGCCTGAGGAGGAGGTGGATGCACTCCTGGGCAAGAACAAGTAG
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00168</identifier>
        <name>C2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>chromaffin granule membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell junction</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular membrane-bounded organelle</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>synaptic vesicle membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium ion binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>clathrin binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>calcium-dependent phospholipid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>inositol 1,3,4,5 tetrakisphosphate binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>syntaxin binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of dendrite extension</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>synaptic vesicle endocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>calcium ion-dependent exocytosis of neurotransmitter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of calcium ion-dependent exocytosis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>vesicle fusion</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00043</drugbank-id>
  <drugbank-id>BTD00081</drugbank-id>
  <drugbank-id>BIOD00081</drugbank-id>
  <name>Omalizumab</name>
  <description>A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.</description>
  <cas-number>242138-07-4</cas-number>
  <unii>2P471X1Z11</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>12672069</pubmed-id>
        <citation>Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of asthma caused by allergies</indication>
  <pharmacodynamics>Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.</pharmacodynamics>
  <mechanism-of-action>Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.</mechanism-of-action>
  <toxicity/>
  <metabolism>Most likely removed by opsonization via the reticuloendothelial system.</metabolism>
  <absorption/>
  <half-life>26 days</half-life>
  <protein-binding/>
  <route-of-elimination>Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.</route-of-elimination>
  <volume-of-distribution>* 78 ± 32 mL/kg</volume-of-distribution>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Xolair</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02260565</dpd-id>
      <started-marketing-on>2005-02-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>150 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xolair</name>
      <labeller>Genentech, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50242-040</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2003-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>202.5 mg/1.4mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA103976</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xolair</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459795</dpd-id>
      <started-marketing-on>2017-07-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>150 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xolair</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02459787</dpd-id>
      <started-marketing-on>2017-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>75 mg</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Xolair</name>
      <ingredients>Omalizumab</ingredients>
    </mixture>
    <mixture>
      <name>Xolair</name>
      <ingredients>Omalizumab</ingredients>
    </mixture>
    <mixture>
      <name>Xolair</name>
      <ingredients>Omalizumab</ingredients>
    </mixture>
    <mixture>
      <name>Xolair</name>
      <ingredients>Omalizumab</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genentech Inc.</name>
      <url>http://www.gene.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Xolair 150 mg vial</description>
      <cost currency="USD">715.42</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Agents to Treat Airway Disease</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Allergic Agents</category>
      <mesh-id>D018926</mesh-id>
    </category>
    <category>
      <category>Anti-Asthmatic Agents</category>
      <mesh-id>D018927</mesh-id>
    </category>
    <category>
      <category>Antibodies</category>
      <mesh-id>D000906</mesh-id>
    </category>
    <category>
      <category>Antibodies, Anti-Idiotypic</category>
      <mesh-id>D000888</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal</category>
      <mesh-id>D000911</mesh-id>
    </category>
    <category>
      <category>Antibodies, Monoclonal, Humanized</category>
      <mesh-id>D061067</mesh-id>
    </category>
    <category>
      <category>Blood Proteins</category>
      <mesh-id>D001798</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Drugs for Obstructive Airway Diseases</category>
      <mesh-id/>
    </category>
    <category>
      <category>Globulins</category>
      <mesh-id>D005916</mesh-id>
    </category>
    <category>
      <category>Immunoglobulins</category>
      <mesh-id>D007136</mesh-id>
    </category>
    <category>
      <category>Immunoproteins</category>
      <mesh-id>D007162</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Respiratory System</category>
      <mesh-id>D012137</mesh-id>
    </category>
    <category>
      <category>Respiratory System Agents</category>
      <mesh-id>D019141</mesh-id>
    </category>
    <category>
      <category>Serum Globulins</category>
      <mesh-id>D012712</mesh-id>
    </category>
    <category>
      <category>Therapeutic Uses</category>
      <mesh-id>D045506</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>202.5 mg/1.4mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>150 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>150 mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>75 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R03DX05">
      <level code="R03DX">Other systemic drugs for obstructive airway diseases</level>
      <level code="R03D">OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R03">DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>48:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1IGT</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00043.pdf?1265922796</fda-label>
  <patents>
    <patent>
      <number>2113813</number>
      <country>Canada</country>
      <approved>2005-04-12</approved>
      <expires>2012-08-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1340233</number>
      <country>Canada</country>
      <approved>1998-12-15</approved>
      <expires>2015-12-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB08879</drugbank-id>
      <name>Belimumab</name>
      <description>The risk or severity of adverse effects can be increased when Omalizumab is combined with Belimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Omalizumab is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10283</drugbank-id>
      <name>Rabies virus inactivated antigen, A</name>
      <description>The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04914</drugbank-id>
      <name>G17DT</name>
      <description>The therapeutic efficacy of G17DT can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05322</drugbank-id>
      <name>INGN 201</name>
      <description>The therapeutic efficacy of INGN 201 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05325</drugbank-id>
      <name>INGN 225</name>
      <description>The therapeutic efficacy of INGN 225 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05374</drugbank-id>
      <name>Rindopepimut</name>
      <description>The therapeutic efficacy of CDX-110 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05440</drugbank-id>
      <name>SRP 299</name>
      <description>The therapeutic efficacy of SRP 299 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05942</drugbank-id>
      <name>GI-5005</name>
      <description>The therapeutic efficacy of GI-5005 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06584</drugbank-id>
      <name>TG4010</name>
      <description>The therapeutic efficacy of TG4010 can be decreased when used in combination with Omalizumab.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Omalizumab heavy chain
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNY
ADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVS
SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
    <sequence format="FASTA">&gt;Omalizumab light chain
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
      <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.432</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>7.03</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>145058.2</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C6450H9916N1714O2023S38</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13365</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>J00228</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164752253</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01857</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000387</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Omalizumab</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201589</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/xolair.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/omalizumab.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000015</id>
      <name>High affinity immunoglobulin epsilon receptor subunit alpha</name>
      <organism>Human</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <pubmed-id>15356552</pubmed-id>
            <citation>Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30.</citation>
          </article>
          <article>
            <pubmed-id>17368811</pubmed-id>
            <citation>Mirkina I, Schweighoffer T, Kricek F: Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007 Apr 15;109(2):120-8. Epub 2007 Mar 1.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P12319" source="Swiss-Prot">
    <name>High affinity immunoglobulin epsilon receptor subunit alpha</name>
    <general-function>Ige receptor activity</general-function>
    <specific-function>Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines.</specific-function>
    <gene-name>FCER1A</gene-name>
    <locus>1q23</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>206-224</transmembrane-regions>
    <signal-regions>1-25</signal-regions>
    <theoretical-pi>6.67</theoretical-pi>
    <molecular-weight>29595.67</molecular-weight>
    <chromosome-location>1</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:3609</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>FCER1A</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X06948</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P12319</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCERA_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>Fc-epsilon RI-alpha</synonym>
      <synonym>FCE1A</synonym>
      <synonym>FcERI</synonym>
      <synonym>IgE Fc receptor subunit alpha</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0015997|High affinity immunoglobulin epsilon receptor subunit alpha
MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS
STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE
VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV
WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR
KGFRLLNPHPKPNPKNN</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0015998|High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A)
ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA
GATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA
ATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT
TCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT
GTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG
AGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG
GTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG
TACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC
ATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG
TGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG
AAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA
GGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG
AAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF13895</identifier>
        <name>Ig_2</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intracellular</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>IgE receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mast cell degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of type I hypersensitivity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>serotonin secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of JUN kinase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>leukotriene biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of calcium-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-3 biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
    <target>
      <id>BE0002139</id>
      <name>High affinity immunoglobulin epsilon receptor subunit beta</name>
      <organism>Human</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>17073688</pubmed-id>
            <citation>DuBuske LM: IgE, allergic diseases, and omalizumab. Curr Pharm Des. 2006;12(30):3929-44.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q01362" source="Swiss-Prot">
    <name>High affinity immunoglobulin epsilon receptor subunit beta</name>
    <general-function>Ige receptor activity</general-function>
    <specific-function>High affinity receptor that binds to the Fc region of immunoglobulins epsilon. Aggregation of FCER1 by multivalent antigens is required for the full mast cell response, including the release of preformed mediators (such as histamine) by degranulation and de novo production of lipid mediators and cytokines. Also mediates the secretion of important lymphokines. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators responsible for the manifestations of allergy.</specific-function>
    <gene-name>MS4A2</gene-name>
    <locus>11q13</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>60-79
98-117
131-150
181-200</transmembrane-regions>
    <signal-regions/>
    <theoretical-pi>4.78</theoretical-pi>
    <molecular-weight>26533.365</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:7316</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>MS4A2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>D10583</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>219882</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>Q01362</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>FCERB_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>APY</synonym>
      <synonym>Fc epsilon receptor I beta-chain</synonym>
      <synonym>FCER1B</synonym>
      <synonym>FcERI</synonym>
      <synonym>IgE Fc receptor subunit beta</synonym>
      <synonym>IGER</synonym>
      <synonym>Membrane-spanning 4-domains subfamily A member 2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0011551|High affinity immunoglobulin epsilon receptor subunit beta
MDTESNRRANLALPQEPSSVPAFEVLEISPQEVSSGRLLKSASSPPLHTWLTVLKKEQEF
LGVTQILTAMICLCFGTVVCSVLDISHIEGDIFSSFKAGYPFWGAIFFSISGMLSIISER
RNATYLVRGSLGANTASSIAGGTGITILIINLKKSLAYIHIHSCQKFFETKCFMASFSTE
IVVMMLFLTILGLGSAVSLTICGAGEELKGNKVPEDRVYEELNIYSATYSELEDPGEMSP
PIDL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0011552|High affinity immunoglobulin epsilon receptor subunit beta (MS4A2)
ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTG
CCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAG
TCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTC
CTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGC
TCTGTACTTGATATTTCACACATTGAGGGAGACATTTTTTCATCATTTAAAGCAGGTTAT
CCATTCTGGGGAGCCATATTTTTTTCTATTTCTGGAATGTTGTCAATTATATCTGAAAGG
AGAAATGCAACATATCTGGTGAGAGGAAGCCTGGGAGCAAACACTGCCAGCAGCATAGCT
GGGGGAACGGGAATTACCATCCTGATCATCAACCTGAAGAAGAGCTTGGCCTATATCCAC
ATCCACAGTTGCCAGAAATTTTTTGAGACCAAGTGCTTTATGGCTTCCTTTTCCACTGAA
ATTGTAGTGATGATGCTGTTTCTCACCATTCTGGGACTTGGTAGTGCTGTGTCACTCACA
ATCTGTGGAGCTGGGGAAGAACTCAAAGGAAACAAGGTTCCAGAGGATCGTGTTTATGAA
GAATTAAACATATATTCAGCTACTTACAGTGAGTTGGAAGACCCAGGGGAAATGTCTCCT
CCCATTGATTTATAA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF04103</identifier>
        <name>CD20</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Fc-epsilon receptor I complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>IgE receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of release of sequestered calcium ion into cytosol</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>Fc-epsilon receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of mast cell degranulation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of phospholipase C activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00044</drugbank-id>
  <drugbank-id>BTD00056</drugbank-id>
  <drugbank-id>BIOD00056</drugbank-id>
  <name>Lutropin alfa</name>
  <description>Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH ("LH surge") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.</description>
  <cas-number>152923-57-4</cas-number>
  <unii>3JGY52XJNA</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>3972</pubmed-id>
        <citation>Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46.</citation>
      </article>
      <article>
        <pubmed-id>1122882</pubmed-id>
        <citation>Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86.</citation>
      </article>
      <article>
        <pubmed-id>11476792</pubmed-id>
        <citation>Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7.</citation>
      </article>
      <article>
        <pubmed-id>20161981</pubmed-id>
        <citation>Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17.</citation>
      </article>
      <article>
        <pubmed-id>18627209</pubmed-id>
        <citation>Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Link</title>
        <url>http://search.ebscohost.com/login.aspx?direct=true&amp;site=DynaMed&amp;id=233015</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH &lt;1.2 international units [IU]/L)</indication>
  <pharmacodynamics>Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Lutropin alfa also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Lutropin alfa and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Lutropin alfa substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Lutropin alfa induces and maintains the corpus luteum, which then secretes progesterone.</pharmacodynamics>
  <mechanism-of-action>Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes. </mechanism-of-action>
  <toxicity>Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus. </toxicity>
  <metabolism>&lt;5% of dose excreted renally as unchanged drug.</metabolism>
  <absorption>Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours </absorption>
  <half-life>Biphasic; terminal half-life is approximately 18 hours.</half-life>
  <protein-binding/>
  <route-of-elimination>Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.</route-of-elimination>
  <volume-of-distribution>The steady state volume of distribution is around 10-14 L.</volume-of-distribution>
  <clearance>* 2 – 3 L/h [healthy female following subcutaneous administration]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">ICSH</synonym>
    <synonym language="" coder="">Insterstiial cell-stimulating hormone</synonym>
    <synonym language="" coder="">LH</synonym>
    <synonym language="" coder="">LH-B</synonym>
    <synonym language="" coder="">LSH- beta</synonym>
    <synonym language="" coder="">LSH-B</synonym>
    <synonym language="" coder="">Luteinizing hormone</synonym>
    <synonym language="" coder="">Luteinizing hormone beta subunit</synonym>
    <synonym language="" coder="">Lutrophin</synonym>
    <synonym language="" coder="">Lutropin alpha</synonym>
    <synonym language="" coder="">Lutropin beta chain precursor</synonym>
  </synonyms>
  <products>
    <product>
      <name>Humegon Inj 75 I.U.</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01958992</dpd-id>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2006-08-17</ended-marketing-on>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Luveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02269066</dpd-id>
      <started-marketing-on>2005-06-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>75 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Luveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02339757</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>450 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergonal 75 I.U.</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00254916</dpd-id>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2007-05-07</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pergoveris</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02445301</dpd-id>
      <started-marketing-on>2015-10-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Luveris</name>
      <ingredients>Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Humegon Inj 75 I.U.</name>
      <ingredients>Lutropin alfa + Sodium Chloride + Urofollitropin</ingredients>
    </mixture>
    <mixture>
      <name>Pergonal 75 I.U.</name>
      <ingredients>Lutropin alfa + Urofollitropin</ingredients>
    </mixture>
    <mixture>
      <name>Luveris</name>
      <ingredients>Lutropin alfa</ingredients>
    </mixture>
    <mixture>
      <name>Pergoveris</name>
      <ingredients>Follitropin + Lutropin alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>EMD Canada Inc.</name>
      <url>http://www.emdcanada.com</url>
    </packager>
    <packager>
      <name>Merck Serono SPA</name>
      <url>http://www.merckserono.net</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Emd serono inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Luveris 75 unit vial</description>
      <cost currency="USD">38.88</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropins</category>
      <mesh-id>D006062</mesh-id>
    </category>
    <category>
      <category>Gonadotropins, Pituitary</category>
      <mesh-id>D006065</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones</category>
      <mesh-id>D010907</mesh-id>
    </category>
    <category>
      <category>Pituitary Hormones, Anterior</category>
      <mesh-id>D010908</mesh-id>
    </category>
    <category>
      <category>Sex Hormones and Modulators of the Genital System</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength>75 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>450 unit</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G03GA07">
      <level code="G03GA">Gonadotropins</level>
      <level code="G03G">GONADOTROPINS AND OTHER OVULATION STIMULANTS</level>
      <level code="G03">SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:18.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>1XWD</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00044.pdf?1265922800</fda-label>
  <patents>
    <patent>
      <number>5767251</number>
      <country>United States</country>
      <approved>1995-06-16</approved>
      <expires>2015-06-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Alpha Chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS</sequence>
    <sequence format="FASTA">&gt;Beta Chain (LH)
SREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR
DVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF
L</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>55 °C</value>
      <source>Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)</source>
    </property>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.063</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>8.44</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>30000.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1014H1609N287O294S27</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>15875</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7347</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X00264</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164750539</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P01229</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001103</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Lutropin_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201419</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/lutropin-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000134</id>
      <name>Lutropin-choriogonadotropic hormone receptor</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <pubmed-id>20161981</pubmed-id>
            <citation>Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17.</citation>
          </article>
          <article>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P22888" source="Swiss-Prot">
    <name>Lutropin-choriogonadotropic hormone receptor</name>
    <general-function>Luteinizing hormone receptor activity</general-function>
    <specific-function>Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.</specific-function>
    <gene-name>LHCGR</gene-name>
    <locus>2p21</locus>
    <cellular-location>Cell membrane</cellular-location>
    <transmembrane-regions>364-385
396-416
440-462
483-505
526-549
571-594
606-627</transmembrane-regions>
    <signal-regions>1-26</signal-regions>
    <theoretical-pi>8.58</theoretical-pi>
    <molecular-weight>78642.01</molecular-weight>
    <chromosome-location>2</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:6585</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>LHCGR</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>M73746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>903746</identifier>
      </external-identifier>
      <external-identifier>
        <resource>IUPHAR</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>Guide to Pharmacology</resource>
        <identifier>254</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P22888</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>LSHR_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>LCGR</synonym>
      <synonym>LGR2</synonym>
      <synonym>LH/CG-R</synonym>
      <synonym>LHR</synonym>
      <synonym>LHRHR</synonym>
      <synonym>LSH-R</synonym>
      <synonym>Luteinizing hormone receptor</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor
MKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP
VKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI
NLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK
LYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY
GLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF
SKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD
FLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS
QTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL
RHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF
IICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT
VTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT
SNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)
ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG
CTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC
GCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT
GTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC
TCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG
TCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA
AATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT
GTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC
ATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA
CTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT
TCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG
GCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT
GGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA
TCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT
GCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT
TCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG
CTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA
CCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC
TTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT
CTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT
CTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC
CAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC
ACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC
ACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA
AGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG
CCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA
ACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC
ATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT
ACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC
TGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA
GTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA
TTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA
TTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC
TCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG
TCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA
</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00001</identifier>
        <name>7tm_1</name>
      </pfam>
      <pfam>
        <identifier>PF13306</identifier>
        <name>LRR_5</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>endosome</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>luteinizing hormone receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>G-protein coupled peptide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>choriogonadotropin hormone binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to gonadotropin stimulus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>female gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cognition</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>luteinizing hormone signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male genitalia development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>hormone-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>ovulation cycle process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>male gonad development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cAMP-mediated signaling</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>spermatogenesis</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inositol trisphosphate biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>uterus development</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>activation of adenylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>G-protein coupled receptor signaling pathway</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2016-08-17">
  <drugbank-id primary="true">DB00045</drugbank-id>
  <drugbank-id>BTD00054</drugbank-id>
  <drugbank-id>BIOD00054</drugbank-id>
  <name>OspA lipoprotein</name>
  <description>Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.</description>
  <cas-number/>
  <unii/>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For prophylactic treatment of Lyme Disease</indication>
  <pharmacodynamics>OspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease.</pharmacodynamics>
  <mechanism-of-action>OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>1.2 hours (mammalian reticulocytes, in vitro).</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Outer surface protein A precursor</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>LYMErix</name>
      <company>SmithKline Beecham</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1FJ1</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt; OspA lipoprotein
MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDN
VDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKST
TEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVE
IKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNG
TITVQNYDSAGTKLEGSAAEIKKLDELKNALR</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Hydrophobicity</kind>
      <value>-0.652</value>
      <source/>
    </property>
    <property>
      <kind>Isoelectric Point</kind>
      <value>6.72</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>27743.1</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1198H2012N322O422S2</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X16467</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164743058</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P14013</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001334</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001164</id>
      <name>Toll-like receptor 2</name>
      <organism>Human</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <pubmed-id>14617145</pubmed-id>
            <citation>Welty DM, Snyder DS: Internalization of OspA in rsCD14 complex and aggregated forms. Mol Microbiol. 2003 Nov;50(3):835-43.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O60603" source="Swiss-Prot">
    <name>Toll-like receptor 2</name>
    <general-function>Triacyl lipopeptide binding</general-function>
    <specific-function>Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Cooperates with TLR1 or TLR6 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:17889651). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins (PubMed:10426996). Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6 (PubMed:11441107). Acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36).The lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen (PubMed:19362712). Forms activation clusters composed of several receptors depending on the ligand, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. Forms the cluster TLR2:TLR6:CD14:CD36 in response to diacylated lipopeptides and TLR2:TLR1:CD14 in response to triacylated lipopeptides (PubMed:16880211).</specific-function>
    <gene-name>TLR2</gene-name>
    <locus>4q32</locus>
    <cellular-location>Membrane</cellular-location>
    <transmembrane-regions>589-609</transmembrane-regions>
    <signal-regions>1-18</signal-regions>
    <theoretical-pi>6.59</theoretical-pi>
    <molecular-weight>89836.575</molecular-weight>
    <chromosome-location>4</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:11848</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenAtlas</resource>
        <identifier>TLR2</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>AF051152</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>3132528</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>O60603</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>TLR2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>TIL4</synonym>
      <synonym>Toll/interleukin-1 receptor-like protein 4</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010812|Toll-like receptor 2
MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS
NNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF
KPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE
IDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS
ELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN
DRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK
SLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI
SKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK
ELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE
FLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL
LILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV
QELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS
HFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA
AIKS</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0010813|Toll-like receptor 2 (TLR2)
ATGCCACATACTTTGTGGATGGTGTGGGTCTTGGGGGTCATCATCAGCCTCTCCAAGGAA
GAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA
GGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC
AACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT
CTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC
AGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC
AAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG
GAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC
ACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG
ATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA
AGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT
ACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA
GAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA
ATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA
GAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT
GACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA
AGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA
ATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA
TCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA
GCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA
TCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC
AGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT
TTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA
ATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA
GAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG
TTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC
TCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA
TTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA
AATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC
TCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG
CTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG
ATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC
TATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC
CAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT
CCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC
TTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC
CATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT
GAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC
TACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT
GCGATAAAGTCCTAG</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF01463</identifier>
        <name>LRRCT</name>
      </pfam>
      <pfam>
        <identifier>PF01582</identifier>
        <name>TIR</name>
      </pfam>
      <pfam>
        <identifier>PF13855</identifier>
        <name>LRR_8</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>external side of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>integral component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>intrinsic component of plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cytoplasm</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Toll-like receptor 1-Toll-like receptor 2 protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Toll-like receptor 2-Toll-like receptor 6 protein complex</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>cell surface</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>membrane raft</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>Golgi apparatus</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipopolysaccharide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>triacyl lipopeptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipopolysaccharide receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>diacyl lipopeptide binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>lipoteichoic acid binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>transmembrane signaling receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>protein heterodimerization activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>peptidoglycan binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>signaling pattern recognition receptor activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>Toll-like receptor binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>response to molecule of fungal origin</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-12 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>induction by symbiont of defense-related host nitric oxide production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>innate immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric-oxide synthase biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cell surface pattern recognition receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of Wnt signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>interleukin-10 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB import into nucleus</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>lipopolysaccharide-mediated signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to bacterial lipopeptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of NF-kappaB transcription factor activity</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of interleukin-12 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>I-kappaB phosphorylation</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to diacyl bacterial lipopeptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>defense response to Gram-positive bacterium</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cytokine secretion</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>apoptotic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-8 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to lipoteichoic acid</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>MyD88-dependent toll-like receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interferon-beta production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of transcription from RNA polymerase II promoter</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of chemokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to peptidoglycan</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toll-like receptor 2 signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-18 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of interleukin-6 production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of gene expression</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cellular response to triacyl bacterial lipopeptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toll-like receptor 4 signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of macrophage cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of tumor necrosis factor production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>chloramphenicol transport</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toll-like receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of toll-like receptor signaling pathway</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of growth of symbiont in host</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cytokine secretion involved in immune response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toll-like receptor TLR1</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of tumor necrosis factor biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of inflammatory response</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of leukocyte migration</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of diacyl bacterial lipopeptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>toll-like receptor TLR6</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>regulation of dendritic cell cytokine production</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of nitric oxide biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>detection of triacyl bacterial lipopeptide</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>negative regulation of interleukin-17 production</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
<drug type="biotech" created="2005-06-13" updated="2017-08-08">
  <drugbank-id primary="true">DB00046</drugbank-id>
  <drugbank-id>BTD00065</drugbank-id>
  <drugbank-id>BIOD00065</drugbank-id>
  <drugbank-id>DB01310</drugbank-id>
  <name>Insulin Lispro</name>
  <description>Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996.</description>
  <cas-number>133107-64-9</cas-number>
  <unii>GFX7QIS1II</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>18454569</pubmed-id>
        <citation>Miles HL, Acerini CL: Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs. 2008;10(3):163-76.</citation>
      </article>
      <article>
        <pubmed-id>17026485</pubmed-id>
        <citation>Zib I, Raskin P: Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump. </indication>
  <pharmacodynamics>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin lispro is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin lispro is 10-15 minutes. Its activity peaks 60 minutes following subcutaneous injection and its duration of action is 4-5 hours. Compared to regular human insulin, insulin lispro  has a more rapid onset of action and a shorter duration of action. Insulin lispro is also shown to be equipotent to human insulin on a molar basis.  </pharmacodynamics>
  <mechanism-of-action>Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and &lt;i&gt;m&lt;/i&gt;-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties. </mechanism-of-action>
  <toxicity>Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Rare cases of lipoatrophy or lipohypertrophy reactions have been observed. </toxicity>
  <metabolism>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</metabolism>
  <absorption>Rapidly absorbed following subcutaneous administration. It is also absorbed more quickly than regular human insulin. Peak serum levels occur 30-90 minutes after injection in healthy subjects. Absorption also differs depending on the site of injection. After insulin lispro was administered in the abdomen, serum drug levels were higher and the duration of action was slightly shorter than after deltoid or thigh administration.&#13;
Bioavailability, 0.1 - 0.2 unit/kg = 55% - 77%. </absorption>
  <half-life>SubQ administration = 1 hour</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>When administered intravenously as bolus injections of 0.1 and 0.2 U/kg dose in two separate groups of healthy subjects, the mean volume of distribution of insulin lispro appeared to decrease with increase in dose (1.55 and 0.72 L/kg, respectively). </volume-of-distribution>
  <clearance>Clearance is dose dependent. When a dose of 0.1 unit/kg and 0.2 unit/kg were administered intravenously, the mean clearance was 21.0 mL/min/kg and 9.6 mL/min/kg respectively. </clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Insulin lispro (genetical recombination)</synonym>
    <synonym language="" coder="">Insulin lispro (rDNA origin)</synonym>
    <synonym language="" coder="">Insulin lispro protamine</synonym>
    <synonym language="" coder="">Insulin lispro protamine recombinant</synonym>
    <synonym language="" coder="">Insulin lispro recombinant</synonym>
    <synonym language="" coder="">Insulin,lispro,human/rDNA</synonym>
    <synonym language="" coder="">Insulin,lispro,protamine/rDNA</synonym>
  </synonyms>
  <products>
    <product>
      <name>Humalog</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229704</dpd-id>
      <started-marketing-on>1996-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7510</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7516</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1998-02-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5108</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2005-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog</name>
      <labeller>Dispensing Solutions, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55045-3602</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1375</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-06-14</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog  (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02229705</dpd-id>
      <started-marketing-on>1996-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog  (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403412</dpd-id>
      <started-marketing-on>2013-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog  Junior KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7714</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1996-06-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog 200 Units/ml Kwikpen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02439611</dpd-id>
      <started-marketing-on>2015-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>200 unit</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Cartridge</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5836</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7712</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2015-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA205747</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog KwikPen</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1663</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-09-06</started-marketing-on>
      <ended-marketing-on>2017-06-20</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8799</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Mix 25 (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240294</dpd-id>
      <started-marketing-on>1999-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 25 (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240294</dpd-id>
      <started-marketing-on>1999-07-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 25 (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403420</dpd-id>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 25 (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403420</dpd-id>
      <started-marketing-on>2013-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 25 (pen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240295</dpd-id>
      <started-marketing-on>2000-01-10</started-marketing-on>
      <ended-marketing-on>2011-04-29</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 25 (pen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240295</dpd-id>
      <started-marketing-on>2000-01-10</started-marketing-on>
      <ended-marketing-on>2011-04-29</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 50 (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240297</dpd-id>
      <started-marketing-on>2007-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 50 (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02240297</dpd-id>
      <started-marketing-on>2007-01-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 50 (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403439</dpd-id>
      <started-marketing-on>2014-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix 50 (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403439</dpd-id>
      <started-marketing-on>2014-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humalog Mix50/50</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7512</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021018</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Mix50/50 KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8798</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2006-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021018</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Mix75/25</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-7511</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1999-12-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021017</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Mix75/25 KwikPen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8797</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2007-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA021017</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Pen</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5899</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2008-05-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020563</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog Pen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02241283</dpd-id>
      <started-marketing-on>2000-01-10</started-marketing-on>
      <ended-marketing-on>2011-04-29</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength>100 unit</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Humalog  (cartridge)</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog  (kwikpen)</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Pen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog 200 Units/ml Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Basal</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Basal</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix25 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix25 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Basal Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Basal Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix25 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix25 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix50 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Mix50 Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Basal</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Basal</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Basal Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Basal Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Liprolog Kwikpen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Cartridge</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Pen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (cartridge)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (cartridge)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 50 (cartridge)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 50 (cartridge)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (kwikpen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (kwikpen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (pen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 25 (pen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 50 (kwikpen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix 50 (kwikpen)</name>
      <ingredients>Insulin Lispro + Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix75/25</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50/50</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix75/25 KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog Mix50/50 KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
    <mixture>
      <name>Humalog  Junior KwikPen</name>
      <ingredients>Insulin Lispro</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Lilly Del Caribe Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Midwest IV and Home Care</name>
      <url>http://midwestmed.org/iv</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Eli lilly and co</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Humalog 100 unit/ml</description>
      <cost currency="USD">2.95</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humalog 100 unit/ml Cartridge</description>
      <cost currency="USD">9.37</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humalog mix 50/50 kwikpen</description>
      <cost currency="USD">11.83</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Humalog 100 unit/ml kwikpen</description>
      <cost currency="USD">15.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Humalog 100 unit/ml pen</description>
      <cost currency="USD">15.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Humalog mix 50-50 kwikpen</description>
      <cost currency="USD">15.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Humalog mix 50-50 pen</description>
      <cost currency="USD">15.4</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>HumaLOG 100 unit/ml Solution 10ml Vial</description>
      <cost currency="USD">124.36</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>HumaLOG 100 unit/ml Solution 1 Box = Five 3ml Cartridges = 15ml</description>
      <cost currency="USD">231.0</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>HumaLOG KwikPen 100 unit/ml Solution (1box = 5 Pens = 15ml)</description>
      <cost currency="USD">240.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>HumaLOG Mix 50/50 KwikPen 50-50% Suspension Five 3ml Pens Per Box = 15ml</description>
      <cost currency="USD">240.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>HumaLOG Mix 75/25 KwikPen 75-25% Suspension Five 3ml Pen Per Box = 15ml</description>
      <cost currency="USD">240.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>HumaLOG Mix 75/25 Pen 75-25% Suspension 15ml Box</description>
      <cost currency="USD">240.18</cost>
      <unit>box</unit>
    </price>
    <price>
      <description>HumaLOG Pen (five 3ml Pens Per Box) 15ml Box</description>
      <cost currency="USD">240.18</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Blood Glucose Lowering Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers</category>
      <mesh-id>D065694</mesh-id>
    </category>
    <category>
      <category>Drugs Used in Diabetes</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypoglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypoglycemic Agents</category>
      <mesh-id>D007004</mesh-id>
    </category>
    <category>
      <category>Insulin, Short-Acting</category>
      <mesh-id>D061266</mesh-id>
    </category>
    <category>
      <category>Insulins</category>
      <mesh-id>D061385</mesh-id>
    </category>
    <category>
      <category>Insulins and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Insulins and Analogues for Injection, Intermediate- or Long-Acting Combined With Fast-Acting</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pancreatic Hormones</category>
      <mesh-id>D010187</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 U/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>200 unit</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 U/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 U/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 unit</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A10AC04">
      <level code="A10AC">Insulins and analogues for injection, intermediate-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AB04">
      <level code="A10AB">Insulins and analogues for injection, fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AD04">
      <level code="A10AD">Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:20.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2VJZ</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00046.pdf?1372114128</fda-label>
  <patents>
    <patent>
      <number>5474978</number>
      <country>United States</country>
      <approved>1994-06-16</approved>
      <expires>2014-06-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5514646</number>
      <country>United States</country>
      <approved>1993-05-07</approved>
      <expires>2013-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2151564</number>
      <country>Canada</country>
      <approved>2003-02-11</approved>
      <expires>2015-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2151560</number>
      <country>Canada</country>
      <approved>2000-05-09</approved>
      <expires>2015-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7291132</number>
      <country>United States</country>
      <approved>2004-08-09</approved>
      <expires>2024-08-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6551992</number>
      <country>United States</country>
      <approved>1998-06-11</approved>
      <expires>2018-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6034054</number>
      <country>United States</country>
      <approved>1998-06-11</approved>
      <expires>2018-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Inject subcutaneuosly 15 minutes before meal</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic Acid</name>
      <description>Lipoic Acid may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin Human</name>
      <description>Insulin Human may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin Glargine</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin Aspart</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Insulin Aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin Detemir</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Insulin Detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin Glulisine</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Insulin Glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>Insulin Lispro may increase the hypoglycemic activities of Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02665</drugbank-id>
      <name>Trans-2-Phenylcyclopropylamine</name>
      <description>Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>Iproclozide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Moxifloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Grepafloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Enoxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Pefloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Ciprofloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Trovafloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic Acid</name>
      <description>Nalidixic Acid may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Rosoxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Cinoxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Lomefloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Gatifloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Norfloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Levofloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Gemifloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Ofloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Sparfloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Temafloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Fleroxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Garenoxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Nemonoxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Flumequine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Pazufloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Prulifloxacin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>Fluoxetine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>Paroxetine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>Citalopram may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>Escitalopram may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>Sertraline may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>Fluvoxamine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>Duloxetine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>Nefazodone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>Desvenlafaxine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>Milnacipran may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>Venlafaxine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>Levomilnacipran may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>Dapoxetine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>Indalpine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>Zimelidine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Etoperidone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Piperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinyl Estradiol</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethinyl Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Mestranol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Histrelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Articaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>Oxandrolone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Dihydrotestosterone</name>
      <description>Dihydrotestosterone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>Oxymetholone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06718</drugbank-id>
      <name>Stanozolol</name>
      <description>Stanozolol may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01185</drugbank-id>
      <name>Fluoxymesterone</name>
      <description>Fluoxymesterone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Methyltestosterone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin Pork</name>
      <description>Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Troglitazone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Metformin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>Acetohexamide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00419</drugbank-id>
      <name>Miglustat</name>
      <description>Miglustat may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>Miglitol may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>Phenformin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>Pioglitazone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>Gliquidone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>Mitiglinide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Sitagliptin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Exenatide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>Pramlintide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>Aicar may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01816</drugbank-id>
      <name>Castanospermine</name>
      <description>Castanospermine may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>Buformin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>Vildagliptin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>Voglibose may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Alogliptin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Sulodexide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Saxagliptin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>Liraglutide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>Linagliptin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>Glibornuride may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Empagliflozin may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>Dulaglutide may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>Ciglitazone may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>Thiazolidinedione may increase the hypoglycemic activities of Insulin Lispro.</description>
    </drug-interaction>
